<?xml version="1.0" encoding="UTF-8"?><search-results xmlns="http://www.w3.org/2005/Atom" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:opensearch="http://a9.com/-/spec/opensearch/1.1/" xmlns:dc="http://purl.org/dc/elements/1.1/"><opensearch:totalResults>2992343</opensearch:totalResults><opensearch:startIndex>0</opensearch:startIndex><opensearch:itemsPerPage>100</opensearch:itemsPerPage><opensearch:Query role="request" searchTerms="heart" startPage="0"/><link ref="self" href="http://api.elsevier.com:80/content/search/index:scopus?start=0&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="first" href="http://api.elsevier.com:80/content/search/index:scopus?start=0&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="next" href="http://api.elsevier.com:80/content/search/index:scopus?start=100&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="last" href="http://api.elsevier.com:80/content/search/index:scopus?start=4900&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225760"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225760?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225760&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225760&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0308814615008183"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225760</prism:url><dc:identifier>SCOPUS_ID:84930225760</dc:identifier><eid>2-s2.0-84930225760</eid><dc:title>Near Infrared Spectroscopy (NIRS) for the determination of the milk fat fatty acid profile of goats</dc:title><dc:creator>Núñez-Sánchez N.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>190</prism:volume><prism:pageRange>244-252</prism:pageRange><prism:coverDate>2016-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2016</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2015.05.083</prism:doi><pii>S0308814615008183</pii><dc:description>© 2015 Elsevier Ltd. All rights reserved. Milk fatty acid (FA) composition is important for the goat dairy industry because of its influence on cheese properties and human health. The aim of the present work was to evaluate the feasibility of NIRS reflectance (oven-dried milk using the DESIR method) and transflectance (liquid milk) analysis to predict milk FA profile and groups of fats in milk samples from individual goats. NIRS analysis of milk samples allowed to estimate FA contents and their ratios and indexes in fat with high precision and accuracy. In general, transflectance analysis gave better or similar results than reflectance mode. Interestingly, NIRS analysis allowed direct prediction of the Atherogenicity and Thrombogenicity indexes, which are useful for the interpretation of the nutritional value of goat milk. Therefore, the calibrations obtained in the present work confirm the viability of NIRS as a fast, reliable and effective analytical method to provide nutritional information of milk samples.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003138</affiliation-url><afid>60003138</afid><affilname>Universidad de Cordoba</affilname><name-variant>University of Cordoba</name-variant><affiliation-city>Cordoba</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033284</affiliation-url><afid>60033284</afid><affilname>Universidad de Sevilla</affilname><name-variant>University of Seville</name-variant><affiliation-city>Sevilla</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069612</affiliation-url><afid>60069612</afid><affilname>Instituto Murciano de Investigacion y Desarrollo Agrario y Alimentario</affilname><name-variant>Instituto Murciano de Investigación y Desarrollo Agrario y Alimentario</name-variant><affiliation-city>La Alberca</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:25225668300</author-url><authid>25225668300</authid><authname>Núñez-Sánchez N.</authname><surname>Núñez-Sánchez</surname><given-name>N.</given-name><initials>N.</initials><afid>60003138</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6507136729</author-url><authid>6507136729</authid><authname>Martínez-Marín A.</authname><surname>Martínez-Marín</surname><given-name>A. L.</given-name><initials>A.L.</initials><afid>60003138</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6506724882</author-url><authid>6506724882</authid><authname>Polvillo O.</authname><surname>Polvillo</surname><given-name>O.</given-name><initials>O.</initials><afid>60033284</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:12142212100</author-url><authid>12142212100</authid><authname>Fernández-Cabanás V.</authname><surname>Fernández-Cabanás</surname><given-name>V. M.</given-name><initials>V.M.</initials><afid>60033284</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6701572944</author-url><authid>6701572944</authid><authname>Carrizosa J.</authname><surname>Carrizosa</surname><given-name>J.</given-name><initials>J.</initials><afid>60069612</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6508350808</author-url><authid>6508350808</authid><authname>Urrutia B.</authname><surname>Urrutia</surname><given-name>B.</given-name><initials>B.</initials><afid>60069612</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6602625878</author-url><authid>6602625878</authid><authname>Serradilla J.</authname><surname>Serradilla</surname><given-name>J. M.</given-name><initials>J.M.</initials><afid>60003138</afid></author><authkeywords>Goats | Milk fatty acids | Near Infrared Spectroscopy (NIRS) | Omega 3 | Omega 6</authkeywords><intid>36086687</intid><source-id>24039</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929379033"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929379033?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929379033&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929379033&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929379033</prism:url><dc:identifier>SCOPUS_ID:84929379033</dc:identifier><eid>2-s2.0-84929379033</eid><dc:title>Extracting features from ECG and respiratory signals for automatic supervised classification of heartbeat using neural networks</dc:title><dc:creator>Oussama B.</dc:creator><prism:publicationName>Asian Journal of Information Technology</prism:publicationName><prism:issn>16823915</prism:issn><prism:eIssn>19935994</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>5-11</prism:pageRange><prism:coverDate>2016-01-01</prism:coverDate><prism:coverDisplayDate>2016</prism:coverDisplayDate><prism:doi>10.3923/ajit.2016.5.11</prism:doi><dc:description>© Medwell Journals, 2016. Electrocardiogram (ECG) is today one of the essential pillars of the diagnosis of heart problems. The analysis of this signal and the identification of its parameters is an important step for diagnosis. In this study, we present a new algorithm for ECG signal classification. Respiratory signal simultaneously recorded with the ECG signal will be used to classify each heart beat into two classes (abnormal and normal class) by the extraction of their parameters using various Multi-Layered Perceptron Neural Classifiers (MLPNNs). Principal Component Analysis (PCA) is used to reduce dimensions of input features and improve the performance of the neural classifiers. This algorithm is tested on Apnea-ECG database from the universal MIT PhysioNet As it will be shown later, the proposed algorithm allows to achieve high classification performances, describes both by sensitivity, specificity and the rate of correct classification parameters.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068756</affiliation-url><afid>60068756</afid><affilname>University of Tlemcen</affilname><name-variant>Université de Tlemcen</name-variant><affiliation-city>Tlemcen</affiliation-city><affiliation-country>Algeria</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56644827400</author-url><authid>56644827400</authid><authname>Oussama B.</authname><surname>Oussama</surname><given-name>Benali Medjahed</given-name><initials>B.M.</initials><afid>60068756</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56644581300</author-url><authid>56644581300</authid><authname>Saadi B.</authname><surname>Saadi</surname><given-name>Bachir M Hamed</given-name><initials>B.M.H.</initials><afid>60068756</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56644894200</author-url><authid>56644894200</authid><authname>Zine-Eddine H.</authname><surname>Zine-Eddine</surname><given-name>Hadj Slimane</given-name><initials>H.S.</initials><afid>60068756</afid></author><authkeywords>Apnea-ECG database | ECG signal | Multi-layered perceptron neural classifiers | Principal component analysis | Respiratory signal</authkeywords><intid>35945191</intid><source-id>19700171018</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928392835"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928392835?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928392835&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928392835&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928392835</prism:url><dc:identifier>SCOPUS_ID:84928392835</dc:identifier><eid>2-s2.0-84928392835</eid><dc:title>N-terminal Pro-Brain natriuretic peptide in the early diagnosis of Anthracycline-Induced cardiomyopathy</dc:title><dc:creator>Bisoc A.</dc:creator><prism:publicationName>Acta Endocrinologica</prism:publicationName><prism:issn>18410987</prism:issn><prism:volume>11</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>39-45</prism:pageRange><prism:coverDate>2016-01-01</prism:coverDate><prism:coverDisplayDate>2016</prism:coverDisplayDate><prism:doi>10.4183/acb.2015.39</prism:doi><dc:description>© 2015, Editura Academiei Romane. All rights reserved. Background. Early prediction of anticancer therapy cardiotoxicity is essential for applying proper preventive and supporting therapeutic strategies. Objective. To evaluate plasma N-terminal fragment of pro-brain natriuretic peptide(NT-proBNP) related to cardiac dysfunction assessed by transthoracic 2 D echocardiography (2D-TTE) in patients with cancer and early onset asymptomatic anthracycline-induced cardiomyopathy (AIC). Methods. Prospective study of 68 patients with cancer treated with anthracyclines, followed up for 6 months. Diagnosis of AIC was set at 6 months by decreasing of left ventricular ejection fraction(LVEF) below 50% or with more than 10 units or 20% from baseline. NT-proBNP and 2D-TTE were assessed at enrollment, and thereafter at 3 and 6 months. Results. Fifteen(22.1%) patients developed AIC at 6 months of anthracycline treatment (group 1), and 53(77.95%) patients did not evolve with AIC (group 2). At 3 months, in patients from group 1 NT pro-BNP was significantly higher compared to group 2 [121.0 (119.8:140.8) pg/mL v.v. 97.7(75.5:111.7) pg/mL, P=0.0001, values expressed as median (25&lt;sup&gt;lh&lt;/sup&gt;: 75&lt;sup&gt;lh&lt;/sup&gt; percentiles)]. Left ventricular(LV) diastolic dysfunction was significantly more frequent in group 1(93.3%) v.v. group 2(37.7%). P=0.0002. NT-proBNP at 3 months proved accurate in predicting asymptomatic AIC at 6 months [area under the receiver operating characteristic curve(AUC)=0.845, 95%Confidence Interval(CI): 0.735-0.954. P=0.0001[. New- installed diastolic dysfunction at 3 months had a sensitivity of 60%. a specificity of 77% in predicting AIC at 6 months. NT-proBNP assessed at 3 months above a cut-off=l 18.5pg/ mL. was an independent predictor of AIC at 6 months. Conclusions. Plasma NT-proBNP at 3 months of anthracycline therapy proved to be an early independent predictor of asymptomatic anthracycline-induced cardiomyopathy.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023654</affiliation-url><afid>60023654</afid><affilname>Universitatea Transilvania din Brasov</affilname><name-variant>Transilvania University of Brasov</name-variant><affiliation-city>Brasov</affiliation-city><affiliation-country>Romania</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56605052500</author-url><authid>56605052500</authid><authname>Bisoc A.</authname><surname>Bisoc</surname><given-name>A.</given-name><initials>A.</initials><afid>60023654</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8285538500</author-url><authid>8285538500</authid><authname>Radoi M.</authname><surname>Radoi</surname><given-name>M.</given-name><initials>M.</initials><afid>60023654</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:15756229800</author-url><authid>15756229800</authid><authname>Pascu A.</authname><surname>Pascu</surname><given-name>A. M.</given-name><initials>A.M.</initials><afid>60023654</afid></author><authkeywords>Anthracycline-induced cardiomyopathy | Left atrial remodeling | NT-proBNP. diastolic dysfunction</authkeywords><intid>1035773834</intid><source-id>5100155028</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84894791191"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84894791191?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84894791191&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84894791191&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84894791191</prism:url><dc:identifier>SCOPUS_ID:84894791191</dc:identifier><eid>2-s2.0-84894791191</eid><dc:title>What's in a name?: Forging a theoretical framework for African women's theologies1</dc:title><dc:creator>Phiri I.</dc:creator><prism:publicationName>Biblical Studies, Theology, Religion and Philosophy: An Introduction for African Universities</prism:publicationName><prism:isbn>9789966734129</prism:isbn><prism:pageRange>213-227</prism:pageRange><prism:coverDate>2016-01-01</prism:coverDate><prism:coverDisplayDate>2016</prism:coverDisplayDate><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010499</affiliation-url><afid>60010499</afid><affilname>University of KwaZulu-Natal</affilname><name-variant>University of KwaZulu-Natal</name-variant><affiliation-city/><affiliation-country>South Africa</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010499</affiliation-url><afid>60010499</afid><affilname>University of KwaZulu-Natal</affilname><name-variant>University of KwaZulu-Natal</name-variant><affiliation-city/><affiliation-country>South Africa</affiliation-country></affiliation><prism:aggregationType>Book</prism:aggregationType><subtype>ch</subtype><subtypeDescription>Chapter</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26034966700</author-url><authid>26034966700</authid><authname>Phiri I.</authname><surname>Phiri</surname><given-name>Isabel Apawo</given-name><initials>I.A.</initials><afid>60010499</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26422367500</author-url><authid>26422367500</authid><authname>Nadar S.</authname><surname>Nadar</surname><given-name>Sarojini</given-name><initials>S.</initials><afid>60010499</afid></author><intid>1030174509</intid><source-id>21100287674</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84894761528"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84894761528?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84894761528&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84894761528&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84894761528</prism:url><dc:identifier>SCOPUS_ID:84894761528</dc:identifier><eid>2-s2.0-84894761528</eid><dc:title>Phenomenology of religion</dc:title><dc:creator>Chitando E.</dc:creator><prism:publicationName>Biblical Studies, Theology, Religion and Philosophy: An Introduction for African Universities</prism:publicationName><prism:isbn>9789966734129</prism:isbn><prism:pageRange>263-281</prism:pageRange><prism:coverDate>2016-01-01</prism:coverDate><prism:coverDisplayDate>2016</prism:coverDisplayDate><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033774</affiliation-url><afid>60033774</afid><affilname>University of Zimbabwe</affilname><name-variant>University of Zimbabwe</name-variant><affiliation-city>Harare</affiliation-city><affiliation-country>Zimbabwe</affiliation-country></affiliation><prism:aggregationType>Book</prism:aggregationType><subtype>ch</subtype><subtypeDescription>Chapter</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26631663900</author-url><authid>26631663900</authid><authname>Chitando E.</authname><surname>Chitando</surname><given-name>Ezra</given-name><initials>E.</initials><afid>60033774</afid></author><intid>30183482</intid><source-id>21100287674</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929493788"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929493788?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929493788&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929493788&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0305048315000626"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929493788</prism:url><dc:identifier>SCOPUS_ID:84929493788</dc:identifier><eid>2-s2.0-84929493788</eid><dc:title>DEANN: A healthcare analytic methodology of data envelopment analysis and artificial neural networks for the prediction of organ recipient functional status</dc:title><dc:creator>Misiunas N.</dc:creator><prism:publicationName>Omega (United Kingdom)</prism:publicationName><prism:issn>03050483</prism:issn><prism:volume>58</prism:volume><prism:pageRange>46-54</prism:pageRange><prism:coverDate>2016-01-01</prism:coverDate><prism:coverDisplayDate>January 01, 2016</prism:coverDisplayDate><prism:doi>10.1016/j.omega.2015.03.010</prism:doi><pii>S0305048315000626</pii><dc:description>© 2015 Elsevier Ltd. The problem of effectively preprocessing a dataset containing a large number of performance metrics and an even larger number of records is crucial when utilizing an ANN. As such, this study proposes deploying DEA to preprocess the data to remove outliers and hence, preserve monotonicity as well as to reduce the size of the dataset used to train the ANN. The results of this novel data analytic approach, i.e. DEANN, proved that the accuracy of the ANN can be maintained while the size of the training dataset is significantly reduced. DEANN methodology is implemented via the problem of predicting the functional status of patients in organ transplant operations. The results yielded are very promising which validates the proposed method.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033461</affiliation-url><afid>60033461</afid><affilname>University of Massachusetts Lowell</affilname><name-variant>University of Massachusetts</name-variant><affiliation-city>Lowell</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033461</affiliation-url><afid>60033461</afid><affilname>University of Massachusetts Lowell</affilname><name-variant>University of Massachusetts</name-variant><affiliation-city>Lowell</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033461</affiliation-url><afid>60033461</afid><affilname>University of Massachusetts Lowell</affilname><name-variant>University of Massachusetts</name-variant><affiliation-city>Lowell</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54387321600</author-url><authid>54387321600</authid><authname>Misiunas N.</authname><surname>Misiunas</surname><given-name>Nicholas</given-name><initials>N.</initials><afid>60033461</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26635754100</author-url><authid>26635754100</authid><authname>Oztekin A.</authname><surname>Oztekin</surname><given-name>Asil</given-name><initials>A.</initials><afid>60033461</afid><afid>60033461</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26635754100</author-url><authid>26635754100</authid><authname>Oztekin A.</authname><surname>Oztekin</surname><given-name>Asil</given-name><initials>A.</initials><afid>60033461</afid><afid>60033461</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56647974700</author-url><authid>56647974700</authid><authname>Chen Y.</authname><surname>Chen</surname><given-name>Yao</given-name><initials>Y.</initials><afid>60033461</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7103234424</author-url><authid>7103234424</authid><authname>Chandra K.</authname><surname>Chandra</surname><given-name>Kavitha</given-name><initials>K.</initials><afid>60033461</afid></author><authkeywords>Artificial neural networks (ANN) | Data envelopment analysis (DEA) | Healthcare analytics | Organ transplant | Stratification of efficiency layers | Training data reduction</authkeywords><intid>1035958224</intid><source-id>21915</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929601098"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929601098?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929601098&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929601098&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0308814615008195"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929601098</prism:url><dc:identifier>SCOPUS_ID:84929601098</dc:identifier><eid>2-s2.0-84929601098</eid><dc:title>Feasibility of combining spectra with texture data of multispectral imaging to predict heme and non-heme iron contents in pork sausages</dc:title><dc:creator>Ma F.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>190</prism:volume><prism:pageRange>142-149</prism:pageRange><prism:coverDate>2016-01-01</prism:coverDate><prism:coverDisplayDate>1 January 2016</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2015.05.084</prism:doi><pii>S0308814615008195</pii><dc:description>© 2015 Elsevier Ltd. Abstract To precisely determine heme and non-heme iron contents in meat product, the feasibility of combining spectral with texture features extracted from multispectral imaging data (405-970 nm) was assessed. In our study, spectra and textures of 120 pork sausages (PSs) treated by different temperatures (30-80 °C) were analyzed using different calibration models including partial least squares regression (PLSR) and LIB support vector machine (Lib-SVM) for predicting heme and non-heme iron contents in PSs. Based on a combination of spectral and textural features, optimized PLSR models were obtained with determination coefficient (R&lt;sup&gt;2&lt;/sup&gt;) of 0.912 for heme and of 0.901 for non-heme iron prediction, which demonstrated the superiority of combining spectra with texture data. Results of satisfactory determination and visualization of heme and non-heme iron contents indicated that multispectral imaging could serve as a feasible approach for online industrial applications in the future.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002836</affiliation-url><afid>60002836</afid><affilname>Hefei University of Technology</affilname><name-variant>Hefei University of Technology</name-variant><affiliation-city>Hefei</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002836</affiliation-url><afid>60002836</afid><affilname>Hefei University of Technology</affilname><name-variant>Hefei University of Technology</name-variant><affiliation-city>Hefei</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002836</affiliation-url><afid>60002836</afid><affilname>Hefei University of Technology</affilname><name-variant>Hefei University of Technology</name-variant><affiliation-city>Hefei</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56650507200</author-url><authid>56650507200</authid><authname>Ma F.</authname><surname>Ma</surname><given-name>Fei</given-name><initials>F.</initials><afid>60002836</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56104947400</author-url><authid>56104947400</authid><authname>Qin H.</authname><surname>Qin</surname><given-name>Hao</given-name><initials>H.</initials><afid>60002836</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56650566200</author-url><authid>56650566200</authid><authname>Shi K.</authname><surname>Shi</surname><given-name>Kefu</given-name><initials>K.</initials><afid>60002836</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56650375700</author-url><authid>56650375700</authid><authname>Zhou C.</authname><surname>Zhou</surname><given-name>Cunliu</given-name><initials>C.</initials><afid>60002836</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56650333100</author-url><authid>56650333100</authid><authname>Chen C.</authname><surname>Chen</surname><given-name>Conggui</given-name><initials>C.</initials><afid>60002836</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56650343700</author-url><authid>56650343700</authid><authname>Hu X.</authname><surname>Hu</surname><given-name>Xiaohua</given-name><initials>X.</initials><afid>60002836</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35228233800</author-url><authid>35228233800</authid><authname>Zheng L.</authname><surname>Zheng</surname><given-name>Lei</given-name><initials>L.</initials><afid>60002836</afid><afid>60002836</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35228233800</author-url><authid>35228233800</authid><authname>Zheng L.</authname><surname>Zheng</surname><given-name>Lei</given-name><initials>L.</initials><afid>60002836</afid><afid>60002836</afid></author><authkeywords>Heme iron | Multispectral imaging | Non-heme iron | Pork sausage | Texture | Visualization</authkeywords><intid>1535982019</intid><article-number>17631</article-number><source-id>24039</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84920156971"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84920156971?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84920156971&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84920156971&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84920156971</prism:url><dc:identifier>SCOPUS_ID:84920156971</dc:identifier><eid>2-s2.0-84920156971</eid><dc:title>Pathogenesis of target organ damage in hypertension: Role of mitochondrial oxidative stress</dc:title><dc:creator>Rubattu S.</dc:creator><prism:publicationName>International Journal of Molecular Sciences</prism:publicationName><prism:issn>16616596</prism:issn><prism:eIssn>14220067</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>823-839</prism:pageRange><prism:coverDate>2015-12-31</prism:coverDate><prism:coverDisplayDate>31 December 2015</prism:coverDisplayDate><prism:doi>10.3390/ijms16010823</prism:doi><dc:description>© 2014 by the authors; licensee MDPI, Basel, Switzerland. Hypertension causes target organ damage (TOD) that involves vasculature, heart, brain and kidneys. Complex biochemical, hormonal and hemodynamic mechanisms are involved in the pathogenesis of TOD. Common to all these processes is an increased bioavailability of reactive oxygen species (ROS). Both in vitro and in vivo studies explored the role of mitochondrial oxidative stress as a mechanism involved in the pathogenesis of TOD in hypertension, especially focusing on atherosclerosis, heart disease, renal failure, cerebrovascular disease. Both dysfunction of mitochondrial proteins, such as uncoupling protein-2 (UCP2), superoxide dismutase (SOD) 2, peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α), calcium channels, and the interaction between mitochondria and other sources of ROS, such as NADPH oxidase, play an important role in the development of endothelial dysfunction, cardiac hypertrophy, renal and cerebral damage in hypertension. Commonly used anti-hypertensive drugs have shown protective effects against mitochondrial-dependent oxidative stress. Notably, few mitochondrial proteins can be considered therapeutic targets on their own. In fact, antioxidant therapies specifically targeted at mitochondria represent promising strategies to reduce mitochondrial dysfunction and related hypertensive TOD. In the present article, we discuss the role of mitochondrial oxidative stress as a contributing factor to hypertensive TOD development. We also provide an overview of mitochondria-based treatment strategies that may reveal useful to prevent TOD and reduce its progression.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032350</affiliation-url><afid>60032350</afid><affilname>Universita degli Studi di Roma La Sapienza</affilname><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114773328</affiliation-url><afid>114773328</afid><affilname>Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Neuromed</affilname><name-variant>Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Neuromed</name-variant><affiliation-city/><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7005952042</author-url><authid>7005952042</authid><authname>Rubattu S.</authname><surname>Rubattu</surname><given-name>Speranza</given-name><initials>S.</initials><afid>60032350</afid><afid>114773328</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7005952042</author-url><authid>7005952042</authid><authname>Rubattu S.</authname><surname>Rubattu</surname><given-name>Speranza</given-name><initials>S.</initials><afid>60032350</afid><afid>114773328</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55364715000</author-url><authid>55364715000</authid><authname>Pagliaro B.</authname><surname>Pagliaro</surname><given-name>Beniamino</given-name><initials>B.</initials><afid>60032350</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55771540700</author-url><authid>55771540700</authid><authname>Pierelli G.</authname><surname>Pierelli</surname><given-name>Giorgia</given-name><initials>G.</initials><afid>60032350</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55509597600</author-url><authid>55509597600</authid><authname>Santolamazza C.</authname><surname>Santolamazza</surname><given-name>Caterina</given-name><initials>C.</initials><afid>60032350</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:14619095300</author-url><authid>14619095300</authid><authname>Di Castro S.</authname><surname>Di Castro</surname><given-name>Sara</given-name><initials>S.</initials><afid>114773328</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:54953332500</author-url><authid>54953332500</authid><authname>Mennuni S.</authname><surname>Mennuni</surname><given-name>Silvia</given-name><initials>S.</initials><afid>60032350</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7102295300</author-url><authid>7102295300</authid><authname>Volpe M.</authname><surname>Volpe</surname><given-name>Massimo</given-name><initials>M.</initials><afid>60032350</afid><afid>114773328</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7102295300</author-url><authid>7102295300</authid><authname>Volpe M.</authname><surname>Volpe</surname><given-name>Massimo</given-name><initials>M.</initials><afid>60032350</afid><afid>114773328</afid></author><authkeywords>Hypertension | Mitochondrial dysfunction | Oxidative stress | Target organ damage</authkeywords><intid>34440277</intid><source-id>25879</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84920260816"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84920260816?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84920260816&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84920260816&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84920260816</prism:url><dc:identifier>SCOPUS_ID:84920260816</dc:identifier><eid>2-s2.0-84920260816</eid><dc:title>Exploring the arabidopsis proteome: Influence of protein solubilization buffers on proteome coverage</dc:title><dc:creator>Marondedze C.</dc:creator><prism:publicationName>International Journal of Molecular Sciences</prism:publicationName><prism:issn>16616596</prism:issn><prism:eIssn>14220067</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>857-870</prism:pageRange><prism:coverDate>2015-12-31</prism:coverDate><prism:coverDisplayDate>31 December 2015</prism:coverDisplayDate><prism:doi>10.3390/ijms16010857</prism:doi><dc:description>© 2014 by the authors; licensee MDPI, Basel, Switzerland. The study of proteomes provides new insights into stimulus-specific responses of protein synthesis and turnover, and the role of post-translational modifications at the systems level. Due to the diverse chemical nature of proteins and shortcomings in the analytical techniques used in their study, only a partial display of the proteome is achieved in any study, and this holds particularly true for plant proteomes. Here we show that different solubilization and separation methods have profound effects on the resulting proteome. In particular, we observed that the type of detergents employed in the solubilization buffer preferentially enriches proteins in different functional categories. These include proteins with a role in signaling, transport, response to temperature stimuli and metabolism. This data may offer a functional bias on comparative analysis studies. In order to obtain a broader coverage, we propose a two-step solubilization protocol with first a detergent-free buffer and then a second step utilizing a combination of two detergents to solubilize proteins.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60092945</affiliation-url><afid>60092945</afid><affilname>King Abdullah University of Science and Technology</affilname><name-variant>King Abdullah University of Science and Technology (KAUST)</name-variant><affiliation-city>Jeddah</affiliation-city><affiliation-country>Saudi Arabia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031101</affiliation-url><afid>60031101</afid><affilname>University of Cambridge</affilname><name-variant>University of Cambridge</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:53880028500</author-url><authid>53880028500</authid><authname>Marondedze C.</authname><surname>Marondedze</surname><given-name>Claudius</given-name><initials>C.</initials><afid>60092945</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55785720000</author-url><authid>55785720000</authid><authname>Wong A.</authname><surname>Wong</surname><given-name>Aloysius</given-name><initials>A.</initials><afid>60092945</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:54886937100</author-url><authid>54886937100</authid><authname>Groen A.</authname><surname>Groen</surname><given-name>Arnoud</given-name><initials>A.</initials><afid>60031101</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56467840500</author-url><authid>56467840500</authid><authname>Serrano N.</authname><surname>Serrano</surname><given-name>Natalia</given-name><initials>N.</initials><afid>60092945</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:54792087800</author-url><authid>54792087800</authid><authname>Jankovic B.</authname><surname>Jankovic</surname><given-name>Boris</given-name><initials>B.</initials><afid>60092945</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7007045074</author-url><authid>7007045074</authid><authname>Lilley K.</authname><surname>Lilley</surname><given-name>Kathryn</given-name><initials>K.</initials><afid>60031101</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7006666681</author-url><authid>7006666681</authid><authname>Gehring C.</authname><surname>Gehring</surname><given-name>Christoph</given-name><initials>C.</initials><afid>60092945</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:26326584800</author-url><authid>26326584800</authid><authname>Thomas L.</authname><surname>Thomas</surname><given-name>Ludivine</given-name><initials>L.</initials><afid>60092945</afid></author><authkeywords>Arabidopsis thaliana | Detergent | Mass spectrometry (MS) | OFFGEL fractionation | Two-dimensional gel electrophoresis (2DE)</authkeywords><intid>34448360</intid><source-id>25879</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924089024"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924089024?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924089024&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924089024&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924089024</prism:url><dc:identifier>SCOPUS_ID:84924089024</dc:identifier><eid>2-s2.0-84924089024</eid><dc:title>CRISPR-Cas9-mediated single-gene and gene family disruption in Trypanosoma cruzi</dc:title><dc:creator>Peng D.</dc:creator><prism:publicationName>mBio</prism:publicationName><prism:issn>21612129</prism:issn><prism:eIssn>21507511</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-30</prism:coverDate><prism:coverDisplayDate>30 December 2015</prism:coverDisplayDate><prism:doi>10.1128/mBio.02097-14</prism:doi><dc:description>© 2014 Peng et al. Trypanosoma cruzi is a protozoan parasite of humans and animals, affecting 10 to 20 million people and innumerable animals, primarily in the Americas. Despite being the largest cause of infection-induced heart disease worldwide, even among the neglected tropical diseases (NTDs) T. cruzi is considered one of the least well understood and understudied. The genetic complexity of T. cruzi as well as the limited set of efficient techniques for genome engineering contribute significantly to the relative lack of progress in and understanding of this pathogen. Here, we adapted the CRISPR-Cas9 system for the genetic engineering of T. cruzi, demonstrating rapid and efficient knockout of multiple endogenous genes, including essential genes. We observed that in the absence of a template, repair of the Cas9-induced double-stranded breaks (DSBs) in T. cruzi occurs exclusively by microhomology-mediated end joining (MMEJ) with various-sized deletions. When a template for DNA repair is provided, DSB repair by homologous recombination is achieved at an efficiency several orders of magnitude higher than that in the absence of CRISPR-Cas9-induced DSBs. We also demonstrate the high multiplexing capacity of CRISPR-Cas9 in T. cruzi by knocking down expression of an enzyme gene family consisting of 65 members, resulting in a significant reduction of enzymatic product with no apparent off-target mutations. Lastly, we show that Cas9 can mediate disruption of its own coding sequence, rescuing a growth defect in stable Cas9-expressing parasites. These results establish a powerful new tool for the analysis of gene functions in T. cruzi, enabling the study of essential genes and their functions and analysis of the many large families of related genes that occupy a substantial portion of the T. cruzi genome. IMPORTANCE Trypanosoma cruzi, the causative agent of human Chagas disease, is the leading worldwide cause of infectious myocarditis. Diagnostics for the infection are relatively poor, treatment options are limited and of variable effectiveness, and suitable vaccines are nonexistent. The T. cruzi genome is replete with genes of unknown function and greatly expanded gene families with hundreds of members. The absence of facile genetic engineering tools, including RNA interference, for T. cruzi has prevented elucidation of gene and gene family function and the development of better infection prevention and control measures. In this study, we demonstrate that the CRISPR-Cas9 system is a versatile and powerful tool for genome manipulations in T. cruzi, bringing new opportunities for unraveling the functions of previously uncharacterized genes and how this human pathogen engages its large families of genes encoding surface proteins to interact with human and animal hosts.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029747</affiliation-url><afid>60029747</afid><affilname>The University of Georgia</affilname><name-variant>University of Georgia</name-variant><affiliation-city>Athens</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029747</affiliation-url><afid>60029747</afid><affilname>The University of Georgia</affilname><name-variant>University of Georgia</name-variant><affiliation-city>Athens</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024324</affiliation-url><afid>60024324</afid><affilname>University of Iowa</affilname><name-variant>University of Iowa</name-variant><affiliation-city>Iowa City</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56537650400</author-url><authid>56537650400</authid><authname>Peng D.</authname><surname>Peng</surname><given-name>Duo</given-name><initials>D.</initials><afid>60029747</afid><afid>60029747</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56537650400</author-url><authid>56537650400</authid><authname>Peng D.</authname><surname>Peng</surname><given-name>Duo</given-name><initials>D.</initials><afid>60029747</afid><afid>60029747</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24343864300</author-url><authid>24343864300</authid><authname>Kurup S.</authname><surname>Kurup</surname><given-name>Samarchith P.</given-name><initials>S.P.</initials><afid>60029747</afid><afid>60029747</afid><afid>60024324</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24343864300</author-url><authid>24343864300</authid><authname>Kurup S.</authname><surname>Kurup</surname><given-name>Samarchith P.</given-name><initials>S.P.</initials><afid>60029747</afid><afid>60029747</afid><afid>60024324</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24343864300</author-url><authid>24343864300</authid><authname>Kurup S.</authname><surname>Kurup</surname><given-name>Samarchith P.</given-name><initials>S.P.</initials><afid>60029747</afid><afid>60029747</afid><afid>60024324</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56537790700</author-url><authid>56537790700</authid><authname>Yao P.</authname><surname>Yao</surname><given-name>Phil Y.</given-name><initials>P.Y.</initials><afid>60029747</afid><afid>60029747</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56537790700</author-url><authid>56537790700</authid><authname>Yao P.</authname><surname>Yao</surname><given-name>Phil Y.</given-name><initials>P.Y.</initials><afid>60029747</afid><afid>60029747</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6507871514</author-url><authid>6507871514</authid><authname>Minning T.</authname><surname>Minning</surname><given-name>Todd A.</given-name><initials>T.A.</initials><afid>60029747</afid><afid>60029747</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6507871514</author-url><authid>6507871514</authid><authname>Minning T.</authname><surname>Minning</surname><given-name>Todd A.</given-name><initials>T.A.</initials><afid>60029747</afid><afid>60029747</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7007130277</author-url><authid>7007130277</authid><authname>Tarleton R.</authname><surname>Tarleton</surname><given-name>Rick L.</given-name><initials>R.L.</initials><afid>60029747</afid><afid>60029747</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7007130277</author-url><authid>7007130277</authid><authname>Tarleton R.</authname><surname>Tarleton</surname><given-name>Rick L.</given-name><initials>R.L.</initials><afid>60029747</afid><afid>60029747</afid></author><intid>1535082060</intid><article-number>e02097</article-number><source-id>19700188403</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84920289018"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84920289018?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84920289018&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84920289018&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84920289018</prism:url><dc:identifier>SCOPUS_ID:84920289018</dc:identifier><eid>2-s2.0-84920289018</eid><dc:title>Chlamydia pneumoniae and oxidative stress in cardiovascular disease: State of the art and prevention strategies</dc:title><dc:creator>Di Pietro M.</dc:creator><prism:publicationName>International Journal of Molecular Sciences</prism:publicationName><prism:issn>16616596</prism:issn><prism:eIssn>14220067</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>724-735</prism:pageRange><prism:coverDate>2015-12-30</prism:coverDate><prism:coverDisplayDate>30 December 2015</prism:coverDisplayDate><prism:doi>10.3390/ijms16010724</prism:doi><dc:description>© 2014 by the authors; licensee MDPI, Basel, Switzerland. Chlamydia pneumoniae, a pathogenic bacteria responsible for respiratory tract infections, is known as the most implicated infectious agent in atherosclerotic cardiovascular diseases (CVDs). Accumulating evidence suggests that C. pneumoniae-induced oxidative stress may play a critical role in the pathogenesis of CVDs. Indeed, the overproduction of reactive oxygen species (ROS) within macrophages, endothelial cells, platelets and vascular smooth muscle cells (VSMCs) after C. pneumoniae exposure, has been shown to cause low density lipoprotein oxidation, foam cell formation, endothelial dysfunction, platelet adhesion and aggregation, and VSMC proliferation and migration, all responsible for the typical pathological changes of atherosclerotic plaque. The aim of this review is to improve our insight into C. pneumoniae-induced oxidative stress in order to suggest potential strategies for CVD prevention. Several antioxidants, acting on multi-enzymatic targets related to ROS production induced by C. pneumoniae, have been discussed. A future strategy for the prevention of C. pneumoniae-associated CVDs will be to target chlamydial HSP60, involved in oxidative stress.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032350</affiliation-url><afid>60032350</afid><affilname>Universita degli Studi di Roma La Sapienza</affilname><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7007072420</author-url><authid>7007072420</authid><authname>Di Pietro M.</authname><surname>Di Pietro</surname><given-name>Marisa</given-name><initials>M.</initials><afid>60032350</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55336962900</author-url><authid>55336962900</authid><authname>Filardo S.</authname><surname>Filardo</surname><given-name>Simone</given-name><initials>S.</initials><afid>60032350</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55337044600</author-url><authid>55337044600</authid><authname>De Santis F.</authname><surname>De Santis</surname><given-name>Fiorenzo</given-name><initials>F.</initials><afid>60032350</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55982889600</author-url><authid>55982889600</authid><authname>Mastromarino P.</authname><surname>Mastromarino</surname><given-name>Paola</given-name><initials>P.</initials><afid>60032350</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7007086380</author-url><authid>7007086380</authid><authname>Sessa R.</authname><surname>Sessa</surname><given-name>Rosa</given-name><initials>R.</initials><afid>60032350</afid></author><authkeywords>C. pneumonia | Cardiovascular disease | Oxidative stress | Prevention strategies</authkeywords><intid>1034442440</intid><source-id>25879</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226618"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226618?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226618&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226618&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226618</prism:url><dc:identifier>SCOPUS_ID:84930226618</dc:identifier><eid>2-s2.0-84930226618</eid><dc:title>The diagnosis of right heart thrombus by focused cardiac ultrasound in a critically ill patient in compensated shock</dc:title><dc:creator>Jammal M.</dc:creator><prism:publicationName>Critical Ultrasound Journal</prism:publicationName><prism:issn>20363176</prism:issn><prism:eIssn>20367902</prism:eIssn><prism:volume>7</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-27</prism:coverDate><prism:coverDisplayDate>27 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s13089-015-0023-7</prism:doi><dc:description>© 2015, Jammal et al.; licensee Springer. Right heart thrombus (RHT) is a life-threatening diagnosis that is rarely made in the emergency department (ED), but with the increasing use of focused cardiac ultrasound (FocUS), more of these cases may be identified in a timely fashion. We present a case of an ill-appearing patient who had an immediate change in management due to the visualization of RHT soon after arrival to the ED. The diagnosis was confirmed after a cardiology-performed ultrasound (US). This case illustrates the value of the recognition of RHT on FocUS and how US protocols designed for the evaluation of shock and shortness of breath may potentially be expanded to patients in a ‘compensated’ or ‘pre-shock’ state to expedite the correct diagnosis and to facilitate more timely management.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:108341916</affiliation-url><afid>108341916</afid><affilname>Division of Emergency Medicine</affilname><name-variant>Division of Emergency Medicine</name-variant><affiliation-city>Stanford</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009207</affiliation-url><afid>60009207</afid><affilname>Los Angeles County USC Medical Center</affilname><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55651374800</author-url><authid>55651374800</authid><authname>Jammal M.</authname><surname>Jammal</surname><given-name>Mansour</given-name><initials>M.</initials><afid>108341916</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36981081000</author-url><authid>36981081000</authid><authname>Milano P.</authname><surname>Milano</surname><given-name>Peter</given-name><initials>P.</initials><afid>60009207</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56662827800</author-url><authid>56662827800</authid><authname>Cardenas R.</authname><surname>Cardenas</surname><given-name>Renzo</given-name><initials>R.</initials><afid>60009207</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35332476200</author-url><authid>35332476200</authid><authname>Mailhot T.</authname><surname>Mailhot</surname><given-name>Thomas</given-name><initials>T.</initials><afid>60009207</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6603675784</author-url><authid>6603675784</authid><authname>Mandavia D.</authname><surname>Mandavia</surname><given-name>Diku</given-name><initials>D.</initials><afid>60009207</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:24076725200</author-url><authid>24076725200</authid><authname>Perera P.</authname><surname>Perera</surname><given-name>Phillips</given-name><initials>P.</initials><afid>108341916</afid></author><authkeywords>Bedside ultrasound | Cardiac ultrasound | Echocardiography | Focused cardiac ultrasound (FocUS) | Pulmonary embolus | Right heart thrombus | RUSH exam-rapid ultrasound in shock exam in the critically ill patient | Ultrasound in shock | Ultrasound in shortness of breath</authkeywords><intid>1786088131</intid><source-id>19500157826</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924176736"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924176736?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924176736&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924176736&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924176736</prism:url><dc:identifier>SCOPUS_ID:84924176736</dc:identifier><eid>2-s2.0-84924176736</eid><dc:title>Cardiac surgery in 260 octogenarians: A case series</dc:title><dc:creator>Scandroglio M.</dc:creator><prism:publicationName>BMC Anesthesiology</prism:publicationName><prism:eIssn>14712253</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-26</prism:coverDate><prism:coverDisplayDate>December 26, 2015</prism:coverDisplayDate><prism:doi>10.1186/1471-2253-15-15</prism:doi><dc:description>© Scandroglio et al. Background: The elderly undergo cardiac surgery more and more frequently, often present multiple comorbidities, assume chronic therapies, and present a unique physiology. Aim of our study was to analyze the experience of a referral cardiac surgery center with all types of cardiac surgery interventions performed in patients ≥80 years old over a six years' period. Methods: A retrospective observational study performed in a university hospital. 260 patients were included in the study (3.5% of the patients undergoing cardiac surgery in the study period). Results: Mean age was 82 ± 1.8 years. Eighty-five percent of patients underwent elective surgery, 15% unplanned surgery and 4.2% redo surgery. Intervention for aortic valve pathology and coronary artery bypass grafting were performed in 51% and 46% of the patients, respectively. Interventions involving the mitral valve were the 26% of the total, those on the tricuspid valve were 13% and those on the ascending aortic arch the 9.6%. Postoperative low output syndrome was identified in 44 patients (17%). Mortality was 3.9% and most of the patients (91%) were discharged from hospital in good clinical conditions. Hospital mortality was lower in planned vs unplanned surgery: 3.8% vs 14% respectively. Chronic obstructive pulmonary disease (OR 9.106, CI 2.275 - 36.450) was the unique independent predictor of mortality. Conclusions: Clinicians should be aware that cardiac surgery can be safely performed at all ages, that risk stratification is mandatory and that hemodynamic treatment to avoid complications is expected.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60082964</affiliation-url><afid>60082964</afid><affilname>Fondazione San Raffaele del Monte Tabor</affilname><name-variant>Fondazione San Raffaele del Monte Tabor</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032259</affiliation-url><afid>60032259</afid><affilname>Universita degli Studi di Cagliari</affilname><name-variant>University of Cagliari</name-variant><affiliation-city>Cagliari</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60082964</affiliation-url><afid>60082964</afid><affilname>Fondazione San Raffaele del Monte Tabor</affilname><name-variant>Fondazione San Raffaele del Monte Tabor</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009622</affiliation-url><afid>60009622</afid><affilname>Universita Vita-Salute San Raffaele</affilname><name-variant>Università Vita-Salute San Raffaele</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">15</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6506663226</author-url><authid>6506663226</authid><authname>Scandroglio M.</authname><surname>Scandroglio</surname><given-name>Mara M.</given-name><initials>M.M.</initials><afid>60082964</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6701333349</author-url><authid>6701333349</authid><authname>Finco G.</authname><surname>Finco</surname><given-name>Gabriele</given-name><initials>G.</initials><afid>60032259</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36647900100</author-url><authid>36647900100</authid><authname>Pieri M.</authname><surname>Pieri</surname><given-name>Marina</given-name><initials>M.</initials><afid>60082964</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56538715900</author-url><authid>56538715900</authid><authname>Ascari R.</authname><surname>Ascari</surname><given-name>Roberto</given-name><initials>R.</initials><afid>60082964</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56538108400</author-url><authid>56538108400</authid><authname>Calabrò G.</authname><surname>Calabrò</surname><given-name>Grazia G.</given-name><initials>G.G.</initials><afid>60082964</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55913902900</author-url><authid>55913902900</authid><authname>Taddeo D.</authname><surname>Taddeo</surname><given-name>Daiana</given-name><initials>D.</initials><afid>60082964</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55177321400</author-url><authid>55177321400</authid><authname>Isella F.</authname><surname>Isella</surname><given-name>Francesca</given-name><initials>F.</initials><afid>60082964</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55493428800</author-url><authid>55493428800</authid><authname>Franco A.</authname><surname>Franco</surname><given-name>Annalisa</given-name><initials>A.</initials><afid>60082964</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7801550155</author-url><authid>7801550155</authid><authname>Musu M.</authname><surname>Musu</surname><given-name>Mario</given-name><initials>M.</initials><afid>60032259</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7003479273</author-url><authid>7003479273</authid><authname>Landoni G.</authname><surname>Landoni</surname><given-name>Giovanni</given-name><initials>G.</initials><afid>60082964</afid><afid>60009622</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7003479273</author-url><authid>7003479273</authid><authname>Landoni G.</authname><surname>Landoni</surname><given-name>Giovanni</given-name><initials>G.</initials><afid>60082964</afid><afid>60009622</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7006850825</author-url><authid>7006850825</authid><authname>Alfieri O.</authname><surname>Alfieri</surname><given-name>Ottavio</given-name><initials>O.</initials><afid>60082964</afid><afid>60009622</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7006850825</author-url><authid>7006850825</authid><authname>Alfieri O.</authname><surname>Alfieri</surname><given-name>Ottavio</given-name><initials>O.</initials><afid>60082964</afid><afid>60009622</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:6604084943</author-url><authid>6604084943</authid><authname>Zangrillo A.</authname><surname>Zangrillo</surname><given-name>Alberto</given-name><initials>A.</initials><afid>60082964</afid><afid>60009622</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:6604084943</author-url><authid>6604084943</authid><authname>Zangrillo A.</authname><surname>Zangrillo</surname><given-name>Alberto</given-name><initials>A.</initials><afid>60082964</afid><afid>60009622</afid></author><authkeywords>Anesthesia | Cardiac surgery | Complications | Intensive care | Mortality | Octogenarian</authkeywords><intid>1785086465</intid><article-number>15</article-number><source-id>21855</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930201419"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930201419?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930201419&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930201419&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930201419</prism:url><dc:identifier>SCOPUS_ID:84930201419</dc:identifier><eid>2-s2.0-84930201419</eid><dc:title>Framework for classifying compliance and medical immediacy among low-acuity presentations at an urban trauma center</dc:title><dc:creator>Behr J.</dc:creator><prism:publicationName>International Journal of Emergency Medicine</prism:publicationName><prism:issn>18651372</prism:issn><prism:eIssn>18651380</prism:eIssn><prism:volume>8</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-26</prism:coverDate><prism:coverDisplayDate>26 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12245-015-0051-x</prism:doi><dc:description>© 2015, Behr et al.; licensee Springer. Background: This research offers two exploratory frameworks, one for medical regimen compliance and one for medical immediacy. The first classifies compliance awareness, compliance mitigation, and financial limitation for those patients that exhibit nonadherence with a medical regimen. The second classifies medical immediacy and characterizes avoidable utilization. Methods: Representative sampling of adult patients presenting at an emergency department (62,000/ppy) triaged as low acuity; emergency department physician assessment of noncompliance with medical regimen for those patients with a complaint related to a chronic condition; and emergency department physician assessment of medical immediacy and avoidable utilization. Results: Physicians report 48.3% (95% confidence interval (CI) 43.5% to 53.1%) of patients with at least a single chronic condition are presenting with symptoms or complaint related to a chronic condition, and 39.6% (CI 31.7% to 47.4%) of these exhibit noncompliance with the medical regimen associated with that chronic condition. 16.4% (CI 6.6% to 26.1%) of the patients exhibit pseudo compliance, a belief that the medical regimen is in compliance when in fact it is not. If the patient had been in compliance, 85.9% (CI 77.0% to 94.8%) of the presenting conditions may have been mitigated. Noncompliance cases (34.5% (CI 22.0% to 47.1%)) are partly attributable to financial constraints. Further, 19.1% (CI 15.7% to 22.5%) are assessed as requiring no medical intervention and 3.4% (CI 1.8% to 4.9%) require immediate stabilization. Conclusions: A large portion of low-acuity presentations are related to a chronic condition and noncompliance with the associated medical regimen contributes to the need to seek medical services. Interventions addressing literacy and financial constraints may increase compliance and decrease utilization.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007652</affiliation-url><afid>60007652</afid><affilname>Old Dominion University</affilname><name-variant>Old Dominion University</name-variant><affiliation-city>Norfolk</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015057</affiliation-url><afid>60015057</afid><affilname>Eastern Virginia Medical School</affilname><name-variant>Eastern Virginia Medical School</name-variant><affiliation-city>Norfolk</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002162</affiliation-url><afid>60002162</afid><affilname>New Mexico State University Las Cruces</affilname><name-variant>New Mexico State University</name-variant><affiliation-city>Las Cruces</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8354664200</author-url><authid>8354664200</authid><authname>Behr J.</authname><surname>Behr</surname><given-name>Joshua G.</given-name><initials>J.G.</initials><afid>60007652</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:16136670700</author-url><authid>16136670700</authid><authname>Diaz R.</authname><surname>Diaz</surname><given-name>Rafael</given-name><initials>R.</initials><afid>60007652</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006707589</author-url><authid>7006707589</authid><authname>Knapp B.</authname><surname>Knapp</surname><given-name>Barry</given-name><initials>B.</initials><afid>60015057</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6505819223</author-url><authid>6505819223</authid><authname>Kratzke C.</authname><surname>Kratzke</surname><given-name>Cynthia</given-name><initials>C.</initials><afid>60002162</afid></author><authkeywords>Access | Avoidable | Chronic condition | Compliance | Emergency department | Emergent | Financial | Immediacy | Low acuity | Triage | Utilization</authkeywords><intid>1536087689</intid><article-number>7</article-number><source-id>14500154757</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929379547"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929379547?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929379547&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929379547&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929379547</prism:url><dc:identifier>SCOPUS_ID:84929379547</dc:identifier><eid>2-s2.0-84929379547</eid><dc:title>Factors associated with disability and impact of tension-type headache: findings of the Korean headache survey</dc:title><dc:creator>Kim B.</dc:creator><prism:publicationName>Journal of Headache and Pain</prism:publicationName><prism:issn>11292369</prism:issn><prism:eIssn>11292377</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-18</prism:coverDate><prism:coverDisplayDate>18 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s10194-015-0524-6</prism:doi><dc:description>© 2015, Kim et al.; licensee Springer. Background: Although mostly mild in symptom severity, tension-type headache (TTH) can cause disability. However, factors associated with disability of TTH have been rarely reported. This study sought to assess the factors associated with TTH-related disability and impact. Methods: We analyzed data form the Korean Headache Survey, a nation-wide survey regarding headache in all Korean adults aged 19–69 years. TTH-related disability was measured by surveying actual disability and Headache Impact Test-6 (HIT-6). Actual disability was defined as having one or more days of activity restriction or missed activity due to headache in the last 3 months. The HIT-6 score ≥ 50 was regarded as significant headache impact associated with TTH. We assessed factors associated with TTH-related disability and impact using logistic regression analyses adjusting for sociodemographic variables and headache characteristics. Results: Among 1507 individuals, the 1-year prevalence rate of TTH was 30.7% (n = 463), of which 4.8% reported actual disability and 21.3% had headache impact, respectively. In univariate analyses, sociodemographic variables were not associated with actual disability and headache impact, respectively. There were relationships between several headache characteristics and actual disability/headache impact. After adjustment of potential confounders, moderate headache intensity was correlated with actual disability (odds ratio [OR]: 4.41, 95% confidence interval [CI]: 1.46–13.27), while an inverse association was observed between no aggravation by routine activity and actual disability (OR: 0.32, 95% CI: 0.12–0.88). Multivariate analyses showed that ORs for headache impact were increased in those with higher headache frequency (OR: 2.54, 95% CI: 1.47–4.39 for 1–14 days/month; OR: 23.83, 95% CI: 5.46–104.03 for ≥ 15 days/month), longer headache time duration (OR: 1.84, 95% CI: 1.04–3.25 for ≥ 1 and &lt; 4 hours; OR: 2.44 95% CI: 1.17–5.11 for ≥ 4 hours), and phonophobia (OR: 1.73, 95% CI: 1.02–2.95), whereas decreased in those with no aggravation by routine activity (OR: 0.32, 95% CI: 0.12–0.88). Conclusions: Several headache characteristics were associated with actual disability and headache impact among TTH individuals. Our findings suggest that there needs to be consideration careful of troublesome headache characteristics for TTH individuals suffering from disability and impact.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60080544</affiliation-url><afid>60080544</afid><affilname>Daejin Medical Center</affilname><name-variant>Bundang Jesaeng General Hospital</name-variant><affiliation-city>Seongnam</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016329</affiliation-url><afid>60016329</afid><affilname>SungKyunKwan University, School of Medicine</affilname><name-variant>Sungkyunkwan University School of Medicine</name-variant><affiliation-city>Suwon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006034</affiliation-url><afid>60006034</afid><affilname>Hallym University, College of Medicine</affilname><name-variant>Hallym University College of Medicine</name-variant><affiliation-city>Chuncheon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006034</affiliation-url><afid>60006034</afid><affilname>Hallym University, College of Medicine</affilname><name-variant>Hallym University College of Medicine</name-variant><affiliation-city>Chuncheon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022417</affiliation-url><afid>60022417</afid><affilname>Chungnam National University</affilname><name-variant>Chungnam National University</name-variant><affiliation-city>Daejeon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56643414800</author-url><authid>56643414800</authid><authname>Kim B.</authname><surname>Kim</surname><given-name>Byung Su</given-name><initials>B.S.</initials><afid>60080544</afid><afid>60016329</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56643414800</author-url><authid>56643414800</authid><authname>Kim B.</authname><surname>Kim</surname><given-name>Byung Su</given-name><initials>B.S.</initials><afid>60080544</afid><afid>60016329</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7403613322</author-url><authid>7403613322</authid><authname>Chung C.</authname><surname>Chung</surname><given-name>Chin Sang</given-name><initials>C.S.</initials><afid>60016329</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:24491536700</author-url><authid>24491536700</authid><authname>Chu M.</authname><surname>Chu</surname><given-name>Min Kyung</given-name><initials>M.K.</initials><afid>60006034</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:45561117100</author-url><authid>45561117100</authid><authname>Chung Y.</authname><surname>Chung</surname><given-name>Yun Kyung</given-name><initials>Y.K.</initials><afid>60006034</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56643348300</author-url><authid>56643348300</authid><authname>Lee C.</authname><surname>Lee</surname><given-name>Chung Bin</given-name><initials>C.B.</initials><afid>60016329</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:34769781900</author-url><authid>34769781900</authid><authname>Kim J.</authname><surname>Kim</surname><given-name>Jae Moon</given-name><initials>J.M.</initials><afid>60022417</afid></author><authkeywords>Disability | Epidemiology | Headache | Tension-type headache</authkeywords><intid>535945411</intid><source-id>16714</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929358948"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929358948?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929358948&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929358948&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929358948</prism:url><dc:identifier>SCOPUS_ID:84929358948</dc:identifier><eid>2-s2.0-84929358948</eid><dc:title>Diagnostic values of chest pain history, ECG, troponin and clinical gestalt in patients with chest pain and potential acute coronary syndrome assessed in the emergency department</dc:title><dc:creator>Mokhtari A.</dc:creator><prism:publicationName>SpringerPlus</prism:publicationName><prism:eIssn>21931801</prism:eIssn><prism:volume>4</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-18</prism:coverDate><prism:coverDisplayDate>18 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s40064-015-0992-9</prism:doi><dc:description>© 2015, Mokhtari et al.; licensee Springer. In the assessment of chest pain patients with suspected acute coronary syndrome (ACS) in the emergency department (ED), physicians rely on global diagnostic impressions (‘gestalt’). The aim of this study was to determine the diagnostic value of the ED physician’s overall assessment of ACS likelihood, and the values of the main diagnostic modalities underlying this assessment, namely the chest pain history, the ECG and the initial troponin result. 1,151 consecutive ED chest pain patients were prospectively included. The ED physician’s interpretation of the chest pain history, the ECG, and the global likelihood of ACS were recorded on special forms. The discharge diagnoses were retrieved from the medical records. A chart review was carried out to determine whether patients with a non-ACS diagnosis at the index visit had ACS or suffered cardiac death within 30 days. The gestalt was better than its components both at ruling in (“Obvious ACS”, LR 29) and at ruling out (“No Suspicion of ACS”, LR 0.01) ACS. In the “Strong suspicion of ACS” group, 60% of the patients did not have ACS. A positive TnT (LR 24.9) and an ischemic ECG (LR 8.3) were strong predictors of ACS and seemed superior to pain history for ruling in ACS. In patients with a normal TnT and non-ischemic ECG, chest pain history typical of AMI was not a significant predictor of AMI (LR 1.9) while pain history typical of unstable angina (UA) was a moderate predictor of UA (LR 4.7). Clinical gestalt was better than its components both at ruling in and at ruling out ACS, but overestimated the likelihood of ACS when cases were assessed as strong suspicion of ACS. Among the components of the gestalt, TnT and ECG were superior to the chest pain history for ruling in ACS, while pain history was superior for ruling out ACS.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014077</affiliation-url><afid>60014077</afid><affilname>Universitssjukhuset i Lund</affilname><name-variant>University Hospital</name-variant><affiliation-city>Lund</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014077</affiliation-url><afid>60014077</afid><affilname>Universitssjukhuset i Lund</affilname><name-variant>University Hospital</name-variant><affiliation-city>Lund</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029170</affiliation-url><afid>60029170</afid><affilname>Lunds Universitet</affilname><name-variant>University of Lund</name-variant><affiliation-city>Lund</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14008217000</author-url><authid>14008217000</authid><authname>Mokhtari A.</authname><surname>Mokhtari</surname><given-name>Arash</given-name><initials>A.</initials><afid>60014077</afid><afid>60029170</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14008217000</author-url><authid>14008217000</authid><authname>Mokhtari A.</authname><surname>Mokhtari</surname><given-name>Arash</given-name><initials>A.</initials><afid>60014077</afid><afid>60029170</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6507667628</author-url><authid>6507667628</authid><authname>Dryver E.</authname><surname>Dryver</surname><given-name>Eric</given-name><initials>E.</initials><afid>60014077</afid><afid>60029170</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6507667628</author-url><authid>6507667628</authid><authname>Dryver E.</authname><surname>Dryver</surname><given-name>Eric</given-name><initials>E.</initials><afid>60014077</afid><afid>60029170</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55314620400</author-url><authid>55314620400</authid><authname>Söderholm M.</authname><surname>Söderholm</surname><given-name>Martin</given-name><initials>M.</initials><afid>60014077</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004141339</author-url><authid>7004141339</authid><authname>Ekelund U.</authname><surname>Ekelund</surname><given-name>Ulf</given-name><initials>U.</initials><afid>60014077</afid><afid>60029170</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004141339</author-url><authid>7004141339</authid><authname>Ekelund U.</authname><surname>Ekelund</surname><given-name>Ulf</given-name><initials>U.</initials><afid>60014077</afid><afid>60029170</afid></author><authkeywords>Acute coronary syndrome | Chest pain | Diagnosis | ECG | Gestalt | Probability</authkeywords><intid>1035941301</intid><source-id>21100228569</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929192787"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929192787?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929192787&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929192787&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929192787</prism:url><dc:identifier>SCOPUS_ID:84929192787</dc:identifier><eid>2-s2.0-84929192787</eid><dc:title>Hemodynamic characteristics of high-altitude headache following acute high altitude exposure at 3700 m in young Chinese men</dc:title><dc:creator>Bian S.</dc:creator><prism:publicationName>Journal of Headache and Pain</prism:publicationName><prism:issn>11292369</prism:issn><prism:eIssn>11292377</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-16</prism:coverDate><prism:coverDisplayDate>16 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s10194-015-0527-3</prism:doi><dc:description>© 2015, Bian et al.; licensee Springer. Background: This study aimed to identify the systemic and cerebral hemodynamic characteristics and their roles in high-altitude headache (HAH) among young Chinese men following acute exposure. Methods: The subjects (n = 385) were recruited in June and July of 2012. They completed case report form questionnaires, as well as heart rate (HR), blood pressure, echocardiogram and transcranial Doppler examinations at 3700 m following a two-hour plane flight. A subgroup of 129 participants was examined at two altitudes (500 and 3700 m). Results: HAH was characterized by increased HR and cardiac output (CO) and lower saturation pulse oxygen (SpO&lt;inf&gt;2&lt;/inf&gt;) (all p &lt; 0.05). The change in tricuspid regurgitation was also different between the HAH positive (HAH+) and HAH negative (HAH-) subjects. Furthermore, the HAH+ subjects exhibited faster mean (V&lt;inf&gt;m&lt;/inf&gt;), systolic (V&lt;inf&gt;s&lt;/inf&gt;) and diastolic (V&lt;inf&gt;d&lt;/inf&gt;) velocities in the basilar artery (BA; all p &lt; 0.05) and a faster V&lt;inf&gt;d&lt;/inf&gt; (25.96 ± 4.97 cm/s vs. 24.76 ± 4.76 cm/s, p = 0.045) in the left vertebral artery (VA). The bilateral VA asymmetry was also significantly different between the two groups. The pulsatility index (PI) and resistance index (RI) of left VA were lower in the HAH subjects (p &lt; 0.05) and were negatively correlated with HAH (p &lt; 0.05). Baseline CO and V&lt;inf&gt;m&lt;/inf&gt; in left VA (or right MCA in different regressions) were independent predictors for HAH, whereas CO/HR and ΔV&lt;inf&gt;d&lt;/inf&gt; (V&lt;inf&gt;d&lt;/inf&gt; difference between bilateral VAs) were independent risk factors for HAH at 3700 m. Conclusions: HAH was characterized, in part, by increased systemic hemodynamics and posterior cerebral circulation, which was reflected by the BA and left VA velocities, and lower arterial resistance and compliance. Furthermore, baseline CO and V&lt;inf&gt;m&lt;/inf&gt; in left VA or right MCA at sea level were independent predictors for HAH, whilst bilateral VA asymmetry may contribute to the development of HAH at high altitude.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023797</affiliation-url><afid>60023797</afid><affilname>Third Military Medical University</affilname><name-variant>Third Military Medical University</name-variant><affiliation-city>Chongqing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023797</affiliation-url><afid>60023797</afid><affilname>Third Military Medical University</affilname><name-variant>Third Military Medical University</name-variant><affiliation-city>Chongqing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023797</affiliation-url><afid>60023797</afid><affilname>Third Military Medical University</affilname><name-variant>Third Military Medical University</name-variant><affiliation-city>Chongqing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023797</affiliation-url><afid>60023797</afid><affilname>Third Military Medical University</affilname><name-variant>Third Military Medical University</name-variant><affiliation-city>Chongqing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">17</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55624050700</author-url><authid>55624050700</authid><authname>Bian S.</authname><surname>Bian</surname><given-name>Shi Zhu</given-name><initials>S.Z.</initials><afid>60023797</afid><afid>60023797</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55624050700</author-url><authid>55624050700</authid><authname>Bian S.</authname><surname>Bian</surname><given-name>Shi Zhu</given-name><initials>S.Z.</initials><afid>60023797</afid><afid>60023797</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56430254500</author-url><authid>56430254500</authid><authname>Jin J.</authname><surname>Jin</surname><given-name>Jun</given-name><initials>J.</initials><afid>60023797</afid><afid>60023797</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56430254500</author-url><authid>56430254500</authid><authname>Jin J.</authname><surname>Jin</surname><given-name>Jun</given-name><initials>J.</initials><afid>60023797</afid><afid>60023797</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55628179400</author-url><authid>55628179400</authid><authname>Li Q.</authname><surname>Li</surname><given-name>Qian Ning</given-name><initials>Q.N.</initials><afid>60023797</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55574203539</author-url><authid>55574203539</authid><authname>Yu J.</authname><surname>Yu</surname><given-name>Jie</given-name><initials>J.</initials><afid>60023797</afid><afid>60023797</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55574203539</author-url><authid>55574203539</authid><authname>Yu J.</authname><surname>Yu</surname><given-name>Jie</given-name><initials>J.</initials><afid>60023797</afid><afid>60023797</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56640257500</author-url><authid>56640257500</authid><authname>Tang C.</authname><surname>Tang</surname><given-name>Cai Fa</given-name><initials>C.F.</initials><afid>60023797</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56501200400</author-url><authid>56501200400</authid><authname>Rao R.</authname><surname>Rao</surname><given-name>Rong Sheng</given-name><initials>R.S.</initials><afid>60023797</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56175823400</author-url><authid>56175823400</authid><authname>Yu S.</authname><surname>Yu</surname><given-name>Shi Yong</given-name><initials>S.Y.</initials><afid>60023797</afid><afid>60023797</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56175823400</author-url><authid>56175823400</authid><authname>Yu S.</authname><surname>Yu</surname><given-name>Shi Yong</given-name><initials>S.Y.</initials><afid>60023797</afid><afid>60023797</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55547111837</author-url><authid>55547111837</authid><authname>Zhao X.</authname><surname>Zhao</surname><given-name>Xiao Hui</given-name><initials>X.H.</initials><afid>60023797</afid><afid>60023797</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55547111837</author-url><authid>55547111837</authid><authname>Zhao X.</authname><surname>Zhao</surname><given-name>Xiao Hui</given-name><initials>X.H.</initials><afid>60023797</afid><afid>60023797</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55701302100</author-url><authid>55701302100</authid><authname>Qin J.</authname><surname>Qin</surname><given-name>Jun</given-name><initials>J.</initials><afid>60023797</afid><afid>60023797</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55701302100</author-url><authid>55701302100</authid><authname>Qin J.</authname><surname>Qin</surname><given-name>Jun</given-name><initials>J.</initials><afid>60023797</afid><afid>60023797</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:34769889600</author-url><authid>34769889600</authid><authname>Huang L.</authname><surname>Huang</surname><given-name>Lan</given-name><initials>L.</initials><afid>60023797</afid><afid>60023797</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:34769889600</author-url><authid>34769889600</authid><authname>Huang L.</authname><surname>Huang</surname><given-name>Lan</given-name><initials>L.</initials><afid>60023797</afid><afid>60023797</afid></author><authkeywords>Acute exposure | Cerebral circulation | Hemodynamic characteristics | High-altitude headache | Systemic circulation</authkeywords><intid>1785918031</intid><source-id>16714</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927650074"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927650074?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927650074&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927650074&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927650074</prism:url><dc:identifier>SCOPUS_ID:84927650074</dc:identifier><eid>2-s2.0-84927650074</eid><dc:title>The impact of HIV/AIDS on compliance with antidepressant treatment in major depressive disorder: A prospective study in a South African private healthcare cohort</dc:title><dc:creator>Slabbert F.</dc:creator><prism:publicationName>AIDS Research and Therapy</prism:publicationName><prism:eIssn>17426405</prism:eIssn><prism:volume>12</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-16</prism:coverDate><prism:coverDisplayDate>December 16, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12981-015-0050-2</prism:doi><dc:description>© Slabbert et al.; licensee BioMed Central. Background: MDD and HIV/AIDS have a high prevalence worldwide with severe consequences for patients. In both conditions, compliance with treatment is key to successfully treat these disorders. In the current study, we examine the effect of MDD on the compliance with ADs in patients diagnosed with co-morbid HIV/AIDS and how different classes of ADs influence compliance in this group of patients. Methods: A prospective, cohort study design was used to analyse nationally representative medicine claims data submitted to a privately-owned South African Pharmaceutical Benefit Management (PBM) company. Two groups were distinguished in the database, namely patients with only MDD and patients with both MDD and HIV/AIDS, over a six-year study period. The study population was determined by the following inclusion criteria: patients older than 18 years, MDD should be diagnosed by a psychiatrist supported by an appropriate ICD-10 code, and all patients have to be on combination antiretroviral treatment (cARV) treatment. The medicine possession ratio (MPR) was used as proxy to determine patient compliance with AD medication. Results: 127 patients (i.e. 0.24%) met the criteria of co-morbid MDD and HIV/AIDS. Females have a significantly higher prevalence of MDD and HIV/AIDS when compared to males. Patients diagnosed with both HIV/AIDS and MDD (74.43. ± 32.03, 95% Cl: 71.51-77.34) have a statistical significantly (p &lt; 0.0001) lower compliance with AD treatment vs. MDD patients (80.94% ± 29.44, 95% Cl: 80.56-81.33), but the practical significance thereof, is low (Cohen's d = 0.2255). In this group only 26.83% of TCA had acceptable compliance compared to the 58.57% of SNRIs. Noteworthy observations were that 75% (p &lt; 0.0217; Cramer's V = 0.0388) of venlafaxine and 28.6% (p &lt; 0.0197; Cramer's V = -0.0705) of the paroxetine items were compliant in patients diagnosed with both HIV/AIDS and MDD. Conclusions: AD compliance is statistical significantly lower in depressed HIV/AIDS vs. depressed non-HIV/AIDS patients. However, these differences is of low practical or clinical significance, meaning that depressed HIV/AIDS patients would have missed approximately two AD doses (6.5% of a 30-day treatment period) more than the non-HIV/AIDS depressed patient over the same treatment period.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029714</affiliation-url><afid>60029714</afid><affilname>North-West University</affilname><name-variant>North-West University</name-variant><affiliation-city>Potchefstroom</affiliation-city><affiliation-country>South Africa</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029714</affiliation-url><afid>60029714</afid><affilname>North-West University</affilname><name-variant>North-West University</name-variant><affiliation-city>Potchefstroom</affiliation-city><affiliation-country>South Africa</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029714</affiliation-url><afid>60029714</afid><affilname>North-West University</affilname><name-variant>North-West University</name-variant><affiliation-city>Potchefstroom</affiliation-city><affiliation-country>South Africa</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56429509700</author-url><authid>56429509700</authid><authname>Slabbert F.</authname><surname>Slabbert</surname><given-name>Francois N.</given-name><initials>F.N.</initials><afid>60029714</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7103106766</author-url><authid>7103106766</authid><authname>Harvey B.</authname><surname>Harvey</surname><given-name>Brian H.</given-name><initials>B.H.</initials><afid>60029714</afid><afid>60029714</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7103106766</author-url><authid>7103106766</authid><authname>Harvey B.</authname><surname>Harvey</surname><given-name>Brian H.</given-name><initials>B.H.</initials><afid>60029714</afid><afid>60029714</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35569705100</author-url><authid>35569705100</authid><authname>Brink C.</authname><surname>Brink</surname><given-name>Christiaan B.</given-name><initials>C.B.</initials><afid>60029714</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:14422510800</author-url><authid>14422510800</authid><authname>Lubbe M.</authname><surname>Lubbe</surname><given-name>Martie S.</given-name><initials>M.S.</initials><afid>60029714</afid></author><authkeywords>Antidepressants | Compliance | HIV/AIDS | Major depressive disorder | Venlafaxine</authkeywords><intid>2035641625</intid><article-number>9</article-number><source-id>4700153004</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84918802345"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84918802345?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84918802345&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84918802345&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014299914007031"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84918802345</prism:url><dc:identifier>SCOPUS_ID:84918802345</dc:identifier><eid>2-s2.0-84918802345</eid><dc:title>Quercetin, luteolin and epigallocatechin gallate alleviate TXNIP and NLRP3-mediated inflammation and apoptosis with regulation of AMPK in endothelial cells</dc:title><dc:creator>Wu J.</dc:creator><prism:publicationName>European Journal of Pharmacology</prism:publicationName><prism:issn>00142999</prism:issn><prism:eIssn>18790712</prism:eIssn><prism:volume>745</prism:volume><prism:pageRange>59-68</prism:pageRange><prism:coverDate>2015-12-15</prism:coverDate><prism:coverDisplayDate>15 December 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejphar.2014.09.046</prism:doi><pii>S0014299914007031</pii><dc:description>© 2014 Elsevier B.V. All rights reserved. Endoplasmic reticulum stress (ER stress)-associated thioredoxin-interacting protein (TXNIP) and NOD-like receptor pyrin domain containing-3 (NLRP3) signaling is a key event in the endothelial dysfunction. It induces the IL-1β production and thus accounts for inflammation and cell death. Quercetin, luteolin and epigallocatechin gallate (EGCG) are flavonoids with beneficial effects on cardiovascular functions, and we wondered whether these flavonoids protect endothelial functions against ER stress-associated impairments. Palmitate stimulation evoked oxidative stress and then induced TXNIP and NLRP3 inflammasome activation in the endothelial cells. Quercetin, luteolin and EGCG reduced reactive oxygen species production and inhibited TXNIP and NLRP3 inflammasome activation, lead to the downregulation of IL-1β expression. Meanwhile, these agents protected cells from apoptosis by restoration of mitochondrial membrane potential (Δψm) and inhibition of caspase-3 activity. PA stimulation induced inflammation accompanied by the loss of NO production in endothelial cells, but these alterations were reversed by treatment with quercetin, luteolin and EGCG. Co-treatment with AMPK inhibitor compound C diminished the beneficial effects of these flavonoids, suggesting the involvement of AMPK. In conclusion, quercetin, luteolin and EGCG inhibited ER stress-associated TXNIP and NLRP3 inflammasome activation, and thereby protected endothelial cells from inflammatory and apoptotic damage.</dc:description><citedby-count>2</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005500</affiliation-url><afid>60005500</afid><affilname>China Pharmaceutical University</affilname><name-variant>China Pharmaceutical University</name-variant><affiliation-city>Nanjing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033100</affiliation-url><afid>60033100</afid><affilname>Nanjing University</affilname><name-variant>Nanjing University</name-variant><affiliation-city>Nanjing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005500</affiliation-url><afid>60005500</afid><affilname>China Pharmaceutical University</affilname><name-variant>China Pharmaceutical University</name-variant><affiliation-city>Nanjing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56449637300</author-url><authid>56449637300</authid><authname>Wu J.</authname><surname>Wu</surname><given-name>Jianjun</given-name><initials>J.</initials><afid>60005500</afid><afid>60033100</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56449637300</author-url><authid>56449637300</authid><authname>Wu J.</authname><surname>Wu</surname><given-name>Jianjun</given-name><initials>J.</initials><afid>60005500</afid><afid>60033100</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56449645600</author-url><authid>56449645600</authid><authname>Xu X.</authname><surname>Xu</surname><given-name>Xiaoshan</given-name><initials>X.</initials><afid>60005500</afid><afid>60033100</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56449645600</author-url><authid>56449645600</authid><authname>Xu X.</authname><surname>Xu</surname><given-name>Xiaoshan</given-name><initials>X.</initials><afid>60005500</afid><afid>60033100</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56451226400</author-url><authid>56451226400</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yi</given-name><initials>Y.</initials><afid>60005500</afid><afid>60033100</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56451226400</author-url><authid>56451226400</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yi</given-name><initials>Y.</initials><afid>60005500</afid><afid>60033100</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56450306400</author-url><authid>56450306400</authid><authname>Kou J.</authname><surname>Kou</surname><given-name>Junping</given-name><initials>J.</initials><afid>60005500</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56449850900</author-url><authid>56449850900</authid><authname>Huang F.</authname><surname>Huang</surname><given-name>Fang</given-name><initials>F.</initials><afid>60005500</afid><afid>60033100</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56449850900</author-url><authid>56449850900</authid><authname>Huang F.</authname><surname>Huang</surname><given-name>Fang</given-name><initials>F.</initials><afid>60005500</afid><afid>60033100</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56183438400</author-url><authid>56183438400</authid><authname>Liu B.</authname><surname>Liu</surname><given-name>Baolin</given-name><initials>B.</initials><afid>60005500</afid><afid>60033100</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56183438400</author-url><authid>56183438400</authid><authname>Liu B.</authname><surname>Liu</surname><given-name>Baolin</given-name><initials>B.</initials><afid>60005500</afid><afid>60033100</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56281672800</author-url><authid>56281672800</authid><authname>Liu K.</authname><surname>Liu</surname><given-name>Kang</given-name><initials>K.</initials><afid>60005500</afid><afid>60033100</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56281672800</author-url><authid>56281672800</authid><authname>Liu K.</authname><surname>Liu</surname><given-name>Kang</given-name><initials>K.</initials><afid>60005500</afid><afid>60033100</afid></author><authkeywords>Endoplasmic reticulum stress | Endothelial cells | Flavonoids | NLRP3 | TXNIP</authkeywords><intid>1034201131</intid><source-id>21333</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84922808656"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84922808656?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84922808656&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84922808656&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84922808656</prism:url><dc:identifier>SCOPUS_ID:84922808656</dc:identifier><eid>2-s2.0-84922808656</eid><dc:title>Circadian rhythmicity of antioxidant markers in rats exposed to 1.8 ghz radiofrequency fields</dc:title><dc:creator>Cao H.</dc:creator><prism:publicationName>International Journal of Environmental Research and Public Health</prism:publicationName><prism:issn>16617827</prism:issn><prism:eIssn>16604601</prism:eIssn><prism:volume>12</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>2071-2087</prism:pageRange><prism:coverDate>2015-12-12</prism:coverDate><prism:coverDisplayDate>12 December 2015</prism:coverDisplayDate><prism:doi>10.3390/ijerph120202071</prism:doi><dc:description>© 2015 by the authors; licensee MDPI, Basel, Switzerland. Background: The potential health risks of exposure to Radiofrequency Fields (RF) emitted by mobile phones are currently of considerable public interest, such as the adverse effects on the circadian rhythmicities of biological systems. To determine whether circadian rhythms of the plasma antioxidants (Mel, GSH-Px and SOD) are affected by RF, we performed a study on male Sprague Dawley rats exposed to the 1.8 GHz RF. Methods: All animals were divided into seven groups. The animals in six groups were exposed to 1.8 GHz RF (201.7 μW/cm2 power density, 0.05653 W/kg specific absorption rate) at a specific period of the day (3, 7, 11, 15, 19 and 23 h GMT, respectively), for 2 h/day for 32 consecutive days. The rats in the seventh group were used as sham-exposed controls. At the end of last RF exposure, blood samples were collected from each rat every 4 h (total period of 24 h) and also at similar times from sham-exposed animals. The concentrations of three antioxidants (Mel, GSH-Px and SOD) were determined. The data in RF-exposed rats were compared with those in sham-exposed animals. Results: circadian rhythms in the synthesis of Mel and antioxidant enzymes, GSH-Px and SOD, were shifted in RF-exposed rats compared to sham-exposed animals: the Mel, GSH-Px and SOD levels were significantly decreased when RF exposure was given at 23 and 3 h GMT. Conclusion: The overall results indicate that there may be adverse effects of RF exposure on antioxidant function, in terms of both the daily antioxidative levels, as well as the circadian rhythmicity.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010432</affiliation-url><afid>60010432</afid><affilname>Soochow University</affilname><name-variant>Suzhou University</name-variant><affiliation-city>Suzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073673</affiliation-url><afid>60073673</afid><affilname>University of Science and Technology of Suzhou</affilname><name-variant>Suzhou University of Science and Technology</name-variant><affiliation-city>Suzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010432</affiliation-url><afid>60010432</afid><affilname>Soochow University</affilname><name-variant>Suzhou University</name-variant><affiliation-city>Suzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24476009800</author-url><authid>24476009800</authid><authname>Cao H.</authname><surname>Cao</surname><given-name>Honglong</given-name><initials>H.</initials><afid>60010432</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56516154700</author-url><authid>56516154700</authid><authname>Qin F.</authname><surname>Qin</surname><given-name>Fenju</given-name><initials>F.</initials><afid>60073673</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55109690900</author-url><authid>55109690900</authid><authname>Liu X.</authname><surname>Liu</surname><given-name>Xueguan</given-name><initials>X.</initials><afid>60010432</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55971564400</author-url><authid>55971564400</authid><authname>Wang J.</authname><surname>Wang</surname><given-name>Jiajun</given-name><initials>J.</initials><afid>60010432</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55276310100</author-url><authid>55276310100</authid><authname>Cao Y.</authname><surname>Cao</surname><given-name>Yi</given-name><initials>Y.</initials><afid>60010432</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7202724441</author-url><authid>7202724441</authid><authname>Tong J.</authname><surname>Tong</surname><given-name>Jian</given-name><initials>J.</initials><afid>60010432</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7404778148</author-url><authid>7404778148</authid><authname>Zhao H.</authname><surname>Zhao</surname><given-name>Heming</given-name><initials>H.</initials><afid>60010432</afid></author><authkeywords>Antioxidant markers | Circadian rhythmicity | GSH-Px | Mel | Radio frequency | SOD</authkeywords><intid>1784870779</intid><source-id>144989</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929029304"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929029304?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929029304&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929029304&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929029304</prism:url><dc:identifier>SCOPUS_ID:84929029304</dc:identifier><eid>2-s2.0-84929029304</eid><dc:title>Presence of gingivitis and periodontitis significantly increases hospital charges in patients undergoing heart valve surgery</dc:title><dc:creator>Allareddy V.</dc:creator><prism:publicationName>Journal of the Massachusetts Dental Society</prism:publicationName><prism:issn>00254800</prism:issn><prism:volume>63</prism:volume><prism:issueIdentifier>4</prism:issueIdentifier><prism:pageRange>10-16</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><dc:description>OBJECTIVE: To examine the prevalence and impact of gingivitis and periodontitis in patients having heart valve surgical procedures. METHODS: Nationwide Inpatient Sample for the years 2004-2010 was used. All patients who had heart valve surgical procedures were selected. Prevalence of gingivitis/periodontitis was examined in these patients. Impact of gingivitis/periodontitis on hospital charges, length of stay, and infectious complications was examined. RESULTS: 596,190 patients had heart valve surgical procedures. Gingivitis/periodontitis was present in 0.2 percent. Outcomes included: median hospital charges ($175,418 with gingivitis/ periodontitis versus $149,353 without gingivitis/periodontitis) and median length of stay (14 days with gingivitis/periodontitis versus 8 days without gingivitis/periodontitis). After adjusting for the effects of patient- and hospital-level confounding factors, hospital charges and length of stay were significantly higher (p &lt; 0.001) in those with gingivitis/periodontitis compared to their counterparts. Further, patients with gingivitis/periodontitis had significantly higher odds for having bacterial infections (OR = 3.41, 95% CI = 2.33-4.98, p &lt; 0.0001) when compared to those without gingivitis/periodontitis. CONCLUSION: Presence of gingivitis and periodontitis is associated with higher risk for bacterial infections and significant hospital resource utilization.</dc:description><citedby-count>0</citedby-count><pubmed-id>25872281</pubmed-id><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8417322600</author-url><authid>8417322600</authid><authname>Allareddy V.</authname><surname>Allareddy</surname><given-name>Veerasathpurush</given-name><initials>V.</initials></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36143822800</author-url><authid>36143822800</authid><authname>Elangovan S.</authname><surname>Elangovan</surname><given-name>Satheesh</given-name><initials>S.</initials></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:54391462000</author-url><authid>54391462000</authid><authname>Rampa S.</authname><surname>Rampa</surname><given-name>Sankeerth</given-name><initials>S.</initials></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56513080500</author-url><authid>56513080500</authid><authname>Shin K.</authname><surname>Shin</surname><given-name>Kyungsup</given-name><initials>K.</initials></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36544226900</author-url><authid>36544226900</authid><authname>Nalliah R.</authname><surname>Nalliah</surname><given-name>Romesh P.</given-name><initials>R.P.</initials></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:22033809000</author-url><authid>22033809000</authid><authname>Allareddy V.</authname><surname>Allareddy</surname><given-name>Veerajalandhar</given-name><initials>V.</initials></author><intid>2035882981</intid><source-id>26225</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928599076"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928599076?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928599076&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928599076&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928599076</prism:url><dc:identifier>SCOPUS_ID:84928599076</dc:identifier><eid>2-s2.0-84928599076</eid><dc:title>Human umbilical cord blood-derived mononuclear cells improve murine ventricular function upon intramyocardial delivery in right ventricular chronic pressure overload</dc:title><dc:creator>Oommen S.</dc:creator><prism:publicationName>Stem Cell Research and Therapy</prism:publicationName><prism:eIssn>17576512</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s13287-015-0044-y</prism:doi><dc:description>© 2015 Oommen et al. Abstract Introduction: Stem cell therapy has emerged as potential therapeutic strategy for damaged heart muscles. Umbilical cord blood (UCB) cells are the most prevalent stem cell source available, yet have not been fully tested in cardiac regeneration. Herein, studies were performed to evaluate the cardiovascular safety and beneficial effect of mononuclear cells (MNCs) isolated from human umbilical cord blood upon intramyocardial delivery in a murine model of right ventricle (RV) heart failure due to pressure overload. Methods: UCB-derived MNCs were delivered into the myocardium of a diseased RV cardiac model. Pulmonary artery banding (PAB) was used to produce pressure overload in athymic nude mice that were then injected intramyocardially with UCB-MNCs (0.4 × 10^6 cells/heart). Cardiac functions were then monitored by telemetry, echocardiography, magnetic resonance imaging (MRI) and pathologic analysis of heart samples to determine the ability for cell-based repair. Results: The cardio-toxicity studies provided evidence that UCB cell transplantation has a safe therapeutic window between 0.4 to 0.8 million cells/heart without altering QT or ST-segments or the morphology of electrocardiograph waves. The PAB cohort demonstrated significant changes in RV chamber dilation and functional defects consistent with severe pressure overload. Using cardiac MRI analysis, UCB-MNC transplantation in the setting of PAB demonstrated an improvement in RV structure and function in this surgical mouse model. The RV volume load in PAB-only mice was 24.09 ± 3.9 compared to 11.05 ± 2.09 in the cell group (mm&lt;sup&gt;3&lt;/sup&gt;, P-value &lt;0.005). The analysis of pathogenic gene expression (BNP, ANP, Acta1, Myh7) in the cell-transplanted group showed a significant reversal with respect to the diseased PAB mice with a robust increase in cardiac progenitor gene expression such as GATA4, Kdr, Mef2c and Nkx2.5. Histological analysis indicated significant fibrosis in the RV in response to PAB that was reduced following UCB-MNC's transplantation along with concomitant increased Ki-67 expression and CD31 positive vessels as a marker of angiogenesis within the myocardium. Conclusions: These findings indicate that human UCB-derived MNCs promote an adaptive regenerative response in the right ventricle upon intramyocardial transplantation in the setting of chronic pressure overload heart failure.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005558</affiliation-url><afid>60005558</afid><affilname>Mayo Clinic</affilname><name-variant>Mayo Clinic</name-variant><affiliation-city>Rochester</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005558</affiliation-url><afid>60005558</afid><affilname>Mayo Clinic</affilname><name-variant>Mayo Clinic</name-variant><affiliation-city>Rochester</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005558</affiliation-url><afid>60005558</afid><affilname>Mayo Clinic</affilname><name-variant>Mayo Clinic</name-variant><affiliation-city>Rochester</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005558</affiliation-url><afid>60005558</afid><affilname>Mayo Clinic</affilname><name-variant>Mayo Clinic</name-variant><affiliation-city>Rochester</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023020</affiliation-url><afid>60023020</afid><affilname>Universidad Autonoma de Barcelona</affilname><name-variant>Universitat Autonoma de Barcelona</name-variant><affiliation-city>Barcelona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005558</affiliation-url><afid>60005558</afid><affilname>Mayo Clinic</affilname><name-variant>Mayo Clinic</name-variant><affiliation-city>Rochester</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005558</affiliation-url><afid>60005558</afid><affilname>Mayo Clinic</affilname><name-variant>Mayo Clinic</name-variant><affiliation-city>Rochester</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">20</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15136941500</author-url><authid>15136941500</authid><authname>Oommen S.</authname><surname>Oommen</surname><given-name>Saji</given-name><initials>S.</initials><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15136941500</author-url><authid>15136941500</authid><authname>Oommen S.</authname><surname>Oommen</surname><given-name>Saji</given-name><initials>S.</initials><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15136941500</author-url><authid>15136941500</authid><authname>Oommen S.</authname><surname>Oommen</surname><given-name>Saji</given-name><initials>S.</initials><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56493692900</author-url><authid>56493692900</authid><authname>Yamada S.</authname><surname>Yamada</surname><given-name>Satsuki</given-name><initials>S.</initials><afid>60005558</afid><afid>60005558</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56493692900</author-url><authid>56493692900</authid><authname>Yamada S.</authname><surname>Yamada</surname><given-name>Satsuki</given-name><initials>S.</initials><afid>60005558</afid><afid>60005558</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56222370100</author-url><authid>56222370100</authid><authname>Cantero Peral S.</authname><surname>Cantero Peral</surname><given-name>Susana</given-name><initials>S.</initials><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid><afid>60023020</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56222370100</author-url><authid>56222370100</authid><authname>Cantero Peral S.</authname><surname>Cantero Peral</surname><given-name>Susana</given-name><initials>S.</initials><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid><afid>60023020</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56222370100</author-url><authid>56222370100</authid><authname>Cantero Peral S.</authname><surname>Cantero Peral</surname><given-name>Susana</given-name><initials>S.</initials><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid><afid>60023020</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56222370100</author-url><authid>56222370100</authid><authname>Cantero Peral S.</authname><surname>Cantero Peral</surname><given-name>Susana</given-name><initials>S.</initials><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid><afid>60023020</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56608607000</author-url><authid>56608607000</authid><authname>Campbell K.</authname><surname>Campbell</surname><given-name>Katherine A.</given-name><initials>K.A.</initials><afid>60005558</afid><afid>60005558</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56608607000</author-url><authid>56608607000</authid><authname>Campbell K.</authname><surname>Campbell</surname><given-name>Katherine A.</given-name><initials>K.A.</initials><afid>60005558</afid><afid>60005558</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6506570309</author-url><authid>6506570309</authid><authname>Bruinsma E.</authname><surname>Bruinsma</surname><given-name>Elizabeth S.</given-name><initials>E.S.</initials><afid>60005558</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004939597</author-url><authid>7004939597</authid><authname>Terzic A.</authname><surname>Terzic</surname><given-name>Andre</given-name><initials>A.</initials><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004939597</author-url><authid>7004939597</authid><authname>Terzic A.</authname><surname>Terzic</surname><given-name>Andre</given-name><initials>A.</initials><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004939597</author-url><authid>7004939597</authid><authname>Terzic A.</authname><surname>Terzic</surname><given-name>Andre</given-name><initials>A.</initials><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004939597</author-url><authid>7004939597</authid><authname>Terzic A.</authname><surname>Terzic</surname><given-name>Andre</given-name><initials>A.</initials><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:24348581500</author-url><authid>24348581500</authid><authname>Nelson T.</authname><surname>Nelson</surname><given-name>Timothy J.</given-name><initials>T.J.</initials><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:24348581500</author-url><authid>24348581500</authid><authname>Nelson T.</authname><surname>Nelson</surname><given-name>Timothy J.</given-name><initials>T.J.</initials><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:24348581500</author-url><authid>24348581500</authid><authname>Nelson T.</authname><surname>Nelson</surname><given-name>Timothy J.</given-name><initials>T.J.</initials><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:24348581500</author-url><authid>24348581500</authid><authname>Nelson T.</authname><surname>Nelson</surname><given-name>Timothy J.</given-name><initials>T.J.</initials><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid><afid>60005558</afid></author><intid>1035809033</intid><article-number>50</article-number><source-id>19700201524</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925372636"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925372636?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925372636&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925372636&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0011393X15000028"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925372636</prism:url><dc:identifier>SCOPUS_ID:84925372636</dc:identifier><eid>2-s2.0-84925372636</eid><dc:title>Oral Levosimendan Increases Cerebral Blood Flow Velocities in Patients with a History of Stroke or Transient Ischemic Attack: A Pilot Safety Study</dc:title><dc:creator>Kivikko M.</dc:creator><prism:publicationName>Current Therapeutic Research - Clinical and Experimental</prism:publicationName><prism:issn>0011393X</prism:issn><prism:eIssn>18790313</prism:eIssn><prism:volume>77</prism:volume><prism:pageRange>46-51</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>December 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.curtheres.2015.01.001</prism:doi><pii>S0011393X15000028</pii><dc:description>© 2015 The Authors. Background: Intravenous levosimendan is indicated for acute heart failure. The compound has shown promising beneficial effects in ischemic stroke models. Objective: We evaluated the efficacy and safety of oral levosimendan in patients with a history of cerebral ischemia. Methods: In a randomized, double-blind, placebo-controlled, parallel-group study, 16 patients with a history of ischemic stroke/transient ischemic attack received oral levosimendan in 5 escalating doses from 0.125 to 2.0 mg daily for 18-day intervals of each dose; 5 patients received placebo. Twenty-four-hour ambulatory ECG and cerebral blood flow velocities using transcranial Doppler ultrasound were recorded at baseline and at the end of each dosing period. Vasomotor reactivity was assessed via the breath holding index. In addition, plasma levels of N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) and the metabolites of levosimendan were determined. Results: Levosimendan induced an increase in cerebral blood flow velocities and a decrease in NT-pro-BNP compared with placebo. There was no significant effect on breath holding index. Doses ≥0.5 mg increased heart rate by 5 to 9 beats/min. The dose level of 2.0 mg exceeded the preset safety margin of ventricular extrasystoles per hour (ie, upper 90% CI of the ratio of levosimendan to placebo above 2) with an estimate of 3.10 (90% CI, 0.95-10.07). Conclusions: Oral levosimendan increases cerebral blood flow velocities and diminishes NT-pro-BNP levels in patients with earlier ischemic cerebrovascular event. Daily doses up to 1.0 mg were well tolerated, whereas the 2.0 mg dose level induced an increase in ventricular extrasystoles. ClinicalTrials.gov identifier: NCT00698763.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016987</affiliation-url><afid>60016987</afid><affilname>Helsinki University Central Hospital</affilname><name-variant>Helsinki University Central Hospital</name-variant><affiliation-city>Helsinki</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003432</affiliation-url><afid>60003432</afid><affilname>Orion Corporation</affilname><name-variant>Orion Corporation</name-variant><affiliation-city>Abo</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016987</affiliation-url><afid>60016987</afid><affilname>Helsinki University Central Hospital</affilname><name-variant>Helsinki University Central Hospital</name-variant><affiliation-city>Helsinki</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002952</affiliation-url><afid>60002952</afid><affilname>Helsingin Yliopisto</affilname><name-variant>University of Helsinki</name-variant><affiliation-city>Helsinki</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025765</affiliation-url><afid>60025765</afid><affilname>Turun Yliopistollinen Keskussairaala</affilname><name-variant>Turku University Central Hospital</name-variant><affiliation-city>Abo</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6506416406</author-url><authid>6506416406</authid><authname>Kivikko M.</authname><surname>Kivikko</surname><given-name>Matti</given-name><initials>M.</initials><afid>60016987</afid><afid>60003432</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6506416406</author-url><authid>6506416406</authid><authname>Kivikko M.</authname><surname>Kivikko</surname><given-name>Matti</given-name><initials>M.</initials><afid>60016987</afid><afid>60003432</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55947025000</author-url><authid>55947025000</authid><authname>Kuoppamäki M.</authname><surname>Kuoppamäki</surname><given-name>Mikko</given-name><initials>M.</initials><afid>60003432</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602159639</author-url><authid>6602159639</authid><authname>Soinne L.</authname><surname>Soinne</surname><given-name>Lauri</given-name><initials>L.</initials><afid>60016987</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7006120773</author-url><authid>7006120773</authid><authname>Sundberg S.</authname><surname>Sundberg</surname><given-name>Stig</given-name><initials>S.</initials><afid>60002952</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:15760735400</author-url><authid>15760735400</authid><authname>Pohjanjousi P.</authname><surname>Pohjanjousi</surname><given-name>Pasi</given-name><initials>P.</initials><afid>60003432</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56521469600</author-url><authid>56521469600</authid><authname>Ellmen J.</authname><surname>Ellmen</surname><given-name>Juha</given-name><initials>J.</initials><afid>60003432</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35811369200</author-url><authid>35811369200</authid><authname>Roine R.</authname><surname>Roine</surname><given-name>Risto O.</given-name><initials>R.O.</initials><afid>60025765</afid></author><authkeywords>Ambulatory ECG | Cerebral blood flow | Levosimendan | Stroke | TIA</authkeywords><intid>2035283329</intid><source-id>12328</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929147224"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929147224?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929147224&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929147224&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929147224</prism:url><dc:identifier>SCOPUS_ID:84929147224</dc:identifier><eid>2-s2.0-84929147224</eid><dc:title>Severity of aortic regurgitation assessed by area of vena contracta: A clinical two-dimensional and three-dimensional color Doppler imaging study</dc:title><dc:creator>Sato H.</dc:creator><prism:publicationName>Cardiovascular Ultrasound</prism:publicationName><prism:eIssn>14767120</prism:eIssn><prism:volume>13</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12947-015-0016-5</prism:doi><dc:description>© 2015 Sato et al.; licensee BioMed Central. Abstract Background: Quantitation of aortic regurgitation (AR) using two-dimensional (2D) echocardiography, including vena contracta width (VCW) measurement, is still challenging. Three-dimensional (3D) echocardiography can directly measure the vena contracta area (VCA), regardless of the rheological characteristics. We intended to assess the possibility of 3D vena contracta area (3DVCA) as well as 2D vena contracta area (2DVCA) in the assessment of AR severity. Methods: Sixty-one patients with AR [17 female (32.7%); mean age: 74.0 ± 10.1 years] underwent 2D and 3D color Doppler echocardiography. Using conventional 2D color Doppler imaging, we measured VCW, 2DVCA, regurgitant volume (RV), and effective regurgitant orifice area (EROA). We also measured 3DVCA manually off-line from 3D full-volume color Doppler datasets for reference. Comprehensive 2D and 3D data on AR severity were successfully obtained from 52 of the 61 (85.2%) patients. Results: Significant correlations existed between 2DVCA and EROA (r = 0.89; p &lt; 0.001). The cut-off 2DVCA for grading severe AR was 34 mm&lt;sup&gt;2&lt;/sup&gt; (area under curve: 0.95; sensitivity: 78%; specificity: 95%). Significant correlations existed between 3DVCA and EROA (r = 0.89; p &lt; 0.001). The cut-off 3DVCA for grading severe AR was 32 mm&lt;sup&gt;2&lt;/sup&gt; (area under curve: 0.96; sensitivity: 89%; specificity: 98%). Significant correlations existed between 2DVCA and 3DVCA (r = 0.97; p &lt; 0.001). Conclusion: Two-dimensional, as well as three dimensional, vena contracta area measurement is a simple technique suitable for clinical use during comprehensive Doppler echocardiographic AR assessment.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100335729</affiliation-url><afid>100335729</afid><affilname>Matsue City Hospital</affilname><name-variant>Matsue City Hospital</name-variant><affiliation-city>Matsue</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026275</affiliation-url><afid>60026275</afid><affilname>Shimane University</affilname><name-variant>Shimane University</name-variant><affiliation-city>Matsue</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56623672100</author-url><authid>56623672100</authid><authname>Sato H.</authname><surname>Sato</surname><given-name>Hirotomo</given-name><initials>H.</initials><afid>100335729</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56623803800</author-url><authid>56623803800</authid><authname>Ohta T.</authname><surname>Ohta</surname><given-name>Tetsuro</given-name><initials>T.</initials><afid>100335729</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602314059</author-url><authid>6602314059</authid><authname>Hiroe K.</authname><surname>Hiroe</surname><given-name>Kimiko</given-name><initials>K.</initials><afid>100335729</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56623807100</author-url><authid>56623807100</authid><authname>Okada S.</authname><surname>Okada</surname><given-name>Seiji</given-name><initials>S.</initials><afid>100335729</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56623724900</author-url><authid>56623724900</authid><authname>Shimizu K.</authname><surname>Shimizu</surname><given-name>Koji</given-name><initials>K.</initials><afid>100335729</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56624038600</author-url><authid>56624038600</authid><authname>Murakami R.</authname><surname>Murakami</surname><given-name>Rinji</given-name><initials>R.</initials><afid>100335729</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7401523314</author-url><authid>7401523314</authid><authname>Tanabe K.</authname><surname>Tanabe</surname><given-name>Kazuaki</given-name><initials>K.</initials><afid>60026275</afid></author><authkeywords>Aortic regurgitation | Doppler echocardiography | Vena contracta</authkeywords><intid>535919643</intid><article-number>16</article-number><source-id>16598</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927134676"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927134676?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927134676&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927134676&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927134676</prism:url><dc:identifier>SCOPUS_ID:84927134676</dc:identifier><eid>2-s2.0-84927134676</eid><dc:title>Echocardiographic detection of transpulmonary bubble transit during acute respiratory distress syndrome</dc:title><dc:creator>Boissier F.</dc:creator><prism:publicationName>Annals of Intensive Care</prism:publicationName><prism:eIssn>21105820</prism:eIssn><prism:volume>5</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>1-9</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s13613-015-0046-z</prism:doi><dc:description>© 2015, Boissier et al.; licensee Springer. Background: Transpulmonary bubble transit (TPBT) detected with contrast echocardiography is reported as a sign of intrapulmonary shunt during cirrhosis or exercise in healthy humans. However, its physiological meaning is not clear during acute respiratory distress syndrome (ARDS). Our aim was to determine the prevalence, significance, and prognosis of TPBT detection during ARDS. Methods: This was a prospective observational study in an academic medical intensive care unit in France. Two hundred and sixteen consecutive patients with moderate-to-severe ARDS underwent transesophageal echocardiography with modified gelatine contrast. Moderate-to-large TPBT was defined as right-to-left passage of at least ten bubbles through a pulmonary vein more than three cardiac cycles after complete opacification of the right atrium. Patients with intra-cardiac shunt through patent foramen ovale were excluded. Conclusions: Moderate-to-large TPBT was detected with contrast echocardiography in 26% of patients with ARDS. This finding was associated with a hyperdynamic and septic state, but did not influence oxygenation. Results: The prevalence of moderate-to-large TPBT was 26% (including 42 patients with moderate and 15 with large TPBT). Patients with moderate-to-large TPBT had higher values of cardiac index and heart rate as compared to those without TPBT. There was no significant difference in PaO&lt;inf&gt;2&lt;/inf&gt;/FIO&lt;inf&gt;2&lt;/inf&gt; ratio between groups, and TPBT was not influenced by end-expiratory positive pressure level in 93% of tested patients. Prevalence of septic shock was higher in the group with moderate-to-large TPBT. Patients with moderate-to-large TPBT had fewer ventilator-free days and intensive care unit-free days within the first 28 days, and higher in-hospital mortality as compared to others.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023970</affiliation-url><afid>60023970</afid><affilname>Hopital Henri Mondor</affilname><name-variant>Hôpital Henri Mondor</name-variant><affiliation-city>Creteil</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000905</affiliation-url><afid>60000905</afid><affilname>Inserm</affilname><name-variant>INSERM</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60085092</affiliation-url><afid>60085092</afid><affilname>Universite Paris-Est</affilname><name-variant>Université Paris-Est</name-variant><affiliation-city>Marne-la-Vallee</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032653</affiliation-url><afid>60032653</afid><affilname>Universite de Poitiers</affilname><name-variant>Université de Poitiers</name-variant><affiliation-city>Poitiers</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030009</affiliation-url><afid>60030009</afid><affilname>Hospital Verge de la Cinta</affilname><name-variant>Hospital de Tortosa Verge de la Cinta</name-variant><affiliation-city>Tarragona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000832</affiliation-url><afid>60000832</afid><affilname>Centre Hospitalier Intercommunal Creteil</affilname><name-variant>Centre Hospitalier Intercommunal de Créteil</name-variant><affiliation-city>Creteil</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072151</affiliation-url><afid>60072151</afid><affilname>Centre hospitalier St Joseph St Luc</affilname><name-variant>Hopital Saint-Joseph</name-variant><affiliation-city>Lyon</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017018</affiliation-url><afid>60017018</afid><affilname>Saint Michael's Hospital University of Toronto</affilname><name-variant>St. Michael's Hospital</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">19</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23501462400</author-url><authid>23501462400</authid><authname>Boissier F.</authname><surname>Boissier</surname><given-name>Florence</given-name><initials>F.</initials><afid>60023970</afid><afid>60000905</afid><afid>60085092</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23501462400</author-url><authid>23501462400</authid><authname>Boissier F.</authname><surname>Boissier</surname><given-name>Florence</given-name><initials>F.</initials><afid>60023970</afid><afid>60000905</afid><afid>60085092</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23501462400</author-url><authid>23501462400</authid><authname>Boissier F.</authname><surname>Boissier</surname><given-name>Florence</given-name><initials>F.</initials><afid>60023970</afid><afid>60000905</afid><afid>60085092</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:25959299700</author-url><authid>25959299700</authid><authname>Razazi K.</authname><surname>Razazi</surname><given-name>Keyvan</given-name><initials>K.</initials><afid>60023970</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:14822412400</author-url><authid>14822412400</authid><authname>Thille A.</authname><surname>Thille</surname><given-name>Arnaud W.</given-name><initials>A.W.</initials><afid>60023970</afid><afid>60032653</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:14822412400</author-url><authid>14822412400</authid><authname>Thille A.</authname><surname>Thille</surname><given-name>Arnaud W.</given-name><initials>A.W.</initials><afid>60023970</afid><afid>60032653</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35759145500</author-url><authid>35759145500</authid><authname>Roche-Campo F.</authname><surname>Roche-Campo</surname><given-name>Ferran</given-name><initials>F.</initials><afid>60023970</afid><afid>60030009</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35759145500</author-url><authid>35759145500</authid><authname>Roche-Campo F.</authname><surname>Roche-Campo</surname><given-name>Ferran</given-name><initials>F.</initials><afid>60023970</afid><afid>60030009</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:23980292900</author-url><authid>23980292900</authid><authname>Leon R.</authname><surname>Leon</surname><given-name>Rusel</given-name><initials>R.</initials><afid>60023970</afid><afid>60000832</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:23980292900</author-url><authid>23980292900</authid><authname>Leon R.</authname><surname>Leon</surname><given-name>Rusel</given-name><initials>R.</initials><afid>60023970</afid><afid>60000832</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7006036974</author-url><authid>7006036974</authid><authname>Vivier E.</authname><surname>Vivier</surname><given-name>Emmanuel</given-name><initials>E.</initials><afid>60023970</afid><afid>60072151</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7006036974</author-url><authid>7006036974</authid><authname>Vivier E.</authname><surname>Vivier</surname><given-name>Emmanuel</given-name><initials>E.</initials><afid>60023970</afid><afid>60072151</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7103399801</author-url><authid>7103399801</authid><authname>Brochard L.</authname><surname>Brochard</surname><given-name>Laurent</given-name><initials>L.</initials><afid>60017018</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:54924006000</author-url><authid>54924006000</authid><authname>Brun-Buisson C.</authname><surname>Brun-Buisson</surname><given-name>Christian</given-name><initials>C.</initials><afid>60023970</afid><afid>60000905</afid><afid>60085092</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:54924006000</author-url><authid>54924006000</authid><authname>Brun-Buisson C.</authname><surname>Brun-Buisson</surname><given-name>Christian</given-name><initials>C.</initials><afid>60023970</afid><afid>60000905</afid><afid>60085092</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:54924006000</author-url><authid>54924006000</authid><authname>Brun-Buisson C.</authname><surname>Brun-Buisson</surname><given-name>Christian</given-name><initials>C.</initials><afid>60023970</afid><afid>60000905</afid><afid>60085092</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6602889252</author-url><authid>6602889252</authid><authname>Mekontso Dessap A.</authname><surname>Mekontso Dessap</surname><given-name>Armand</given-name><initials>A.</initials><afid>60023970</afid><afid>60000905</afid><afid>60085092</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6602889252</author-url><authid>6602889252</authid><authname>Mekontso Dessap A.</authname><surname>Mekontso Dessap</surname><given-name>Armand</given-name><initials>A.</initials><afid>60023970</afid><afid>60000905</afid><afid>60085092</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6602889252</author-url><authid>6602889252</authid><authname>Mekontso Dessap A.</authname><surname>Mekontso Dessap</surname><given-name>Armand</given-name><initials>A.</initials><afid>60023970</afid><afid>60000905</afid><afid>60085092</afid></author><authkeywords>Acute respiratory distress syndrome | Echocardiography | Shunt</authkeywords><intid>2035564881</intid><source-id>21100200831</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929302277"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929302277?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929302277&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929302277&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929302277</prism:url><dc:identifier>SCOPUS_ID:84929302277</dc:identifier><eid>2-s2.0-84929302277</eid><dc:title>Saffron as an antidote or a protective agent against natural or chemical toxicities</dc:title><dc:creator>Razavi B.</dc:creator><prism:publicationName>DARU, Journal of Pharmaceutical Sciences</prism:publicationName><prism:issn>15608115</prism:issn><prism:eIssn>20082231</prism:eIssn><prism:volume>23</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s40199-015-0112-y</prism:doi><dc:description>© 2015 Razavi and Hosseinzadeh; licensee BioMed Central. Abstract Saffron (Crocus sativus) is an extensively used food additive for its color and taste. Since ancient times this plant has been introduced as a marvelous medicine throughout the world. The wide spectrum of saffron pharmacological activities is related to its major constituents including crocin, crocetin and safranal. Based on several studies, saffron and its active ingredients have been used as an antioxidant, antiinflammatory and antinociceptive, antidepressant, antitussive, anticonvulsant, memory enhancer, hypotensive and anticancer. According to the literatures, saffron has remarkable therapeutic effects. The protective effects of saffron and its main constituents in different tissues including brain, heart, liver, kidney and lung have been reported against some toxic materials either natural or chemical toxins in animal studies. In this review article, we have summarized different in vitro and animal studies in scientific databases which investigate the antidotal and protective effects of saffron and its major components against natural toxins and chemical-induced toxicities. Due to the lake of human studies, further investigations are required to ascertain the efficacy of saffron as an antidote or a protective agent in human intoxication.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001500</affiliation-url><afid>60001500</afid><affilname>Mashhad University of Medical Sciences</affilname><name-variant>Mashhad University of Medical Sciences</name-variant><affiliation-city>Mashad</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001500</affiliation-url><afid>60001500</afid><affilname>Mashhad University of Medical Sciences</affilname><name-variant>Mashhad University of Medical Sciences</name-variant><affiliation-city>Mashad</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:25221890200</author-url><authid>25221890200</authid><authname>Razavi B.</authname><surname>Razavi</surname><given-name>Bibi Marjan</given-name><initials>B.M.</initials><afid>60001500</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56212454800</author-url><authid>56212454800</authid><authname>Hosseinzadeh H.</authname><surname>Hosseinzadeh</surname><given-name>Hossein</given-name><initials>H.</initials><afid>60001500</afid></author><authkeywords>Antidote | Chemical toxin | Crocetin | Crocin | Crocus sativus L | Natural toxin | Protective | Saffron | Safranal</authkeywords><intid>1535944731</intid><article-number>112</article-number><source-id>20710</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928242475"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928242475?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928242475&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928242475&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928242475</prism:url><dc:identifier>SCOPUS_ID:84928242475</dc:identifier><eid>2-s2.0-84928242475</eid><dc:title>Effect of postconditioning on dynamic expression of tenascin-C and left ventricular remodeling after myocardial ischemia and reperfusion</dc:title><dc:creator>Taki J.</dc:creator><prism:publicationName>EJNMMI Research</prism:publicationName><prism:eIssn>2191219X</prism:eIssn><prism:volume>5</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s13550-015-0100-8</prism:doi><dc:description>© 2015, Taki et al.; licensee Springer. Background: Tenascin-C (TNC), an extracellular matrix glycoprotein, is expressed transiently in distinct areas in association with active tissue remodeling. This study aimed to explore how ischemic postconditioning (PC) affects myocardial expression of TNC and ventricular remodeling using &lt;sup&gt;125&lt;/sup&gt;I-labeled anti-TNC antibody (&lt;sup&gt;125&lt;/sup&gt;I-TNC-Ab) in a rat model of ischemia and reperfusion. Methods: In control rats (n = 27), the left coronary artery (LCA) was occluded for 30 min followed by reperfusion for 1, 3, 7, and 14 days. PC (n = 27) was performed just after the reperfusion. At the time of the study, &lt;sup&gt;125&lt;/sup&gt;I-TNC-Ab (1.0 to 2.5 MBq) was injected. Six to 9 h later, to verify the area at risk, &lt;sup&gt;99m&lt;/sup&gt;Tc-MIBI (100 to 200 MBq) was injected intravenously just after the LCA reocclusion, with the rats sacrificed 1 min later. Dual tracer autoradiography was performed to assess &lt;sup&gt;125&lt;/sup&gt;I-TNC-Ab uptake and area at risk. To examine the ventricular remodeling, echocardiography was performed 2 M after reperfusion in both groups. Results: In control rats, &lt;sup&gt;125&lt;/sup&gt;I-TNC-Ab uptake ratio at 1 day after reperfusion was 3.73 ± 0.71 and increased at 3 days (4.65 ± 0.87), followed by a significant reduction at 7 days (2.91 ± 0.55, P &lt; 0.005 vs 3 days) and14 days (2.01 ± 0.17, P &lt; 0.005 vs 1 and 3 days). PC attenuated the &lt;sup&gt;125&lt;/sup&gt;I-TNC-Ab uptake throughout the reperfusion time from 1 to 14 days; 2.59 ± 0.59 at 1 day, P &lt; 0.05: 3.10 ± 0.42 at 3 days, P &lt; 0.005: 1.93 ± 0.37 at 7 days, P &lt; 0.05: 1.40 ± 0.07 at 14 days, P &lt; 0.001. In echocardiography, PC reduced the ventricular end-diastolic and systolic dimensions (1.00 ± 0.06 cm to 0.83 ± 0.14 cm (P &lt; 0.05) and 0.90 ± 0.15 cm to 0.62 ± 0.19 cm (P &lt; 0.05), respectively) and prevented a decline of ventricular percentage fractional shortening (10.5 ± 3.7 to 28.2 ± 10.7, P &lt; 0.005). Conclusions: These data indicate that &lt;sup&gt;125&lt;/sup&gt;I-TNC-Ab imaging may be a way to monitor myocardial injury, the subsequent repair process, and its response to novel therapeutic interventions like PC by visualizing TNC expression.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016178</affiliation-url><afid>60016178</afid><affilname>Kanazawa University Hospital</affilname><name-variant>Kanazawa University Hospital</name-variant><affiliation-city>Kanazawa</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101127269</affiliation-url><afid>101127269</afid><affilname>Medical and Pharmacological Research Center Foundation</affilname><name-variant>Med. and Pharmacol. Res. Ctr. Found.</name-variant><affiliation-city>Ishikawa</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021475</affiliation-url><afid>60021475</afid><affilname>Mie University School of Medicine</affilname><name-variant>Mie University Graduate School of Medicine</name-variant><affiliation-city>Tsu</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024784</affiliation-url><afid>60024784</afid><affilname>Kanazawa University</affilname><name-variant>Kanazawa University</name-variant><affiliation-city>Kanazawa</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022886</affiliation-url><afid>60022886</afid><affilname>International Medical Center of Japan</affilname><name-variant>International Medical Center of Japan</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024784</affiliation-url><afid>60024784</afid><affilname>Kanazawa University</affilname><name-variant>Kanazawa University</name-variant><affiliation-city>Kanazawa</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006603759</author-url><authid>7006603759</authid><authname>Taki J.</authname><surname>Taki</surname><given-name>Junichi</given-name><initials>J.</initials><afid>60016178</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35409189600</author-url><authid>35409189600</authid><authname>Inaki A.</authname><surname>Inaki</surname><given-name>Anri</given-name><initials>A.</initials><afid>60016178</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35111893100</author-url><authid>35111893100</authid><authname>Wakabayashi H.</authname><surname>Wakabayashi</surname><given-name>Hiroshi</given-name><initials>H.</initials><afid>60016178</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7006258154</author-url><authid>7006258154</authid><authname>Matsunari I.</authname><surname>Matsunari</surname><given-name>Ichiro</given-name><initials>I.</initials><afid>101127269</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003970157</author-url><authid>7003970157</authid><authname>Imanaka-Yoshida K.</authname><surname>Imanaka-Yoshida</surname><given-name>Kyoko</given-name><initials>K.</initials><afid>60021475</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35551820800</author-url><authid>35551820800</authid><authname>Ogawa K.</authname><surname>Ogawa</surname><given-name>Kazuma</given-name><initials>K.</initials><afid>60024784</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7006070100</author-url><authid>7006070100</authid><authname>Hiroe M.</authname><surname>Hiroe</surname><given-name>Michiaki</given-name><initials>M.</initials><afid>60022886</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7202098417</author-url><authid>7202098417</authid><authname>Shiba K.</authname><surname>Shiba</surname><given-name>Kazuhiro</given-name><initials>K.</initials><afid>60024784</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7501317495</author-url><authid>7501317495</authid><authname>Yoshida T.</authname><surname>Yoshida</surname><given-name>Toshimichi</given-name><initials>T.</initials><afid>60021475</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7006481475</author-url><authid>7006481475</authid><authname>Kinuya S.</authname><surname>Kinuya</surname><given-name>Seigo</given-name><initials>S.</initials><afid>60016178</afid></author><authkeywords>I-125-anti-tenascin-C antibody | Myocardial ischemia and reperfusion | Postconditioning | Tenascin-C | Ventricular remodeling</authkeywords><intid>35753797</intid><source-id>21100235610</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928809170"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928809170?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928809170&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928809170&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928809170</prism:url><dc:identifier>SCOPUS_ID:84928809170</dc:identifier><eid>2-s2.0-84928809170</eid><dc:title>Hypertensive emergency presenting as blurry vision in a patient with hypertensive chorioretinopathy</dc:title><dc:creator>Stacey A.</dc:creator><prism:publicationName>International Journal of Emergency Medicine</prism:publicationName><prism:issn>18651372</prism:issn><prism:eIssn>18651380</prism:eIssn><prism:volume>8</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12245-015-0063-6</prism:doi><dc:description>© 2015, Stacey et al.; licensee Springer. A 42-year-old man presented with 3 weeks of blurry vision in the right eye. His exam was significant for decreased vision in the right eye, diffuse retinopathy in both eyes, and serous retinal detachment in the right eye. The patient was found to be hypertensive with blood pressure of 256/160 mmHg. He was diagnosed with hypertensive emergency with end-organ damage due to features of hypertensive chorioretinopathy. He was admitted with abnormal urinalysis, elevated troponin, and abnormal EKG. After appropriate control of his blood pressure, his vision and his labs normalized. Hypertensive emergencies can be manifested first in the eyes. When the choroid is associated, the hypertensive event is often more acute and associated with increased morbidity. It is imperative to obtain a fundus exam in any patient with elevated blood pressure and concomitant vision complaints.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025778</affiliation-url><afid>60025778</afid><affilname>University Michigan Ann Arbor</affilname><name-variant>University of Michigan</name-variant><affiliation-city>Ann Arbor</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025778</affiliation-url><afid>60025778</afid><affilname>University Michigan Ann Arbor</affilname><name-variant>University of Michigan</name-variant><affiliation-city>Ann Arbor</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56613004200</author-url><authid>56613004200</authid><authname>Stacey A.</authname><surname>Stacey</surname><given-name>Andrew W.</given-name><initials>A.W.</initials><afid>60025778</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55363709700</author-url><authid>55363709700</authid><authname>Sozener C.</authname><surname>Sozener</surname><given-name>Cemal B.</given-name><initials>C.B.</initials><afid>60025778</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6508232103</author-url><authid>6508232103</authid><authname>Besirli C.</authname><surname>Besirli</surname><given-name>Cagri G.</given-name><initials>C.G.</initials><afid>60025778</afid></author><authkeywords>Fundus photography | Hypertensive choroidopathy | Hypertensive emergency | Hypertensive retinopathy</authkeywords><intid>1535851065</intid><source-id>14500154757</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930204606"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930204606?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930204606&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930204606&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930204606</prism:url><dc:identifier>SCOPUS_ID:84930204606</dc:identifier><eid>2-s2.0-84930204606</eid><dc:title>Point-of-care ultrasound in the diagnosis of pulmonary embolism</dc:title><dc:creator>Squizzato A.</dc:creator><prism:publicationName>Critical Ultrasound Journal</prism:publicationName><prism:issn>20363176</prism:issn><prism:eIssn>20367902</prism:eIssn><prism:volume>7</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s13089-015-0025-5</prism:doi><dc:description>© 2015, Squizzato et al.; licensee Springer. The best diagnostic strategy to confirm or exclude pulmonary embolism (PE) suspicion needs an appropriate combination of clinical assessment, plasma D-dimer measurement, and computed tomographic pulmonary angiography (CTPA). CTPA should be used with caution in some patient groups, such as patients with known allergy to contrast media, those with severe renal insufficiency, and pregnant women, and could be not immediately available in case of unstable patients. In the emergency setting, alternative diagnostic strategies should be implemented to overcome CTPA limitations. Ultrasonography is certainly a valuable alternative diagnostic tool. In addition to echocardiography and lower limb compressive venous ultrasonography, lung ultrasound (US) may play an important role in selected patients’ subgroups. Recent data on the diagnostic performance of a triple point-of-care US (lung, heart, and leg vein US) are discussed in the present paper, and pros and cons of triple point-of-care US are compared with those of standard diagnostic approaches.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005400</affiliation-url><afid>60005400</afid><affilname>Universita degli Studi dell'Insubria</affilname><name-variant>Università dell'Insubria</name-variant><affiliation-city>Varese</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009374</affiliation-url><afid>60009374</afid><affilname>Slotervaart Hospital</affilname><name-variant>Slotervaart Hospital</name-variant><affiliation-city>Amsterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001157</affiliation-url><afid>60001157</afid><affilname>Academic Medical Centre, University of Amsterdam</affilname><name-variant>University of Amsterdam</name-variant><affiliation-city>Amsterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100758621</affiliation-url><afid>100758621</afid><affilname>Ospedale di Circolo</affilname><name-variant>Ospedale di Circolo</name-variant><affiliation-city>Desio</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6603268379</author-url><authid>6603268379</authid><authname>Squizzato A.</authname><surname>Squizzato</surname><given-name>Alessandro</given-name><initials>A.</initials><afid>60005400</afid><afid>100758621</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6603268379</author-url><authid>6603268379</authid><authname>Squizzato A.</authname><surname>Squizzato</surname><given-name>Alessandro</given-name><initials>A.</initials><afid>60005400</afid><afid>100758621</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:12752979800</author-url><authid>12752979800</authid><authname>Galli L.</authname><surname>Galli</surname><given-name>Luca</given-name><initials>L.</initials><afid>60005400</afid><afid>60009374</afid><afid>60001157</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:12752979800</author-url><authid>12752979800</authid><authname>Galli L.</authname><surname>Galli</surname><given-name>Luca</given-name><initials>L.</initials><afid>60005400</afid><afid>60009374</afid><afid>60001157</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:12752979800</author-url><authid>12752979800</authid><authname>Galli L.</authname><surname>Galli</surname><given-name>Luca</given-name><initials>L.</initials><afid>60005400</afid><afid>60009374</afid><afid>60001157</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6701370173</author-url><authid>6701370173</authid><authname>Gerdes V.</authname><surname>Gerdes</surname><given-name>Victor E A</given-name><initials>V.E.A.</initials><afid>60009374</afid><afid>60001157</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6701370173</author-url><authid>6701370173</authid><authname>Gerdes V.</authname><surname>Gerdes</surname><given-name>Victor E A</given-name><initials>V.E.A.</initials><afid>60009374</afid><afid>60001157</afid></author><authkeywords>Echocardiography | Lower limb compressive venous ultrasonography | Lung ultrasound | Point-of-care ultrasound | Pulmonary embolism diagnosis | Venous thromboembolism</authkeywords><intid>1786088483</intid><article-number>7</article-number><source-id>19500157826</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928569750"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928569750?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928569750&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928569750&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928569750</prism:url><dc:identifier>SCOPUS_ID:84928569750</dc:identifier><eid>2-s2.0-84928569750</eid><dc:title>Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease</dc:title><dc:creator>Farlow M.</dc:creator><prism:publicationName>Alzheimer's Research and Therapy</prism:publicationName><prism:eIssn>17589193</prism:eIssn><prism:volume>7</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>1-13</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s13195-015-0108-3</prism:doi><dc:description>© 2015 Farlow et al. Abstract Introduction: CAD106 is designed to stimulate amyloid-β (Aβ)-specific antibody responses while avoiding T-cell autoimmune responses. The CAD106 first-in-human study demonstrated a favorable safety profile and promising antibody response. We investigated long-term safety, tolerability and antibody response after repeated CAD106 injections. Methods: Two phase IIa, 52-week, multicenter, randomized, double-blind, placebo-controlled core studies (2201; 2202) and two 66-week open-label extension studies (2201E; 2202E) were conducted in patients with mild Alzheimer's disease (AD) aged 40 to 85 years. Patients were randomized to receive 150μg CAD106 or placebo given as three subcutaneous (2201) or subcutaneous/intramuscular (2202) injections, followed by four injections (150 μg CAD106; subcutaneous, 2201E1; intramuscular, 2202E1). Our primary objective was to evaluate the safety and tolerability of repeated injections, including monitoring cerebral magnetic resonance imaging scans, adverse events (AEs) and serious AEs (SAEs). Further objectives were to assess Aβ-specific antibody response in serum and Aβ-specific T-cell response (core only). Comparable Aβ-immunoglobulin G (IgG) exposure across studies supported pooled immune response assessments. Results: Fifty-eight patients were randomized (CAD106, n = 47; placebo, n = 11). Baseline demographics and characteristics were balanced. Forty-five patients entered extension studies. AEs occurred in 74.5% of CAD106-treated patients versus 63.6% of placebo-treated patients (core), and 82.2% experienced AEs during extension studies. Most AEs were mild to moderate in severity, were not study medication-related and did not require discontinuation. SAEs occurred in 19.1% of CAD106-treated patients and 36.4% of placebo-treated patients (core). One patient (CAD106-treated; 2201) reported a possibly study drug-related SAE of intracerebral hemorrhage. Four patients met criteria for amyloid-related imaging abnormalities (ARIA) corresponding to microhemorrhages: one was CAD106-treated (2201), one placebo-treated (2202) and two open-label CAD106-treated. No ARIA corresponded to vasogenic edema. Two patients discontinued extension studies because of SAEs (rectal neoplasm and rapid AD progression, respectively). Thirty CAD106-treated patients (63.8%) were serological responders. Sustained Aβ-IgG titers and prolonged time to decline were observed in extensions versus core studies. Neither Aβ&lt;inf&gt;1-6&lt;/inf&gt; nor Aβ&lt;inf&gt;1-42&lt;/inf&gt; induced specific T-cell responses; however, positive control responses were consistently detected with the CAD106 carrier. Conclusions: No unexpected safety findings or Aβ-specific T-cell responses support the CAD106 favorable tolerability profile. Long-term treatment-induced Aβ-specific antibody titers and prolonged time to decline indicate antibody exposure may increase with additional injections. CAD106 may be a valuable therapeutic option in AD. Trial registration: ClinicalTrials.gov identifiers: NCT00733863, registered 8 August 2008; NCT00795418, registered 10 November 2008; NCT00956410, registered 10 August 2009; NCT01023685, registered 1 December 2009.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021947</affiliation-url><afid>60021947</afid><affilname>Indiana University School of Medicine Indianapolis</affilname><name-variant>Indiana University School of Medicine</name-variant><affiliation-city>Indianapolis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012311</affiliation-url><afid>60012311</afid><affilname>Karolinska Institutet</affilname><name-variant>Karolinska Institutet</name-variant><affiliation-city>Stockholm</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019295</affiliation-url><afid>60019295</afid><affilname>Karolinska University Hospital</affilname><name-variant>Karolinska University Hospital</name-variant><affiliation-city>Stockholm</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009968</affiliation-url><afid>60009968</afid><affilname>Novartis</affilname><name-variant>Novartis Pharma AG</name-variant><affiliation-city>Basel</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006267199</author-url><authid>7006267199</authid><authname>Farlow M.</authname><surname>Farlow</surname><given-name>Martin R.</given-name><initials>M.R.</initials><afid>60021947</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7102011511</author-url><authid>7102011511</authid><authname>Andreasen N.</authname><surname>Andreasen</surname><given-name>Niels</given-name><initials>N.</initials><afid>60012311</afid><afid>60019295</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7102011511</author-url><authid>7102011511</authid><authname>Andreasen N.</authname><surname>Andreasen</surname><given-name>Niels</given-name><initials>N.</initials><afid>60012311</afid><afid>60019295</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:15721161200</author-url><authid>15721161200</authid><authname>Riviere M.</authname><surname>Riviere</surname><given-name>Marie Emmanuelle</given-name><initials>M.E.</initials><afid>60009968</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6602253125</author-url><authid>6602253125</authid><authname>Vostiar I.</authname><surname>Vostiar</surname><given-name>Igor</given-name><initials>I.</initials><afid>60009968</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8626502300</author-url><authid>8626502300</authid><authname>Vitaliti A.</authname><surname>Vitaliti</surname><given-name>Alessandra</given-name><initials>A.</initials><afid>60009968</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6602146028</author-url><authid>6602146028</authid><authname>Sovago J.</authname><surname>Sovago</surname><given-name>Judit</given-name><initials>J.</initials><afid>60009968</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7102635342</author-url><authid>7102635342</authid><authname>Caputo A.</authname><surname>Caputo</surname><given-name>Angelika</given-name><initials>A.</initials><afid>60009968</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:36048831500</author-url><authid>36048831500</authid><authname>Winblad B.</authname><surname>Winblad</surname><given-name>Bengt</given-name><initials>B.</initials><afid>60012311</afid><afid>60019295</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:36048831500</author-url><authid>36048831500</authid><authname>Winblad B.</authname><surname>Winblad</surname><given-name>Bengt</given-name><initials>B.</initials><afid>60012311</afid><afid>60019295</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7006625257</author-url><authid>7006625257</authid><authname>Graf A.</authname><surname>Graf</surname><given-name>Ana</given-name><initials>A.</initials><afid>60009968</afid></author><intid>1035797349</intid><article-number>108</article-number><source-id>19700174935</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927775476"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927775476?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927775476&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927775476&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927775476</prism:url><dc:identifier>SCOPUS_ID:84927775476</dc:identifier><eid>2-s2.0-84927775476</eid><dc:title>Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: A retrospective cohort study</dc:title><dc:creator>Peter W.</dc:creator><prism:publicationName>BMC Nephrology</prism:publicationName><prism:eIssn>14712369</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12882-015-0030-8</prism:doi><dc:description>© 2015 St. Peter et al.; licensee BioMed Central. Background: Cinacalcet reduces parathyroid hormone (PTH) levels in patients receiving hemodialysis, but no non-experimental studies have evaluated the association between changes in PTH levels following cinacalcet initiation and clinical outcomes. We assessed whether short-term change in PTH levels after first cinacalcet prescription could serve as a surrogate marker for improvements in longer-term clinical outcomes. Methods: United States Renal Data System data were linked with data from a large dialysis organization. We created a point prevalent cohort of adult hemodialysis patients with Medicare as primary payer who initiated cinacalcet November 1, 2004-February 1, 2007, and were on cinacalcet for ≥ 40 days. We grouped patients into quartiles of PTH change after first cinacalcet prescription. We used Cox proportional hazard modeling to evaluate associations between short-term PTH change and time to first composite event (hospitalization for cardiovascular events or mortality) within 1 year. Overall models and models stratified by baseline PTH levels were adjusted for several patient-related factors. Results: For 2485 of 3467 included patients (72%), PTH levels decreased after first cinacalcet prescription; for 982 (28%), levels increased or were unchanged. Several characteristics differed between PTH change groups, including age and mineral-and-bone-disorder laboratory values. In adjusted models, we did not identify an association between greater short-term PTH reduction and lower composite event rates within 1 year, overall or in models stratified by baseline PTH levels. Conclusions: Short-term change in PTH levels after first cinacalcet prescription does not appear to be a useful surrogate for longer-term improvements in cardiovascular or survival risk.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023559</affiliation-url><afid>60023559</afid><affilname>Chronic Disease Research Group</affilname><name-variant>Minneapolis Medical Research Foundation</name-variant><affiliation-city>Minneapolis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029445</affiliation-url><afid>60029445</afid><affilname>University of Minnesota Twin Cities</affilname><name-variant>University of Minnesota</name-variant><affiliation-city>Minneapolis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001673</affiliation-url><afid>60001673</afid><affilname>Amgen Incorporated</affilname><name-variant>Amgen, Inc.</name-variant><affiliation-city>Thousand Oaks</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56594626500</author-url><authid>56594626500</authid><authname>Peter W.</authname><surname>Peter</surname><given-name>Wendy L St</given-name><initials>W.L.S.</initials><afid>60023559</afid><afid>60029445</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56594626500</author-url><authid>56594626500</authid><authname>Peter W.</authname><surname>Peter</surname><given-name>Wendy L St</given-name><initials>W.L.S.</initials><afid>60023559</afid><afid>60029445</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55532479800</author-url><authid>55532479800</authid><authname>Yusuf A.</authname><surname>Yusuf</surname><given-name>Akeem A.</given-name><initials>A.A.</initials><afid>60023559</afid><afid>60029445</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55532479800</author-url><authid>55532479800</authid><authname>Yusuf A.</authname><surname>Yusuf</surname><given-name>Akeem A.</given-name><initials>A.A.</initials><afid>60023559</afid><afid>60029445</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35733510700</author-url><authid>35733510700</authid><authname>Do T.</authname><surname>Do</surname><given-name>Thy</given-name><initials>T.</initials><afid>60001673</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55426469200</author-url><authid>55426469200</authid><authname>Lowe K.</authname><surname>Lowe</surname><given-name>Kimberly A.</given-name><initials>K.A.</initials><afid>60001673</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8231785500</author-url><authid>8231785500</authid><authname>Liu J.</authname><surname>Liu</surname><given-name>Jiannong</given-name><initials>J.</initials><afid>60023559</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7003743977</author-url><authid>7003743977</authid><authname>Nieman K.</authname><surname>Nieman</surname><given-name>Kimberly M.</given-name><initials>K.M.</initials><afid>60023559</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7003803290</author-url><authid>7003803290</authid><authname>Bradbury B.</authname><surname>Bradbury</surname><given-name>Brian D.</given-name><initials>B.D.</initials><afid>60001673</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56533070500</author-url><authid>56533070500</authid><authname>Collins A.</authname><surname>Collins</surname><given-name>Allan J.</given-name><initials>A.J.</initials><afid>60023559</afid><afid>60029445</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56533070500</author-url><authid>56533070500</authid><authname>Collins A.</authname><surname>Collins</surname><given-name>Allan J.</given-name><initials>A.J.</initials><afid>60023559</afid><afid>60029445</afid></author><authkeywords>Cinacalcet | Hemodialysis | Parathyroid hormone | Secondary hyperparathyroidism</authkeywords><intid>2035660760</intid><source-id>19395</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927727753"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927727753?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927727753&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927727753&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S2213007114000562"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927727753</prism:url><dc:identifier>SCOPUS_ID:84927727753</dc:identifier><eid>2-s2.0-84927727753</eid><dc:title>Emphysema mimicking interstitial lung disease: Two case reports</dc:title><dc:creator>Juhl K.</dc:creator><prism:publicationName>Respiratory Medicine Case Reports</prism:publicationName><prism:eIssn>22130071</prism:eIssn><prism:volume>15</prism:volume><prism:pageRange>24-26</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>December 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.rmcr.2014.12.004</prism:doi><pii>S2213007114000562</pii><dc:description>© 2015 The Authors. Honeycombing in general is a sign of severe end-stage fibrosis. Here we present two cases, where the combination of emphysema, acute inflammation and pulmonary embolism gave an appearance of honeycombing seen in pulmonary fibrosis. HRCT interpretation in the evaluation of acutely ill patients with pulmonary infection is a challenge. Our case reports emphasize the importance of a multidisciplinary approach, when it comes to patients with suspected complicated pulmonary diseases. At the same time they give very realistic examples of the challenges found in diagnosing patients with simultaneous acute and chronic pulmonary diseases.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023882</affiliation-url><afid>60023882</afid><affilname>Arhus Universitetshospital</affilname><name-variant>Aarhus University Hospital</name-variant><affiliation-city>Arhus</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023882</affiliation-url><afid>60023882</afid><affilname>Arhus Universitetshospital</affilname><name-variant>Aarhus University Hospital</name-variant><affiliation-city>Arhus</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56594838600</author-url><authid>56594838600</authid><authname>Juhl K.</authname><surname>Juhl</surname><given-name>Kasper S.</given-name><initials>K.S.</initials><afid>60023882</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:46961082700</author-url><authid>46961082700</authid><authname>Bendstrup E.</authname><surname>Bendstrup</surname><given-name>Elisabeth</given-name><initials>E.</initials><afid>60023882</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:34979144700</author-url><authid>34979144700</authid><authname>Rasmussen F.</authname><surname>Rasmussen</surname><given-name>Finn</given-name><initials>F.</initials><afid>60023882</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603827733</author-url><authid>6603827733</authid><authname>Hilberg O.</authname><surname>Hilberg</surname><given-name>Ole</given-name><initials>O.</initials><afid>60023882</afid></author><authkeywords>Emphysema | Honeycombing | HRCT | Interstitial | Mimicking | Pulmonary embolism</authkeywords><intid>1785668291</intid><source-id>21100203501</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84914168650"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84914168650?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84914168650&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84914168650&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84914168650</prism:url><dc:identifier>SCOPUS_ID:84914168650</dc:identifier><eid>2-s2.0-84914168650</eid><dc:title>Design of randomized experiments in networks</dc:title><dc:creator>Walker D.</dc:creator><prism:publicationName>Proceedings of the IEEE</prism:publicationName><prism:issn>00189219</prism:issn><prism:volume>102</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>1940-1951</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1109/JPROC.2014.2363674</prism:doi><dc:description>© 1963-2012 IEEE. Over the last decade, the emergence of pervasive online and digitally enabled environments has created a rich source of detailed data on human behavior. Yet, the promise of big data has recently come under fire for its inability to separate correlation from causation - to derive actionable insights and yield effective policies. Fortunately, the same online platforms on which we interact on a day-to-day basis permit experimentation at large scales, ushering in a new movement toward big experiments. Randomized controlled trials are the heart of the scientific method and when designed correctly provide clean causal inferences that are robust and reproducible. However, the realization that our world is highly connected and that behavioral and economic outcomes at the individual and population level depend upon this connectivity challenges the very principles of experimental design. The proper design and analysis of experiments in networks is, therefore, critically important. In this work, we categorize and review the emerging strategies to design and analyze experiments in networks and discuss their strengths and weaknesses.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019674</affiliation-url><afid>60019674</afid><affilname>Boston University</affilname><name-variant>Boston University</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007903</affiliation-url><afid>60007903</afid><affilname>Hebrew University of Jerusalem</affilname><name-variant>Hebrew University of Jerusalem</name-variant><affiliation-city>Jerusalem</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55468081100</author-url><authid>55468081100</authid><authname>Walker D.</authname><surname>Walker</surname><given-name>Dylan</given-name><initials>D.</initials><afid>60019674</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602324237</author-url><authid>6602324237</authid><authname>Muchnik L.</authname><surname>Muchnik</surname><given-name>Lev</given-name><initials>L.</initials><afid>60007903</afid></author><authkeywords>Behavioral science | general | science | sociology | systems, man, and cybernetics</authkeywords><intid>1783429680</intid><source-id>17915</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84921860898"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84921860898?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84921860898&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84921860898&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84921860898</prism:url><dc:identifier>SCOPUS_ID:84921860898</dc:identifier><eid>2-s2.0-84921860898</eid><dc:title>Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups</dc:title><dc:creator>Assaad-Khalil S.</dc:creator><prism:publicationName>Vascular Health and Risk Management</prism:publicationName><prism:issn>11766344</prism:issn><prism:eIssn>11782048</prism:eIssn><prism:volume>11</prism:volume><prism:pageRange>71-78</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.2147/VHRM.S76599</prism:doi><dc:description>© 2015 Assaad-Khalil et al. Background: The clinical EXCITE (EXperienCe of amlodIpine and valsarTan in hypErtension) study reported clinically relevant blood pressure (BP) reductions across all doses of amlodipine/valsartan (Aml/Val) and Aml/Val/hydrochlorothiazide (HCT) single-pill combinations. The study prospectively observed a multiethnic population of hypertensive patients for 26 weeks who were treated according to routine clinical practice. Here, we present the results in high-risk subgroups including the elderly, obese patients, and patients with diabetes or isolated systolic hypertension. In addition, we present a post hoc analysis as per prior antihypertensive monotherapy and dual therapy. Methods: Patients prescribed Aml/Val or Aml/Val/HCT were assessed in this 26±8 week, noninterventional, multicenter study across 13 countries in the Middle East and Asia. Changes in mean sitting systolic BP, mean sitting diastolic BP, and overall safety were assessed. Results: Of a total of 9,794 patients analyzed, 8,603 and 1,191 patients were prescribed Aml/Val and Aml/Val/HCT, respectively. Among these, 15.5% were elderly, 32.5% were obese, 31.3% had diabetes, and 9.8% had isolated systolic hypertension. Both Aml/Val and Aml/Val/HCT single-pill combinations, respectively, were associated with clinically relevant and significant mean sitting systolic/diastolic BP reductions across all subgroups: elderly patients (−32.2/−14.3 mmHg and −38.5/−16.5 mmHg), obese patients (−32.2/−17.9 mmHg and −38.5/−18.4 mmHg), diabetic patients (−30.3/−16.1 mmHg and −34.4/−16.6 mmHg), and patients with isolated systolic hypertension (−25.5/−4.1 mmHg and −30.2/−5.9 mmHg). Incremental BP reductions with Aml/Val or Aml/Val/HCT single-pill combinations were also observed in patients receiving prior monotherapy or dual therapy for hypertension. Overall, both Aml/Val and Aml/Val/HCT were generally well tolerated. Conclusion: This large, multiethnic study supports the evidence that Aml/Val and Aml/Val/HCT single-pill combinations are effective in diverse and clinically important subgroups of patients with hypertension.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033041</affiliation-url><afid>60033041</afid><affilname>Alexandria University</affilname><name-variant>Alexandria University</name-variant><affiliation-city>Alexandria</affiliation-city><affiliation-country>Egypt</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068774</affiliation-url><afid>60068774</afid><affilname>Universite Libanaise</affilname><name-variant>Lebanese University</name-variant><affiliation-city>Beirut</affiliation-city><affiliation-country>Lebanon</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60089588</affiliation-url><afid>60089588</afid><affilname>De La Salle University-Manila, LaSalle University Medical Center</affilname><name-variant>Cardinal Santos Medical Center</name-variant><affiliation-city>Dasmarinas</affiliation-city><affiliation-country>Philippines</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60061091</affiliation-url><afid>60061091</afid><affilname>Pakistan Institute of Medical Sciences</affilname><name-variant>Pakistan Institute of Medical Sciences (PIMS)</name-variant><affiliation-city>Islamabad</affiliation-city><affiliation-country>Pakistan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000656</affiliation-url><afid>60000656</afid><affilname>Seoul National University College of Medicine</affilname><name-variant>Seoul Natl. Univ. Coll. of Medicine</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073390</affiliation-url><afid>60073390</afid><affilname>Chung Shan Medical University Hospital</affilname><name-variant>Chung Shan Medical University Hospital</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009968</affiliation-url><afid>60009968</afid><affilname>Novartis</affilname><name-variant>Novartis Pharma AG</name-variant><affiliation-city>Basel</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56525381300</author-url><authid>56525381300</authid><authname>Assaad-Khalil S.</authname><surname>Assaad-Khalil</surname><given-name>Samir Helmy</given-name><initials>S.H.</initials><afid>60033041</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603185099</author-url><authid>6603185099</authid><authname>Najem R.</authname><surname>Najem</surname><given-name>Robert</given-name><initials>R.</initials><afid>60068774</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36764809200</author-url><authid>36764809200</authid><authname>Sison J.</authname><surname>Sison</surname><given-name>Jorge</given-name><initials>J.</initials><afid>60089588</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56497045000</author-url><authid>56497045000</authid><authname>Kitchlew A.</authname><surname>Kitchlew</surname><given-name>Asad Riaz</given-name><initials>A.R.</initials><afid>60061091</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:24401032400</author-url><authid>24401032400</authid><authname>Cho B.</authname><surname>Cho</surname><given-name>Belong</given-name><initials>B.</initials><afid>60000656</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8152637500</author-url><authid>8152637500</authid><authname>Ueng K.</authname><surname>Ueng</surname><given-name>Kwo Chang</given-name><initials>K.C.</initials><afid>60073390</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:15844812700</author-url><authid>15844812700</authid><authname>Ditommaso S.</authname><surname>Ditommaso</surname><given-name>Shelley</given-name><initials>S.</initials><afid>60009968</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56496722900</author-url><authid>56496722900</authid><authname>Shete A.</authname><surname>Shete</surname><given-name>Abhiji</given-name><initials>A.</initials><afid>60009968</afid></author><authkeywords>Amlodipine | Hydrochlorothiazide | Real world | Single-pill combinations | Valsartan</authkeywords><intid>1784717313</intid><source-id>4100151702</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927944358"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927944358?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927944358&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927944358&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927944358</prism:url><dc:identifier>SCOPUS_ID:84927944358</dc:identifier><eid>2-s2.0-84927944358</eid><dc:title>Assessment of Worldwide Acute Kidney Injury, Renal Angina and Epidemiology in critically ill children (AWARE): Study protocol for a prospective observational study</dc:title><dc:creator>Basu R.</dc:creator><prism:publicationName>BMC Nephrology</prism:publicationName><prism:eIssn>14712369</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12882-015-0016-6</prism:doi><dc:description>© 2015 Basu et al.; licensee BioMed Central. Background: Acute kidney injury (AKI) is associated with poor outcome in critically ill children. While data extracted from retrospective study of pediatric populations demonstrate a high incidence of AKI, the literature lacks focused and comprehensive multicenter studies describing AKI risk factors, epidemiology, and outcome. Additionally, very few pediatric studies have examined novel urinary biomarkers outside of the cardiopulmonary bypass population. Methods/Design: This is a prospective observational study. We anticipate collecting data on over 5000 critically ill children admitted to 31 pediatric intensive care units (PICUs) across the world during the calendar year of 2014. Data will be collected for seven days on all children older than 90 days and younger than 25 years without baseline stage 5 chronic kidney disease, chronic renal replacement therapy, and outside of 90 days of a kidney transplant or from surgical correction of congenital heart disease. Data to be collected includes demographic information, admission diagnoses and co-morbidities, and details on fluid and vasoactive resuscitation used. The renal angina index will be calculated integrating risk factors and early changes in serum creatinine and fluid overload. On days 2-7, all hemodynamic and pertinent laboratory values will be captured focusing on AKI pertinent values. Daily calculated values will include % fluid overload, fluid corrected creatinine, and KDIGO AKI stage. Urine will be captured twice daily for biomarker analysis on Days 0-3 of admission. Biomarkers to be measured include neutrophil gelatinase lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatty acid binding protein (l-FABP), and interleukin-18 (IL-18). The primary outcome to be quantified is incidence rate of severe AKI on Day 3 (Day 3 - AKI). Prediction of Day 3 - AKI by the RAI and after incorporation of biomarkers with RAI will be analyzed. Discussion: The Assessment of Worldwide Acute Kidney Injury, Renal Angina and Epidemiology (AWARE) study, creates the first prospective international pediatric all cause AKI data warehouse and biologic sample repository, providing a broad and invaluable resource for critical care nephrologists seeking to study risk factors, prediction, identification, and treatment options for a disease syndrome with high associated morbidity affecting a significant proportion of hospitalized children. Trial registration: ClinicalTrials.gov: NCT01987921</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115164798</affiliation-url><afid>115164798</afid><affilname>Cincinnati Children's Hospital</affilname><name-variant>Cincinnati Children's Hospital and Medical Center</name-variant><affiliation-city>Cincinnati</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025152</affiliation-url><afid>60025152</afid><affilname>University of Cincinnati</affilname><name-variant>University of Cincinnati</name-variant><affiliation-city>Cincinnati</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115164798</affiliation-url><afid>115164798</afid><affilname>Cincinnati Children's Hospital</affilname><name-variant>Cincinnati Children's Hospital and Medical Center</name-variant><affiliation-city>Cincinnati</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36597783600</author-url><authid>36597783600</authid><authname>Basu R.</authname><surname>Basu</surname><given-name>Rajit K.</given-name><initials>R.K.</initials><afid>115164798</afid><afid>115164798</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36597783600</author-url><authid>36597783600</authid><authname>Basu R.</authname><surname>Basu</surname><given-name>Rajit K.</given-name><initials>R.K.</initials><afid>115164798</afid><afid>115164798</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56270406100</author-url><authid>56270406100</authid><authname>Kaddourah A.</authname><surname>Kaddourah</surname><given-name>Ahmad</given-name><initials>A.</initials><afid>115164798</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56596407100</author-url><authid>56596407100</authid><authname>Terrell T.</authname><surname>Terrell</surname><given-name>Tara</given-name><initials>T.</initials><afid>115164798</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6506908545</author-url><authid>6506908545</authid><authname>Mottes T.</authname><surname>Mottes</surname><given-name>Theresa</given-name><initials>T.</initials><afid>115164798</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56596192000</author-url><authid>56596192000</authid><authname>Arnold P.</authname><surname>Arnold</surname><given-name>Patricia</given-name><initials>P.</initials><afid>115164798</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56596040700</author-url><authid>56596040700</authid><authname>Jacobs J.</authname><surname>Jacobs</surname><given-name>Judd</given-name><initials>J.</initials><afid>60025152</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6507162542</author-url><authid>6507162542</authid><authname>Andringa J.</authname><surname>Andringa</surname><given-name>Jennifer</given-name><initials>J.</initials><afid>60025152</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7402140713</author-url><authid>7402140713</authid><authname>Goldstein S.</authname><surname>Goldstein</surname><given-name>Stuart L.</given-name><initials>S.L.</initials><afid>115164798</afid></author><authkeywords>Acute kidney injury | Critical care | Pediatrics | Renal angina</authkeywords><intid>1785702779</intid><article-number>24</article-number><source-id>19395</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929999290"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929999290?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929999290&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929999290&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929999290</prism:url><dc:identifier>SCOPUS_ID:84929999290</dc:identifier><eid>2-s2.0-84929999290</eid><dc:title>Adipose-derived mesenchymal stromal cells modulate tendon fibroblast responses to macrophage-induced inflammation in vitro</dc:title><dc:creator>Manning C.</dc:creator><prism:publicationName>Stem Cell Research and Therapy</prism:publicationName><prism:eIssn>17576512</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>1DUMMY</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s13287-015-0059-4</prism:doi><dc:description>© 2015 Manning et al. Abstract Introduction: Macrophage-driven inflammation is a key feature of the early period following tendon repair, but excessive inflammation has been associated with poor clinical outcomes. Modulation of the inflammatory environment using molecular or cellular treatments may provide a means to enhance tendon healing. Methods: To examine the effect of pro-inflammatory cytokines secreted by macrophages on tendon fibroblasts (TF), we established in vitro models of cytokine and macrophage-induced inflammation. Gene expression, protein expression, and cell viability assays were used to examine TF responses. In an effort to reduce the negative effects of inflammatory cytokines on TFs, adipose-derived mesenchymal stromal cells (ASCs) were incorporated into the model and their ability to modulate inflammation was investigated. Results: The inflammatory cytokine interleukin 1 beta (IL-1β) and macrophages of varying phenotypes induced up-regulation of pro-inflammatory factors and matrix degradation factors and down-regulation of factors related to extracellular matrix formation by TFs in culture. ASCs did not suppress these presumably negative effects induced by IL-1β. However, ASC co-culture with M1 (pro-inflammatory) macrophages successfully suppressed the effects of M1 macrophages on TFs by inducing a phenotypic switch from a pro-inflammatory macrophage phenotype to an anti-inflammatory macrophage phenotype, thus resulting in exposure of TFs to lower levels of pro-inflammatory cytokines (e.g., IL-1β, tumor necrosis factor alpha (TNFα)). Conclusions: These findings suggest that IL-1β and M1 macrophages are detrimental to tendon healing and that ASC-mediated modulation of the post-operative inflammatory response may be beneficial for tendon healing.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015424</affiliation-url><afid>60015424</afid><affilname>University of Washington</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015424</affiliation-url><afid>60015424</afid><affilname>University of Washington</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009507</affiliation-url><afid>60009507</afid><affilname>Universite de Montreal</affilname><name-variant>University of Montreal</name-variant><affiliation-city>Montreal</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010261</affiliation-url><afid>60010261</afid><affilname>Washington University in St. Louis</affilname><name-variant>Washington University in St. Louis</name-variant><affiliation-city>St Louis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36139586300</author-url><authid>36139586300</authid><authname>Manning C.</authname><surname>Manning</surname><given-name>Cionne N.</given-name><initials>C.N.</initials><afid>60015424</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7102742165</author-url><authid>7102742165</authid><authname>Martel C.</authname><surname>Martel</surname><given-name>Catherine</given-name><initials>C.</initials><afid>60015424</afid><afid>60009507</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7102742165</author-url><authid>7102742165</authid><authname>Martel C.</authname><surname>Martel</surname><given-name>Catherine</given-name><initials>C.</initials><afid>60015424</afid><afid>60009507</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602592265</author-url><authid>6602592265</authid><authname>Sakiyama-Elbert S.</authname><surname>Sakiyama-Elbert</surname><given-name>Shelly E.</given-name><initials>S.E.</initials><afid>60010261</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7403410528</author-url><authid>7403410528</authid><authname>Silva M.</authname><surname>Silva</surname><given-name>Matthew J.</given-name><initials>M.J.</initials><afid>60015424</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56290081500</author-url><authid>56290081500</authid><authname>Shah S.</authname><surname>Shah</surname><given-name>Shivam</given-name><initials>S.</initials><afid>60015424</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7103123803</author-url><authid>7103123803</authid><authname>Gelberman R.</authname><surname>Gelberman</surname><given-name>Richard H.</given-name><initials>R.H.</initials><afid>60015424</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7005496713</author-url><authid>7005496713</authid><authname>Thomopoulos S.</authname><surname>Thomopoulos</surname><given-name>Stavros</given-name><initials>S.</initials><afid>60015424</afid></author><intid>536050303</intid><article-number>74</article-number><source-id>19700201524</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928969616"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928969616?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928969616&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928969616&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928969616</prism:url><dc:identifier>SCOPUS_ID:84928969616</dc:identifier><eid>2-s2.0-84928969616</eid><dc:title>Interleukin-6 and microRNA profiles induced by oral bacteria in human atheroma derived and healthy smooth muscle cells</dc:title><dc:creator>Pessi T.</dc:creator><prism:publicationName>SpringerPlus</prism:publicationName><prism:eIssn>21931801</prism:eIssn><prism:volume>4</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s40064-015-0993-8</prism:doi><dc:description>© 2015, Pessi et al.; licensee Springer. Background: Atherosclerosis is an inflammatory disease with possible contributions from bacterial antigens. We aimed to investigate the role of oral bacteria as inducers of inflammatory cascades in smooth muscle cells from carotid endarterectomy patients (AthSMCs) and healthy controls (HSMCs). Findings: Inactivated Streptococcus mitis, S. sanguinis, S. gorgonii, Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis were used to stimulate inflammation in HSMCs and AthSMCs. Tumor necrosis factor-α (TNFα) was used as a positive control in all stimulations. Interleukin-6 (IL-6) levels were determined from cell culture supernatants and microRNA expression profiles from cells after 24 h of bacterial stimulation. Genome wide expression (GWE) analyses were performed after 5 h stimulation. All studied bacteria induced pro inflammatory IL-6 production in both SMCs. The most powerful inducer of IL-6 was A. actinomycetemcomitans (p &lt; 0.001). Of the 84 studied miRNAs, expression of 9 miRNAs differed significantly (p ≤ 0.001) between HSMCs and AthSMCs stimulated with inactivated bacteria or TNFα. The data was divided into two groups: high IL-6 producers (A. actinomytectemcomititans and TNFα) and low IL-6 producers (streptococcal strains and P. gingivalis). The expression of 4 miRNAs (miR-181-5p, −186-5p, −28-5p and −155-5p) differed statistically significantly (p &lt; 0.001) between healthy HSMCs and AthSMCs in the low IL-6 producer group. According to multidimensional scaling, two gene expression clusters were seen: one in HSMCs and one AthSMCs. Conclusions: Our results suggest that inactivated oral bacteria induce inflammation that is differently regulated in healthy and atherosclerotic SMCs.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011170</affiliation-url><afid>60011170</afid><affilname>Tampereen Yliopisto</affilname><name-variant>University of Tampere</name-variant><affiliation-city>Tampere</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026851</affiliation-url><afid>60026851</afid><affilname>University of Oxford</affilname><name-variant>Oxford University</name-variant><affiliation-city>Oxford</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024007</affiliation-url><afid>60024007</afid><affilname>Helmholtz Center Munich German Research Center for Environmental Health</affilname><affiliation-city>Neuherberg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024007</affiliation-url><afid>60024007</afid><affilname>Helmholtz Center Munich German Research Center for Environmental Health</affilname><affiliation-city>Neuherberg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:105749815</affiliation-url><afid>105749815</afid><affilname>Lounatmaa Ltd</affilname><name-variant>Lounatmaa Ltd.</name-variant><affiliation-city>Helsinki</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014090</affiliation-url><afid>60014090</afid><affilname>University of Tampere, Medical School</affilname><name-variant>University of Tampere Medical School</name-variant><affiliation-city>Tampere</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">14</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14023413700</author-url><authid>14023413700</authid><authname>Pessi T.</authname><surname>Pessi</surname><given-name>Tanja</given-name><initials>T.</initials><afid>60011170</afid><afid>60026851</afid><afid>60014090</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14023413700</author-url><authid>14023413700</authid><authname>Pessi T.</authname><surname>Pessi</surname><given-name>Tanja</given-name><initials>T.</initials><afid>60011170</afid><afid>60026851</afid><afid>60014090</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14023413700</author-url><authid>14023413700</authid><authname>Pessi T.</authname><surname>Pessi</surname><given-name>Tanja</given-name><initials>T.</initials><afid>60011170</afid><afid>60026851</afid><afid>60014090</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6507734930</author-url><authid>6507734930</authid><authname>Viiri L.</authname><surname>Viiri</surname><given-name>Leena E.</given-name><initials>L.E.</initials><afid>60026851</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:38663008300</author-url><authid>38663008300</authid><authname>Raitoharju E.</authname><surname>Raitoharju</surname><given-name>Emma</given-name><initials>E.</initials><afid>60011170</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56624520400</author-url><authid>56624520400</authid><authname>Astola N.</authname><surname>Astola</surname><given-name>Nagora</given-name><initials>N.</initials><afid>60026851</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:54927389100</author-url><authid>54927389100</authid><authname>Seppälä I.</authname><surname>Seppälä</surname><given-name>Ilkka</given-name><initials>I.</initials><afid>60011170</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36657610100</author-url><authid>36657610100</authid><authname>Waldenberger M.</authname><surname>Waldenberger</surname><given-name>Melanie</given-name><initials>M.</initials><afid>60024007</afid><afid>60024007</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36657610100</author-url><authid>36657610100</authid><authname>Waldenberger M.</authname><surname>Waldenberger</surname><given-name>Melanie</given-name><initials>M.</initials><afid>60024007</afid><afid>60024007</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7003286048</author-url><authid>7003286048</authid><authname>Lounatmaa K.</authname><surname>Lounatmaa</surname><given-name>Kari</given-name><initials>K.</initials><afid>105749815</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55469000400</author-url><authid>55469000400</authid><authname>Davies A.</authname><surname>Davies</surname><given-name>Alun H.</given-name><initials>A.H.</initials><afid>60026851</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7006539182</author-url><authid>7006539182</authid><authname>Lehtimäki T.</authname><surname>Lehtimäki</surname><given-name>Terho</given-name><initials>T.</initials><afid>60011170</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:35479278600</author-url><authid>35479278600</authid><authname>Karhunen P.</authname><surname>Karhunen</surname><given-name>Pekka J.</given-name><initials>P.J.</initials><afid>60011170</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7006885373</author-url><authid>7006885373</authid><authname>Monaco C.</authname><surname>Monaco</surname><given-name>Claudia</given-name><initials>C.</initials><afid>60026851</afid></author><authkeywords>Atherosclerosis | Genome wide expression | Inflammation | microRNA | Oral bacteria | Smooth muscle cells</authkeywords><intid>35877825</intid><source-id>21100228569</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927778499"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927778499?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927778499&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927778499&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927778499</prism:url><dc:identifier>SCOPUS_ID:84927778499</dc:identifier><eid>2-s2.0-84927778499</eid><dc:title>Variability in estimated glomerular filtration rate values is a risk factor in chronic kidney disease progression among patients with diabetes</dc:title><dc:creator>Tseng C.</dc:creator><prism:publicationName>BMC Nephrology</prism:publicationName><prism:eIssn>14712369</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12882-015-0025-52015</prism:doi><dc:description>© 2015 Tseng et al.; licensee BioMed Central. Background: It is unknown whether variability of estimated Glomerular Filtration Rate (eGFR) is a risk factor for dialysis or death in patients with chronic kidney disease (CKD). This study aimed to evaluate variability of estimated Glomerular Filtration Rate (eGFR) as a risk factor for dialysis or death to facilitate optimum care among high risk patients. Methods: A longitudinal retrospective cohort study of 70,598 Veterans Health Administration veteran patients with diabetes and CKD (stage 3-4) in 2000 with up to 5 years of follow-up. VHA and Medicare files were linked to derive study variables. We used Cox proportional hazards models to evaluate association between time to initial dialysis/death and key independent variables: time-varying eGFR variability (measured by standard deviation (SD)) and eGFR means and slopes while adjusting for prior hospitalizations, and comorbidities. Results: There were 76.7% older than 65 years, 97.5% men, and 81.9% Whites. Patients were largely in early stage 3 (61.2%), followed by late stage 3 (28.9%), and stage 4 (9.9%); 29.1%, 46.8%, and 73.3%, respectively, died or had dialysis during the follow-up. eGFR SDs (median: 5.8, 5.1, and 4.0 ml/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;) and means (median: 54.1, 41.0, 27.2 ml/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;) from all two-year moving intervals decreased as CKD advanced; eGFR variability (relative to the mean) increased when CKD progressed (median coefficient of variation: 10.9, 12.8, and 15.4). Cox regressions revealed that one unit increase in a patient's standard deviation of eGFRs from prior two years was significantly associated with about 7% increase in risk of dialysis/death in the current year, similarly in all three CKD stages. This was after adjusting for concurrent means and slopes of eGFRs, demographics, prior hospitalization, and comorbidities. For example, the hazard of dialysis/death increased by 7.2% (hazard ratio:1.072; 95% CI = 1.067, 1.080) in early stage 3. Conclusion: eGFR variability was independently associated with elevated risk of dialysis/death even after controlling for eGFR means and slopes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Department of Veteran Affairs-New Jersey Health Care System</affilname><affiliation-city>East Orange</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000473</affiliation-url><afid>60000473</afid><affilname>Rutgers University-Newark Campus</affilname><name-variant>Rutgers University</name-variant><affiliation-city>Newark</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009507</affiliation-url><afid>60009507</afid><affilname>Universite de Montreal</affilname><name-variant>University of Montreal</name-variant><affiliation-city>Montreal</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030623</affiliation-url><afid>60030623</afid><affilname>Rutgers, The State University of New Jersey</affilname><name-variant>Rutgers University</name-variant><affiliation-city>New Brunswick</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014232</affiliation-url><afid>60014232</afid><affilname>VA Medical Center</affilname><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019674</affiliation-url><afid>60019674</afid><affilname>Boston University</affilname><name-variant>Boston University</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8300313300</author-url><authid>8300313300</authid><authname>Tseng C.</authname><surname>Tseng</surname><given-name>Chin Lin</given-name><initials>C.L.</initials><afid/><afid>60000473</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8300313300</author-url><authid>8300313300</authid><authname>Tseng C.</authname><surname>Tseng</surname><given-name>Chin Lin</given-name><initials>C.L.</initials><afid/><afid>60000473</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6601962550</author-url><authid>6601962550</authid><authname>Lafrance J.</authname><surname>Lafrance</surname><given-name>Jean Philippe</given-name><initials>J.P.</initials><afid>60009507</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56573128900</author-url><authid>56573128900</authid><authname>Lu S.</authname><surname>Lu</surname><given-name>Shou En</given-name><initials>S.E.</initials><afid>60030623</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:54789247900</author-url><authid>54789247900</authid><authname>Soroka O.</authname><surname>Soroka</surname><given-name>Orysya</given-name><initials>O.</initials><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8642984600</author-url><authid>8642984600</authid><authname>Miller D.</authname><surname>Miller</surname><given-name>Donald R.</given-name><initials>D.R.</initials><afid>60014232</afid><afid>60019674</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8642984600</author-url><authid>8642984600</authid><authname>Miller D.</authname><surname>Miller</surname><given-name>Donald R.</given-name><initials>D.R.</initials><afid>60014232</afid><afid>60019674</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:12776043500</author-url><authid>12776043500</authid><authname>Maney M.</authname><surname>Maney</surname><given-name>Miriam</given-name><initials>M.</initials><afid/></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7004292615</author-url><authid>7004292615</authid><authname>Pogach L.</authname><surname>Pogach</surname><given-name>Leonard M.</given-name><initials>L.M.</initials><afid/><afid>60000473</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7004292615</author-url><authid>7004292615</authid><authname>Pogach L.</authname><surname>Pogach</surname><given-name>Leonard M.</given-name><initials>L.M.</initials><afid/><afid>60000473</afid></author><authkeywords>Chronic kidney disease | Diabetes | Dialysis | Glomerular filtration rate | Mortality</authkeywords><intid>35665144</intid><article-number>34</article-number><source-id>19395</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927669516"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927669516?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927669516&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927669516&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S2352250X15001335"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927669516</prism:url><dc:identifier>SCOPUS_ID:84927669516</dc:identifier><eid>2-s2.0-84927669516</eid><dc:title>Moral judgments and impressions</dc:title><dc:creator>Wojciszke B.</dc:creator><prism:publicationName>Current Opinion in Psychology</prism:publicationName><prism:issn>2352250X</prism:issn><prism:volume>6</prism:volume><prism:pageRange>50-54</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>December 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.copsyc.2015.03.028</prism:doi><pii>S2352250X15001335</pii><dc:description>© 2015 Elsevier Ltd. Moral psychology is booming and recent years brought a large body of research on moral judgments and impressions. We review up to date results about this important constituent of human morality focusing mainly on: (1) how deontology vs. utilitarianism drives moral judgments, (2) what is the role of intuition and deliberation in moral judgments, (3) how and why morality influences impressions of persons, and (4) how people perceive moral character. We also highlight some limitations of previous research and show how these limitations are being overcome recently.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>University of Social Sciences and Humanities</affilname><name-variant>Department of Psychology</name-variant><affiliation-city>Sopot</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55892756200</author-url><authid>55892756200</authid><authname>Wojciszke B.</authname><surname>Wojciszke</surname><given-name>Bogdan</given-name><initials>B.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24344807400</author-url><authid>24344807400</authid><authname>Parzuchowski M.</authname><surname>Parzuchowski</surname><given-name>Michal</given-name><initials>M.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56189170900</author-url><authid>56189170900</authid><authname>Bocian K.</authname><surname>Bocian</surname><given-name>Konrad</given-name><initials>K.</initials><afid/></author><intid>2035643662</intid><source-id>21100372442</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928542045"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928542045?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928542045&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928542045&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928542045</prism:url><dc:identifier>SCOPUS_ID:84928542045</dc:identifier><eid>2-s2.0-84928542045</eid><dc:title>Prevalence of plasma small dense LDL is increased in obesity in a Thai population</dc:title><dc:creator>Kulanuwat S.</dc:creator><prism:publicationName>Lipids in Health and Disease</prism:publicationName><prism:eIssn>1476511X</prism:eIssn><prism:volume>14</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12944-015-0034-1</prism:doi><dc:description>© 2015 Kulanuwat et al. Abstract Background: Plasma low density lipoprotein (LDL) particles vary in size, density, electrical charge and chemical composition. An increased presence of small dense LDL (sdLDL), along with raised triglyceride concentrations and decreased high density lipoprotein (HDL) cholesterol concentrations is commonly known as the atherogenic triad and has been observed in some cases of obesity, principally in Europe and America. This study examines the prevalence of sdLDL in the plasma of an obese (BMI ≥ 25 kg/m&lt;sup&gt;2&lt;/sup&gt;) Thai population. Methods: Plasma from fasted obese (n = 48) and non-obese (n = 16) Thai participants was subjected to density gradient ultracentrifugation in iodixanol to separate lipoproteins. Gradients were unloaded top-to-bottom into 20 fractions which were assayed for cholesterol, triglyceride, apo B and apo A-1 to identify lipoprotein types and subtypes. Results: LDL cholesterol was subfractionated into LDL I + II (fractions 3-6, ρ = 1.021-1.033 g/ml) which was considered to represent large buoyant LDL (lbLDL), LDL III (fractions 7-9, ρ = 1.036-1.039 g/ml) which was considered to represent sdLDL, and, LDL IV (fractions 10-12, ρ = 1.044-1.051 g/ml) which was considered to represent very sdLDL. Concentrations of LDL III and IV were increased by 15-20% in obese participants whilst that of LDL I + II was concomitantly decreased by 10%. This was accompanied by a 50% increase in plasma triglyceride concentrations and 15% decrease in HDL cholesterol concentrations. Only 3/16 (19%) non-obese participants had a pattern B LDL cholesterol profile (peak density of &gt;1.033 g/ml), whilst 28/48 (58%) obese participants were pattern B. When expressed as a fraction of the LDL concentration, total sdLDL (i.e. LDL III + IV) showed highly significant correlations to plasma triglyceride concentrations and the triglyceride/HDL cholesterol ratio. Conclusions: The prevalence of sdLDL is increased in obesity in a Thai population such that they demonstrate a similar atherogenic triad to that previously observed in European and American populations.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012718</affiliation-url><afid>60012718</afid><affilname>Mahidol University</affilname><name-variant>Mahidol University</name-variant><affiliation-city>Nakon Pathom</affiliation-city><affiliation-country>Thailand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028355</affiliation-url><afid>60028355</afid><affilname>Liverpool John Moores University</affilname><name-variant>Liverpool John Moores University</name-variant><affiliation-city>Liverpool</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028355</affiliation-url><afid>60028355</afid><affilname>Liverpool John Moores University</affilname><name-variant>Liverpool John Moores University</name-variant><affiliation-city>Liverpool</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56136286100</author-url><authid>56136286100</authid><authname>Kulanuwat S.</authname><surname>Kulanuwat</surname><given-name>Sirikul</given-name><initials>S.</initials><afid>60012718</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7003737990</author-url><authid>7003737990</authid><authname>Tungtrongchitr R.</authname><surname>Tungtrongchitr</surname><given-name>Rungsunn</given-name><initials>R.</initials><afid>60012718</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005505253</author-url><authid>7005505253</authid><authname>Billington D.</authname><surname>Billington</surname><given-name>David</given-name><initials>D.</initials><afid>60028355</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202939629</author-url><authid>7202939629</authid><authname>Davies I.</authname><surname>Davies</surname><given-name>Ian G.</given-name><initials>I.G.</initials><afid>60028355</afid></author><authkeywords>BMI | Iodixanol | Large buoyant LDL | Obesity | Small dense LDL | Triglyceride | Ultracentrifugation</authkeywords><intid>535803322</intid><article-number>34</article-number><source-id>14126</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927714379"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927714379?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927714379&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927714379&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927714379</prism:url><dc:identifier>SCOPUS_ID:84927714379</dc:identifier><eid>2-s2.0-84927714379</eid><dc:title>Effect of VDRA on survival in incident hemodialysis patients: Results of the FARO-2 observational study</dc:title><dc:creator>Messa P.</dc:creator><prism:publicationName>BMC Nephrology</prism:publicationName><prism:eIssn>14712369</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12882-015-0006-8</prism:doi><dc:description>© 2015 Messa et al.; licensee BioMed Central. Background: Mortality rate among patients with stage five chronic kidney disease (CKD) maintained on hemodialysis (HD) is high. Although evidence suggests that use of Vitamin D Receptor Activators (VDRA) in CKD patients increases survival, few studies have examined the effect of VDRA in incident HD patients. The FARO-2 study evaluated the clinical outcome of VDRA therapy on mortality in incident HD patients. Methods: FARO-2 was a longitudinal epidemiological study performed on 568 incident HD patients followed prospectively from 26 dialysis centers over a 3-year period. Data were collected every 6 months using a questionnaire, obtaining clinical, biochemical and therapeutic parameters. Kaplan-Meier curves and Cox proportional hazard regression models were used to determine cumulative probability of time-to-death and adjusted hazard ratios. Results: 568 patients (68% male) with an average age of 65.5 years were followed up. Mean dialysis duration at study entry was 3 months. VDRA use increased from 46% at 6 months to 54.7% at 36 months of follow-up (p = 0.08). No difference was observed in the presence of comorbid diseases at baseline in patients with and without VDRA therapy. Cumulative probability of survival at 24 months was 74.5% (95% CI: 70.2-78.3). Patients receiving VDRA therapy showed a significant increase in survival at 24 months (80.7%; 95% CI: 75.7-84.8) compared to those without (63.3%; 95% CI: 54.8-70.7, p &lt;0.01). The presence of vascular disease, decreased hemoglobin, increased P and lack of VDRA treatment were significantly associated with an increased risk of mortality. Lack of VDRA treatment still remained significant as a predictor of mortality after adjusting for levels of PTH, P and Ca (HR = 2.16, 95% CI: 1.09-4.30, p = 0.03). Conclusions: Findings from FARO-2 indicate that in incident HD patients VDRA therapy was associated with increased survival.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103762</affiliation-url><afid>60103762</afid><affilname>IRCCS Foundation Rome</affilname><name-variant>IRCCS</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030318</affiliation-url><afid>60030318</afid><affilname>Universita degli Studi di Milano</affilname><name-variant>University of Milan</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100774402</affiliation-url><afid>100774402</afid><affilname>Dialysis Unit</affilname><name-variant>Renal and Dialysis Unit</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004531</affiliation-url><afid>60004531</afid><affilname>Azienda Ospedaliera Universitaria San Martino</affilname><name-variant>Ospedale S. Martino</name-variant><affiliation-city>Genoa</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60086768</affiliation-url><afid>60086768</afid><affilname>Azienda Ospedaliera di Cremona</affilname><name-variant>Hospital of Cremona</name-variant><affiliation-city>Cremona</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60105169</affiliation-url><afid>60105169</afid><affilname>AbbVie</affilname><name-variant>AbbVie Inc.</name-variant><affiliation-city>North Chicago</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032350</affiliation-url><afid>60032350</afid><affilname>Universita degli Studi di Roma La Sapienza</affilname><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7004425945</author-url><authid>7004425945</authid><authname>Messa P.</authname><surname>Messa</surname><given-name>Piergiorgio</given-name><initials>P.</initials><afid>60103762</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6701688398</author-url><authid>6701688398</authid><authname>Cozzolino M.</authname><surname>Cozzolino</surname><given-name>Mario</given-name><initials>M.</initials><afid>60030318</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36607448100</author-url><authid>36607448100</authid><authname>Brancaccio D.</authname><surname>Brancaccio</surname><given-name>Diego</given-name><initials>D.</initials><afid>100774402</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:24597185500</author-url><authid>24597185500</authid><authname>Cannella G.</authname><surname>Cannella</surname><given-name>Giuseppe</given-name><initials>G.</initials><afid>60004531</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005168442</author-url><authid>7005168442</authid><authname>Malberti F.</authname><surname>Malberti</surname><given-name>Fabio</given-name><initials>F.</initials><afid>60086768</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:46061795700</author-url><authid>46061795700</authid><authname>Costanzo A.</authname><surname>Costanzo</surname><given-name>Anna Maria</given-name><initials>A.M.</initials><afid>60105169</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6504043400</author-url><authid>6504043400</authid><authname>Paparatti U.</authname><surname>Paparatti</surname><given-name>Umberto Di Luzio</given-name><initials>U.D.L.</initials><afid>60105169</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56458033600</author-url><authid>56458033600</authid><authname>Festa V.</authname><surname>Festa</surname><given-name>Vincenzo</given-name><initials>V.</initials><afid>60105169</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56595021500</author-url><authid>56595021500</authid><authname>Gualberti G.</authname><surname>Gualberti</surname><given-name>Giuliana</given-name><initials>G.</initials><afid>60105169</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7003416740</author-url><authid>7003416740</authid><authname>Mazzaferro S.</authname><surname>Mazzaferro</surname><given-name>Sandro</given-name><initials>S.</initials><afid>60032350</afid></author><authkeywords>Calcitriol | CKD-MBD | Hemodialysis | Paricalcitol | PTH</authkeywords><intid>35664406</intid><article-number>11</article-number><source-id>19395</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928324992"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928324992?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928324992&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928324992&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928324992</prism:url><dc:identifier>SCOPUS_ID:84928324992</dc:identifier><eid>2-s2.0-84928324992</eid><dc:title>Use of 4-factor prothrombin complex concentrate in the treatment of a gastrointestinal hemorrhage complicated by dabigatran</dc:title><dc:creator>McGovern T.</dc:creator><prism:publicationName>International Journal of Emergency Medicine</prism:publicationName><prism:issn>18651372</prism:issn><prism:eIssn>18651380</prism:eIssn><prism:volume>8</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12245-015-0059-2</prism:doi><dc:description>© 2015, McGovern et al.; licensee Springer. Target-specific oral anticoagulants (TSOACs) provide patients and healthcare providers with an alternative to vitamin K antagonists (VKA). The TSOACs are of similar or superior efficacy to warfarin, but unlike VKAs, there are no approved ‘antidotes’ for rapid reversal of life-threatening bleeding on therapy. We report here the case of an 83-year-old gentleman, who presented to the emergency department with severe gastrointestinal hemorrhage and coagulopathy (hemoglobin: 5.3 g/dL and INR: 2.2) while on the direct thrombin inhibitor dabigatran. His coagulopathy reversed rapidly after administration of 4-factor prothrombin complex concentrate (4 F-PCC), and after initial administration of 2 units of packed red blood cells, no further product transfusions were required. He was discharged 4 days later without further complications.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027317</affiliation-url><afid>60027317</afid><affilname>St. Joseph's Regional Medical Center</affilname><name-variant>St. Joseph's Regional Medical Center</name-variant><affiliation-city>Paterson</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027317</affiliation-url><afid>60027317</afid><affilname>St. Joseph's Regional Medical Center</affilname><name-variant>St. Joseph's Regional Medical Center</name-variant><affiliation-city>Paterson</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56603842700</author-url><authid>56603842700</authid><authname>McGovern T.</authname><surname>McGovern</surname><given-name>Terrance R.</given-name><initials>T.R.</initials><afid>60027317</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56119410500</author-url><authid>56119410500</authid><authname>McNamee J.</authname><surname>McNamee</surname><given-name>Justin J.</given-name><initials>J.J.</initials><afid>60027317</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56604163000</author-url><authid>56604163000</authid><authname>Malabanan C.</authname><surname>Malabanan</surname><given-name>Christopher</given-name><initials>C.</initials><afid>60027317</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56603843000</author-url><authid>56603843000</authid><authname>Fouad M.</authname><surname>Fouad</surname><given-name>Mohamed A.</given-name><initials>M.A.</initials><afid>60027317</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56603580300</author-url><authid>56603580300</authid><authname>Patel N.</authname><surname>Patel</surname><given-name>Nilesh</given-name><initials>N.</initials><afid>60027317</afid></author><authkeywords>Dabigatran | Emergency medicine | Prothrombin complex concentrate | Reversal | Target-specific oral anticoagulants</authkeywords><intid>535768248</intid><source-id>14500154757</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928998200"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928998200?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928998200&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928998200&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S187220321400047X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928998200</prism:url><dc:identifier>SCOPUS_ID:84928998200</dc:identifier><eid>2-s2.0-84928998200</eid><dc:title>Association and relative importance of multiple obesity measures with bone mineral density: the National Health and Nutrition Examination Survey 2005–2006</dc:title><dc:creator>Yang S.</dc:creator><prism:publicationName>Archives of Osteoporosis</prism:publicationName><prism:issn>18623522</prism:issn><prism:eIssn>18623514</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>1-8</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1007/s11657-015-0219-2</prism:doi><dc:description>© 2015, International Osteoporosis Foundation and National Osteoporosis Foundation. Summary: All obesity measures were positively associated with femoral neck bone mineral density (BMD), but not with lumbar spine BMD. Hip circumference was the most important obesity measure in relation to BMD. Purpose: Multiple measures are used to quantify obesity; different obesity measures have diverse relationship with BMD. Which obesity measure has the most important value in relation to BMD is still poorly understood. We examined the association between multiple obesity measures and BMD and determined the relative importance (RI, percentage of variation) of multiple obesity measures associated with BMD. Methods: Data from 5287 men and women aged between 8 and 69 years (mean age = 29 years) in the National Health and Nutrition Examination Survey 2005–2006 were analyzed. Body mass index (BMI), waist circumference, hip circumference, body fat mass (FM) index, total body FM, abdominal FM, and appendicular FM were considered the exposures and femoral neck and lumbar spine BMD the outcomes. Results: In the multivariable analysis, greater BMI and hip circumference were associated with increased BMD at the lumbar spine and femoral neck (all P &lt; 0.001). The remaining obesity variables were positively associated with increased femoral neck BMD only (all P &lt; 0.001). RI of all obesity measures associated with femoral neck BMD was much greater than that associated with lumbar spine BMD. Moreover, hip circumference had higher RI (19.8 for femoral neck BMD; 7.0 for lumbar spine BMD) than other obesity measures (all RIs ≤14.1 for femoral neck BMD; all RIs ≤3.5 for lumbar spine BMD) in relation to BMD. Conclusions: All obesity measures were positively associated with femoral neck BMD, but not with lumbar spine BMD. Hip circumference was the most important obesity measure in relation to BMD.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009697</affiliation-url><afid>60009697</afid><affilname>University of Manitoba</affilname><name-variant>University of Manitoba</name-variant><affiliation-city>Winnipeg</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115221380</affiliation-url><afid>115221380</afid><affilname>Laobian People’s Hospital</affilname><name-variant>Laobian People’s Hospital</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:39062501200</author-url><authid>39062501200</authid><authname>Yang S.</authname><surname>Yang</surname><given-name>Shuman</given-name><initials>S.</initials><afid>60009697</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56625412300</author-url><authid>56625412300</authid><authname>Shen X.</authname><surname>Shen</surname><given-name>Xuejun</given-name><initials>X.</initials><afid>115221380</afid></author><authkeywords>Bone mineral density | Fat mass | Hip circumference | Obesity | Waist circumference</authkeywords><intid>1535883593</intid><source-id>6000195386</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929298682"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929298682?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929298682&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929298682&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929298682</prism:url><dc:identifier>SCOPUS_ID:84929298682</dc:identifier><eid>2-s2.0-84929298682</eid><dc:title>Hispano-Americans in Europe: What do we know about their health status and determinants? A scoping review</dc:title><dc:creator>Roura M.</dc:creator><prism:publicationName>BMC Public Health</prism:publicationName><prism:eIssn>14712458</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12889-015-1799-x</prism:doi><dc:description>© 2015 Roura et al.; licensee BioMed Central. Abstract Background: Policy makers and health practitioners are in need of guidance to respond to the growing geographic mobility of Hispano-American migrants in Europe. Drawing from contributions from epidemiology, social sciences, demography, psychology, psychiatry and economy, this scoping review provides an up-to-date and comprehensive synthesis of studies addressing the health status and determinants of this population. We describe major research gaps and suggest specific avenues of further inquiry. Methods: We identified systematically papers that addressed the concepts "health" and "Hispano Americans" indexed in five data bases from Jan 1990 to May 2014 with no language restrictions. We screened the 4,464 citations retrieved against exclusion criteria and classified 193 selected references in 12 thematic folders with the aid of the reference management software ENDNOTE X6. After reviewing the full text of all papers we extracted relevant data systematically into a table template to facilitate the synthesising process. Results: Most studies focused on a particular disease, leaving unexplored the interlinkages between different health conditions and how these relate to legislative, health services, environmental, occupational, and other health determinants. We elucidated some consistent results but there were many heterogeneous findings and several popular beliefs were not fully supported by empirical evidence. Few studies adopted a trans-national perspective and many consisted of cross-sectional descriptions that considered "Hispano-Americans" as a homogeneous category, limiting our analysis. Our results are also constrained by the availability and varying quality of studies reviewed. Conclusions: Burgeoning research has produced some consistent findings but there are huge gaps in knowledge. To prevent unhelpful generalisations we need a more holistic and nuanced understanding of how mobility, ethnicity, income, gender, legislative status, employment status, working conditions, neighbourhood characteristics and social status intersect with demographic variables and policy contexts to influence the health of the diverse Hispano-American populations present in Europe.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001576</affiliation-url><afid>60001576</afid><affilname>Universitat de Barcelona</affilname><name-variant>Universitat de Barcelona</name-variant><affiliation-city>Barcelona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023020</affiliation-url><afid>60023020</afid><affilname>Universidad Autonoma de Barcelona</affilname><name-variant>Universitat Autonoma de Barcelona</name-variant><affiliation-city>Barcelona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032942</affiliation-url><afid>60032942</afid><affilname>Universitat Pompeu Fabra</affilname><name-variant>Universitat Pompeu Fabra</name-variant><affiliation-city>Barcelona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002483</affiliation-url><afid>60002483</afid><affilname>University of Amsterdam</affilname><name-variant>University of Amsterdam</name-variant><affiliation-city>Amsterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26422486000</author-url><authid>26422486000</authid><authname>Roura M.</authname><surname>Roura</surname><given-name>Maria</given-name><initials>M.</initials><afid>60001576</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35993033800</author-url><authid>35993033800</authid><authname>Domingo A.</authname><surname>Domingo</surname><given-name>Andreu</given-name><initials>A.</initials><afid>60023020</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:17135208600</author-url><authid>17135208600</authid><authname>Leyva-Moral J.</authname><surname>Leyva-Moral</surname><given-name>Juan M.</given-name><initials>J.M.</initials><afid>60032942</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7103248551</author-url><authid>7103248551</authid><authname>Pool R.</authname><surname>Pool</surname><given-name>Robert</given-name><initials>R.</initials><afid>60002483</afid></author><authkeywords>Ethnic minorities | Europe | Hispano-Americans | Latin-Americans | Latinos' health | Migrants' health | Mobility and health | Population movements | Research agenda | Social determinants of health | Social epidemiology | Social sciences</authkeywords><intid>1535943524</intid><article-number>1799</article-number><source-id>19621</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929330688"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929330688?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929330688&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929330688&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929330688</prism:url><dc:identifier>SCOPUS_ID:84929330688</dc:identifier><eid>2-s2.0-84929330688</eid><dc:title>Sex differences in the impact of the Mediterranean diet on systemic inflammation</dc:title><dc:creator>Bédard A.</dc:creator><prism:publicationName>Nutrition Journal</prism:publicationName><prism:eIssn>14752891</prism:eIssn><prism:volume>14</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12937-015-0035-y</prism:doi><dc:description>© 2015 Bédard et al.; licensee BioMed Central. Abstract Background: Some intervention trials have reported a reduction in systemic inflammation with the Mediterranean diet (MedDiet) while others have observed no effect. Despite the fact that sex differences have been highlighted in the inflammatory regulation, it is still not known whether MedDiet exerts similar effects on systemic inflammation in men and women. The aim of this study was therefore to investigate sex differences in the effects of the MedDiet on high-sensitivity C-reactive protein (hs-CRP). Findings: Participants were 35 men and 27 premenopausal women (24-53 years) presenting a slightly deteriorated lipid profile. All foods were provided to participants during a 4-week isocaloric MedDiet. At baseline, women had higher hs-CRP concentrations than men (P = 0.03). No sex difference was observed in hs-CRP response to the MedDiet (P for sex-by-time interaction = 0.36), with both men and women experiencing no change (respectively P = 0.62 and P &gt; 0.99). When subgroups were formed according to hs-CRP concentration before the MedDiet phase, men with elevated baseline values (≥2 mg/l) experienced a reduction in hs-CRP over time with the MedDiet (-26.5 %) while an increase was observed in men with lower baseline values (+96.6 %; P for group-by-time interaction = 0.02). This pattern of change was not observed in women. Conclusions: Results from this controlled feeding study suggest that men and women have similar effects from the MedDiet on systemic inflammation. The individual's overall inflammatory status seems to influence these effects, but only in men. Trial registration: This clinical trial was registered at www.clinicaltrials.gov as NCT01293344.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032619</affiliation-url><afid>60032619</afid><affilname>Universite Laval</affilname><name-variant>Université Laval</name-variant><affiliation-city>Quebec</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032619</affiliation-url><afid>60032619</afid><affilname>Universite Laval</affilname><name-variant>Université Laval</name-variant><affiliation-city>Quebec</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032619</affiliation-url><afid>60032619</afid><affilname>Universite Laval</affilname><name-variant>Université Laval</name-variant><affiliation-city>Quebec</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36715974900</author-url><authid>36715974900</authid><authname>Bédard A.</authname><surname>Bédard</surname><given-name>Alexandra</given-name><initials>A.</initials><afid>60032619</afid><afid>60032619</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36715974900</author-url><authid>36715974900</authid><authname>Bédard A.</authname><surname>Bédard</surname><given-name>Alexandra</given-name><initials>A.</initials><afid>60032619</afid><afid>60032619</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55409540700</author-url><authid>55409540700</authid><authname>Lamarche B.</authname><surname>Lamarche</surname><given-name>Benoît</given-name><initials>B.</initials><afid>60032619</afid><afid>60032619</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55409540700</author-url><authid>55409540700</authid><authname>Lamarche B.</authname><surname>Lamarche</surname><given-name>Benoît</given-name><initials>B.</initials><afid>60032619</afid><afid>60032619</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6603116639</author-url><authid>6603116639</authid><authname>Corneau L.</authname><surname>Corneau</surname><given-name>Louise</given-name><initials>L.</initials><afid>60032619</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603919262</author-url><authid>6603919262</authid><authname>Dodin S.</authname><surname>Dodin</surname><given-name>Sylvie</given-name><initials>S.</initials><afid>60032619</afid><afid>60032619</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603919262</author-url><authid>6603919262</authid><authname>Dodin S.</authname><surname>Dodin</surname><given-name>Sylvie</given-name><initials>S.</initials><afid>60032619</afid><afid>60032619</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004556060</author-url><authid>7004556060</authid><authname>Lemieux S.</authname><surname>Lemieux</surname><given-name>Simone</given-name><initials>S.</initials><afid>60032619</afid><afid>60032619</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004556060</author-url><authid>7004556060</authid><authname>Lemieux S.</authname><surname>Lemieux</surname><given-name>Simone</given-name><initials>S.</initials><afid>60032619</afid><afid>60032619</afid></author><authkeywords>C-reactive protein | Mediterranean diet | Men | Sex | Women</authkeywords><intid>1035941447</intid><article-number>35</article-number><source-id>12653</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928573383"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928573383?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928573383&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928573383&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928573383</prism:url><dc:identifier>SCOPUS_ID:84928573383</dc:identifier><eid>2-s2.0-84928573383</eid><dc:title>Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: A double-blind, randomized, cross-over clinical trial</dc:title><dc:creator>Cicero A.</dc:creator><prism:publicationName>Nutrition Journal</prism:publicationName><prism:eIssn>14752891</prism:eIssn><prism:volume>14</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>1-6</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12937-015-0019-y</prism:doi><dc:description>© 2015 Cicero et al.; licensee BioMed Central. Abstract Background: Overweight subjects easily develop alterations of the glucose and lipid metabolism and are exposed to an increased cardiometabolic risk. This condition is potentially reversible through the improvement of dietary and behavioural habits. However, a well-assembled nutraceutical would be a useful tool to better improve the metabolic parameters associated to overweight and insulin resistance. Methods: To evaluate the effect of a combined nutraceutical containing berberine, chlorogenic acid and tocotrienols, we performed a double blind, cross-over designed trial versus placebo, in 40 overweight subjects with mixed hyperlipidaemia. After the first 8 weeks of treatment (or placebo), patients were asked to observe a 2-week washout period, and they were then assigned to the alternative treatment for a further period of 8 weeks. Clinical and laboratory data associated to hyperlipidaemia and insulin resistance have been obtained at the baseline, at the end of the first treatment period, after the washout, and again after the second treatment period. Results: Both groups experienced a significant improvement of anthropometric and biochemical parameters versus baseline. However, total cholesterol, LDL cholesterol, triglycerides, non-HDL cholesterol, fasting insulin, HOMA-IR, GOT and Lipid Accumulation Product decreased more significantly in the nutraceutical group versus placebo. Conclusions: This combination seems to improve a large number of metabolic and liver parameters on the short-term in overweight subjects. Further studies are needed to confirm these observations on the middle- and long-term.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028218</affiliation-url><afid>60028218</afid><affilname>Alma Mater Studiorum Universita di Bologna</affilname><name-variant>University of Bologna</name-variant><affiliation-city>Bologna</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114912466</affiliation-url><afid>114912466</afid><affilname>Hypertension Research Center</affilname><name-variant>Hypertension Research Center</name-variant><affiliation-city>Bologna</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55409152800</author-url><authid>55409152800</authid><authname>Cicero A.</authname><surname>Cicero</surname><given-name>Arrigo FG</given-name><initials>A.F.</initials><afid>60028218</afid><afid>114912466</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55409152800</author-url><authid>55409152800</authid><authname>Cicero A.</authname><surname>Cicero</surname><given-name>Arrigo FG</given-name><initials>A.F.</initials><afid>60028218</afid><afid>114912466</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:37054598600</author-url><authid>37054598600</authid><authname>Rosticci M.</authname><surname>Rosticci</surname><given-name>Martina</given-name><initials>M.</initials><afid>60028218</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56343808900</author-url><authid>56343808900</authid><authname>Parini A.</authname><surname>Parini</surname><given-name>Angelo</given-name><initials>A.</initials><afid>60028218</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56341321600</author-url><authid>56341321600</authid><authname>Morbini M.</authname><surname>Morbini</surname><given-name>Martino</given-name><initials>M.</initials><afid>60028218</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56236087300</author-url><authid>56236087300</authid><authname>Urso R.</authname><surname>Urso</surname><given-name>Riccardo</given-name><initials>R.</initials><afid>60028218</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7006578865</author-url><authid>7006578865</authid><authname>Grandi E.</authname><surname>Grandi</surname><given-name>Elisa</given-name><initials>E.</initials><afid>60028218</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7102731762</author-url><authid>7102731762</authid><authname>Borghi C.</authname><surname>Borghi</surname><given-name>Claudio</given-name><initials>C.</initials><afid>60028218</afid></author><authkeywords>Berberine | Chlorogenic acid | Insulin-sensitivity | Lipoproteins | Liver steatosis | Nutraceutical</authkeywords><intid>1035797441</intid><article-number>19</article-number><source-id>12653</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927739358"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927739358?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927739358&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927739358&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927739358</prism:url><dc:identifier>SCOPUS_ID:84927739358</dc:identifier><eid>2-s2.0-84927739358</eid><dc:title>Urinary albumin excretion in healthy adults: A cross sectional study of 24-hour versus timed overnight samples and impact of GFR and other personal characteristics</dc:title><dc:creator>Fagerstrom P.</dc:creator><prism:publicationName>BMC Nephrology</prism:publicationName><prism:eIssn>14712369</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/1471-2369-16-8</prism:doi><dc:description>© 2015 Fagerstrom et al.; licensee BioMed Central. Background: Urinary albumin can be measured in 24 h or spot samples. The 24 h urinary albumin excretion rate is considered the gold standard, but is cumbersome to collect. Instead, often an overnight sample is collected, and adjusted for dilution. Proxies for 24 h excretion rate have been studied in diabetics, but seldom in healthy individuals. Our aims were to compare 24 h and overnight albumin excretion, to assess the impact of personal characteristics, and to examine correlations between the 24 h excretion rate and proxies such as the albumin to creatinine ratio (ACR). Methods: Separate 24 h and overnight urine samples were collected from 152 healthy kidney donors. Urinary creatinine, specific gravity, collection time, and sample volume determined. Differences between 24 h and overnight samples were examined, and the effects of age, sex, smoking, body mass, glomerular filtration rate, and urinary flow rate were assessed. Results: The 24 h albumin excretion rate and ACR were both significantly higher than their overnight counterparts. Unadjusted albumin was unsurprisingly higher in the more concentrated overnight samples, while concentrations adjusted for specific gravity were similar. In multivariate analysis, the 24 h excretion rate and proxies were positively associated with glomerular filtration rate, as was ACR in overnight samples. There were positive associations between urinary albumin and body mass. Conclusions: Proxies for the 24 h albumin excretion rate showed relatively high correlations with this gold standard, but differences due to sampling period, adjustment method, and personal characteristics were large enough to be worth considering in studies of albumin excretion in healthy individuals.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027675</affiliation-url><afid>60027675</afid><affilname>Sahlgrenska Academy</affilname><name-variant>Göteborg University</name-variant><affiliation-city>Gothenburg</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027675</affiliation-url><afid>60027675</afid><affilname>Sahlgrenska Academy</affilname><name-variant>Göteborg University</name-variant><affiliation-city>Gothenburg</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56594909400</author-url><authid>56594909400</authid><authname>Fagerstrom P.</authname><surname>Fagerstrom</surname><given-name>Peter</given-name><initials>P.</initials><afid>60027675</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56259794500</author-url><authid>56259794500</authid><authname>Sallsten G.</authname><surname>Sallsten</surname><given-name>Gerd</given-name><initials>G.</initials><afid>60027675</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:37051777800</author-url><authid>37051777800</authid><authname>Akerstrom M.</authname><surname>Akerstrom</surname><given-name>Magnus</given-name><initials>M.</initials><afid>60027675</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:19733858100</author-url><authid>19733858100</authid><authname>Haraldsson B.</authname><surname>Haraldsson</surname><given-name>Borje</given-name><initials>B.</initials><afid>60027675</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55953218700</author-url><authid>55953218700</authid><authname>Barregard L.</authname><surname>Barregard</surname><given-name>Lars</given-name><initials>L.</initials><afid>60027675</afid></author><authkeywords>24-hour samples | Glomerular filtration rate | Overnight samples | Timed urine samples | Urinary albumin</authkeywords><intid>535667713</intid><source-id>19395</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929084881"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929084881?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929084881&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929084881&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929084881</prism:url><dc:identifier>SCOPUS_ID:84929084881</dc:identifier><eid>2-s2.0-84929084881</eid><dc:title>Efficacy of virtual reality-based intervention on balance and mobility disorders post-stroke: A scoping review</dc:title><dc:creator>Darekar A.</dc:creator><prism:publicationName>Journal of NeuroEngineering and Rehabilitation</prism:publicationName><prism:eIssn>17430003</prism:eIssn><prism:volume>12</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12984-015-0035-3</prism:doi><dc:description>© 2015 Darekar et al.; licensee BioMed Central. Abstract Rehabilitation interventions involving virtual reality (VR) technology have been developed for the promotion of functional independence post stroke. A scoping review was performed to examine the efficacy of VR-based interventions on balance and mobility disorders post stroke. Twenty-four articles in the English language examining VR game-based interventions and outcomes directed at balance and mobility disorders were included. Various VR systems (customized and commercially available) were used as rehabilitation tools. Outcome measures included laboratory and clinical measures of balance and gait. Outcome measures of dynamic balance showed significant improvements following VR-based interventions as compared to other interventions. Further, it was observed that VR-based intervention may have favorable effects in improving walking speed and the ability to deal with environmental challenges, which may also facilitate independent community ambulation. VR-based therapy thus has the potential to be a useful tool for balance and gait training for stroke rehabilitation. Utilization of motor learning principles related to task-related training may have been an important factor leading to positive results. Other principles such as repetition, feedback etc. were used in studies but were not explored explicitly and may need to be investigated to further improve the strength of results. Lastly, robust study designs with appropriate attention towards the intensity and dose-response aspects of VR training, clear study objectives and suitable outcomes would further aid in determining evidence-based efficacy for VR game-based interventions in the future.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002494</affiliation-url><afid>60002494</afid><affilname>McGill University</affilname><name-variant>McGill University</name-variant><affiliation-city>Montreal</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009729</affiliation-url><afid>60009729</afid><affilname>Jewish Rehabilitation Hospital</affilname><name-variant>Jewish Rehabilitation Hospital</name-variant><affiliation-city>Laval</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032619</affiliation-url><afid>60032619</afid><affilname>Universite Laval</affilname><name-variant>Université Laval</name-variant><affiliation-city>Quebec</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:50060972700</author-url><authid>50060972700</authid><authname>Darekar A.</authname><surname>Darekar</surname><given-name>Anuja</given-name><initials>A.</initials><afid>60002494</afid><afid>60009729</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:50060972700</author-url><authid>50060972700</authid><authname>Darekar A.</authname><surname>Darekar</surname><given-name>Anuja</given-name><initials>A.</initials><afid>60002494</afid><afid>60009729</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004877191</author-url><authid>7004877191</authid><authname>McFadyen B.</authname><surname>McFadyen</surname><given-name>Bradford J.</given-name><initials>B.J.</initials><afid>60032619</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005939483</author-url><authid>7005939483</authid><authname>Lamontagne A.</authname><surname>Lamontagne</surname><given-name>Anouk</given-name><initials>A.</initials><afid>60002494</afid><afid>60009729</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005939483</author-url><authid>7005939483</authid><authname>Lamontagne A.</authname><surname>Lamontagne</surname><given-name>Anouk</given-name><initials>A.</initials><afid>60002494</afid><afid>60009729</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7203073358</author-url><authid>7203073358</authid><authname>Fung J.</authname><surname>Fung</surname><given-name>Joyce</given-name><initials>J.</initials><afid>60002494</afid><afid>60009729</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7203073358</author-url><authid>7203073358</authid><authname>Fung J.</authname><surname>Fung</surname><given-name>Joyce</given-name><initials>J.</initials><afid>60002494</afid><afid>60009729</afid></author><authkeywords>Balance deficits | Cerebrovascular accident | Gait | Gait retraining | Game-based rehabilitation | Physiotherapy | Posture | Rehabilitation | Stroke | Virtual reality</authkeywords><intid>1785901744</intid><article-number>35</article-number><source-id>130095</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928711292"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928711292?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928711292&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928711292&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928711292</prism:url><dc:identifier>SCOPUS_ID:84928711292</dc:identifier><eid>2-s2.0-84928711292</eid><dc:title>Immune cells subpopulations in cerebrospinal fluid and peripheral blood of patients with Aneurysmal Subarachnoid Hemorrhage</dc:title><dc:creator>Moraes L.</dc:creator><prism:publicationName>SpringerPlus</prism:publicationName><prism:eIssn>21931801</prism:eIssn><prism:volume>4</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s40064-015-0970-2</prism:doi><dc:description>© 2015, Moraes et al.; licensee Springer. Background: There is growing evidence supporting the role of inflammation in aneurysmal subarachnoid hemorrhage (aSAH) pathophysiology and it is of great interest to elucidate which immune mechanisms are involved. Methods: 12 aSAH patients and 28 healthy controls were enrolled prospectively. We assessed leukocytes subpopulations and their activation status by flow cytometry in cerebrospinal fluid (CSF) and peripheral blood (PB) of SAH patients at the same time and in PB of controls. Results: Monocytes and neutrophils were activated in CSF of aSAH patients. The percentage of CD14&lt;sup&gt;++&lt;/sup&gt;CD16&lt;sup&gt;+&lt;/sup&gt; monocytes were higher in CSF than in PB of aSAH patients, and were also increased in PB of aSAH patients compared with controls. An enhanced expression of CD69 was shown in CSF neutrophils compared with PB in aSAH patients. PB of aSAH patients showed lower percentage of total lymphocytes compared with controls PB. Additionally, lymphocytes were activated in CSF and PB of aSAH patients. CD4&lt;sup&gt;+&lt;/sup&gt; and CD8&lt;sup&gt;+&lt;/sup&gt; T cells had a decreased expression on CD3 and higher levels of CD69 in CSF compared with PB in aSAH patients. Moreover, PB CD4&lt;sup&gt;+&lt;/sup&gt; and CD8&lt;sup&gt;+&lt;/sup&gt; T cells of aSAH patients were activated compared with controls. Additionally, CD28 expression was decreased on CSF T lymphocytes. Conclusions: Our data suggest an important recruitment of leukocytes to the site of injury in aSAH as well as an increased activation at this level. Overall, these results indicate that aSAH probably stimulates both the innate and adaptive immune responses.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60071612</affiliation-url><afid>60071612</afid><affilname>Universidad de la Republica</affilname><name-variant>Universidad de la República</name-variant><affiliation-city>Montevideo</affiliation-city><affiliation-country>Uruguay</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60071612</affiliation-url><afid>60071612</afid><affilname>Universidad de la Republica</affilname><name-variant>Universidad de la República</name-variant><affiliation-city>Montevideo</affiliation-city><affiliation-country>Uruguay</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60071613</affiliation-url><afid>60071613</afid><affilname>Universidad de la Republica Facultad de Medicina</affilname><name-variant>Fac. Med.</name-variant><affiliation-city>Montevideo</affiliation-city><affiliation-country>Uruguay</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60071612</affiliation-url><afid>60071612</afid><affilname>Universidad de la Republica</affilname><name-variant>Universidad de la República</name-variant><affiliation-city>Montevideo</affiliation-city><affiliation-country>Uruguay</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15840268400</author-url><authid>15840268400</authid><authname>Moraes L.</authname><surname>Moraes</surname><given-name>Leandro</given-name><initials>L.</initials><afid>60071612</afid><afid>60071612</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15840268400</author-url><authid>15840268400</authid><authname>Moraes L.</authname><surname>Moraes</surname><given-name>Leandro</given-name><initials>L.</initials><afid>60071612</afid><afid>60071612</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24824402000</author-url><authid>24824402000</authid><authname>Grille S.</authname><surname>Grille</surname><given-name>Sofía</given-name><initials>S.</initials><afid>60071612</afid><afid>60071613</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24824402000</author-url><authid>24824402000</authid><authname>Grille S.</authname><surname>Grille</surname><given-name>Sofía</given-name><initials>S.</initials><afid>60071612</afid><afid>60071613</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56611620000</author-url><authid>56611620000</authid><authname>Morelli P.</authname><surname>Morelli</surname><given-name>Paula</given-name><initials>P.</initials><afid>60071612</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:24824829700</author-url><authid>24824829700</authid><authname>Mila R.</authname><surname>Mila</surname><given-name>Rafael</given-name><initials>R.</initials><afid>60071612</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56612016300</author-url><authid>56612016300</authid><authname>Trias N.</authname><surname>Trias</surname><given-name>Natalia</given-name><initials>N.</initials><afid>60071612</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8150248600</author-url><authid>8150248600</authid><authname>Brugnini A.</authname><surname>Brugnini</surname><given-name>Andreína</given-name><initials>A.</initials><afid>60071612</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55672381600</author-url><authid>55672381600</authid><authname>LLuberas N.</authname><surname>LLuberas</surname><given-name>Natalia</given-name><initials>N.</initials><afid>60071612</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603494763</author-url><authid>6603494763</authid><authname>Biestro A.</authname><surname>Biestro</surname><given-name>Alberto</given-name><initials>A.</initials><afid>60071612</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6602595381</author-url><authid>6602595381</authid><authname>Lens D.</authname><surname>Lens</surname><given-name>Daniela</given-name><initials>D.</initials><afid>60071612</afid></author><authkeywords>Aneurysmal subarachnoid hemorrhage | Cerebrospinal fluid | Flow cytometry | Neuroinflammation | Systemic inflammation</authkeywords><intid>35838983</intid><source-id>21100228569</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929158727"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929158727?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929158727&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929158727&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0261517715000813"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929158727</prism:url><dc:identifier>SCOPUS_ID:84929158727</dc:identifier><eid>2-s2.0-84929158727</eid><dc:title>Staff turnover in hotels: Exploring the quadratic and linear relationships</dc:title><dc:creator>Mohsin A.</dc:creator><prism:publicationName>Tourism Management</prism:publicationName><prism:issn>02615177</prism:issn><prism:volume>51</prism:volume><prism:pageRange>35-48</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>December 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.tourman.2015.04.005</prism:doi><pii>S0261517715000813</pii><dc:description>© 2015 Elsevier Ltd. The aim of this study is to assess whether the relationship between intention to leave the job and its antecedents is quadratic or linear. To explore those relationships a theoretical model (see Fig. 1) and eight hypotheses are proposed. Each linear hypothesis is followed by an alternative quadratic hypothesis. The alternative hypotheses propose that the relationship between the four antecedent constructs and intention to leave the job might not be linear, as the existing literature suggests. Findings from the analyses of 884 responses representing the staff of luxury hotels in India, suggest that the effect of two antecedents i.e. job security, earnings and organisational loyalty, were found to be linear. The two other antecedents i.e. organisational enthusiasm and stimulating job, confirmed a quadratic relationship with intention to leave the job, although one result suggesting that neither high salary nor job security are guarantees of improvements in staff turnover has been somewhat surprising. These results are unique within the context of human resource practices in luxury hotels. The study is distinctive with its findings based on quadratic analysis. It has implications for managers of luxury hotels to the effect that too much of a good thing may not ensure that employees will remain in the job. Secondly, there is little evidence in the literature of similar analytical approaches within the context of luxury hotels in India or elsewhere being undertaken to assess staff turnover. In this way, the outcomes have implications for both practice and theory.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004424</affiliation-url><afid>60004424</afid><affilname>University of Waikato</affilname><name-variant>University of Waikato</name-variant><affiliation-city>Hamilton</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028300</affiliation-url><afid>60028300</afid><affilname>Instituto Universitário de Lisboa</affilname><name-variant>ISCTE</name-variant><affiliation-city>Lisbon</affiliation-city><affiliation-country>Portugal</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028300</affiliation-url><afid>60028300</afid><affilname>Instituto Universitário de Lisboa</affilname><name-variant>ISCTE</name-variant><affiliation-city>Lisbon</affiliation-city><affiliation-country>Portugal</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:21233970200</author-url><authid>21233970200</authid><authname>Mohsin A.</authname><surname>Mohsin</surname><given-name>Asad</given-name><initials>A.</initials><afid>60004424</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:54967966400</author-url><authid>54967966400</authid><authname>Lengler J.</authname><surname>Lengler</surname><given-name>Jorge</given-name><initials>J.</initials><afid>60028300</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56115759500</author-url><authid>56115759500</authid><authname>Aguzzoli R.</authname><surname>Aguzzoli</surname><given-name>Roberta</given-name><initials>R.</initials><afid>60028300</afid></author><authkeywords>Hotels | India | Quadratic analysis | Staff turnover</authkeywords><intid>35916553</intid><source-id>16547</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928632949"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928632949?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928632949&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928632949&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928632949</prism:url><dc:identifier>SCOPUS_ID:84928632949</dc:identifier><eid>2-s2.0-84928632949</eid><dc:title>A survey of diet self-efficacy and food intake in students with high and low perceived stress</dc:title><dc:creator>Nastaskin R.</dc:creator><prism:publicationName>Nutrition Journal</prism:publicationName><prism:eIssn>14752891</prism:eIssn><prism:volume>14</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12937-015-0026-z</prism:doi><dc:description>© 2015 Nataskin and Fiocco. Abstract Objective: Given the rise in obesity and obesity-related disorders, understanding the relationship between stress, self-efficacy and food choice in young adulthood may have implications for preventing negative health outcomes later in life that stem from poor eating habits. The current study examined whether stress levels and diet self-efficacy may be associated with unhealthy eating habits in young adults. Methods: Male and female undergraduate students (N = 136) completed questionnaires that tap into diet self-efficacy (DSE), perceived stress (PS), sodium, and fat intake. Sex differences in choice of food were predicted, and low levels of perceived stress and high diet self-efficacy were expected to be associated with lower fat and sodium intake. Results: Findings indicate an interaction between perceived stress and diet self-efficacy on fat intake and a main effect for diet self-efficacy on sodium intake in this population. As expected, low levels of perceived stress and high diet self-efficacy were associated with the lowest levels of fat and sodium intake in students. Findings were driven by females. Conclusions: This study provides preliminary evidence that diet self-efficacy and perceived stress levels relate to nutrient intake in young adult females, and that increasing diet self-efficacy and reducing perceived stress in young adult females may lead to reductions in fat and sodium intake, leading to healthier eating habits.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030838</affiliation-url><afid>60030838</afid><affilname>Ryerson University</affilname><name-variant>Ryerson University</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56609186300</author-url><authid>56609186300</authid><authname>Nastaskin R.</authname><surname>Nastaskin</surname><given-name>Robyn S.</given-name><initials>R.S.</initials><afid>60030838</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6505928777</author-url><authid>6505928777</authid><authname>Fiocco A.</authname><surname>Fiocco</surname><given-name>Alexandra J.</given-name><initials>A.J.</initials><afid>60030838</afid></author><authkeywords>Diet self-efficacy | Fat | Food intake | Sodium | Stress</authkeywords><intid>1035809631</intid><article-number>26</article-number><source-id>12653</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927771835"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927771835?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927771835&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927771835&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927771835</prism:url><dc:identifier>SCOPUS_ID:84927771835</dc:identifier><eid>2-s2.0-84927771835</eid><dc:title>A pharmacist based intervention to improve the care of patients with CKD: A pragmatic, randomized, controlled trial</dc:title><dc:creator>Cooney D.</dc:creator><prism:publicationName>BMC Nephrology</prism:publicationName><prism:eIssn>14712369</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12882-015-0052-2</prism:doi><dc:description>© 2015 Cooney et al.; licensee BioMed Central. Background: Primary care providers do not routinely follow guidelines for the care of patients with chronic kidney disease (CKD). Multidisciplinary efforts may improve care for patients with chronic disease. Pharmacist based interventions have effectively improved management of hypertension. We performed a pragmatic, randomized, controlled trial to evaluate the effect of a pharmacist based quality improvement program on 1) outcomes for patients with CKD and 2) adherence to CKD guidelines in the primary care setting. Methods: Patients with moderate to severe CKD receiving primary care services at one of thirteen community-based Veterans Affairs outpatient clinics were randomized to a multifactorial intervention that included a phone-based pharmacist intervention, pharmacist-physician collaboration, patient education, and a CKD registry (n = 1070) or usual care (n = 1129). The primary process outcome was measurement of parathyroid hormone (PTH) during the one year study period. The primary clinical outcome was blood pressure (BP) control in subjects with poorly controlled hypertension at baseline. Results: Among those with poorly controlled baseline BP, there was no difference in the last recorded BP or the percent at goal BP during the study period (42.0% vs. 41.2% in the control arm). Subjects in the intervention arm were more likely to have a PTH measured during the study period (46.9% vs. 16.1% in the control arm, P &lt;0.001) and were on more classes of antihypertensive medications at the end of the study (P = 0.02). Conclusions: A one-time pharmacist based intervention proved feasible in patients with CKD. While the intervention did not improve BP control, it did improve guideline adherence and increased the number of antihypertensive medications prescribed to subjects with poorly controlled BP. These findings can inform the design of quality improvement programs and future studies which are needed to improve care of patients with CKD. Trial registration: ClinicalTrials.gov: NCT01290614.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014232</affiliation-url><afid>60014232</afid><affilname>VA Medical Center</affilname><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000305</affiliation-url><afid>60000305</afid><affilname>Case Western Reserve University</affilname><name-variant>Case Western Reserve University</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026695</affiliation-url><afid>60026695</afid><affilname>UT Southwestern Medical Center</affilname><name-variant>University of Texas Southwestern Medical Center</name-variant><affiliation-city>Dallas</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027486</affiliation-url><afid>60027486</afid><affilname>MetroHealth Medical Center Cleveland</affilname><name-variant>MetroHealth Medical Center</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005745</affiliation-url><afid>60005745</afid><affilname>University of Minnesota System</affilname><name-variant>University of Minnesota</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26649783300</author-url><authid>26649783300</authid><authname>Cooney D.</authname><surname>Cooney</surname><given-name>Danielle</given-name><initials>D.</initials><afid>60014232</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56594200400</author-url><authid>56594200400</authid><authname>Moon H.</authname><surname>Moon</surname><given-name>Helen</given-name><initials>H.</initials><afid>60014232</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56594458100</author-url><authid>56594458100</authid><authname>Liu Y.</authname><surname>Liu</surname><given-name>Yang</given-name><initials>Y.</initials><afid>60000305</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56605530600</author-url><authid>56605530600</authid><authname>Miller R.</authname><surname>Miller</surname><given-name>Richard Tyler</given-name><initials>R.T.</initials><afid>60026695</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36979453700</author-url><authid>36979453700</authid><authname>Perzynski A.</authname><surname>Perzynski</surname><given-name>Adam</given-name><initials>A.</initials><afid>60000305</afid><afid>60027486</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36979453700</author-url><authid>36979453700</authid><authname>Perzynski A.</authname><surname>Perzynski</surname><given-name>Adam</given-name><initials>A.</initials><afid>60000305</afid><afid>60027486</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:15756231200</author-url><authid>15756231200</authid><authname>Watts B.</authname><surname>Watts</surname><given-name>Brook</given-name><initials>B.</initials><afid>60014232</afid><afid>60000305</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:15756231200</author-url><authid>15756231200</authid><authname>Watts B.</authname><surname>Watts</surname><given-name>Brook</given-name><initials>B.</initials><afid>60014232</afid><afid>60000305</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:25521104500</author-url><authid>25521104500</authid><authname>Drawz P.</authname><surname>Drawz</surname><given-name>Paul E.</given-name><initials>P.E.</initials><afid>60005745</afid></author><authkeywords>Care management | Chronic disease | Hypertension | Medical informatics | Randomized trials</authkeywords><intid>2035660098</intid><article-number>56</article-number><source-id>19395</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928901672"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928901672?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928901672&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928901672&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928901672</prism:url><dc:identifier>SCOPUS_ID:84928901672</dc:identifier><eid>2-s2.0-84928901672</eid><dc:title>Insights and limits of translational research in critical care medicine</dc:title><dc:creator>Pène F.</dc:creator><prism:publicationName>Annals of Intensive Care</prism:publicationName><prism:eIssn>21105820</prism:eIssn><prism:volume>5</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s13613-015-0050-3</prism:doi><dc:description>© 2015, Pène et al.; licensee Springer. Experimental research has always been the cornerstone of pathophysiological and therapeutic advances in critical care medicine, where clinical observations and basic research mutually fed each other in a so-called translational approach. The objective of this review is to address the different aspects of translational research in the field of critical care medicine. We herein highlighted some demonstrative examples including the animal-to-human approach to study host-pathogen interactions, the human-to-animal approach for sepsis-induced immunosuppression, the still restrictive human approach to study critical illness-related neuromyopathy, and the technological developments to assess the microcirculatory changes in critically ill patients. These examples not only emphasize how translational research resulted in major improvements in the comprehension of the pathophysiology of severe clinical conditions and offered promising perspectives in critical care medicine but also point out the obstacles to translate such achievements into clinical practice.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019163</affiliation-url><afid>60019163</afid><affilname>Hopital Cochin AP-HP</affilname><name-variant>Hôpital Cochin</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028950</affiliation-url><afid>60028950</afid><affilname>Universite Paris Descartes</affilname><name-variant>Université Paris Descartes</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009907</affiliation-url><afid>60009907</afid><affilname>Hopital Saint-Antoine</affilname><name-variant>Hopital Saint-Antoine</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001422</affiliation-url><afid>60001422</afid><affilname>Universite Pierre et Marie Curie</affilname><name-variant>Université Pierre et Marie Curie</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068575</affiliation-url><afid>60068575</afid><affilname>Hospital Erasme</affilname><name-variant>Université Libre de Bruxelles</name-variant><affiliation-city>Brussels</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018139</affiliation-url><afid>60018139</afid><affilname>Hopital Edouard Herriot</affilname><name-variant>Hôpital Edouard Herriot</name-variant><affiliation-city>Lyon</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023578</affiliation-url><afid>60023578</afid><affilname>Universite Claude Bernard Lyon 1</affilname><name-variant>Université Lyon 1</name-variant><affiliation-city>Villeurbanne</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013727</affiliation-url><afid>60013727</afid><affilname>Hopital Raymond Poincare</affilname><name-variant>Hôpital Raymond Poincaré</name-variant><affiliation-city>Garches</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029937</affiliation-url><afid>60029937</afid><affilname>Universite de Versailles Saint-Quentin-en-Yvelines</affilname><name-variant>Université de Versailles</name-variant><affiliation-city>Versailles</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015028</affiliation-url><afid>60015028</afid><affilname>Hopital Charles Nicolle</affilname><name-variant>Hôpital Charles Nicolle</name-variant><affiliation-city>Rouen</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115266269</affiliation-url><afid>115266269</afid><affilname>Institut de Recherche et Innovation Biomédicale (IRIB)</affilname><name-variant>Institut de Recherche et Innovation Biomédicale (IRIB)</name-variant><affiliation-city/><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8912414300</author-url><authid>8912414300</authid><authname>Pène F.</authname><surname>Pène</surname><given-name>Frédéric</given-name><initials>F.</initials><afid>60019163</afid><afid>60028950</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8912414300</author-url><authid>8912414300</authid><authname>Pène F.</authname><surname>Pène</surname><given-name>Frédéric</given-name><initials>F.</initials><afid>60019163</afid><afid>60028950</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8898424000</author-url><authid>8898424000</authid><authname>Ait-Oufella H.</authname><surname>Ait-Oufella</surname><given-name>Hafid</given-name><initials>H.</initials><afid>60009907</afid><afid>60001422</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8898424000</author-url><authid>8898424000</authid><authname>Ait-Oufella H.</authname><surname>Ait-Oufella</surname><given-name>Hafid</given-name><initials>H.</initials><afid>60009907</afid><afid>60001422</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6701704462</author-url><authid>6701704462</authid><authname>Taccone F.</authname><surname>Taccone</surname><given-name>Fabio Silvio</given-name><initials>F.S.</initials><afid>60068575</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7003291558</author-url><authid>7003291558</authid><authname>Monneret G.</authname><surname>Monneret</surname><given-name>Guillaume</given-name><initials>G.</initials><afid>60018139</afid><afid>60023578</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7003291558</author-url><authid>7003291558</authid><authname>Monneret G.</authname><surname>Monneret</surname><given-name>Guillaume</given-name><initials>G.</initials><afid>60018139</afid><afid>60023578</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004157942</author-url><authid>7004157942</authid><authname>Sharshar T.</authname><surname>Sharshar</surname><given-name>Tarek</given-name><initials>T.</initials><afid>60013727</afid><afid>60029937</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004157942</author-url><authid>7004157942</authid><authname>Sharshar T.</authname><surname>Sharshar</surname><given-name>Tarek</given-name><initials>T.</initials><afid>60013727</afid><afid>60029937</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56015096900</author-url><authid>56015096900</authid><authname>Tamion F.</authname><surname>Tamion</surname><given-name>Fabienne</given-name><initials>F.</initials><afid>60015028</afid><afid>115266269</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56015096900</author-url><authid>56015096900</authid><authname>Tamion F.</authname><surname>Tamion</surname><given-name>Fabienne</given-name><initials>F.</initials><afid>60015028</afid><afid>115266269</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55959021500</author-url><authid>55959021500</authid><authname>Mira J.</authname><surname>Mira</surname><given-name>Jean Paul</given-name><initials>J.P.</initials><afid>60019163</afid><afid>60028950</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55959021500</author-url><authid>55959021500</authid><authname>Mira J.</authname><surname>Mira</surname><given-name>Jean Paul</given-name><initials>J.P.</initials><afid>60019163</afid><afid>60028950</afid></author><authkeywords>Critical care medicine | Critical illness-related neuromyopathy | Microcirculation | Sepsis | Translational research</authkeywords><intid>535862852</intid><source-id>21100200831</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928553688"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928553688?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928553688&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928553688&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928553688</prism:url><dc:identifier>SCOPUS_ID:84928553688</dc:identifier><eid>2-s2.0-84928553688</eid><dc:title>A prospective observational study comparing a non-operator dependent automatic PWV analyser to pulse pressure, in assessing arterial stiffness in hemodialysis</dc:title><dc:creator>Salvadé I.</dc:creator><prism:publicationName>BMC Nephrology</prism:publicationName><prism:eIssn>14712369</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12882-015-0058-9</prism:doi><dc:description>© 2015 Salvadé et al. Abstract Background Chronic kidney disease (CKD) accelerates vascular stiffening related to age. Arterial stiffness may be evaluated measuring the carotid-femoral pulse wave velocity (PWV) or more simply, as recommended by KDOQI, monitoring pulse pressure (PP). Both correlate to survival and incidence of cardiovascular disease. PWV can also be estimated on the brachial artery using a Mobil-O-Graph; a non-operator dependent automatic device. The aim was to analyse whether, in a dialysis population, PWV obtained by Mobil-O-Graph (MogPWV) is more sensitive for vascular aging than PP. Methods A cohort of 143 patients from 4 dialysis units has been followed measuring MogPWV and PP every 3 to 6 months and compared to a control group with the same risk factors but an eGFR &gt; 30 ml/min. Results MogPWV contrarily to PP did discriminate the dialysis population from the control group. The mean difference translated in age between the two populations was 8.4 years. The increase in MogPWV, as a function of age, was more rapid in the dialysis group. 13.3% of the dialysis patients but only 3.0% of the control group were outliers for MogPWV. The mortality rate (16 out of 143) was similar in outliers and inliers (7.4 and 8.0%/year). Stratifying patients according to MogPWV, a significant difference in survival was seen. A high parathormone (PTH) and to be dialysed for a hypertensive nephropathy were associated to a higher baseline MogPWV. Conclusions Assessing PWV on the brachial artery using a Mobil-O-Graph is a valid and simple alternative, which, in the dialysis population, is more sensitive for vascular aging than PP. As demonstrated in previous studies PWV correlates to mortality. Among specific CKD risk factors only PTH is associated with a higher baseline PWV. Trial registration ClinicalTrials.gov Identifier: NCT02327962.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101203074</affiliation-url><afid>101203074</afid><affilname>Division of Nephrology</affilname><name-variant>Division of Nephrology</name-variant><affiliation-city>Aarau</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018252</affiliation-url><afid>60018252</afid><affilname>Ospedale Civico, Lugano</affilname><name-variant>Ospedale Civico</name-variant><affiliation-city>Lugano</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069238</affiliation-url><afid>60069238</afid><affilname>Ospedale Beata Vergine</affilname><name-variant>Osp. Beata Vergine</name-variant><affiliation-city>Mendrisio</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024217</affiliation-url><afid>60024217</afid><affilname>Ospedale San Giovanni</affilname><name-variant>Ospedale San Giovanni</name-variant><affiliation-city>Bellinzona</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023561</affiliation-url><afid>60023561</afid><affilname>Centre Hospitalier Universitaire Vaudois</affilname><name-variant>CHUV</name-variant><affiliation-city>Lausanne</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:37071143900</author-url><authid>37071143900</authid><authname>Salvadé I.</authname><surname>Salvadé</surname><given-name>Igor</given-name><initials>I.</initials><afid>101203074</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56174179000</author-url><authid>56174179000</authid><authname>Schätti-Stählin S.</authname><surname>Schätti-Stählin</surname><given-name>Sibylle</given-name><initials>S.</initials><afid>101203074</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6506160041</author-url><authid>6506160041</authid><authname>Violetti E.</authname><surname>Violetti</surname><given-name>Eleonora</given-name><initials>E.</initials><afid>60018252</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6506641271</author-url><authid>6506641271</authid><authname>Schönholzer C.</authname><surname>Schönholzer</surname><given-name>Carlo</given-name><initials>C.</initials><afid>60018252</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36338863200</author-url><authid>36338863200</authid><authname>Cereghetti C.</authname><surname>Cereghetti</surname><given-name>Claudio</given-name><initials>C.</initials><afid>60069238</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7006809465</author-url><authid>7006809465</authid><authname>Zwahlen H.</authname><surname>Zwahlen</surname><given-name>Hugo</given-name><initials>H.</initials><afid>60024217</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:16165200200</author-url><authid>16165200200</authid><authname>Berwert L.</authname><surname>Berwert</surname><given-name>Lorenzo</given-name><initials>L.</initials><afid>60024217</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7102984134</author-url><authid>7102984134</authid><authname>Burnier M.</authname><surname>Burnier</surname><given-name>Michel</given-name><initials>M.</initials><afid>60023561</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6603720688</author-url><authid>6603720688</authid><authname>Gabutti L.</authname><surname>Gabutti</surname><given-name>Luca</given-name><initials>L.</initials><afid>101203074</afid></author><authkeywords>Arterial stiffness | Hemodialysis | Mobil-o-graph | Pulse pressure | Pulse wave analysis | Pulse wave velocity</authkeywords><intid>35802184</intid><article-number>58</article-number><source-id>19395</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84915732147"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84915732147?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84915732147&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84915732147&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0928493114002434"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84915732147</prism:url><dc:identifier>SCOPUS_ID:84915732147</dc:identifier><eid>2-s2.0-84915732147</eid><dc:title>Biodegradable polymers for electrospinning: Towards biomedical applications</dc:title><dc:creator>Kai D.</dc:creator><prism:publicationName>Materials Science and Engineering C</prism:publicationName><prism:issn>09284931</prism:issn><prism:volume>45</prism:volume><prism:pageRange>659-670</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1016/j.msec.2014.04.051</prism:doi><pii>S0928493114002434</pii><dc:description>© 2014 Elsevier Ltd. All rights reserved. Electrospinning has received much attention recently due to the growing interest in nano-technologies and the unique material properties. This review focuses on recent progress in applying electrospinning technique in production of biodegradable nanofibers to the emerging field of biomedical. It first introduces the basic theory and parameters of nanofibers fabrication, with focus on factors affecting the morphology and fiber diameter of biodegradable nanofibers. Next, commonly electrospun biodegradable nanofibers are discussed, and the comparison of the degradation rate of nanoscale materials with macroscale materials are highlighted. The article also assesses the recent advancement of biodegradable nanofibers in different biomedical applications, including tissue engineering, drug delivery, biosensor and immunoassay. Future perspectives of biodegradable nanofibers are discussed in the last section, which emphasizes on the innovation and development in electrospinning of hydrogels nanofibers, pore size control and scale-up productions.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030743</affiliation-url><afid>60030743</afid><affilname>Institute of Materials Research and Engineering, A-Star, Singapore</affilname><name-variant>Inst. of Mat. Res. and Engineering</name-variant><affiliation-city>Singapore City</affiliation-city><affiliation-country>Singapore</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017161</affiliation-url><afid>60017161</afid><affilname>National University of Singapore</affilname><name-variant>National University of Singapore</name-variant><affiliation-city>Singapore City</affiliation-city><affiliation-country>Singapore</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024285</affiliation-url><afid>60024285</afid><affilname>Singapore Eye Research Institute</affilname><name-variant>Singapore Eye Research Institute</name-variant><affiliation-city>Singapore City</affiliation-city><affiliation-country>Singapore</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:34872404500</author-url><authid>34872404500</authid><authname>Kai D.</authname><surname>Kai</surname><given-name>Dan</given-name><initials>D.</initials><afid>60030743</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26423126300</author-url><authid>26423126300</authid><authname>Liow S.</authname><surname>Liow</surname><given-name>Sing Shy</given-name><initials>S.S.</initials><afid>60030743</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8603628300</author-url><authid>8603628300</authid><authname>Loh X.</authname><surname>Loh</surname><given-name>Xian Jun</given-name><initials>X.J.</initials><afid>60030743</afid><afid>60017161</afid><afid>60024285</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8603628300</author-url><authid>8603628300</authid><authname>Loh X.</authname><surname>Loh</surname><given-name>Xian Jun</given-name><initials>X.J.</initials><afid>60030743</afid><afid>60017161</afid><afid>60024285</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8603628300</author-url><authid>8603628300</authid><authname>Loh X.</authname><surname>Loh</surname><given-name>Xian Jun</given-name><initials>X.J.</initials><afid>60030743</afid><afid>60017161</afid><afid>60024285</afid></author><authkeywords>Biodegradable polyesters | Biosensors | Drug delivery | Electrospun nanofibers | Tissue engineering</authkeywords><intid>2033700706</intid><source-id>17813</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928631246"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928631246?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928631246&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928631246&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378426614003434"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928631246</prism:url><dc:identifier>SCOPUS_ID:84928631246</dc:identifier><eid>2-s2.0-84928631246</eid><dc:title>Lipopolysaccharide preconditioning of adipose-derived stem cells improves liver-regenerating activity of the secretome</dc:title><dc:creator>Lee S.</dc:creator><prism:publicationName>Stem Cell Research and Therapy</prism:publicationName><prism:eIssn>17576512</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>1-11</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s13287-015-0072-7</prism:doi><dc:description>© 2015 Lee et al. Abstract Introduction: Growing recognition of paracrine mechanisms in stem cell plasticity has resulted in considerable interest in stem cell-derived secretome. The aim of this study was to investigate the effects of lipopolysaccharide (LPS) preconditioning on the composition and hepatic regenerative activity of adipose-derived stem cell (ASC) secretome. Methods: Conditioned medium (CM) and LPS-CM were obtained after culturing human ASCs without or with low-dose LPS (0.5 ng/mL) for 24 hours. Untreated and thioacetamide-treated mouse AML12 hepatocytes were incubated for 24 hours with the control medium, LPS (0.5 ng/mL), CM, and LPS-CM and then cell viabilities were compared. CM and LPS-CM were also intravenously administered to partially hepatectomized mice, and their effects on liver regeneration were assessed by using liver weight measurements, immunohistochemistry, and Western blotting. Results: In the in vitro experiments, LPS preconditioning of ASCs enhanced the mRNA expression levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), hepatocyte growth factor, and vascular endothelial growth factor, which evoke inflammatory response or liver regeneration. LPS-CM significantly promoted thioacetamide-damaged AML12 cell viability compared with CM-incubated cells and the control cells (77%, 69%, and 65% P &lt;0.05). In the in vivo experiment, LPS-CM infusion into the partially hepatectomized mice significantly reduced serum IL-6 and TNF-α levels compared with the other groups (P &lt;0.05) on days 1 and 2 after partial hepatectomy. Moreover, LPS-CM infusion enhanced liver regeneration (based on the liver weight changes at day 7 after partial hepatectomy, 3.73% versus 3.22% in the CM group; P &lt;0.05) and significantly reduced the elevated serum levels of aspartate transaminase and alanine transaminase (at day 1, P &lt;0.05). Conclusions: Our results suggest that LPS preconditioning effectively stimulates ASCs to produce the secretome beneficial to hepatic regeneration. Thus, optimizing ASC secretome profile by LPS preconditioning could be a promising approach to treat liver diseases by using stem cells.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60094148</affiliation-url><afid>60094148</afid><affilname>Daejeon St. Mary's Hospital</affilname><name-variant>Daejeon St. Mary's Hospital</name-variant><affiliation-city>Daejeon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8705764900</author-url><authid>8705764900</authid><authname>Lee S.</authname><surname>Lee</surname><given-name>Sang Chul</given-name><initials>S.C.</initials><afid>60094148</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56587283000</author-url><authid>56587283000</authid><authname>Jeong H.</authname><surname>Jeong</surname><given-name>Hye Jin</given-name><initials>H.J.</initials><afid>60094148</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:27171429900</author-url><authid>27171429900</authid><authname>Lee S.</authname><surname>Lee</surname><given-name>Sang Kuon</given-name><initials>S.K.</initials><afid>60094148</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:42761529000</author-url><authid>42761529000</authid><authname>Kim S.</authname><surname>Kim</surname><given-name>Say June</given-name><initials>S.J.</initials><afid>60094148</afid></author><intid>2035809120</intid><article-number>75</article-number><source-id>19700201524</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927771938"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927771938?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927771938&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927771938&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927771938</prism:url><dc:identifier>SCOPUS_ID:84927771938</dc:identifier><eid>2-s2.0-84927771938</eid><dc:title>Results of a novel screening tool measuring dietary sodium knowledge in patients with chronic kidney disease</dc:title><dc:creator>Wright Nunes J.</dc:creator><prism:publicationName>BMC Nephrology</prism:publicationName><prism:eIssn>14712369</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12882-015-0027-3</prism:doi><dc:description>© 2015 Nunes et al.; licensee BioMed Central. Background: Reducing dietary sodium has potential to benefit patients with chronic kidney disease (CKD). Little research is available defining dietary sodium knowledge gaps in patients with pre-dialysis CKD. We designed a brief screening tool to rapidly identify patient knowledge gaps related to dietary sodium for patients with CKD not yet on dialysis. Methods: A Short Sodium Knowledge Survey (SSKS) was developed and administered to patients with pre-dialysis CKD. We also asked patients if they received counseling on dietary sodium reduction and about recommended intake limits. We performed logistic regression to examine the association between sodium knowledge and patient characteristics. Characteristics of patients who answered all SSKS questions correctly were compared to those who did not. Results: One-hundred fifty-five patients were surveyed. The mean (SD) age was 56.6 (15.1) years, 84 (54%) were men, and 119 (77%) were white. Sixty-seven patients (43.2%) correctly identified their daily intake sodium limit. Fifty-eight (37.4%) were unable to answer all survey questions correctly. In analysis adjusted for age, sex, race, education, health literacy, CKD stage, self-reported hypertension and attendance in a kidney education class, women and patients of non-white race had lower odds of correctly answering survey questions (0.36 [0.16,0.81]; p = 0.01 women versus men and 0.33 [0.14,0.76]; p = 0.01 non-white versus white, respectively). Conclusions: Our survey provides a mechanism to quickly identify dietary sodium knowledge gaps in patients with CKD. Women and patients of non-white race may have knowledge barriers impeding adherence to sodium reduction advice.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007200</affiliation-url><afid>60007200</afid><affilname>University of Michigan Health System</affilname><name-variant>University of Michigan Health System</name-variant><affiliation-city>Ann Arbor</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030612</affiliation-url><afid>60030612</afid><affilname>University of California, San Diego</affilname><name-variant>University of California San Diego</name-variant><affiliation-city>San Diego</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014232</affiliation-url><afid>60014232</afid><affilname>VA Medical Center</affilname><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014232</affiliation-url><afid>60014232</afid><affilname>VA Medical Center</affilname><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54413434600</author-url><authid>54413434600</authid><authname>Wright Nunes J.</authname><surname>Wright Nunes</surname><given-name>Julie A.</given-name><initials>J.A.</initials><afid>60007200</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26423548700</author-url><authid>26423548700</authid><authname>Anderson C.</authname><surname>Anderson</surname><given-name>Cheryl A M</given-name><initials>C.A.M.</initials><afid>60030612</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7402744923</author-url><authid>7402744923</authid><authname>Greene J.</authname><surname>Greene</surname><given-name>Jane H.</given-name><initials>J.H.</initials><afid>60014232</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7003269303</author-url><authid>7003269303</authid><authname>Ikizler T.</authname><surname>Ikizler</surname><given-name>Talat Alp</given-name><initials>T.A.</initials><afid>60014232</afid><afid>60014232</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7003269303</author-url><authid>7003269303</authid><authname>Ikizler T.</authname><surname>Ikizler</surname><given-name>Talat Alp</given-name><initials>T.A.</initials><afid>60014232</afid><afid>60014232</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:16306504700</author-url><authid>16306504700</authid><authname>Cavanaugh K.</authname><surname>Cavanaugh</surname><given-name>Kerri L.</given-name><initials>K.L.</initials><afid>60014232</afid><afid>60014232</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:16306504700</author-url><authid>16306504700</authid><authname>Cavanaugh K.</authname><surname>Cavanaugh</surname><given-name>Kerri L.</given-name><initials>K.L.</initials><afid>60014232</afid><afid>60014232</afid></author><authkeywords>Dietary sodium | Kidney disease | Patient knowledge | Survey</authkeywords><intid>1035662179</intid><source-id>19395</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925933618"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925933618?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925933618&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925933618&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925933618</prism:url><dc:identifier>SCOPUS_ID:84925933618</dc:identifier><eid>2-s2.0-84925933618</eid><dc:title>Predictors and risks of body fat profiles in young New Zealand European, Māori and Pacific women: study protocol for the women’s EXPLORE study</dc:title><dc:creator>Kruger R.</dc:creator><prism:publicationName>SpringerPlus</prism:publicationName><prism:eIssn>21931801</prism:eIssn><prism:volume>4</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>1-11</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s40064-015-0916-8</prism:doi><dc:description>© 2015, Kruger et al.; licensee Springer. Background: Body mass index (BMI) (kg/m2) is used internationally to assess body mass or adiposity. However, BMI does not discriminate body fat content or distribution and may vary among ethnicities. Many women with normal BMI are considered healthy, but may have an unidentified “hidden fat” profile associated with higher metabolic disease risk. If only BMI is used to indicate healthy body size, it may fail to predict underlying risks of diseases of lifestyle among population subgroups with normal BMI and different adiposity levels or distributions. Higher body fat levels are often attributed to excessive dietary intake and/or inadequate physical activity. These environmental influences regulate genes and proteins that alter energy expenditure/storage. Micro ribonucleic acid (miRNAs) can influence these genes and proteins, are sensitive to diet and exercise and may influence the varied metabolic responses observed between individuals. The study aims are to investigate associations between different body fat profiles and metabolic disease risk; dietary and physical activity patterns as predictors of body fat profiles; and whether these risk factors are associated with the expression of microRNAs related to energy expenditure or fat storage in young New Zealand women. Given the rising prevalence of obesity globally, this research will address a unique gap of knowledge in obesity research. Methods/Design: A cross-sectional design to investigate 675 NZ European, Māori, and Pacific women aged 16–45 years. Women are classified into three main body fat profiles (n = 225 per ethnicity; n = 75 per body fat profile): 1) normal BMI, normal body fat percentage (BF%); 2) normal BMI, high BF%; 3) high BMI, high BF%. Regional body composition, biomarkers of metabolic disease risk (i.e. fasting insulin, glucose, HbA1c, lipids), inflammation (i.e. IL-6, TNF-alpha, hs-CRP), associations between lifestyle factors (i.e. dietary intake, physical activity, taste perceptions) and microRNA expression will be investigated. Discussion: This research targets post-menarcheal, premenopausal women, potentially exhibiting lifestyle behaviours resulting in excess body fat affecting metabolic health. These behaviours may be characterised by specific patterns of microRNA expression that will be explored in terms of tailored solutions specific to body fat profile groups and ethnicities. Trial registration: ACTRN12613000714785</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008221</affiliation-url><afid>60008221</afid><affilname>Massey University</affilname><name-variant>Massey University</name-variant><affiliation-city>Palmerston North</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008221</affiliation-url><afid>60008221</afid><affilname>Massey University</affilname><name-variant>Massey University</name-variant><affiliation-city>Palmerston North</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018805</affiliation-url><afid>60018805</afid><affilname>Deakin University</affilname><name-variant>Deakin University</name-variant><affiliation-city>Geelong</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007440</affiliation-url><afid>60007440</afid><affilname>Centre for Public Health Research, Massey University</affilname><name-variant>Massey University</name-variant><affiliation-city>Wellington</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008221</affiliation-url><afid>60008221</afid><affilname>Massey University</affilname><name-variant>Massey University</name-variant><affiliation-city>Palmerston North</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008221</affiliation-url><afid>60008221</afid><affilname>Massey University</affilname><name-variant>Massey University</name-variant><affiliation-city>Palmerston North</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029470</affiliation-url><afid>60029470</afid><affilname>Commonwealth Scientific and Industrial Research Organization</affilname><name-variant>Commonwealth Scientific and Industrial Research Organization</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">15</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:25947519900</author-url><authid>25947519900</authid><authname>Kruger R.</authname><surname>Kruger</surname><given-name>Rozanne</given-name><initials>R.</initials><afid>60008221</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:34067803800</author-url><authid>34067803800</authid><authname>Shultz S.</authname><surname>Shultz</surname><given-name>Sarah P.</given-name><initials>S.P.</initials><afid>60008221</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005425137</author-url><authid>7005425137</authid><authname>McNaughton S.</authname><surname>McNaughton</surname><given-name>Sarah A.</given-name><initials>S.A.</initials><afid>60018805</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7402736021</author-url><authid>7402736021</authid><authname>Russell A.</authname><surname>Russell</surname><given-name>Aaron P.</given-name><initials>A.P.</initials><afid>60018805</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35775959500</author-url><authid>35775959500</authid><authname>Firestone R.</authname><surname>Firestone</surname><given-name>Ridvan T.</given-name><initials>R.T.</initials><afid>60007440</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55200902500</author-url><authid>55200902500</authid><authname>George L.</authname><surname>George</surname><given-name>Lily</given-name><initials>L.</initials><afid>60008221</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35572628300</author-url><authid>35572628300</authid><authname>Beck K.</authname><surname>Beck</surname><given-name>Kathryn L.</given-name><initials>K.L.</initials><afid>60008221</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:24721440200</author-url><authid>24721440200</authid><authname>Conlon C.</authname><surname>Conlon</surname><given-name>Cathryn A.</given-name><initials>C.A.</initials><afid>60008221</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:17136415400</author-url><authid>17136415400</authid><authname>von Hurst P.</authname><surname>von Hurst</surname><given-name>Pamela R.</given-name><initials>P.R.</initials><afid>60008221</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7004417919</author-url><authid>7004417919</authid><authname>Breier B.</authname><surname>Breier</surname><given-name>Bernhard</given-name><initials>B.</initials><afid>60008221</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56576061600</author-url><authid>56576061600</authid><authname>Jayasinghe S.</authname><surname>Jayasinghe</surname><given-name>Shakeela N.</given-name><initials>S.N.</initials><afid>60008221</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56576336100</author-url><authid>56576336100</authid><authname>O’Brien W.</authname><surname>O’Brien</surname><given-name>Wendy J.</given-name><initials>W.J.</initials><afid>60008221</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:8592760200</author-url><authid>8592760200</authid><authname>Jones B.</authname><surname>Jones</surname><given-name>Beatrix</given-name><initials>B.</initials><afid>60008221</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:16067453200</author-url><authid>16067453200</authid><authname>Stonehouse W.</authname><surname>Stonehouse</surname><given-name>Welma</given-name><initials>W.</initials><afid>60008221</afid><afid>60029470</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:16067453200</author-url><authid>16067453200</authid><authname>Stonehouse W.</authname><surname>Stonehouse</surname><given-name>Welma</given-name><initials>W.</initials><afid>60008221</afid><afid>60029470</afid></author><authkeywords>Body fat profile | Dietary practices | Metabolic disease risk | MicroRNA | Overweight and obesity | Physical activity | Predictors | Taste perception | Women</authkeywords><intid>1535386101</intid><source-id>21100228569</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929335286"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929335286?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929335286&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929335286&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929335286</prism:url><dc:identifier>SCOPUS_ID:84929335286</dc:identifier><eid>2-s2.0-84929335286</eid><dc:title>Reduced levels of circulating progenitor cells in juvenile idiopathic arthritis are counteracted by anti TNF-α therapy</dc:title><dc:creator>Martini G.</dc:creator><prism:publicationName>BMC Musculoskeletal Disorders</prism:publicationName><prism:eIssn>14712474</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12891-015-0555-9</prism:doi><dc:description>© 2015 Martini et al.; licensee BioMed Central. Abstract Background: Endothelial progenitor cells (EPC) promote angiogenesis and vascular repair. Though reduced EPC levels have been shown in rheumatoid arthritis, no study has so far evaluated EPCs in children with juvenile idiopathic arthritis (JIA). We aimed to study circulating EPCs in children with JIA, their relation to disease activity, and effects of anti TNF-α treatment. Methods: Circulating EPCs were quantified by flow cytometry based on CD34, CD133 and KDR expression in peripheral blood of 22 patients with oligoarticular JIA and 29 age-matched controls. EPCs were re-assessed in children with methotrexate-resistant oligo-extended JIA before and up to 12 month after initiation of anti-TNF-alpha therapy. Plasma concentrations of inflammatory and EPC-regulating factors were measured using a multiplex array. Confocal immunofluorescence was used to demonstrate EPCs in synovial tissues. Results: Children with active JIA showed a significant reduction of relative and absolute counts of circulating progenitor cells and EPCs compared to age-matched healthy controls. CD34&lt;sup&gt;+&lt;/sup&gt; cell levels were modestly and inversely correlated to disease activity. A strong inverse correlation was found between serum TNF-α and EPC levels. In 8 patients treated with anti TNF-α agents, the number of EPCs rose to values similar to healthy controls. CD34&lt;sup&gt;+&lt;/sup&gt;KDR&lt;sup&gt;+&lt;/sup&gt; EPCs were found in the synovial tissue of JIA children, but not in control. Conclusions: Children with JIA have reduced levels of the vasculoprotective and proangiogenic EPCs. While EPCs may contribute to synovial tissue remodelling, EPC pauperization may indicate an excess cardiovascular risk if projected later in life.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114315807</affiliation-url><afid>114315807</afid><affilname>Paediatric Rheumatology Unit</affilname><name-variant>Paediatric Rheumatology Unit</name-variant><affiliation-city>Padua</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000481</affiliation-url><afid>60000481</afid><affilname>Universita degli Studi di Padova</affilname><name-variant>University of Padova</name-variant><affiliation-city>Padua</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000481</affiliation-url><afid>60000481</afid><affilname>Universita degli Studi di Padova</affilname><name-variant>University of Padova</name-variant><affiliation-city>Padua</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7102069853</author-url><authid>7102069853</authid><authname>Martini G.</authname><surname>Martini</surname><given-name>Giorgia</given-name><initials>G.</initials><afid>114315807</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8563022500</author-url><authid>8563022500</authid><authname>Biscaro F.</authname><surname>Biscaro</surname><given-name>Francesca</given-name><initials>F.</initials><afid>114315807</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:15759236400</author-url><authid>15759236400</authid><authname>Boscaro E.</authname><surname>Boscaro</surname><given-name>Elisa</given-name><initials>E.</initials><afid>60000481</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005767347</author-url><authid>7005767347</authid><authname>Calabrese F.</authname><surname>Calabrese</surname><given-name>Fiorella</given-name><initials>F.</initials><afid>60000481</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:24779771700</author-url><authid>24779771700</authid><authname>Lunardi F.</authname><surname>Lunardi</surname><given-name>Francesca</given-name><initials>F.</initials><afid>60000481</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6603782685</author-url><authid>6603782685</authid><authname>Facco M.</authname><surname>Facco</surname><given-name>Monica</given-name><initials>M.</initials><afid>60000481</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7006420543</author-url><authid>7006420543</authid><authname>Agostini C.</authname><surname>Agostini</surname><given-name>Carlo</given-name><initials>C.</initials><afid>60000481</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:35394731100</author-url><authid>35394731100</authid><authname>Zulian F.</authname><surname>Zulian</surname><given-name>Francesco</given-name><initials>F.</initials><afid>114315807</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6506582748</author-url><authid>6506582748</authid><authname>Fadini G.</authname><surname>Fadini</surname><given-name>Gian Paolo</given-name><initials>G.P.</initials><afid>60000481</afid></author><authkeywords>Angiogenesis | Cardiovascular | Endothelium | Stem cells</authkeywords><intid>35943537</intid><article-number>555</article-number><source-id>29541</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929337186"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929337186?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929337186&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929337186&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929337186</prism:url><dc:identifier>SCOPUS_ID:84929337186</dc:identifier><eid>2-s2.0-84929337186</eid><dc:title>Household illness, poverty and physical and emotional child abuse victimisation: Findings from South Africa's first prospective cohort study</dc:title><dc:creator>Meinck F.</dc:creator><prism:publicationName>BMC Public Health</prism:publicationName><prism:eIssn>14712458</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12889-015-1792-4</prism:doi><dc:description>© 2015 Meinck et al.; licensee BioMed Central. Abstract Background: Physical and emotional abuse of children is a large scale problem in South Africa, with severe negative outcomes for survivors. Although chronic household illness has shown to be a predictor for physical and emotional abuse, no research has thus far investigated the different pathways from household chronic illness to child abuse victimisation in South Africa. Methods: Confidential self-report questionnaires using internationally utilised measures were completed by children aged 10-17 (n = 3515, 56.7% female) using door-to-door sampling in randomly selected areas in rural and urban locations of South Africa. Follow-up surveys were conducted a year later (96.7% retention rate). Using multiple mediation analyses, this study investigated direct and indirect effects of chronic household illness (AIDS or other illness) on frequent (monthly) physical and emotional abuse victimisation with poverty and extent of the ill person's disability as hypothesised mediators. Results: For children in AIDS-ill families, a positive direct effect on physical abuse was obtained. In addition, positive indirect effects through poverty and disability were established. For boys, a positive direct and indirect effect of AIDS-illness on emotional abuse through poverty were detected. For girls, a positive indirect effect through poverty was observed. For children in households with other chronic illness, a negative indirect effect on physical abuse was obtained. In addition, a negative indirect effect through poverty and positive indirect effect through disability was established. For boys, positive and negative indirect effects through poverty and disability were found respectively. For girls, a negative indirect effect through poverty was observed. Conclusions: These results indicate that children in families affected by AIDS-illness are at higher risk of child abuse victimisation, and this risk is mediated by higher levels of poverty and disability. Children affected by other chronic illness are at lower risk for abuse victimisation unless they are subject to higher levels of household disability. Interventions aiming to reduce poverty and increase family support may help prevent child abuse in families experiencing illness in South Africa.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026851</affiliation-url><afid>60026851</afid><affilname>University of Oxford</affilname><name-variant>Oxford University</name-variant><affiliation-city>Oxford</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000356</affiliation-url><afid>60000356</afid><affilname>University of Cape Town</affilname><name-variant>University of Cape Town</name-variant><affiliation-city>Cape Town</affiliation-city><affiliation-country>South Africa</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010499</affiliation-url><afid>60010499</afid><affilname>University of KwaZulu-Natal</affilname><name-variant>University of KwaZulu-Natal</name-variant><affiliation-city/><affiliation-country>South Africa</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031226</affiliation-url><afid>60031226</afid><affilname>Curtin University</affilname><name-variant>Curtin University of Technology</name-variant><affiliation-city>Perth</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54391517900</author-url><authid>54391517900</authid><authname>Meinck F.</authname><surname>Meinck</surname><given-name>Franziska</given-name><initials>F.</initials><afid>60026851</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:17344948600</author-url><authid>17344948600</authid><authname>Cluver L.</authname><surname>Cluver</surname><given-name>Lucie D.</given-name><initials>L.D.</initials><afid>60026851</afid><afid>60000356</afid><afid>60010499</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:17344948600</author-url><authid>17344948600</authid><authname>Cluver L.</authname><surname>Cluver</surname><given-name>Lucie D.</given-name><initials>L.D.</initials><afid>60026851</afid><afid>60000356</afid><afid>60010499</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:17344948600</author-url><authid>17344948600</authid><authname>Cluver L.</authname><surname>Cluver</surname><given-name>Lucie D.</given-name><initials>L.D.</initials><afid>60026851</afid><afid>60000356</afid><afid>60010499</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:26537153900</author-url><authid>26537153900</authid><authname>Boyes M.</authname><surname>Boyes</surname><given-name>Mark E.</given-name><initials>M.E.</initials><afid>60026851</afid><afid>60031226</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:26537153900</author-url><authid>26537153900</authid><authname>Boyes M.</authname><surname>Boyes</surname><given-name>Mark E.</given-name><initials>M.E.</initials><afid>60026851</afid><afid>60031226</afid></author><authkeywords>Adolescent abuse | Child abuse | Chronic illness | HIV/AIDS | Predictors | Risk factor</authkeywords><intid>2035938515</intid><article-number>1792</article-number><source-id>19621</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928573707"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928573707?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928573707&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928573707&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1053811914007125"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928573707</prism:url><dc:identifier>SCOPUS_ID:84928573707</dc:identifier><eid>2-s2.0-84928573707</eid><dc:title>The fine line between 'brave' and 'reckless': Amygdala reactivity and regulation predict recognition of risk</dc:title><dc:creator>Mujica-Parodi L.</dc:creator><prism:publicationName>NeuroImage</prism:publicationName><prism:issn>10538119</prism:issn><prism:eIssn>10959572</prism:eIssn><prism:volume>103</prism:volume><prism:pageRange>1-9</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>December 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.neuroimage.2014.08.038</prism:doi><pii>S1053811914007125</pii><dc:description>© 2014 . Background: High sensation-seekers (HSS) pursue novelty even at the cost of self-harm. When challenged, HSS are less anxious, show blunted physiological (cortisol, startle) and neurobiological (prefrontal-limbic) responses, and devalue aversive outcomes. Here, we investigate how these features interact under conditions of physical danger, in distinguishing between adaptive and maladaptive approaches to risk. Methods: We recruited a cohort of individuals who voluntarily sought out recreational exposure to physical risk, and obtained serial cortisol values over two time-locked days. On the 'baseline' day, we scanned subjects' brains with functional and structural MRI; on the 'skydiving day,' subjects completed a first-time tandem skydive. During neuroimaging, subjects viewed cues that predicted aversive noise; neural data were analyzed for prefrontal-limbic reactivity (activation) and regulation (non-linear complexity), as well as cortical thickness. To probe threat perception, subjects identified aggression for ambiguous faces morphed between neutral and angry poles. Results: Individuals with prefrontal-limbic meso-circuits with less balanced regulation between excitatory and inhibitory components showed both diminished cortisol/anxiety responses to their skydives, as well as less accurate perceptual recognition of threat. This impaired control was localized to the inferior frontal gyrus, with associated cortical thinning. Structural equation modeling suggests that sensation-seeking is primarily mediated via threat-perception, which itself is primarily mediated via neural reactivity and regulation. Conclusions: Our results refine the sensation-seeking construct to provide important distinctions (brain-based, but with endocrine and cognitive consequences) between the brave, who feel fear but nonetheless overcome it, and the reckless, who fail to recognize danger. This distinction has important real-world implications, as those who fail to recognize risk are less likely to mitigate it.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60101642</affiliation-url><afid>60101642</afid><affilname>Stony Brook University School of Medicine</affilname><name-variant>Stony Brook University School of Medicine</name-variant><affiliation-city>Stony Brook</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029929</affiliation-url><afid>60029929</afid><affilname>Massachusetts General Hospital</affilname><name-variant>Massachusetts General Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017409</affiliation-url><afid>60017409</afid><affilname>Northern Michigan University</affilname><name-variant>Northern Michigan University</name-variant><affiliation-city>Marquette</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011605</affiliation-url><afid>60011605</afid><affilname>Columbia University, College of Physicians and Surgeons</affilname><name-variant>Columbia University</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026415</affiliation-url><afid>60026415</afid><affilname>Stony Brook University State University of New York</affilname><name-variant>State University of New York at Stony Brook</name-variant><affiliation-city>Stony Brook</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8568129700</author-url><authid>8568129700</authid><authname>Mujica-Parodi L.</authname><surname>Mujica-Parodi</surname><given-name>L. R.</given-name><initials>L.R.</initials><afid>60101642</afid><afid>60029929</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8568129700</author-url><authid>8568129700</authid><authname>Mujica-Parodi L.</authname><surname>Mujica-Parodi</surname><given-name>L. R.</given-name><initials>L.R.</initials><afid>60101642</afid><afid>60029929</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24757949100</author-url><authid>24757949100</authid><authname>Carlson J.</authname><surname>Carlson</surname><given-name>Joshua M.</given-name><initials>J.M.</initials><afid>60017409</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56543981200</author-url><authid>56543981200</authid><authname>Cha J.</authname><surname>Cha</surname><given-name>Jiook</given-name><initials>J.</initials><afid>60011605</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202307226</author-url><authid>7202307226</authid><authname>Rubin D.</authname><surname>Rubin</surname><given-name>Denis</given-name><initials>D.</initials><afid>60101642</afid><afid>60026415</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202307226</author-url><authid>7202307226</authid><authname>Rubin D.</authname><surname>Rubin</surname><given-name>Denis</given-name><initials>D.</initials><afid>60101642</afid><afid>60026415</afid></author><authkeywords>Amygdala | Complexity | Cortisol | Fear | Limbic | Prefrontal cortex | Resilience | Sensation-seeking | Stress</authkeywords><intid>535812099</intid><source-id>17495</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928978765"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928978765?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928978765&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928978765&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928978765</prism:url><dc:identifier>SCOPUS_ID:84928978765</dc:identifier><eid>2-s2.0-84928978765</eid><dc:title>The protection mechanism of proline from D-galactosamine hepatitis involves the early activation of ROS-eliminating pathway in the liver</dc:title><dc:creator>Obayashi Y.</dc:creator><prism:publicationName>SpringerPlus</prism:publicationName><prism:eIssn>21931801</prism:eIssn><prism:volume>4</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s40064-015-0969-8</prism:doi><dc:description>© 2015, Obayashi et al.; licensee Springer. The oral pre-administration of proline, one on the non-essential amino acids, has been shown to effectively protect the liver from D-galactosamine (GalN)-induced liver injury and dramatically improve the survival rate. In the previous study, we reported that protective effect of proline involves the early activation of IL-6/STAT-3 pathway, an anti-inflammatory and regenerative signaling in the liver. Reactive oxygen species (ROS) are mediator of cellular injury and play an important role in hepatic damage during GalN-induced hepatitis. The aim of this study is to investigate the effect of proline on ROS-eliminating system. The activities of major ROS-detoxifying enzymes, i.e., glutathione peroxidase (GP), glutathione reductase (GR), catalase, and the level of glutathione in the liver were determined. Catalase activity was significantly upregulated in proline group from 0 to 3 h after GalN-injection, although GP and GR were downregulated during this period, compared with control group. From 6 to 12 h, the level of reduced glutathione (GSH) was significantly higher and the ratio of GSH/oxidized glutathione (GSSG) tended to be higher in proline group. Consistently with this, at 6 h, the GR activity in the proline group was significantly higher, followed with the higher tendency of GP activity at 12 h. Catalase activity was also significantly higher at 12 h. Taken together, catalase was activated at the beginning, followed with the significant activation of glutathione redox system around 6 to 12 h in proline group. These results suggest that the elimination of ROS in the liver was accelerated in proline group compared with control group at the very early stage of GalN-induced hepatitis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012600</affiliation-url><afid>60012600</afid><affilname>Ajinomoto Co Inc</affilname><name-variant>Ajinomoto Co. Inc.</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname/><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55213313500</author-url><authid>55213313500</authid><authname>Obayashi Y.</authname><surname>Obayashi</surname><given-name>Yoko</given-name><initials>Y.</initials><afid>60012600</afid><afid/></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55213313500</author-url><authid>55213313500</authid><authname>Obayashi Y.</authname><surname>Obayashi</surname><given-name>Yoko</given-name><initials>Y.</initials><afid>60012600</afid><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602750388</author-url><authid>6602750388</authid><authname>Arisaka H.</authname><surname>Arisaka</surname><given-name>Harumi</given-name><initials>H.</initials><afid>60012600</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56262750100</author-url><authid>56262750100</authid><authname>Yoshida S.</authname><surname>Yoshida</surname><given-name>Shintaro</given-name><initials>S.</initials><afid>60012600</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56623731800</author-url><authid>56623731800</authid><authname>Mori M.</authname><surname>Mori</surname><given-name>Masato</given-name><initials>M.</initials><afid>60012600</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56623627300</author-url><authid>56623627300</authid><authname>Takahashi M.</authname><surname>Takahashi</surname><given-name>Michio</given-name><initials>M.</initials><afid>60012600</afid></author><authkeywords>Antioxidation | Catalase | D-galactosamine | Glutathione | Proline | Reactive oxygen species</authkeywords><intid>1035873353</intid><source-id>21100228569</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929074540"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929074540?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929074540&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929074540&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929074540</prism:url><dc:identifier>SCOPUS_ID:84929074540</dc:identifier><eid>2-s2.0-84929074540</eid><dc:title>A priority health index identifies the top six priority risk and related factors for non-communicable diseases in Brazilian cities</dc:title><dc:creator>Simoes E.</dc:creator><prism:publicationName>BMC Public Health</prism:publicationName><prism:eIssn>14712458</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12889-015-1787-1</prism:doi><dc:description>© 2015 Simoes et al. Abstract Background: In Brazil, 72% of all deaths in 2007 were attributable to non-communicable diseases (NCD). We used a risk and related factor based index to prioritize NCD prevention programs in the combined 26 capital cities and the federal district (i.e., Brasilia) of Brazil. Methods: We used 2006-2011 data (adults) from census and Brazil's surveillance of 12 NCD risk factors and 74 disease group mortality. The risk and related factors were: smoking, physical inactivity, overweight-obesity, low fruits and vegetables intake, binge drinking, insufficient Pap smear screening (women aged 25 to 59 years), insufficient mammography screening (women aged 50 to 69 years), insufficient blood pressure screening, insufficient blood glucose screening, diagnosis of hypercholesterolemia, diagnosis of hypertension and diagnosis of diabetes. We generated six indicators: intervention reduction of the risk factor prevalence, intervention cost per person, prevalence of risk factor, deaths attributable to risk factor, risk factor prevalence trend and ratio of risk factor prevalence between people with and without a high school education. We transformed risk and related factor indicators into priority scores to compute a priority health index (PHI). We implemented sensitivity analysis of PHI by computing it with slightly altered formulas and altering values of indicators under the assumption of bias in their estimation. We ranked risk factors based on PHI values. Results: We found one intermediate (i.e., overweight-obesity) and six top risk and related factors priorities for NCD prevention in Brazil's large urban areas: diagnosed hypertension, physical inactivity, blood pressure screening, diagnosed hypercholesterolemia, smoking and binge drinking. Conclusion: Brazil has already prioritized the six top priorities (i.e., hypertension, physical inactivity, blood pressure screening, hypercholesterolemia, smoking and binge drinking) and one intermediate priority (i.e., overweight-obesity) for NCD prevention identified in this report. Because effective interventions to reduce disease burden associated with each of the six priority risk factors are available, strategies based on these interventions need to be sustained in order to reduce NCD burden in Brazil. PHI can be used to track NCD prevention and health promotion actions at the local and national level in Brazil and in countries with similar public health surveillance systems.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006173</affiliation-url><afid>60006173</afid><affilname>University of Missouri-Columbia</affilname><name-variant>University of Missouri</name-variant><affiliation-city>Columbia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115228795</affiliation-url><afid>115228795</afid><affilname>Min. Saude</affilname><name-variant>Min. Saude</name-variant><affiliation-city>Brasilia</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015481</affiliation-url><afid>60015481</afid><affilname>University of Washington Seattle</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:108132830</affiliation-url><afid>108132830</afid><affilname>Organização Pan-Americana da Saúde</affilname><name-variant>Organização Pan-Americana da Saúde</name-variant><affiliation-city>Brasilia</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027136</affiliation-url><afid>60027136</afid><affilname>Universidade Federal de Goias</affilname><name-variant>Universidade Federal de Goiás</name-variant><affiliation-city>Goiania</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006265423</author-url><authid>7006265423</authid><authname>Simoes E.</authname><surname>Simoes</surname><given-name>Eduardo J.</given-name><initials>E.J.</initials><afid>60006173</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56624214800</author-url><authid>56624214800</authid><authname>Bouras A.</authname><surname>Bouras</surname><given-name>Adam</given-name><initials>A.</initials><afid>60006173</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:24722568500</author-url><authid>24722568500</authid><authname>Cortez-Escalante J.</authname><surname>Cortez-Escalante</surname><given-name>Juan Jose</given-name><initials>J.J.</initials><afid>115228795</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15835283500</author-url><authid>15835283500</authid><authname>Malta D.</authname><surname>Malta</surname><given-name>Deborah C.</given-name><initials>D.C.</initials><afid>115228795</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:37075600600</author-url><authid>37075600600</authid><authname>Porto D.</authname><surname>Porto</surname><given-name>Denise Lopes</given-name><initials>D.L.</initials><afid>115228795</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004813962</author-url><authid>7004813962</authid><authname>Mokdad A.</authname><surname>Mokdad</surname><given-name>Ali H.</given-name><initials>A.H.</initials><afid>60015481</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7003846396</author-url><authid>7003846396</authid><authname>De Moura L.</authname><surname>De Moura</surname><given-name>Lenildo</given-name><initials>L.</initials><afid>108132830</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7004227129</author-url><authid>7004227129</authid><authname>Neto O.</authname><surname>Neto</surname><given-name>Otaliba Libanio Morais</given-name><initials>O.L.M.</initials><afid>60027136</afid></author><intid>2035896215</intid><article-number>1787</article-number><source-id>19621</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928684040"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928684040?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928684040&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928684040&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928684040</prism:url><dc:identifier>SCOPUS_ID:84928684040</dc:identifier><eid>2-s2.0-84928684040</eid><dc:title>Association of knowledge, preventive counseling and personal health behaviors on physical activity and consumption of fruits or vegetables in community health workers Health behavior, health promotion and society</dc:title><dc:creator>Florindo A.</dc:creator><prism:publicationName>BMC Public Health</prism:publicationName><prism:eIssn>14712458</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>1-8</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12889-015-1643-3</prism:doi><dc:description>© 2015 Florindo et al.; licensee BioMed Central. Abstract Background: There is evidence that if a health professional is active and has a healthy diet, he/she is more likely to advise patients about the benefits of physical activity and healthy eating The aims of this study were to: (1) describe the personal physical activity, consumption of fruits and vegetables behaviors and nutritional status of community health workers; (2) evaluate the association between knowledge, delivery of preventive counseling and personal behaviors among community health workers. Methods: This was a cross-sectional study conducted in a nationally sample of health professionals working in primary health care settings in Brazil in 2011. This survey was part of the second phase of the Guide for Useful Interventions for Activity in Brazil and Latin America project, and data were collected through telephone interviews of 269 community health workers from the Unified Health Care system of Brazil. We applied questionnaires about personal reported behaviors, knowledge and preventive counseling in physical activity and consumption of fruits and vegetables. We calculated the prevalence and associations between the variables with logistic regression. Results: The proportion of community health workers that practiced 150 minutes per week of physical activity in leisure time or transportation was high (64.9%). Half of community health workers were overweight and only 26.2% reported consuming five portions/day of fruits or vegetables. Most community health workers reported counseling about physical activity for more than six months (59.7%), and most were not knowledgeable of the fruits and vegetables and physical activity recommendations. Meeting the fruits and vegetables recommendations was associated with correct knowledge (OR = 4.5; CI95% 1.03;19.7), with reporting 150 minutes or more of physical activity per week (OR = 2.0; CI95% 1.03;3.7) and with reporting physical activity in leisure time (OR = 2.0; CI95% 1.05;3.6). Regular physical activity counseling was associated with reporting 10-149 minutes per week (OR = 3.8; CI95% 1.1;13.3) and with more than 150 minutes of physical activity per week (OR = 4.9; CI95% 1.5;16.5). Conclusion: Actions to promote physical activity and healthy eating and to improve knowledge among community health workers within the health care system of Brazil could have a potential positive influence on delivery of preventive counseling to patients on this topic.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008088</affiliation-url><afid>60008088</afid><affilname>Universidade de Sao Paulo - USP</affilname><name-variant>University of São Paulo</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010261</affiliation-url><afid>60010261</afid><affilname>Washington University in St. Louis</affilname><name-variant>Washington University in St. Louis</name-variant><affiliation-city>St Louis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014598</affiliation-url><afid>60014598</afid><affilname>Universidade Federal de Pelotas</affilname><name-variant>Federal University of Pelotas</name-variant><affiliation-city>Pelotas</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013792</affiliation-url><afid>60013792</afid><affilname>Universidade Federal de Sao Carlos</affilname><name-variant>Federal University of São Carlos</name-variant><affiliation-city>Sao Carlos</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010261</affiliation-url><afid>60010261</afid><affilname>Washington University in St. Louis</affilname><name-variant>Washington University in St. Louis</name-variant><affiliation-city>St Louis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014598</affiliation-url><afid>60014598</afid><affilname>Universidade Federal de Pelotas</affilname><name-variant>Federal University of Pelotas</name-variant><affiliation-city>Pelotas</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025315</affiliation-url><afid>60025315</afid><affilname>Rollins School of Public Health</affilname><name-variant>Emory University</name-variant><affiliation-city>Atlanta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024842</affiliation-url><afid>60024842</afid><affilname>University of Missouri System</affilname><name-variant>University of Missouri</name-variant><affiliation-city>Columbia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014992</affiliation-url><afid>60014992</afid><affilname>Universidade Federal de Sao Paulo</affilname><name-variant>Federal University of São Paulo</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016295</affiliation-url><afid>60016295</afid><affilname>Hospital Israelita Albert Einstein</affilname><name-variant>Albert Einstein Hospital</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6602907958</author-url><authid>6602907958</authid><authname>Florindo A.</authname><surname>Florindo</surname><given-name>Alex A.</given-name><initials>A.A.</initials><afid>60008088</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7102104895</author-url><authid>7102104895</authid><authname>Brownson R.</authname><surname>Brownson</surname><given-name>Ross C.</given-name><initials>R.C.</initials><afid>60010261</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55316085100</author-url><authid>55316085100</authid><authname>Mielke G.</authname><surname>Mielke</surname><given-name>Gregore I.</given-name><initials>G.I.</initials><afid>60014598</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35221438900</author-url><authid>35221438900</authid><authname>Gomes G.</authname><surname>Gomes</surname><given-name>Grace AO</given-name><initials>G.A.</initials><afid>60013792</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55760782500</author-url><authid>55760782500</authid><authname>Parra D.</authname><surname>Parra</surname><given-name>Diana C.</given-name><initials>D.C.</initials><afid>60010261</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35589163600</author-url><authid>35589163600</authid><authname>Siqueira F.</authname><surname>Siqueira</surname><given-name>Fernando V.</given-name><initials>F.V.</initials><afid>60014598</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55911702200</author-url><authid>55911702200</authid><authname>Lobelo F.</authname><surname>Lobelo</surname><given-name>Felipe</given-name><initials>F.</initials><afid>60025315</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7006265423</author-url><authid>7006265423</authid><authname>Simoes E.</authname><surname>Simoes</surname><given-name>Eduardo J.</given-name><initials>E.J.</initials><afid>60024842</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7202180615</author-url><authid>7202180615</authid><authname>Ramos L.</authname><surname>Ramos</surname><given-name>Luiz R.</given-name><initials>L.R.</initials><afid>60014992</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7003353863</author-url><authid>7003353863</authid><authname>Bracco M.</authname><surname>Bracco</surname><given-name>Mário M.</given-name><initials>M.M.</initials><afid>60016295</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:6602871937</author-url><authid>6602871937</authid><authname>Hallal P.</authname><surname>Hallal</surname><given-name>Pedro C.</given-name><initials>P.C.</initials><afid>60014598</afid></author><authkeywords>Community health workers | Consumption of fruits and vegetables | Knowledge | Personal behavior | Physical activity | Preventive counseling | Primary health care settings</authkeywords><intid>1785824629</intid><article-number>1643</article-number><source-id>19621</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927755808"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927755808?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927755808&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927755808&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927755808</prism:url><dc:identifier>SCOPUS_ID:84927755808</dc:identifier><eid>2-s2.0-84927755808</eid><dc:title>Current status of collaborative relationships between dialysis facilities and dental facilities in Japan: Results of a nationwide survey</dc:title><dc:creator>Yoshioka M.</dc:creator><prism:publicationName>BMC Nephrology</prism:publicationName><prism:eIssn>14712369</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12882-015-0001-0</prism:doi><dc:description>© 2015 Yoshioka et al.; licensee BioMed Central. Background: Recent studies have reported an association between periodontal disease and mortality among dialysis patients. Therefore, preventive dental care should be considered very important for this population. In Japan, no systematic education has been undertaken regarding the importance of preventive dental care for hemodialysis patients - even though these individuals tend to have oral and dental problems. The aim of this study was to investigate the current state of collaborative relationships between hemodialysis facilities and dental services in Japan and also to identify strategies to encourage preventive dental visits among hemodialysis outpatients. Methods: A nationwide questionnaire on the collaborative relationship between dialysis facilities and dental facilities was sent by mail to all medical facilities in Japan offering outpatient hemodialysis treatment. Results: Responses were obtained from 1414 of 4014 facilities (35.2%). Among the 1414 facilities, 272 (19.2%) had a dental service department. Approximately 100,000 dialysis outpatients were receiving treatment at these participating facilities, which amounts to one-third of all dialysis patients in Japan. Of those patients, 82.9% received hemodialysis at medical facilities without dental departments. Only 87 of 454 small clinics without in-house dental departments (19.2%) had collaborative registered dental clinics. Medical facilities with registered dental clinics demonstrated a significantly more proactive attitude to routine collaboration on dental matters than facilities lacking such clinics. Conclusions: Our nationwide survey revealed that most dialysis facilities in Japan have neither an in-house dental department nor a collaborative relationship with a registered dental clinic. Registration of dental clinics appears to promote collaboration with dental facilities on a routine basis, which would be beneficial for oral health management in hemodialysis patients.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009852</affiliation-url><afid>60009852</afid><affilname>Tokushima University</affilname><name-variant>Tokushima University</name-variant><affiliation-city>Tokushima</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009852</affiliation-url><afid>60009852</afid><affilname>Tokushima University</affilname><name-variant>Tokushima University</name-variant><affiliation-city>Tokushima</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009852</affiliation-url><afid>60009852</afid><affilname>Tokushima University</affilname><name-variant>Tokushima University</name-variant><affiliation-city>Tokushima</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009852</affiliation-url><afid>60009852</afid><affilname>Tokushima University</affilname><name-variant>Tokushima University</name-variant><affiliation-city>Tokushima</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7402480719</author-url><authid>7402480719</authid><authname>Yoshioka M.</authname><surname>Yoshioka</surname><given-name>Masami</given-name><initials>M.</initials><afid>60009852</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56594639600</author-url><authid>56594639600</authid><authname>Shirayama Y.</authname><surname>Shirayama</surname><given-name>Yasuhiko</given-name><initials>Y.</initials><afid>60009852</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006292656</author-url><authid>7006292656</authid><authname>Imoto I.</authname><surname>Imoto</surname><given-name>Issei</given-name><initials>I.</initials><afid>60009852</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701363318</author-url><authid>6701363318</authid><authname>Hinode D.</authname><surname>Hinode</surname><given-name>Daisuke</given-name><initials>D.</initials><afid>60009852</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56594530600</author-url><authid>56594530600</authid><authname>Yanagisawa S.</authname><surname>Yanagisawa</surname><given-name>Shizuko</given-name><initials>S.</initials><afid>60009852</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56594176500</author-url><authid>56594176500</authid><authname>Takeuchi Y.</authname><surname>Takeuchi</surname><given-name>Yuko</given-name><initials>Y.</initials><afid>60009852</afid></author><authkeywords>Collaborative relationship between medical and dental facilities | Hemodialysis patient | Nationwide questionnaire | Oral health care</authkeywords><intid>535666936</intid><article-number>17</article-number><source-id>19395</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927761541"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927761541?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927761541&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927761541&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927761541</prism:url><dc:identifier>SCOPUS_ID:84927761541</dc:identifier><eid>2-s2.0-84927761541</eid><dc:title>A microrna screen to identify regulators of peritoneal fibrosis in a rat model of peritoneal dialysis</dc:title><dc:creator>Lin F.</dc:creator><prism:publicationName>BMC Nephrology</prism:publicationName><prism:eIssn>14712369</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12882-015-0039-z</prism:doi><dc:description>© 2015 Lin et al. Background: Peritoneal fibrosis is a common complication in patients treated with long-term peritoneal dialysis. The aim of this study was to identify the microRNAs (miRNAs) involved in regulation of peritoneal fibrosis in a rat model of peritoneal dialysis. Methods: Twenty-four Sprague-Dawley (SD) rats were randomly allocated into three groups: (i) Control group (Cg, n = 8); (ii) Saline group (Sg, n = 8): daily intraperitoneal injection with 0.9% normal saline; (iii) Hypertonic dialysate group (HDg, n = 8): daily intraperitoneal injection with 4.25% peritoneal dialysis solution. Rats were sacrificed after four weeks for histological evaluation of peritoneal membrane and the expression of α-SMA and COL-1. A miRNA screen was performed using microarray analysis to identify differentially expressed miRNAs, which were then validated by real-time PCR. Results: Compared with the control and the saline groups, hypertonic dialysate group showed impaired peritoneal function accompanied by a spectrum of morphological changes including thicker peritoneal membrane, higher collagen deposition, infiltration of mononuclear cells and neovascularization in the peritoneum. Increased mRNA and protein levels of α -SMA and COL-1 were observed in hypertonic dialysate group, indicating the progression of peritoneal fibrosis. The miRNA screen identified 8 significantly down-regulated miRNAs (miR-31, miR-93, miR-100, miR-152, miR-497, miR-192, miR-194 and miR-200b) and one highly upregulated miRNA (miR-122) in the hypertonic dialysate group. The results were confirmed by real-time PCR. Conclusions: Altered miRNA expression in peritoneum was found in the rat model of peritoneal fibrosis, indicating that these miRNAs may be associated with pathogenesis of peritoneal fibrosis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113682633</affiliation-url><afid>113682633</afid><affilname>Wenzhou Medical University</affilname><name-variant>Wenzhou Medical University</name-variant><affiliation-city>Ningbo</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56594075100</author-url><authid>56594075100</authid><authname>Lin F.</authname><surname>Lin</surname><given-name>Fan</given-name><initials>F.</initials><afid>113682633</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56593900300</author-url><authid>56593900300</authid><authname>Xu W.</authname><surname>Xu</surname><given-name>Wu</given-name><initials>W.</initials><afid>113682633</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56593930600</author-url><authid>56593930600</authid><authname>Zhang H.</authname><surname>Zhang</surname><given-name>Huidi</given-name><initials>H.</initials><afid>113682633</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56594270700</author-url><authid>56594270700</authid><authname>You X.</authname><surname>You</surname><given-name>Xiaohan</given-name><initials>X.</initials><afid>113682633</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56593756800</author-url><authid>56593756800</authid><authname>Zhang Z.</authname><surname>Zhang</surname><given-name>Zhoucang</given-name><initials>Z.</initials><afid>113682633</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56594492300</author-url><authid>56594492300</authid><authname>Shao R.</authname><surname>Shao</surname><given-name>Rongrong</given-name><initials>R.</initials><afid>113682633</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56593765900</author-url><authid>56593765900</authid><authname>Huang C.</authname><surname>Huang</surname><given-name>Chaoxing</given-name><initials>C.</initials><afid>113682633</afid></author><authkeywords>Epithelial-to-mesenchymal transition | MiRNA | Peritoneal dialysis | Peritoneal fibrosis</authkeywords><intid>35665599</intid><article-number>48</article-number><source-id>19395</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929170734"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929170734?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929170734&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929170734&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929170734</prism:url><dc:identifier>SCOPUS_ID:84929170734</dc:identifier><eid>2-s2.0-84929170734</eid><dc:title>Effectiveness of peer support for improving glycaemic control in patients with type 2 diabetes: A meta-analysis of randomized controlled trials</dc:title><dc:creator>Qi L.</dc:creator><prism:publicationName>BMC Public Health</prism:publicationName><prism:eIssn>14712458</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12889-015-1798-y</prism:doi><dc:description>© 2015 Qi et al.; licensee BioMed Central. Abstract Background: To assess the effects of peer support at improving glycemic control in patients with type 2 diabetes. Methods: Relevant electronic databases were sought for this investigation up to Dec 2014. Randomized controlled trials involving patients with type 2 diabetes that evaluated the effect of peer support on glycated hemoglobin (HbA1c) concentrations were included. The pooled mean differences (MD) between intervention and control groups with 95% confidence interval (CI) were calculated using random-effects model. The Cochrane Collaboration's tool was used to assess the risk of bias. Results: Thirteen randomized controlled trials met the inclusion criteria. Peer support resulted in a significant reduction in HbA1c (MD -0.57 [95% CI: -0.78 to -0.36]). Programs with moderate or high frequency of contact showed a significant reduction in HbA1c levels (MD -0.52 [95% CI: -0.60 to -0.44] and -0.75 [95% CI: -1.21 to -0.29], respectively), whereas programs with low frequency of contact showed no significant reduction (MD -0.32 [95% CI: -0.74 to 0.09]). The reduction in HbA1c were greater among patients with a baseline HbA1c ≥ 8.5% (MD -0.78 [95% CI: -1.06 to -0.51]) and between 7.5 ∼ 8.5% (MD -0.76 [95% CI: -1.05 to -0.47]), than patients with HbA1c &lt; 7.5% (MD -0.08 [95% CI: -0.32 to 0.16]). Conclusions: Peer support had a significant impact on HbA&lt;inf&gt;1c&lt;/inf&gt; levels among patients with type 2 diabetes. Priority should be given to programs with moderate or high frequency of contact for target patients with poor glycemic control rather than programs with low frequency of contact that target the overall population of patients.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023797</affiliation-url><afid>60023797</afid><affilname>Third Military Medical University</affilname><name-variant>Third Military Medical University</name-variant><affiliation-city>Chongqing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112606425</affiliation-url><afid>112606425</afid><affilname>Chongqing Municipal Center for Disease Control and Prevention</affilname><name-variant>Center for Disease Control and Prevention in Chongqing Municipality</name-variant><affiliation-city>Chongqing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020870</affiliation-url><afid>60020870</afid><affilname>Chongqing University of Medical Sciences</affilname><name-variant>Chongqing Medical University</name-variant><affiliation-city>Chongqing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016521</affiliation-url><afid>60016521</afid><affilname>Sichuan University</affilname><name-variant>Sichuan University</name-variant><affiliation-city>Chengdu</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56365192900</author-url><authid>56365192900</authid><authname>Qi L.</authname><surname>Qi</surname><given-name>Li</given-name><initials>L.</initials><afid>60023797</afid><afid>112606425</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56365192900</author-url><authid>56365192900</authid><authname>Qi L.</authname><surname>Qi</surname><given-name>Li</given-name><initials>L.</initials><afid>60023797</afid><afid>112606425</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56482372900</author-url><authid>56482372900</authid><authname>Liu Q.</authname><surname>Liu</surname><given-name>Qin</given-name><initials>Q.</initials><afid>60020870</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56285203800</author-url><authid>56285203800</authid><authname>Qi X.</authname><surname>Qi</surname><given-name>Xiaoling</given-name><initials>X.</initials><afid>60016521</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55865613700</author-url><authid>55865613700</authid><authname>Wu N.</authname><surname>Wu</surname><given-name>Na</given-name><initials>N.</initials><afid>60023797</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56623711600</author-url><authid>56623711600</authid><authname>Tang W.</authname><surname>Tang</surname><given-name>Wenge</given-name><initials>W.</initials><afid>112606425</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56623865900</author-url><authid>56623865900</authid><authname>Xiong H.</authname><surname>Xiong</surname><given-name>Hongyan</given-name><initials>H.</initials><afid>60023797</afid></author><authkeywords>Meta-analysis | Peer support | Randomized control trial | Type 2 diabetes</authkeywords><intid>2035910447</intid><article-number>1798</article-number><source-id>19621</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929493815"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929493815?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929493815&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929493815&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929493815</prism:url><dc:identifier>SCOPUS_ID:84929493815</dc:identifier><eid>2-s2.0-84929493815</eid><dc:title>High sensitivity C-reactive protein and cerebral white matter hyperintensities on magnetic resonance imaging in migraine patients</dc:title><dc:creator>Avci A.</dc:creator><prism:publicationName>Journal of Headache and Pain</prism:publicationName><prism:issn>11292369</prism:issn><prism:eIssn>11292377</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/1129-2377-16-9</prism:doi><dc:description>© 2015, Avci et al.; licensee Springer. Background: Migraine is a common headache disorder that may be associated with vascular disease and cerebral white matter hyperintensities (WMHs) on magnetic resonance imaging (MRI) scan. High sensitivity C-reactive protein (hs-CRP) is a marker of inflammation that may predict subclinical atherosclerosis. However, the relation between migraine, vascular risks, and WMHs is unknown. We evaluated hs-CRP levels and the relation between hs-CRP level and WMHs in adult migraine patients. Methods: This case–control study included 432 subjects (216 migraine patients [without aura, 143 patients; with aura, 73 patients]; 216 healthy control subjects without migraine; age range 18–50 y). Migraine diagnosis was determined according to the International Classification of Headache Disorders II diagnostic criteria. The migraine patients and control subjects had no known vascular risk factors, inflammatory disease, or comorbid disease. The presence and number of WMHs on MRI scans were determined, and serum hs-CRP levels were measured by latex-enhanced immunoturbidimetry. Results: Mean hs-CRP level was significantly greater in migraine patients (1.94 ± 2.03 mg/L) than control subjects (0.82 ± 0.58 mg/L; P ≤.0001). The mean number of WMHs per subject and the presence of WMHs was significantly greater in migraine patients (69 patients [31.9%]; 1.68 ± 3.12 mg/dL) than control subjects (21 subjects [9.7%]; 0.3 ± 1.3; P ≤.001). However, there was no correlation between hs-CRP level and WMHs in migraine patients (r = 0.024; not significant). The presence of WMHs was increased 4.35-fold in migraine patients (odds ratio 4.35, P ≤.001). Conclusions: High hs-CRP level may be a marker of the proinflammatory state in migraine patients. However, the absence of correlation between hs-CRP level and WMHs suggests that hs-CRP is not causally involved in the pathogenesis of WMHs in migraine patients. The WMHs were located mostly in the frontal lobe and subcortical area.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028644</affiliation-url><afid>60028644</afid><affilname>Baskent Universitesi</affilname><name-variant>Başkent University</name-variant><affiliation-city>Ankara</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028644</affiliation-url><afid>60028644</afid><affilname>Baskent Universitesi</affilname><name-variant>Başkent University</name-variant><affiliation-city>Ankara</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028644</affiliation-url><afid>60028644</afid><affilname>Baskent Universitesi</affilname><name-variant>Başkent University</name-variant><affiliation-city>Ankara</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:25931378600</author-url><authid>25931378600</authid><authname>Avci A.</authname><surname>Avci</surname><given-name>Aynur Yilmaz</given-name><initials>A.Y.</initials><afid>60028644</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35234014000</author-url><authid>35234014000</authid><authname>Lakadamyali H.</authname><surname>Lakadamyali</surname><given-name>Hatice</given-name><initials>H.</initials><afid>60028644</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:23088416100</author-url><authid>23088416100</authid><authname>Arikan S.</authname><surname>Arikan</surname><given-name>Serap</given-name><initials>S.</initials><afid>60028644</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6507921308</author-url><authid>6507921308</authid><authname>Benli U.</authname><surname>Benli</surname><given-name>Ulku Sibel</given-name><initials>U.S.</initials><afid>60028644</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55196454800</author-url><authid>55196454800</authid><authname>Kilinc M.</authname><surname>Kilinc</surname><given-name>Munire</given-name><initials>M.</initials><afid>60028644</afid></author><authkeywords>Headache | Inflammation | Pathophysiology | Vascular disease</authkeywords><intid>1535964111</intid><source-id>16714</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925841314"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925841314?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925841314&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925841314&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925841314</prism:url><dc:identifier>SCOPUS_ID:84925841314</dc:identifier><eid>2-s2.0-84925841314</eid><dc:title>Multiple extra-ischemic hemorrhages following intravenous thrombolysis in a patient with Trousseau syndrome: case study</dc:title><dc:creator>Ikeda H.</dc:creator><prism:publicationName>SpringerPlus</prism:publicationName><prism:eIssn>21931801</prism:eIssn><prism:volume>4</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s40064-015-0920-z</prism:doi><dc:description>© 2015, Ikeda et al.; licensee Springer. Background: Intracerebral hemorrhage is the most feared complication of intravenous thrombolysis for acute ischemic stroke. Such hemorrhage usually occurs within or at the margin of ischemic or manifestly infarcted brain tissue. A patient with Trousseau syndrome who developed multiple extra-ischemic hemorrhages following intravenous thrombolysis is described.Case description: An 80-year-old Japanese man with no other underlying disease was diagnosed with unresectable advanced lung cancer (stage IV) without brain metastasis and had not yet been treated. The patient suddenly presented with disturbance of consciousness, right hemiplegia, and total aphasia, and was admitted to our hospital. Magnetic resonance imaging revealed acute cerebral infarction extending from the basal ganglia to the corona radiata of the left cerebrum and multiple small areas of bilateral cerebral cortices. Cardiogenic cerebral embolism was considered among the differential diagnoses, but the brain natriuretic peptide level was within the normal range, and no arrhythmias such as atrial fibrillation were observed. With no other causes, the patient was diagnosed with Trousseau syndrome due to hypercoagulability associated with the advanced lung cancer. The patient received intravenous tissue plasminogen activator (t-PA) at 96 minutes after onset of symptoms. His symptoms partially improved, but they suddenly deteriorated at 84 minutes after the thrombolysis. A computed tomography (CT) scan immediately after the neurological deterioration revealed a subcortical hemorrhage in the left occipital lobe. A repeat CT scan the day after onset showed enlargement of the left occipital hemorrhage and two new subcortical hemorrhages in the right frontal and right temporal lobes. These hemorrhages were located in areas remote from the acute ischemic lesions.Conclusion: To the best of our knowledge, this is the first reported case of multiple extra-ischemic hemorrhages following intravenous thrombolysis in a patient with Trousseau syndrome. The course of this case suggests that intravenous t-PA administration for acute ischemic stroke with Trousseau syndrome may be associated with a higher risk of intracranial hemorrhage.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114826066</affiliation-url><afid>114826066</afid><affilname>National Hospital Organization Himeji Medical Center</affilname><name-variant>National Hospital Organization Himeji Medical Center</name-variant><affiliation-city/><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:52463820200</author-url><authid>52463820200</authid><authname>Ikeda H.</authname><surname>Ikeda</surname><given-name>Hiroyuki</given-name><initials>H.</initials><afid>114826066</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:11439016500</author-url><authid>11439016500</authid><authname>Enatsu R.</authname><surname>Enatsu</surname><given-name>Rei</given-name><initials>R.</initials><afid>114826066</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55752716000</author-url><authid>55752716000</authid><authname>Yamana N.</authname><surname>Yamana</surname><given-name>Norikazu</given-name><initials>N.</initials><afid>114826066</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55510184000</author-url><authid>55510184000</authid><authname>Nishimura M.</authname><surname>Nishimura</surname><given-name>Masaki</given-name><initials>M.</initials><afid>114826066</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56574814300</author-url><authid>56574814300</authid><authname>Saiki M.</authname><surname>Saiki</surname><given-name>Masaaki</given-name><initials>M.</initials><afid>114826066</afid></author><authkeywords>Cerebral infarction | Intracerebral hemorrhage | Intravenous thrombolysis | Trousseau syndrome | Vascular disorders</authkeywords><intid>1535371068</intid><source-id>21100228569</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929208726"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929208726?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929208726&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929208726&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0308814615007360"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929208726</prism:url><dc:identifier>SCOPUS_ID:84929208726</dc:identifier><eid>2-s2.0-84929208726</eid><dc:title>Purification and characterization of antioxidant peptides from enzymatically hydrolyzed chicken egg white</dc:title><dc:creator>Nimalaratne C.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>188</prism:volume><prism:pageRange>467-472</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2015.05.014</prism:doi><pii>S0308814615007360</pii><dc:description>© 2015 Published by Elsevier Ltd. Abstract Egg white is considered as a rich source of high quality proteins with various bioactive peptide fractions. Enzymatic hydrolysis of proteins can be used to release bioactive fractions and different enzymes have different abilities in releasing such bioactive fractions depending on the enzyme's site of activity on a protein. In this study, several proteases were examined for their ability to release antioxidant peptides from hen egg white and protease P was selected based on the antioxidant activity and the digestion yield of the crude protein hydrolysate. A combination of several purification steps including ultrafiltration with low molecular weight cut-off membranes, cation exchange chromatography and reversed phase high performance liquid chromatography was used to purify 'protease P egg white hydrolysate'. Sixteen antioxidant peptides, which were derived from ovalbumin, ovotransferrin and cystatin were isolated from the most active fractions. Amino acid sequences of those peptides were determined using LC-MS/MS. Oxygen radical absorbance capacity (ORAC) values of selected short chain peptides were determined using synthetic peptides. Two peptides AEERYP and DEDTQAMP (Ala-Glu-Glu-Arg-Tyr-Pro and Asp-Glu-Asp-Thr-Gln-Ala-Met-Pro) showed the highest ORAC values. The results from this study indicate that egg white is rich in antioxidant peptides which can be used as a potential source for preparing bioactive ingredients using enzymatic hydrolysis followed by purification techniques.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030835</affiliation-url><afid>60030835</afid><affilname>University of Alberta</affilname><name-variant>University of Alberta</name-variant><affiliation-city>Edmonton</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36703376400</author-url><authid>36703376400</authid><authname>Nimalaratne C.</authname><surname>Nimalaratne</surname><given-name>Chamila</given-name><initials>C.</initials><afid>60030835</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:54783991500</author-url><authid>54783991500</authid><authname>Bandara N.</authname><surname>Bandara</surname><given-name>Nandika</given-name><initials>N.</initials><afid>60030835</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7409251383</author-url><authid>7409251383</authid><authname>Wu J.</authname><surname>Wu</surname><given-name>Jianping</given-name><initials>J.</initials><afid>60030835</afid></author><authkeywords>Antioxidant peptides | Chicken egg white | Chromatographic separation | Enzymatic hydrolysis | Ultrafiltration</authkeywords><intid>1785917708</intid><article-number>17560</article-number><source-id>24039</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927757326"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927757326?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927757326&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927757326&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927757326</prism:url><dc:identifier>SCOPUS_ID:84927757326</dc:identifier><eid>2-s2.0-84927757326</eid><dc:title>Effect of delayed graft function, acute rejection and chronic allograft dysfunction on kidney allograft telomere length in patients after transplantation: A prospective cohort study</dc:title><dc:creator>Domański L.</dc:creator><prism:publicationName>BMC Nephrology</prism:publicationName><prism:eIssn>14712369</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1186/s12882-015-0014-8</prism:doi><dc:description>© 2015 Domanski ; licensee BioMed Central. Background: The outcome of kidney allograft transplantation is associated with numerous donor-dependent and recipient-dependent immunological and non-immunological factors. Studies on genetic factors affecting the non-immunological aspects, like ageing of the kidney allograft and patient outcome are still lacking. The aim of this study was the analysis of relative telomere length (RTL; T/S ratio) in the biopsy specimens of the transplanted kidney allograft and its correlation with the delayed graft function (DGF), acute rejection (AR) and chronic allograft dysfunction (CAD). Methods: The study enrolled 119 Caucasian kidney allograft recipients (64 M/55 F, mean age 47.32 ±14.03; transplantation performed between 2001 and 2012). Organs were harvested from cadaveric donors (59.8 M/40.2 F, mean age 45.99 ± 14.62). Results: There were significant differences in RTL assessed in kidney allograft biopsy specimens collected 3-6 months after transplantation between patients with DGF and without DGF (181.8 ± 82.0 vs. 284.6 ± 149.6; p &lt; 0.05) and in RTL of kidney allograft biopsy specimens collected 18-60 months after transplantation between patients with AR and without AR (188.1 ± 162.1 vs. 263.3 ± 134.7; p = 0.047). There were significant differences in RTL assessed in kidney allograft biopsy specimens collected 12-24 months after transplantation between patients with CAD and without CAD (168.0 ± 120.0 vs. 282.1 ± 158.4; p = 0.038). Conclusions: Duration of dialysis before transplantation and PRA influence the kidney allograft ageing. Telomere length assessed in biopsy specimens collected in the peri-transplant period predicts the long-term kidney allograft function. Complications of kidney transplantation, like DGF, AR and CAD are linked with the telomere length and thus, graft ageing.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019189</affiliation-url><afid>60019189</afid><affilname>Pomorska Akademia Medyczna w Szczecinie</affilname><name-variant>Pomeranian Medical University</name-variant><affiliation-city>Szczecin</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019189</affiliation-url><afid>60019189</afid><affilname>Pomorska Akademia Medyczna w Szczecinie</affilname><name-variant>Pomeranian Medical University</name-variant><affiliation-city>Szczecin</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019189</affiliation-url><afid>60019189</afid><affilname>Pomorska Akademia Medyczna w Szczecinie</affilname><name-variant>Pomeranian Medical University</name-variant><affiliation-city>Szczecin</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Department of Laboratory Diagnostics and Molecular Medicine</affilname><affiliation-city>Szczecin</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56255903000</author-url><authid>56255903000</authid><authname>Domański L.</authname><surname>Domański</surname><given-name>Leszek</given-name><initials>L.</initials><afid>60019189</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26433558200</author-url><authid>26433558200</authid><authname>Kłoda K.</authname><surname>Kłoda</surname><given-name>Karolina</given-name><initials>K.</initials><afid>60019189</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:9733363700</author-url><authid>9733363700</authid><authname>Kwiatkowska E.</authname><surname>Kwiatkowska</surname><given-name>Ewa</given-name><initials>E.</initials><afid>60019189</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8615800700</author-url><authid>8615800700</authid><authname>Borowiecka E.</authname><surname>Borowiecka</surname><given-name>Ewa</given-name><initials>E.</initials><afid>60019189</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8417717400</author-url><authid>8417717400</authid><authname>Safranow K.</authname><surname>Safranow</surname><given-name>Krzysztof</given-name><initials>K.</initials><afid>60019189</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36082522600</author-url><authid>36082522600</authid><authname>Drozd A.</authname><surname>Drozd</surname><given-name>Arleta</given-name><initials>A.</initials><afid>60019189</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7004303725</author-url><authid>7004303725</authid><authname>Ciechanowicz A.</authname><surname>Ciechanowicz</surname><given-name>Andrzej</given-name><initials>A.</initials><afid/></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7005319036</author-url><authid>7005319036</authid><authname>Ciechanowski K.</authname><surname>Ciechanowski</surname><given-name>Kazimierz</given-name><initials>K.</initials><afid>60019189</afid></author><authkeywords>Ageing | AR | CAD | Cellular senescence | DGF | Telomere length</authkeywords><intid>1535665714</intid><article-number>23</article-number><source-id>19395</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929616412"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929616412?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929616412&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929616412&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0260877415002186"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929616412</prism:url><dc:identifier>SCOPUS_ID:84929616412</dc:identifier><eid>2-s2.0-84929616412</eid><dc:title>Bioactive compounds as functional food ingredients: Characterization in model system and sensory evaluation in chocolate milk</dc:title><dc:creator>Marsanasco M.</dc:creator><prism:publicationName>Journal of Food Engineering</prism:publicationName><prism:issn>02608774</prism:issn><prism:volume>166</prism:volume><prism:pageRange>55-63</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>1 December 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jfoodeng.2015.05.007</prism:doi><pii>S0260877415002186</pii><dc:description>© 2015 Elsevier Ltd. All rights reserved. The objective was the design and the structural and functional characterization of bioactive compounds (BC) as functional food ingredients for a future industrial application in chocolate milk. Liposomes were made of soy phosphatidylcholine, containing BC (omega-3, omega-6, vitamin E) and encapsulating folic acid (FA). Stearic acid and calcium stearate were added as liposome stabilizers. The oxidative stability, size and shape were analyzed by thiobarbituric acid method, light scattering, and light microscopy, respectively. Membrane packing was also studied. Rheological behavior of liposomes and encapsulation efficiency of FA were analyzed after pasteurization. Studies were performed in food-model. Liposomes showed significant stability of all parameters and a protective effect over thermolabile FA remaining half of this vitamin encapsulated. Sensory evaluations were studied in chocolate milk with BC, demonstrating positive effects on acceptability. For all the above, BC formulations are suitable for a future application and/or scaling up in dairy industry.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008944</affiliation-url><afid>60008944</afid><affilname>Universidad Nacional de Quilmes</affilname><name-variant>Universidad Nacional de Quilmes</name-variant><affiliation-city>Bernal</affiliation-city><affiliation-country>Argentina</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008944</affiliation-url><afid>60008944</afid><affilname>Universidad Nacional de Quilmes</affilname><name-variant>Universidad Nacional de Quilmes</name-variant><affiliation-city>Bernal</affiliation-city><affiliation-country>Argentina</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54392194900</author-url><authid>54392194900</authid><authname>Marsanasco M.</authname><surname>Marsanasco</surname><given-name>Marina</given-name><initials>M.</initials><afid>60008944</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:15727961500</author-url><authid>15727961500</authid><authname>Márquez A.</authname><surname>Márquez</surname><given-name>Andrés L.</given-name><initials>A.L.</initials><afid>60008944</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56424656100</author-url><authid>56424656100</authid><authname>Wagner J.</authname><surname>Wagner</surname><given-name>Jorge R.</given-name><initials>J.R.</initials><afid>60008944</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6507270935</author-url><authid>6507270935</authid><authname>Chiaramoni N.</authname><surname>Chiaramoni</surname><given-name>Nadia S.</given-name><initials>N.S.</initials><afid>60008944</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55666477200</author-url><authid>55666477200</authid><authname>Del V. Alonso S.</authname><surname>Del V. Alonso</surname><given-name>Silvia</given-name><initials>S.</initials><afid>60008944</afid></author><authkeywords>Acceptability | Bioactive compounds | Liposome | Preservation | Stability | Vitamins</authkeywords><intid>1535988632</intid><source-id>20586</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84919934470"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84919934470?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84919934470&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84919934470&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0011393X14000265"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84919934470</prism:url><dc:identifier>SCOPUS_ID:84919934470</dc:identifier><eid>2-s2.0-84919934470</eid><dc:title>Absorption Kinetics of Subcutaneously Administered Ceftazidime in Hypoperfused Guinea Pigs</dc:title><dc:creator>Ebihara T.</dc:creator><prism:publicationName>Current Therapeutic Research - Clinical and Experimental</prism:publicationName><prism:issn>0011393X</prism:issn><prism:eIssn>18790313</prism:eIssn><prism:volume>77</prism:volume><prism:pageRange>7-13</prism:pageRange><prism:coverDate>2015-12-01</prism:coverDate><prism:coverDisplayDate>December 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.curtheres.2014.09.006</prism:doi><pii>S0011393X14000265</pii><dc:description>© 2014 The Authoes. Background: Pneumonia is the most common cause of death in patients with severe motor and intellectual disabilities (SMID), and intravenous ceftazidime (CAZ) is a widely used treatment for such infections. However, intravenous administration in patients with SMID may be difficult because of insufficient vascular development. Objectives: The aim of our study was to determine the feasibility of subcutaneous drug administration by mentholated warm compresses (WMCs) as an alternative delivery method for ceftazidime in patients with SMID. Methods: CAZ was subcutaneously administered to the abdominal region of naphazoline-treated hypoperfused guinea pigs, which were used as a hemodynamic model of patients with SMID. MWCs or warm compresses (WCs) were applied to the injection site to increase blood flow. We calculated the cumulative CAZ absorption over time by using the deconvolution method. Results: Application of MWCs or WCs increased blood flow at the administration site and increased CAZ plasma levels. Application of MWCs or WCs after subcutaneous CAZ injection led to higher CAZ plasma levels than the mutant prevention concentration for a longer period than was observed for CAZ administration without the application of MWCs or WCs. Conclusions: The application of MWCs or WCs enhanced subcutaneous CAZ absorption by increasing blood flow. MWCs and WCs are considered to be safe and routine methods to induce defecation after surgery on the digestive system; thus, the combination of these methods and subcutaneous CAZ administration is a potential method for treating pneumonia in patients with SMID.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112600040</affiliation-url><afid>112600040</afid><affilname>National Rehabilitation Center for Children with Disabilities</affilname><name-variant>National Rehabilitation Center for Children with Disabilities</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015606</affiliation-url><afid>60015606</afid><affilname>Josai University</affilname><name-variant>Josai University</name-variant><affiliation-city>Sakado</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112600040</affiliation-url><afid>112600040</afid><affilname>National Rehabilitation Center for Children with Disabilities</affilname><name-variant>National Rehabilitation Center for Children with Disabilities</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56462286400</author-url><authid>56462286400</authid><authname>Ebihara T.</authname><surname>Ebihara</surname><given-name>Tsuyoshi</given-name><initials>T.</initials><afid>112600040</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:54950258700</author-url><authid>54950258700</authid><authname>Oshima S.</authname><surname>Oshima</surname><given-name>Shinji</given-name><initials>S.</initials><afid>60015606</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56462329100</author-url><authid>56462329100</authid><authname>Okita M.</authname><surname>Okita</surname><given-name>Mitsuyoshi</given-name><initials>M.</initials><afid>60015606</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56462339900</author-url><authid>56462339900</authid><authname>Shiina S.</authname><surname>Shiina</surname><given-name>Sayumi</given-name><initials>S.</initials><afid>60015606</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56462357500</author-url><authid>56462357500</authid><authname>Negishi A.</authname><surname>Negishi</surname><given-name>Akio</given-name><initials>A.</initials><afid>60015606</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56462144400</author-url><authid>56462144400</authid><authname>Ohara K.</authname><surname>Ohara</surname><given-name>Kousuke</given-name><initials>K.</initials><afid>60015606</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:36752280700</author-url><authid>36752280700</authid><authname>Ohshima S.</authname><surname>Ohshima</surname><given-name>Shigeru</given-name><initials>S.</initials><afid>60015606</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56462053400</author-url><authid>56462053400</authid><authname>Iwasaki H.</authname><surname>Iwasaki</surname><given-name>Hiroyuki</given-name><initials>H.</initials><afid>112600040</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56462371100</author-url><authid>56462371100</authid><authname>Yoneyama A.</authname><surname>Yoneyama</surname><given-name>Akira</given-name><initials>A.</initials><afid>112600040</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:6603146533</author-url><authid>6603146533</authid><authname>Kitazumi E.</authname><surname>Kitazumi</surname><given-name>Eiji</given-name><initials>E.</initials><afid>112600040</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56442797600</author-url><authid>56442797600</authid><authname>Kobayashi D.</authname><surname>Kobayashi</surname><given-name>Daisuke</given-name><initials>D.</initials><afid>60015606</afid></author><authkeywords>Blood flow | Ceftazidime | Mentholated warm compress | Severe motor and intellectual disabilities | Subcutaneous absorption</authkeywords><intid>1534387703</intid><source-id>12328</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84910641622"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84910641622?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84910641622&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84910641622&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0006291X1401941X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84910641622</prism:url><dc:identifier>SCOPUS_ID:84910641622</dc:identifier><eid>2-s2.0-84910641622</eid><dc:title>Fatty acid binding protein 3 as a potential mediator for diabetic nephropathy in eNOS deficient mouse</dc:title><dc:creator>Ozawa S.</dc:creator><prism:publicationName>Biochemical and Biophysical Research Communications</prism:publicationName><prism:issn>0006291X</prism:issn><prism:eIssn>10902104</prism:eIssn><prism:volume>454</prism:volume><prism:issueIdentifier>4</prism:issueIdentifier><prism:pageRange>531-536</prism:pageRange><prism:coverDate>2015-11-28</prism:coverDate><prism:coverDisplayDate>28 November 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbrc.2014.10.121</prism:doi><pii>S0006291X1401941X</pii><dc:description>© 2014 The Authors. In human diabetic nephropathy, glomerular injury was found to comprise lipid droplets, suggesting that abnormal lipid metabolism might take place in the development of diabetic glomerular injury. However, its precise mechanism remains unclear. Fatty acid binding protein (FABP) is currently considered as a key molecule for lipid metabolism. Since diabetic eNOS knockout (KO) mouse is considered to be a good model for human diabetic nephropathy, we here investigated whether FABP could mediate glomerular injury in this model. We found that glomerular injuries were associated with inflammatory processes, such as macrophage infiltration and MCP-1 induction. Microarray assay with isolated glomeruli revealed that among 10 isoforms in FABP family, FABP3 mRNA was most highly expressed in diabetic eNOSKO mice compared to non-diabetic eNOSKO mice. FABP3 protein was found to be located in the mesangial cells. Overexpression of FABP3 resulted in a greater response to palmitate, a satulated FA, to induce MCP-1 in the rat mesangial cells. In turn, the heart, a major organ for FABP3 protein in normal condition, failed to alter its expression level under diabetic condition in either wild type or eNOSKO mice. In conclusion, FABP3 is induced in the mesangial cells and likely a mediator to induce MCP-1 in the diabetic nephropathy.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011001</affiliation-url><afid>60011001</afid><affilname>Kyoto University</affilname><name-variant>Kyoto University</name-variant><affiliation-city>Kyoto</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60085763</affiliation-url><afid>60085763</afid><affilname>Mitsubishi Tanabe Pharma Corporation</affilname><name-variant>Mitsubishi Tanabe Pharma Corporation</name-variant><affiliation-city>Osaka</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029730</affiliation-url><afid>60029730</afid><affilname>Teikyo University School of Medicine</affilname><name-variant>Teikyo University School of Medicine</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030354</affiliation-url><afid>60030354</afid><affilname>Kyoto University Faculty of Medicine</affilname><name-variant>Kyoto University School of Medicine</name-variant><affiliation-city>Kyoto</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56417163600</author-url><authid>56417163600</authid><authname>Ozawa S.</authname><surname>Ozawa</surname><given-name>Shota</given-name><initials>S.</initials><afid>60011001</afid><afid>60085763</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56417163600</author-url><authid>56417163600</authid><authname>Ozawa S.</authname><surname>Ozawa</surname><given-name>Shota</given-name><initials>S.</initials><afid>60011001</afid><afid>60085763</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7403292774</author-url><authid>7403292774</authid><authname>Ueda S.</authname><surname>Ueda</surname><given-name>Shuko</given-name><initials>S.</initials><afid>60011001</afid><afid>60029730</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7403292774</author-url><authid>7403292774</authid><authname>Ueda S.</authname><surname>Ueda</surname><given-name>Shuko</given-name><initials>S.</initials><afid>60011001</afid><afid>60029730</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56418737800</author-url><authid>56418737800</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Ying</given-name><initials>Y.</initials><afid>60011001</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56416887200</author-url><authid>56416887200</authid><authname>Mori K.</authname><surname>Mori</surname><given-name>Kiyoshi</given-name><initials>K.</initials><afid>60011001</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56417410300</author-url><authid>56417410300</authid><authname>Asanuma K.</authname><surname>Asanuma</surname><given-name>Katsuhiko</given-name><initials>K.</initials><afid>60011001</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7003412808</author-url><authid>7003412808</authid><authname>Yanagita M.</authname><surname>Yanagita</surname><given-name>Motoko</given-name><initials>M.</initials><afid>60011001</afid><afid>60030354</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7003412808</author-url><authid>7003412808</authid><authname>Yanagita M.</authname><surname>Yanagita</surname><given-name>Motoko</given-name><initials>M.</initials><afid>60011001</afid><afid>60030354</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7404044335</author-url><authid>7404044335</authid><authname>Nakagawa T.</authname><surname>Nakagawa</surname><given-name>Takahiko</given-name><initials>T.</initials><afid>60011001</afid></author><authkeywords>Advanced diabetic nephropathy | Endothelial | FABP | Fatty acid | Inflammation | Nitric oxide</authkeywords><intid>1532829963</intid><source-id>16845</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84910649094"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84910649094?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84910649094&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84910649094&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0006291X14019342"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84910649094</prism:url><dc:identifier>SCOPUS_ID:84910649094</dc:identifier><eid>2-s2.0-84910649094</eid><dc:title>The RLIP76 N-terminus binds ARNO to regulate PI 3-kinase, Arf6 and Rac signaling, cell spreading and migration</dc:title><dc:creator>Lee S.</dc:creator><prism:publicationName>Biochemical and Biophysical Research Communications</prism:publicationName><prism:issn>0006291X</prism:issn><prism:eIssn>10902104</prism:eIssn><prism:volume>454</prism:volume><prism:issueIdentifier>4</prism:issueIdentifier><prism:pageRange>560-565</prism:pageRange><prism:coverDate>2015-11-28</prism:coverDate><prism:coverDisplayDate>28 November 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbrc.2014.10.114</prism:doi><pii>S0006291X14019342</pii><dc:description>© 2014 Elsevier Inc. RLIP76 is a multifunctional protein involved in tumor growth and angiogenesis, and a promising therapeutic target in many cancers. RLIP76 harbors docking sites for many proteins, and we have found that it interacts with ARNO, a guanine nucleotide exchange factor for Arf6, and that RLIP76 regulates activation of Rac1 via Arf6, and regulates cell spreading and migration in an ARNO and Arf6-dependent manner. Here we show that ARNO interacts with the RLIP76 N-terminal domain, and this domain was required for RLIP76-dependent cell spreading and migration. We identified two sites in the RLIP76 N-terminus with differential effects on ARNO binding and downstream signaling: Ser29/Ser30 and Ser62. Ser29/30 mutation to Alanine inhibited ARNO interaction and was sufficient to block RLIP76-dependent cell spreading and migration, as well as RLIP76-dependent Arf6 activation. In contrast, RLIP76(S62A) interacted with ARNO and supported Arf6 activation. However, both sets of mutations blocked Rac1 activation. RLIP76-mediated Rac and Arf6 activation required PI3K activity. S29/30A mutations inhibited RLIP76-dependent PI3K activation, but S62A mutation did not. Together these results show that ARNO interaction with the RLIP76 N-terminus regulates cell spreading and motility via PI3K and Arf6, independent of RLIP76 control of Rac.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013936</affiliation-url><afid>60013936</afid><affilname>Temple University School of Medicine</affilname><name-variant>Temple Univ. Sch. Med.</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009389</affiliation-url><afid>60009389</afid><affilname>Fox Chase Cancer Center</affilname><name-variant>Fox Chase Cancer Center</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55391459100</author-url><authid>55391459100</authid><authname>Lee S.</authname><surname>Lee</surname><given-name>Seunghyung</given-name><initials>S.</initials><afid>60013936</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55312698100</author-url><authid>55312698100</authid><authname>Wurtzel J.</authname><surname>Wurtzel</surname><given-name>Jeremy G T</given-name><initials>J.G.T.</initials><afid>60013936</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602363753</author-url><authid>6602363753</authid><authname>Goldfinger L.</authname><surname>Goldfinger</surname><given-name>Lawrence E.</given-name><initials>L.E.</initials><afid>60013936</afid><afid>60009389</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602363753</author-url><authid>6602363753</authid><authname>Goldfinger L.</authname><surname>Goldfinger</surname><given-name>Lawrence E.</given-name><initials>L.E.</initials><afid>60013936</afid><afid>60009389</afid></author><authkeywords>ARF | Cell migration | Cell signaling | PI 3-kinase (PI3K) | Rac</authkeywords><intid>532841502</intid><source-id>16845</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925446992"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925446992?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925446992&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925446992&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925446992</prism:url><dc:identifier>SCOPUS_ID:84925446992</dc:identifier><eid>2-s2.0-84925446992</eid><dc:title>Association of ischemic heart disease to global and regional longitudinal strain in asymptomatic aortic stenosis</dc:title><dc:creator>Carstensen H.</dc:creator><prism:publicationName>International Journal of Cardiovascular Imaging</prism:publicationName><prism:issn>15695794</prism:issn><prism:eIssn>15730743</prism:eIssn><prism:volume>31</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>485-495</prism:pageRange><prism:coverDate>2015-11-18</prism:coverDate><prism:coverDisplayDate>18 November 2015</prism:coverDisplayDate><prism:doi>10.1007/s10554-014-0572-z</prism:doi><dc:description>© 2014, Springer Science+Business Media Dordrecht. Longitudinal deformation has been shown to deteriorate with progressive aortic stenosis as well as ischemic heart disease. Despite that both conditions share risk factors and are often coexisting, studies have not assessed the influence on longitudinal deformation for both conditions simultaneously. Thus the purpose of this study was to evaluate the association between subclinical ischemic heart disease and global and regional longitudinal strain in asymptomatic patients with significant aortic stenosis. Prevalent patients with a diagnosis of aortic stenosis at six hospitals in the Greater Copenhagen area were screened for inclusion. A total of 104 asymptomatic patients with moderate-severe aortic stenosis (aortic valve area ≤1.5 cm2) fulfilled study criteria and underwent advanced echocardiographic analysis and coronary angiography by multi-detector computed tomography. Angiography revealed coronary stenosis &gt;50 % in 31 % (n = 32). All regional longitudinal strain measures (apical, mid and basal longitudinal strain) were significant predictors of significant coronary stenosis (&gt;70 % stenosis), but only apical and mid longitudinal strain were significant predictors in multivariable analyses independent of aortic valve area, stroke volume index, pro-BNP, valvulo-arterial impedance, body mass index and heart rate. In linear regression models with both aortic valve area and significant coronary stenosis, apical (p &lt; 0.001) and mid (p &lt; 0.01) longitudinal strain were associated to significant coronary stenosis but not aortic valve area. Conversely, basal longitudinal strain was significantly associated to aortic valve area (p = 0.001), but not to significant coronary stenosis. Subclinical coronary artery disease is frequent in moderate and severe aortic stenosis, and should be suspected when regional longitudinal dysfunction is predominant in the apical and mid ventricular segments.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014959</affiliation-url><afid>60014959</afid><affilname>Amtssygehuset i Gentofte</affilname><name-variant>Gentofte Hospital</name-variant><affiliation-city>Hellerup</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006564</affiliation-url><afid>60006564</afid><affilname>Rigshospitalet</affilname><name-variant>Copenhagen University Hospital</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006564</affiliation-url><afid>60006564</afid><affilname>Rigshospitalet</affilname><name-variant>Copenhagen University Hospital</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55520640700</author-url><authid>55520640700</authid><authname>Carstensen H.</authname><surname>Carstensen</surname><given-name>Helle Gervig</given-name><initials>H.G.</initials><afid>60014959</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55797987100</author-url><authid>55797987100</authid><authname>Larsen L.</authname><surname>Larsen</surname><given-name>Linnea Hornbech</given-name><initials>L.H.</initials><afid>60006564</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005846737</author-url><authid>7005846737</authid><authname>Hassager C.</authname><surname>Hassager</surname><given-name>Christian</given-name><initials>C.</initials><afid>60006564</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55665737500</author-url><authid>55665737500</authid><authname>Kofoed K.</authname><surname>Kofoed</surname><given-name>Klaus Fuglsang</given-name><initials>K.F.</initials><afid>60006564</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35463622600</author-url><authid>35463622600</authid><authname>Jensen J.</authname><surname>Jensen</surname><given-name>Jan Skov</given-name><initials>J.S.</initials><afid>60014959</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:15725926700</author-url><authid>15725926700</authid><authname>Mogelvang R.</authname><surname>Mogelvang</surname><given-name>Rasmus</given-name><initials>R.</initials><afid>60006564</afid></author><authkeywords>Asymptomatic aortic stenosis | Deformation | Ischemic heart disease | Regional longitudinal strain</authkeywords><intid>2035289837</intid><source-id>37971</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925445020"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925445020?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925445020&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925445020&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925445020</prism:url><dc:identifier>SCOPUS_ID:84925445020</dc:identifier><eid>2-s2.0-84925445020</eid><dc:title>Echocardiographic assessment of global longitudinal right ventricular function in patients with an acute inferior ST elevation myocardial infarction and proximal right coronary artery occlusion</dc:title><dc:creator>Hutyra M.</dc:creator><prism:publicationName>International Journal of Cardiovascular Imaging</prism:publicationName><prism:issn>15695794</prism:issn><prism:eIssn>15730743</prism:eIssn><prism:volume>31</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>497-507</prism:pageRange><prism:coverDate>2015-11-18</prism:coverDate><prism:coverDisplayDate>18 November 2015</prism:coverDisplayDate><prism:doi>10.1007/s10554-014-0573-y</prism:doi><dc:description>© 2014, Springer Science+Business Media Dordrecht. Right ventricular (RV) myocardial infarction (MI) is a frequent concomitant of an acute inferior MI. We set out to determine the diagnostic value of speckle tracking echocardiography in comparison with cardiac magnetic resonance (CMR) for RV stunning and scar prediction. 55 patients (66 ± 11 years) with an acute inferior ST elevation MI who underwent percutaneous coronary intervention (PCI) of an occlusion in the proximal right coronary artery were prospectively enrolled. An echocardiography was done on the day of presentation and on the 5th day thereafter. A CMR was subsequently performed 1 month after the MI. The CMR was used to differentiate between the group with RV scar (n = 26) and without RV scar (n = 29). RV peak systolic longitudinal strain (RV–LS) at presentation determined RV scar (−21.1 ± 5.1 % vs. −9.9 ± 4.6 %, p &lt; 0.0001). The RV–LS correlated with the scar extent (r = 0.83, p &lt; 0.0001). RV–LS &gt; −15.8 % had a sensitivity of 92 % and a specificity of 83 % in RV scar prediction (AUC 0.93). RV–LS was superior to TAPSE and TDI in determining the presence of RV scar. According to RV–LS values at presentation and on the 5th day, 3 subgroups were defined: G1—normal deformation (RV–LS &lt;−20 %), G2—RV stunning (baseline RV–LS &gt;−20 %, 5th day RV–LS &lt;−20 %) and G3—persistent RV dysfunction (unchanged RV–LS &gt; −20 %). In G1, there was neither RV scar nor clinically relevant hypotension. In G2, 58 % of patients developed RV scar and 36 % had hypotension. In the G3, 83 % developed RV scar and 55 % had hypotension. The myocardial deformation analysis could provide an early prediction of RV scar. It allowed the patients to be divided into subgroups with normal RV function, stunning and persistent RV dysfunction.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008462</affiliation-url><afid>60008462</afid><affilname>University Hospital Olomouc</affilname><name-variant>University Hospital</name-variant><affiliation-city>Olomouc</affiliation-city><affiliation-country>Czech Republic</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008462</affiliation-url><afid>60008462</afid><affilname>University Hospital Olomouc</affilname><name-variant>University Hospital</name-variant><affiliation-city>Olomouc</affiliation-city><affiliation-country>Czech Republic</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003367</affiliation-url><afid>60003367</afid><affilname>Univerzita Palack&amp;eacute;ho v Olomouci</affilname><name-variant>Palacký University</name-variant><affiliation-city>Olomouc</affiliation-city><affiliation-country>Czech Republic</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23496539800</author-url><authid>23496539800</authid><authname>Hutyra M.</authname><surname>Hutyra</surname><given-name>Martin</given-name><initials>M.</initials><afid>60008462</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36070904100</author-url><authid>36070904100</authid><authname>Skála T.</authname><surname>Skála</surname><given-name>Tomáš</given-name><initials>T.</initials><afid>60008462</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56425607600</author-url><authid>56425607600</authid><authname>Horák D.</authname><surname>Horák</surname><given-name>David</given-name><initials>D.</initials><afid>60008462</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7103170877</author-url><authid>7103170877</authid><authname>Köcher M.</authname><surname>Köcher</surname><given-name>Martin</given-name><initials>M.</initials><afid>60008462</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55016347700</author-url><authid>55016347700</authid><authname>Tüdös Z.</authname><surname>Tüdös</surname><given-name>Zbyněk</given-name><initials>Z.</initials><afid>60008462</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7005350249</author-url><authid>7005350249</authid><authname>Zapletalová J.</authname><surname>Zapletalová</surname><given-name>Jana</given-name><initials>J.</initials><afid>60003367</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55011716200</author-url><authid>55011716200</authid><authname>Přeček J.</authname><surname>Přeček</surname><given-name>Jan</given-name><initials>J.</initials><afid>60008462</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56126417900</author-url><authid>56126417900</authid><authname>Louis A.</authname><surname>Louis</surname><given-name>Albert</given-name><initials>A.</initials><afid>60008462</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55747299800</author-url><authid>55747299800</authid><authname>Smékal A.</authname><surname>Smékal</surname><given-name>Aleš</given-name><initials>A.</initials><afid>60008462</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56426612000</author-url><authid>56426612000</authid><authname>Táborský M.</authname><surname>Táborský</surname><given-name>Miloš</given-name><initials>M.</initials><afid>60008462</afid></author><authkeywords>Cardiac magnetic resonance imaging | M-mode | Right ventricular infarction | Speckle tracking echocardiography | Tissue velocity imaging | Two-dimensional strain</authkeywords><intid>35295109</intid><source-id>37971</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925389430"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925389430?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925389430&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925389430&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925389430</prism:url><dc:identifier>SCOPUS_ID:84925389430</dc:identifier><eid>2-s2.0-84925389430</eid><dc:title>Endothelial shear stress estimation in the human carotid artery based on Womersley versus Poiseuille flow</dc:title><dc:creator>Schwarz J.</dc:creator><prism:publicationName>International Journal of Cardiovascular Imaging</prism:publicationName><prism:issn>15695794</prism:issn><prism:eIssn>15730743</prism:eIssn><prism:volume>31</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>585-593</prism:pageRange><prism:coverDate>2015-11-18</prism:coverDate><prism:coverDisplayDate>18 November 2015</prism:coverDisplayDate><prism:doi>10.1007/s10554-014-0571-0</prism:doi><dc:description>© 2014, Springer Science+Business Media Dordrecht. Endothelial shear stress (ESS) dynamics are a major determinant of atherosclerosis development. The frequently used Poiseuille method to estimate ESS dynamics has important limitations. Therefore, we investigated whether Womersley flow may provide a better alternative for estimation of ESS while requiring equally simple hemodynamic parameters. Common carotid blood flow, centerline velocity, lumen diameter and mean wall thickness (MWT) were measured with 3T-MRI in 45 subjects at three different occasions. Mean ESS and two measures of pulsatility [shear pulsatility index (SPI) and oscillatory shear index (OSI)] were estimated based on Poiseuille and Womersley flow and compared to the more complex velocity gradient modelling method. The association between ESS and MWT was tested with multiple linear regression analysis; interscan reproducibility was assessed using intraclass correlation coefficients (ICC). Mean ESS and pulsatility indices based on Womersley flow (ESSwq β = −0.18, P = 0.04; SPIwq β = 0.24, P = 0.02; OSIwq β = 0.18, P = 0.045), showed equally good correlations with carotid MWT as the velocity gradient method (ESSvg β = −0.23, P = 0.01; SPIvg β = 0.21, P = 0.02; OSIvg β = 0.07, P = 0.47). This in contrast to the Poiseuille flow method that only showed a good correlation for mean ESS (ESSpq β = −0.18, P = 0.04; SPIpq β = 0.14, P = 0.14; OSIpq β = 0.04, P = 0.69). Womersley and Poiseuille methods had high intraclass correlation coefficients indicating good interscan reproducibility (both ICC = 0.84, 95 % confidence interval 0.75–0.90). Estimation of ESS dynamics based on Womersley flow modelling is superior to Poiseuille flow modelling and has good interscan reproducibility.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001157</affiliation-url><afid>60001157</afid><affilname>Academic Medical Centre, University of Amsterdam</affilname><name-variant>University of Amsterdam</name-variant><affiliation-city>Amsterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001157</affiliation-url><afid>60001157</afid><affilname>Academic Medical Centre, University of Amsterdam</affilname><name-variant>University of Amsterdam</name-variant><affiliation-city>Amsterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001157</affiliation-url><afid>60001157</afid><affilname>Academic Medical Centre, University of Amsterdam</affilname><name-variant>University of Amsterdam</name-variant><affiliation-city>Amsterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56425005900</author-url><authid>56425005900</authid><authname>Schwarz J.</authname><surname>Schwarz</surname><given-name>Janina C V</given-name><initials>J.C.V.</initials><afid>60001157</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:22979074100</author-url><authid>22979074100</authid><authname>Duivenvoorden R.</authname><surname>Duivenvoorden</surname><given-name>Raphaël</given-name><initials>R.</initials><afid>60001157</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35243156300</author-url><authid>35243156300</authid><authname>Nederveen A.</authname><surname>Nederveen</surname><given-name>Aart J.</given-name><initials>A.J.</initials><afid>60001157</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004092642</author-url><authid>7004092642</authid><authname>Stroes E.</authname><surname>Stroes</surname><given-name>Erik S G</given-name><initials>E.S.G.</initials><afid>60001157</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003720673</author-url><authid>7003720673</authid><authname>VanBavel E.</authname><surname>VanBavel</surname><given-name>Ed</given-name><initials>E.</initials><afid>60001157</afid></author><authkeywords>Cardiovascular magnetic resonance | Common carotid artery | Endothelial shear stress | Intima media thickness</authkeywords><intid>535298910</intid><source-id>37971</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928974789"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928974789?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928974789&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928974789&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0308814615006251"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928974789</prism:url><dc:identifier>SCOPUS_ID:84928974789</dc:identifier><eid>2-s2.0-84928974789</eid><dc:title>New monoterpene glycosides from sunflower seeds and their protective effects against H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt;-induced myocardial cell injury</dc:title><dc:creator>Fei Y.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>187</prism:volume><prism:pageRange>385-390</prism:pageRange><prism:coverDate>2015-11-15</prism:coverDate><prism:coverDisplayDate>15 November 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2015.04.079</prism:doi><pii>S0308814615006251</pii><dc:description>© 2015 Elsevier Ltd. Three new monoterpene glycosides (1-3) and eleven known compounds (4-14) were isolated from seeds of Helianthus annuus L. (sunflower). Their structures were determined by spectroscopic and chemical methods. All the compounds were isolated from sunflower seeds for the first time. Protective effects of compounds 1-14 against H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt;-induced H9c2 cardiomyocyte injury were evaluated, and compounds 1 and 2 showed some cell-protective effects. No significant DPPH radical scavenging activity was observed for compounds 1-14.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010432</affiliation-url><afid>60010432</afid><affilname>Soochow University</affilname><name-variant>Suzhou University</name-variant><affiliation-city>Suzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020462</affiliation-url><afid>60020462</afid><affilname>University of Mississippi School of Pharmacy</affilname><name-variant>Univ. Mississippi</name-variant><affiliation-city>University</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114116434</affiliation-url><afid>114116434</afid><affilname>Suzhou Science and Technology University</affilname><name-variant>Suzhou Science and Technology University</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56096807000</author-url><authid>56096807000</authid><authname>Fei Y.</authname><surname>Fei</surname><given-name>Yonghe</given-name><initials>Y.</initials><afid>60010432</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56168862100</author-url><authid>56168862100</authid><authname>Zhao J.</authname><surname>Zhao</surname><given-name>Jianping</given-name><initials>J.</initials><afid>60020462</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:53981599100</author-url><authid>53981599100</authid><authname>Liu Y.</authname><surname>Liu</surname><given-name>Yanli</given-name><initials>Y.</initials><afid>60010432</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56594254900</author-url><authid>56594254900</authid><authname>Li X.</authname><surname>Li</surname><given-name>Xiaoran</given-name><initials>X.</initials><afid>60010432</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8917777000</author-url><authid>8917777000</authid><authname>Xu Q.</authname><surname>Xu</surname><given-name>Qiongming</given-name><initials>Q.</initials><afid>60010432</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56623581300</author-url><authid>56623581300</authid><authname>Wang T.</authname><surname>Wang</surname><given-name>Taoyun</given-name><initials>T.</initials><afid>60010432</afid><afid>114116434</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56623581300</author-url><authid>56623581300</authid><authname>Wang T.</authname><surname>Wang</surname><given-name>Taoyun</given-name><initials>T.</initials><afid>60010432</afid><afid>114116434</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56247148900</author-url><authid>56247148900</authid><authname>Khan I.</authname><surname>Khan</surname><given-name>Ikhlas A.</given-name><initials>I.A.</initials><afid>60010432</afid><afid>60020462</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56247148900</author-url><authid>56247148900</authid><authname>Khan I.</authname><surname>Khan</surname><given-name>Ikhlas A.</given-name><initials>I.A.</initials><afid>60010432</afid><afid>60020462</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56500878600</author-url><authid>56500878600</authid><authname>Yang S.</authname><surname>Yang</surname><given-name>Shilin</given-name><initials>S.</initials><afid>60010432</afid></author><authkeywords>Cardiomyocytes oxidative injury | DPPH radical scavenging activity | Helianthus annuus L. | Monoterpene glycosides | Sunflower seed</authkeywords><intid>1535876233</intid><source-id>24039</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929497666"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929497666?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929497666&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929497666&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0308814615005300"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929497666</prism:url><dc:identifier>SCOPUS_ID:84929497666</dc:identifier><eid>2-s2.0-84929497666</eid><dc:title>Lipid oxidation in minced beef meat with added Krebs cycle substrates to stabilise colour</dc:title><dc:creator>Yi G.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>187</prism:volume><prism:pageRange>563-571</prism:pageRange><prism:coverDate>2015-11-15</prism:coverDate><prism:coverDisplayDate>15 November 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2015.04.002</prism:doi><pii>S0308814615005300</pii><dc:description>© 2015 Published by Elsevier Ltd. Krebs cycle substrates (KCS) can stabilise the colour of packaged meat by oxygen reduction. This study tested whether this reduction releases reactive oxygen species that may lead to lipid oxidation in minced meat under two different storage conditions. KCS combinations of succinate and glutamate increased peroxide forming potential (PFP, 1.18-1.32 mmol peroxides/kg mince) and thiobarbituric acid reactive substances (TBARS, 0.30-0.38 mg malondialdehyde (MDA) equivalents/kg mince) under low oxygen storage conditions. Both succinate and glutamate were metabolised. Moreover, under high oxygen (75%) storage conditions, KCS combinations of glutamate, citrate and malate increased PFP (from 1.22 to 1.29 mmol peroxides/kg) and TBARS (from 0.37 to 0.40 mg MDA equivalents/kg mince). Only glutamate was metabolised. The KCS combinations that were added to stabilise colour were metabolised during storage, and acted as pro-oxidants that promoted lipid oxidation in both high and low oxygen conditions.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007008</affiliation-url><afid>60007008</afid><affilname>Universitetet for miljo- og biovitenskap</affilname><name-variant>Norwegian University of Life Sciences</name-variant><affiliation-city>As</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007008</affiliation-url><afid>60007008</afid><affilname>Universitetet for miljo- og biovitenskap</affilname><name-variant>Norwegian University of Life Sciences</name-variant><affiliation-city>As</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115249776</affiliation-url><afid>115249776</afid><affilname>Øyvind Langsrud's Company</affilname><name-variant>Øyvind Langsrud's Company</name-variant><affiliation-city/><affiliation-country>Norway</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55770716900</author-url><authid>55770716900</authid><authname>Yi G.</authname><surname>Yi</surname><given-name>G.</given-name><initials>G.</initials><afid>60007008</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56648055100</author-url><authid>56648055100</authid><authname>Grabež V.</authname><surname>Grabež</surname><given-name>V.</given-name><initials>V.</initials><afid>60007008</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:37107135700</author-url><authid>37107135700</authid><authname>Bjelanovic M.</authname><surname>Bjelanovic</surname><given-name>M.</given-name><initials>M.</initials><afid>60007008</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701794636</author-url><authid>6701794636</authid><authname>Slinde E.</authname><surname>Slinde</surname><given-name>E.</given-name><initials>E.</initials><afid>60007008</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56647557800</author-url><authid>56647557800</authid><authname>Olsen K.</authname><surname>Olsen</surname><given-name>K.</given-name><initials>K.</initials><afid>60007008</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55897879000</author-url><authid>55897879000</authid><authname>Langsrud O.</authname><surname>Langsrud</surname><given-name>O.</given-name><initials>O.</initials><afid>115249776</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56647948300</author-url><authid>56647948300</authid><authname>Phung V.</authname><surname>Phung</surname><given-name>V. T.</given-name><initials>V.T.</initials><afid>60007008</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:15033313700</author-url><authid>15033313700</authid><authname>Haug A.</authname><surname>Haug</surname><given-name>A.</given-name><initials>A.</initials><afid>60007008</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:35303395300</author-url><authid>35303395300</authid><authname>Oostindjer M.</authname><surname>Oostindjer</surname><given-name>M.</given-name><initials>M.</initials><afid>60007008</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:6701724313</author-url><authid>6701724313</authid><authname>Egelandsdal B.</authname><surname>Egelandsdal</surname><given-name>B.</given-name><initials>B.</initials><afid>60007008</afid></author><authkeywords>Colour stability | Krebs cycle substrates | Lipid oxidation | Minced meat</authkeywords><intid>1035958583</intid><source-id>24039</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925397323"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925397323?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925397323&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925397323&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925397323</prism:url><dc:identifier>SCOPUS_ID:84925397323</dc:identifier><eid>2-s2.0-84925397323</eid><dc:title>Evaluation of IVOCT imaging of coronary artery metallic stents with neointimal coverage</dc:title><dc:creator>Elahi S.</dc:creator><prism:publicationName>International Journal of Cardiovascular Imaging</prism:publicationName><prism:issn>15695794</prism:issn><prism:eIssn>15730743</prism:eIssn><prism:volume>31</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>463-470</prism:pageRange><prism:coverDate>2015-11-14</prism:coverDate><prism:coverDisplayDate>14 November 2015</prism:coverDisplayDate><prism:doi>10.1007/s10554-014-0569-7</prism:doi><dc:description>© 2014, The Author(s). Accuracy of IVOCT for measurement of neointimal thickness and effect of neointima in the appearance of metallic struts in IVOCT images was investigated. Phantom vessels were constructed and coronary stents were deployed and covered with thick (250–400 μm) and thin (30–70 μm) phantom neointima. High resolution Micro-CT images of the stent struts were recorded as a gold standard. IVOCT images of the phantom vessels were acquired with various luminal blood scattering strengths and measured neointimal thicknesses from IVOCT and Micro-CT images were compared. In transparent lumen, comparison of IVOCT and Micro-CT neointima thickness measurements found no significant difference (p &gt; 0.05) in the thick neointima phantom but a significant difference (p &lt; 0.05) in the thin neointima phantom. For both thick and thin neointima, IVOCT neointimal thickness measurements varied from Micro-CT values by as much as ±35 %. Increased luminal scattering due to presence of blood at concentrations &lt;5 % did not interfere with measurement of thin neointimas and was validated by ANOVA analysis (p = 0.95). IV-OCT measurement of strut feature size with an overlying thin neointima match true values determined with Micro-CT (p = 0.82). Presence of a thick neointima resulted in lateral elongation or merry-go-rounding of stent strut features in IVOCT images. Phantom IVOCT images suggest that thick neointimal layers can result in more than 40 % lateral elongation of stent strut features. Simulated IVOCT images of metallic stent struts with varying neointimal thickness suggest that neointimal light scattering can introduce the merry-go-round effect.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013372</affiliation-url><afid>60013372</afid><affilname>University of Texas at Austin</affilname><name-variant>University of Texas</name-variant><affiliation-city>Austin</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018573</affiliation-url><afid>60018573</afid><affilname>University of Texas Health Science Center at San Antonio</affilname><name-variant>Univ. of Texas Health Science Center</name-variant><affiliation-city>San Antonio</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015618</affiliation-url><afid>60015618</afid><affilname>Leiden University Medical Center - LUMC</affilname><name-variant>University Hospital</name-variant><affiliation-city>Leiden</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55402413500</author-url><authid>55402413500</authid><authname>Elahi S.</authname><surname>Elahi</surname><given-name>Sahar</given-name><initials>S.</initials><afid>60013372</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55311336600</author-url><authid>55311336600</authid><authname>Ho D.</authname><surname>Ho</surname><given-name>Derek</given-name><initials>D.</initials><afid>60013372</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7402261088</author-url><authid>7402261088</authid><authname>Feldman M.</authname><surname>Feldman</surname><given-name>Marc D.</given-name><initials>M.D.</initials><afid>60018573</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7101611206</author-url><authid>7101611206</authid><authname>Dijkstra J.</authname><surname>Dijkstra</surname><given-name>Jouke</given-name><initials>J.</initials><afid>60015618</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7102454059</author-url><authid>7102454059</authid><authname>Milner T.</authname><surname>Milner</surname><given-name>Thomas E.</given-name><initials>T.E.</initials><afid>60013372</afid></author><authkeywords>IVOCT | Merry-go-round | Neointima | Stent</authkeywords><intid>1035291557</intid><source-id>37971</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928316476"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928316476?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928316476&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928316476&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928316476</prism:url><dc:identifier>SCOPUS_ID:84928316476</dc:identifier><eid>2-s2.0-84928316476</eid><dc:title>Developing patient-centred care: An ethnographic study of patient perceptions and influence on quality improvement</dc:title><dc:creator>Renedo A.</dc:creator><prism:publicationName>BMC Health Services Research</prism:publicationName><prism:eIssn>14726963</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-11-01</prism:coverDate><prism:coverDisplayDate>1 November 2015</prism:coverDisplayDate><prism:doi>10.1186/s12913-015-0770-y</prism:doi><dc:description>© 2015 Renedo and Marston; licensee BioMed Central. Background: Understanding quality improvement from a patient perspective is important for delivering patient-centred care. Yet the ways patients define quality improvement remains unexplored with patients often excluded from improvement work. We examine how patients construct ideas of 'quality improvement' when collaborating with healthcare professionals in improvement work, and how they use these understandings when attempting to improve the quality of their local services. Methods: We used in-depth interviews with 23 'patient participants' (patients involved in quality improvement work) and observations in several sites in London as part of a four-year ethnographic study of patient and public involvement (PPI) activities run by Collaborations for Leadership in Applied Health Research and Care for Northwest London. We took an iterative, thematic and discursive analytical approach. Results: When patient participants tried to influence quality improvement or discussed different dimensions of quality improvement their accounts and actions frequently started with talk about improvement as dependent on collective action (e.g. multidisciplinary healthcare professionals and the public), but usually quickly shifted away from that towards a neoliberal discourse emphasising the role of individual patients. Neoliberal ideals about individual responsibility were taken up in their accounts moving them away from the idea of state and healthcare providers being held accountable for upholding patients' rights to quality care, and towards the idea of citizens needing to work on self-improvement. Participants portrayed themselves as governed by self-discipline and personal effort in their PPI work, and in doing so provided examples of how neoliberal appeals for self-regulation and self-determination also permeated their own identity positions. Conclusions: When including patient voices in measuring and defining 'quality', governments and public health practitioners should be aware of how neoliberal rationalities at the heart of policy and services may discourage consumers from claiming rights to quality care by contributing to public unwillingness to challenge the status quo in service provision. If the democratic potential of patient and public involvement initiatives is to be realised, it will be crucial to help citizens to engage critically with how neoliberal rationalities can undermine their abilities to demand quality care.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031331</affiliation-url><afid>60031331</afid><affilname>London School of Hygiene &amp; Tropical Medicine</affilname><name-variant>London School of Hygiene and Tropical Medicine</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:20436631000</author-url><authid>20436631000</authid><authname>Renedo A.</authname><surname>Renedo</surname><given-name>Alicia</given-name><initials>A.</initials><afid>60031331</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56265831100</author-url><authid>56265831100</authid><authname>Marston C.</authname><surname>Marston</surname><given-name>Cicely</given-name><initials>C.</initials><afid>60031331</afid></author><authkeywords>Neoliberalism | Participation | Patient and public engagement | Patient and public involvement | Patient-centred health systems | Quality healthcare | Quality improvement | Service improvement | User involvement</authkeywords><intid>1035762364</intid><article-number>122</article-number><source-id>28098</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928685894"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928685894?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928685894&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928685894&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0956713515002054"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928685894</prism:url><dc:identifier>SCOPUS_ID:84928685894</dc:identifier><eid>2-s2.0-84928685894</eid><dc:title>Flavonoid glycosides as floral origin markers to discriminate of unifloral bee pollen by LC-MS/MS</dc:title><dc:creator>Zhou J.</dc:creator><prism:publicationName>Food Control</prism:publicationName><prism:issn>09567135</prism:issn><prism:volume>57</prism:volume><prism:pageRange>54-61</prism:pageRange><prism:coverDate>2015-11-01</prism:coverDate><prism:coverDisplayDate>November 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodcont.2015.03.035</prism:doi><pii>S0956713515002054</pii><dc:description>© 2015 Elsevier Ltd. The aim of this study was to develop and validate a method for reliable discrimination of bee pollen from different floral origins via simultaneous analysis of three flavonoid glycosides. A simple sample preparation procedure consisted of an ultrasonic-assisted extraction followed by high performance liquid chromatography-electrospray ionization-tandemmass spectrometry (HPLC-ESI-MS/MS) technique to effectively identify and differentiate ten kinds of bee pollens has been developed and optimized in this study. For sample extraction, several parameters were optimized including extraction solvents, extraction patterns, solvent volume, extraction duration and temperature. The analytical method was validated in terms of linearity, limit of detection (LOD), limit of quantitation (LOQ), precision, matrix effect and carryover test using quality control sample. This method can consistently distinguish bee pollen by analyzing three flavonoid glycosides (quercetin-3-O-β- d-glucosyl-(2→l)-β-glucoside, kaempferol-3, 4'-di-O-β- d-glucoside and kaempferol-3-O-β- d-glucosyl-(2→l)-β- d-glucoside). Therefore, this technique will be a suitable to be used as a discrimination method to identify the floral origin of bee pollen via the proposed marker components.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017705</affiliation-url><afid>60017705</afid><affilname>Chinese Academy of Agricultural Sciences</affilname><name-variant>Chinese Academy of Agricultural Sciences</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60087826</affiliation-url><afid>60087826</afid><affilname>Ministry of Agriculture of the People's Republic of China</affilname><name-variant>Ministry of Agriculture</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60087826</affiliation-url><afid>60087826</afid><affilname>Ministry of Agriculture of the People's Republic of China</affilname><name-variant>Ministry of Agriculture</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023304</affiliation-url><afid>60023304</afid><affilname>Texas Heart Institute</affilname><name-variant>Texas Heart Institute</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015023</affiliation-url><afid>60015023</afid><affilname>University of Texas M. D. Anderson Cancer Center</affilname><name-variant>University of Texas</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103284</affiliation-url><afid>60103284</afid><affilname>China Academy of Chinese Medical Sciences</affilname><name-variant>China Academy of Chinese Medical Sciences</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003146</affiliation-url><afid>60003146</afid><affilname>Henan University</affilname><name-variant>Henan University</name-variant><affiliation-city>Kaifeng</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60087826</affiliation-url><afid>60087826</afid><affilname>Ministry of Agriculture of the People's Republic of China</affilname><name-variant>Ministry of Agriculture</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">15</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56549114400</author-url><authid>56549114400</authid><authname>Zhou J.</authname><surname>Zhou</surname><given-name>Jinhui</given-name><initials>J.</initials><afid>60017705</afid><afid>60087826</afid><afid>60087826</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56549114400</author-url><authid>56549114400</authid><authname>Zhou J.</authname><surname>Zhou</surname><given-name>Jinhui</given-name><initials>J.</initials><afid>60017705</afid><afid>60087826</afid><afid>60087826</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56549114400</author-url><authid>56549114400</authid><authname>Zhou J.</authname><surname>Zhou</surname><given-name>Jinhui</given-name><initials>J.</initials><afid>60017705</afid><afid>60087826</afid><afid>60087826</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56549333500</author-url><authid>56549333500</authid><authname>Qi Y.</authname><surname>Qi</surname><given-name>Yitao</given-name><initials>Y.</initials><afid>60023304</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56016444500</author-url><authid>56016444500</authid><authname>Ritho J.</authname><surname>Ritho</surname><given-name>Joan</given-name><initials>J.</initials><afid>60015023</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56609848700</author-url><authid>56609848700</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yongxin</given-name><initials>Y.</initials><afid>60103284</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56609523200</author-url><authid>56609523200</authid><authname>Zheng X.</authname><surname>Zheng</surname><given-name>Xiaowei</given-name><initials>X.</initials><afid>60003146</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56549209700</author-url><authid>56549209700</authid><authname>Wu L.</authname><surname>Wu</surname><given-name>Liming</given-name><initials>L.</initials><afid>60017705</afid><afid>60087826</afid><afid>60087826</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56549209700</author-url><authid>56549209700</authid><authname>Wu L.</authname><surname>Wu</surname><given-name>Liming</given-name><initials>L.</initials><afid>60017705</afid><afid>60087826</afid><afid>60087826</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56549209700</author-url><authid>56549209700</authid><authname>Wu L.</authname><surname>Wu</surname><given-name>Liming</given-name><initials>L.</initials><afid>60017705</afid><afid>60087826</afid><afid>60087826</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55915486100</author-url><authid>55915486100</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yi</given-name><initials>Y.</initials><afid>60017705</afid><afid>60087826</afid><afid>60087826</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55915486100</author-url><authid>55915486100</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yi</given-name><initials>Y.</initials><afid>60017705</afid><afid>60087826</afid><afid>60087826</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55915486100</author-url><authid>55915486100</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yi</given-name><initials>Y.</initials><afid>60017705</afid><afid>60087826</afid><afid>60087826</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56609497700</author-url><authid>56609497700</authid><authname>Sun L.</authname><surname>Sun</surname><given-name>Liping</given-name><initials>L.</initials><afid>60017705</afid><afid>60087826</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56609497700</author-url><authid>56609497700</authid><authname>Sun L.</authname><surname>Sun</surname><given-name>Liping</given-name><initials>L.</initials><afid>60017705</afid><afid>60087826</afid></author><authkeywords>Bee pollen | Classification | Flavonoid glycoside | LC-MS/MS | Marker</authkeywords><intid>2035818430</intid><source-id>22577</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929649428"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929649428?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929649428&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929649428&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0168365915005593"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929649428</prism:url><dc:identifier>SCOPUS_ID:84929649428</dc:identifier><eid>2-s2.0-84929649428</eid><dc:title>Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension</dc:title><dc:creator>McLendon J.</dc:creator><prism:publicationName>Journal of Controlled Release</prism:publicationName><prism:issn>01683659</prism:issn><prism:eIssn>18734995</prism:eIssn><prism:volume>210</prism:volume><prism:pageRange>67-75</prism:pageRange><prism:coverDate>2015-11-01</prism:coverDate><prism:coverDisplayDate>1 November 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jconrel.2015.05.261</prism:doi><pii>S0168365915005593</pii><dc:description>© 2015 Published by Elsevier B.V. Abstract Therapies that exploit RNA interference (RNAi) hold great potential for improving disease outcomes. However, there are several challenges that limit the application of RNAi therapeutics. One of the most important challenges is effective delivery of oligonucleotides to target cells and reduced delivery to non-target cells. We have previously developed a functionalized cationic lipopolyamine (Star:Star-mPEG-550) for in vivo delivery of siRNA to pulmonary vascular cells. This optimized lipid formulation enhances the retention of siRNA in mouse lungs and achieves significant knockdown of target gene expression for at least 10 days following a single intravenous injection. Although this suggests great potential for developing lung-directed RNAi-based therapies, the application of Star:Star-mPEG mediated delivery of RNAi based therapies for pulmonary vascular diseases such as pulmonary arterial hypertension (PAH) remains unknown. We identified differential expression of several microRNAs known to regulate cell proliferation, cell survival and cell fate that are associated with development of PAH, including increased expression of microRNA-145 (miR-145). Here we test the hypothesis that Star:Star-mPEG mediated delivery of an antisense oligonucleotide against miR-145 (antimiR-145) will improve established PAH in rats. We performed a series of experiments testing the in vivo distribution, toxicity, and efficacy of Star:Star-mPEG mediated delivery of antimiR-145 in rats with Sugen-5416/hypoxia induced PAH. We showed that after subchronic therapy of three intravenous injections over 5 weeks at 2 mg/kg, antimiR-145 accumulated in rat lung tissue and reduced expression of endogenous miR-145. Using a novel in situ hybridization approach, we demonstrated substantial distribution of antimiR-145 in the lungs as well as the liver, kidney, and spleen. We assessed toxic effects of Star:Star-mPEG/antimiR-145 with serial complete blood counts of leukocytes and serum metabolic panels, gross pathology, and histopathology and did not detect significant off-target effects. AntimiR-145 reduced the degree of pulmonary arteriopathy, reduced the severity of pulmonary hypertension, and reduced the degree of cardiac dysfunction. The results establish effective and low toxicity of lung delivery of a miRNA-145 inhibitor using functionalized cationic lipopolyamine nanoparticles to repair pulmonary arteriopathy and improve cardiac function in rats with severe PAH.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000705</affiliation-url><afid>60000705</afid><affilname>University of South Alabama</affilname><name-variant>University of South Alabama</name-variant><affiliation-city>Mobile</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000705</affiliation-url><afid>60000705</afid><affilname>University of South Alabama</affilname><name-variant>University of South Alabama</name-variant><affiliation-city>Mobile</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000705</affiliation-url><afid>60000705</afid><affilname>University of South Alabama</affilname><name-variant>University of South Alabama</name-variant><affiliation-city>Mobile</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000705</affiliation-url><afid>60000705</afid><affilname>University of South Alabama</affilname><name-variant>University of South Alabama</name-variant><affiliation-city>Mobile</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115261827</affiliation-url><afid>115261827</afid><affilname>Celsion-EGEN</affilname><name-variant>Celsion-EGEN</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">15</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55065141800</author-url><authid>55065141800</authid><authname>McLendon J.</authname><surname>McLendon</surname><given-name>Jared M.</given-name><initials>J.M.</initials><afid>60000705</afid><afid>60000705</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55065141800</author-url><authid>55065141800</authid><authname>McLendon J.</authname><surname>McLendon</surname><given-name>Jared M.</given-name><initials>J.M.</initials><afid>60000705</afid><afid>60000705</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55063125800</author-url><authid>55063125800</authid><authname>Joshi S.</authname><surname>Joshi</surname><given-name>Sachindra R.</given-name><initials>S.R.</initials><afid>60000705</afid><afid>60000705</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55063125800</author-url><authid>55063125800</authid><authname>Joshi S.</authname><surname>Joshi</surname><given-name>Sachindra R.</given-name><initials>S.R.</initials><afid>60000705</afid><afid>60000705</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:25028920700</author-url><authid>25028920700</authid><authname>Sparks J.</authname><surname>Sparks</surname><given-name>Jeff</given-name><initials>J.</initials><afid>115261827</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004287994</author-url><authid>7004287994</authid><authname>Matar M.</authname><surname>Matar</surname><given-name>Majed</given-name><initials>M.</initials><afid>115261827</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005358568</author-url><authid>7005358568</authid><authname>Fewell J.</authname><surname>Fewell</surname><given-name>Jason G.</given-name><initials>J.G.</initials><afid>115261827</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7404938769</author-url><authid>7404938769</authid><authname>Abe K.</authname><surname>Abe</surname><given-name>Kohtaro</given-name><initials>K.</initials><afid>60000705</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56435318600</author-url><authid>56435318600</authid><authname>Oka M.</authname><surname>Oka</surname><given-name>Masahiko</given-name><initials>M.</initials><afid>60000705</afid><afid>60000705</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56435318600</author-url><authid>56435318600</authid><authname>Oka M.</authname><surname>Oka</surname><given-name>Masahiko</given-name><initials>M.</initials><afid>60000705</afid><afid>60000705</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:35601178500</author-url><authid>35601178500</authid><authname>McMurtry I.</authname><surname>McMurtry</surname><given-name>Ivan F.</given-name><initials>I.F.</initials><afid>60000705</afid><afid>60000705</afid><afid>60000705</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:35601178500</author-url><authid>35601178500</authid><authname>McMurtry I.</authname><surname>McMurtry</surname><given-name>Ivan F.</given-name><initials>I.F.</initials><afid>60000705</afid><afid>60000705</afid><afid>60000705</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:35601178500</author-url><authid>35601178500</authid><authname>McMurtry I.</authname><surname>McMurtry</surname><given-name>Ivan F.</given-name><initials>I.F.</initials><afid>60000705</afid><afid>60000705</afid><afid>60000705</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7004490559</author-url><authid>7004490559</authid><authname>Gerthoffer W.</authname><surname>Gerthoffer</surname><given-name>William T.</given-name><initials>W.T.</initials><afid>60000705</afid><afid>60000705</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7004490559</author-url><authid>7004490559</authid><authname>Gerthoffer W.</authname><surname>Gerthoffer</surname><given-name>William T.</given-name><initials>W.T.</initials><afid>60000705</afid><afid>60000705</afid></author><authkeywords>Antisense oligonucleotide | Lipid nanoparticle | Lung delivery | MicroRNA-145 | Pulmonary hypertension | Sugen5416/hypoxia</authkeywords><intid>1035985040</intid><article-number>7677</article-number><source-id>23010</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929151138"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929151138?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929151138&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929151138&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0894177715001260"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929151138</prism:url><dc:identifier>SCOPUS_ID:84929151138</dc:identifier><eid>2-s2.0-84929151138</eid><dc:title>Horse and dog blood flows in PDMS rectangular microchannels: Experimental characterization of the plasma layer under different flow conditions</dc:title><dc:creator>Sampaio D.</dc:creator><prism:publicationName>Experimental Thermal and Fluid Science</prism:publicationName><prism:issn>08941777</prism:issn><prism:volume>68</prism:volume><prism:pageRange>205-215</prism:pageRange><prism:coverDate>2015-11-01</prism:coverDate><prism:coverDisplayDate>November 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.expthermflusci.2015.04.020</prism:doi><pii>S0894177715001260</pii><dc:description>© 2015 Elsevier Inc. This work characterizes the plasma layer of horse and dog blood flows inside rectangular PDMS microchannels under different conditions (hematocrit of ca. 40% and 45%, respectively, flow rate varying between 1 and 30. μl/min, microchannel width and height varying from 100 to 350. μm and 30 to 40. μm, respectively), and relates it with the pressure drop. For that, images were acquired with a microscope/CMOS camera and digitally processed by a Matlab script. The results show that the cell-free layer thickness varies with the following parameters: it increases non-linearly with the increase of the blood flow rate (the average thickness growth observed with a 100% increase of the blood flow rate was ca. 55%); it increases with both microchannel width and height increase. Moreover, because plasma is a Newtonian fluid, the measured pressure drop varied linearly with the blood flow rate but with an apparent viscosity larger than that of plasma and smaller than that of the whole blood. This allowed inferring that plasma layers act as a lubricant making easier the blood flow. It was also observed a non-instantaneous response time, 3-4. s, of the erythrocytes to a squared-wave pulsatile flow, both when increasing and decreasing the flow rate.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001746</affiliation-url><afid>60001746</afid><affilname>Universidade de Lisboa</affilname><name-variant>University of Lisbon</name-variant><affiliation-city>Lisbon</affiliation-city><affiliation-country>Portugal</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56641070200</author-url><authid>56641070200</authid><authname>Sampaio D.</authname><surname>Sampaio</surname><given-name>Diogo</given-name><initials>D.</initials><afid>60001746</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56640825200</author-url><authid>56640825200</authid><authname>Lopes D.</authname><surname>Lopes</surname><given-name>David</given-name><initials>D.</initials><afid>60001746</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6701412600</author-url><authid>6701412600</authid><authname>Semiao V.</authname><surname>Semiao</surname><given-name>Viriato</given-name><initials>V.</initials><afid>60001746</afid></author><authkeywords>Microfluidics | Plasma layer | Pressure drop | Pulsatile blood flows | Steady blood flows</authkeywords><intid>535919341</intid><source-id>29220</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929521112"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929521112?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929521112&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929521112&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0308814614010966"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929521112</prism:url><dc:identifier>SCOPUS_ID:84929521112</dc:identifier><eid>2-s2.0-84929521112</eid><dc:title>Effect of hemicellulose from rice bran on low fat meatballs chemical and functional properties</dc:title><dc:creator>Hu G.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>186</prism:volume><prism:pageRange>239-243</prism:pageRange><prism:coverDate>2015-11-01</prism:coverDate><prism:coverDisplayDate>1 November 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2014.07.063</prism:doi><pii>S0308814614010966</pii><dc:description>© 2014 Elsevier Ltd.All rights reserved. The paper study the functional properties of hemicellulose B (RBHB) and rice bran insoluble dietary fibre (RBDF) to develop an acceptable low fat meat product enriched with high content fibre from defatted rice bran. Meatballs were produced with three different formulations including 2%, 4% and 6% RBHB or RBDF addition. The total trans fatty acids were lower and the ratio of total unsaturated fatty acids to total saturated fatty acids was higher in the samples with added RBHB than in the control meatballs. Meatballs containing RBHB had lower concentrations of total fat and total trans fatty acids than the control samples. Sensory evaluations revealed that meatballs with 2%, 4% and 6% RBHB were overall acceptable. This confirms that the RBHB preparation from defatted rice bran has great potential in food applications, especially in development of functional foods including functional meat products.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011069</affiliation-url><afid>60011069</afid><affilname>East China University of Science and Technology</affilname><name-variant>East China University of Science and Technology</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114573226</affiliation-url><afid>114573226</afid><affilname>Shanghai Collaborative Innovation Center for Biomanufacturing Technology</affilname><name-variant>Shanghai Collaborative Innovation Center for Biomanufacturing Technology</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:12761922900</author-url><authid>12761922900</authid><authname>Hu G.</authname><surname>Hu</surname><given-name>Guohua</given-name><initials>G.</initials><afid>60011069</afid><afid>114573226</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:12761922900</author-url><authid>12761922900</authid><authname>Hu G.</authname><surname>Hu</surname><given-name>Guohua</given-name><initials>G.</initials><afid>60011069</afid><afid>114573226</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55681429600</author-url><authid>55681429600</authid><authname>Yu W.</authname><surname>Yu</surname><given-name>Wenjian</given-name><initials>W.</initials><afid>60011069</afid></author><authkeywords>Dietary fibre | Functional | Hemicellulose | Meatball | Rice bran</authkeywords><intid>1535968406</intid><source-id>24039</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84907885851"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84907885851?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84907885851&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84907885851&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0301010414000809"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84907885851</prism:url><dc:identifier>SCOPUS_ID:84907885851</dc:identifier><eid>2-s2.0-84907885851</eid><dc:title>Sub-100-ps structural dynamics of horse heart myoglobin probed by time-resolved X-ray solution scattering</dc:title><dc:creator>Oang K.</dc:creator><prism:publicationName>Chemical Physics</prism:publicationName><prism:issn>03010104</prism:issn><prism:volume>442</prism:volume><prism:pageRange>137-142</prism:pageRange><prism:coverDate>2015-10-17</prism:coverDate><prism:coverDisplayDate>17 October 2015</prism:coverDisplayDate><prism:doi>10.1016/j.chemphys.2014.03.004</prism:doi><pii>S0301010414000809</pii><dc:description>© 2014 Elsevier B.V. All rights reserved. Here we report sub-100-ps structural dynamics of horse heart myoglobin revealed by time-resolved X-ray solution scattering. By applying the time-slicing scheme to the measurement and subsequent deconvolution, we investigate the protein structural dynamics that occur faster than the X-ray temporal pulse width of synchrotrons (∼100 ps). The singular value decomposition analysis of the experimental data suggests that two structurally distinguishable intermediates are formed within 100 ps. In particular, the global structural change occurring on the time scale of 70 ps is identified.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60104544</affiliation-url><afid>60104544</afid><affilname>Institute for Basic Science</affilname><name-variant>Institute for Basic Science</name-variant><affiliation-city>Daejeon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032144</affiliation-url><afid>60032144</afid><affilname>Korea Advanced Institute of Science &amp; Technology</affilname><name-variant>KAIST</name-variant><affiliation-city>Yusong</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028876</affiliation-url><afid>60028876</afid><affilname>Inha University, Incheon</affilname><name-variant>Inha University</name-variant><affiliation-city>Incheon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">17</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36662643800</author-url><authid>36662643800</authid><authname>Oang K.</authname><surname>Oang</surname><given-name>Key Young</given-name><initials>K.Y.</initials><afid>60104544</afid><afid>60032144</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36662643800</author-url><authid>36662643800</authid><authname>Oang K.</authname><surname>Oang</surname><given-name>Key Young</given-name><initials>K.Y.</initials><afid>60104544</afid><afid>60032144</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56381732500</author-url><authid>56381732500</authid><authname>Kim K.</authname><surname>Kim</surname><given-name>Kyung Hwan</given-name><initials>K.H.</initials><afid>60104544</afid><afid>60032144</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56381732500</author-url><authid>56381732500</authid><authname>Kim K.</authname><surname>Kim</surname><given-name>Kyung Hwan</given-name><initials>K.H.</initials><afid>60104544</afid><afid>60032144</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56074558400</author-url><authid>56074558400</authid><authname>Jo J.</authname><surname>Jo</surname><given-name>Junbeom</given-name><initials>J.</initials><afid>60104544</afid><afid>60032144</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56074558400</author-url><authid>56074558400</authid><authname>Jo J.</authname><surname>Jo</surname><given-name>Junbeom</given-name><initials>J.</initials><afid>60104544</afid><afid>60032144</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56104230400</author-url><authid>56104230400</authid><authname>Kim Y.</authname><surname>Kim</surname><given-name>Youngmin</given-name><initials>Y.</initials><afid>60104544</afid><afid>60032144</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56104230400</author-url><authid>56104230400</authid><authname>Kim Y.</authname><surname>Kim</surname><given-name>Youngmin</given-name><initials>Y.</initials><afid>60104544</afid><afid>60032144</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:37050703900</author-url><authid>37050703900</authid><authname>Kim J.</authname><surname>Kim</surname><given-name>Jong Goo</given-name><initials>J.G.</initials><afid>60104544</afid><afid>60032144</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:37050703900</author-url><authid>37050703900</authid><authname>Kim J.</authname><surname>Kim</surname><given-name>Jong Goo</given-name><initials>J.G.</initials><afid>60104544</afid><afid>60032144</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:54973395300</author-url><authid>54973395300</authid><authname>Kim T.</authname><surname>Kim</surname><given-name>Tae Wu</given-name><initials>T.W.</initials><afid>60104544</afid><afid>60032144</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:54973395300</author-url><authid>54973395300</authid><authname>Kim T.</authname><surname>Kim</surname><given-name>Tae Wu</given-name><initials>T.W.</initials><afid>60104544</afid><afid>60032144</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35109336700</author-url><authid>35109336700</authid><authname>Jun S.</authname><surname>Jun</surname><given-name>Sunhong</given-name><initials>S.</initials><afid>60104544</afid><afid>60032144</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35109336700</author-url><authid>35109336700</authid><authname>Jun S.</authname><surname>Jun</surname><given-name>Sunhong</given-name><initials>S.</initials><afid>60104544</afid><afid>60032144</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7601388821</author-url><authid>7601388821</authid><authname>Kim J.</authname><surname>Kim</surname><given-name>Jeongho</given-name><initials>J.</initials><afid>60028876</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6602888416</author-url><authid>6602888416</authid><authname>Ihee H.</authname><surname>Ihee</surname><given-name>Hyotcherl</given-name><initials>H.</initials><afid>60104544</afid><afid>60032144</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6602888416</author-url><authid>6602888416</authid><authname>Ihee H.</authname><surname>Ihee</surname><given-name>Hyotcherl</given-name><initials>H.</initials><afid>60104544</afid><afid>60032144</afid></author><authkeywords>Myoglobin | Structural dynamics | Time-resolved X-ray solution scattering | Time-slicing</authkeywords><intid>2032378423</intid><source-id>26584</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84907895005"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84907895005?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84907895005&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84907895005&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0301010414000652"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84907895005</prism:url><dc:identifier>SCOPUS_ID:84907895005</dc:identifier><eid>2-s2.0-84907895005</eid><dc:title>The enzymatic reaction catalyzed by lactate dehydrogenase exhibits one dominant reaction path</dc:title><dc:creator>Masterson J.</dc:creator><prism:publicationName>Chemical Physics</prism:publicationName><prism:issn>03010104</prism:issn><prism:volume>442</prism:volume><prism:pageRange>132-136</prism:pageRange><prism:coverDate>2015-10-17</prism:coverDate><prism:coverDisplayDate>17 October 2015</prism:coverDisplayDate><prism:doi>10.1016/j.chemphys.2014.02.018</prism:doi><pii>S0301010414000652</pii><dc:description>© 2014 Elsevier Ltd. All rights reserved. Enzymes are the most efficient chemical catalysts known, but the exact nature of chemical barrier crossing in enzymes is not fully understood. Application of transition state theory to enzymatic reactions indicates that the rates of all possible reaction paths, weighted by their relative probabilities, must be considered in order to achieve an accurate calculation of the overall rate. Previous studies in our group have shown a single mechanism for enzymatic barrier passage in human heart lactate dehydrogenase (LDH). To ensure that this result was not due to our methodology insufficiently sampling reactive phase space, we implement high-perturbation transition path sampling in both microcanonical and canonical regimes for the reaction catalyzed by human heart LDH. We find that, although multiple, distinct paths through reactive phase space are possible for this enzymatic reaction, one specific reaction path is dominant. Since the frequency of these paths in a canonical ensemble is inversely proportional to the free energy barriers separating them from other regions of phase space, we conclude that the rarer reaction paths are likely to have a negligible contribution. Furthermore, the non-dominate reaction paths correspond to altered reactive conformations and only occur after multiple steps of high perturbation, suggesting that these paths may be the result of non-biologically significant changes to the structure of the enzymatic active site.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010065</affiliation-url><afid>60010065</afid><affilname>University of Arizona</affilname><name-variant>University of Arizona</name-variant><affiliation-city>Tucson</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002388</affiliation-url><afid>60002388</afid><affilname>Albert Einstein College of Medicine of Yeshiva University</affilname><name-variant>Albert Einstein College of Medicine</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55826399300</author-url><authid>55826399300</authid><authname>Masterson J.</authname><surname>Masterson</surname><given-name>Jean E.</given-name><initials>J.E.</initials><afid>60010065</afid><afid>60002388</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55826399300</author-url><authid>55826399300</authid><authname>Masterson J.</authname><surname>Masterson</surname><given-name>Jean E.</given-name><initials>J.E.</initials><afid>60010065</afid><afid>60002388</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55228507900</author-url><authid>55228507900</authid><authname>Schwartz S.</authname><surname>Schwartz</surname><given-name>Steven D.</given-name><initials>S.D.</initials><afid>60010065</afid></author><authkeywords>Enzymatic catalysis | Lactate dehydrogenase | Reaction coordinate | Transition path sampling</authkeywords><intid>1532382987</intid><source-id>26584</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927779912"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927779912?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927779912&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927779912&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0308814615005634"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927779912</prism:url><dc:identifier>SCOPUS_ID:84927779912</dc:identifier><eid>2-s2.0-84927779912</eid><dc:title>Trans fatty acid content in Serbian margarines: Urgent need for legislative changes and consumer information</dc:title><dc:creator>Vučić V.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>185</prism:volume><prism:pageRange>437-440</prism:pageRange><prism:coverDate>2015-10-15</prism:coverDate><prism:coverDisplayDate>15 October 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2015.04.018</prism:doi><pii>S0308814615005634</pii><dc:description>© 2015 Elsevier Ltd. All rights reserved. This study examined the fatty acid (FA) composition of 13 (7 soft and 6 hard) Serbian margarines. Significantly higher amounts of trans fatty acids (TFA) were found in hard margarines (up to 28.84% of total FA), than in soft ones (0.17-6.89%). Saturated FA (SFA) were present with 22.76-51.17%. Oleic acid ranged from 26.78% to 43.78%. The proportion of polyunsaturated FA (PUFA) was 22.15-49.29% in soft margarines, but only 8.02-15.28% in hard margarines, probably due to the hydrogenisation process. The atherogenic and thrombogenic indexes (AI and TI, respectively) in soft margarines were relatively low (AI 0.23-0.63 and TI 0.44-0.97), but in hard margarines AI and particularly TI were high (1.03-1.67 and 1.96-3.04, respectively). These findings suggest that FA composition of Serbian margarines should be improved by replacing atherogenic TFA and SFA with beneficial ones, in order to avoid adverse effects on health. Therefore legislative changes and consumer information are urgently needed.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068815</affiliation-url><afid>60068815</afid><affilname>University of Belgrade</affilname><name-variant>University of Belgrade</name-variant><affiliation-city>Belgrade</affiliation-city><affiliation-country>Serbia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068809</affiliation-url><afid>60068809</afid><affilname>University of Kragujevac</affilname><name-variant>University of Kragujevac</name-variant><affiliation-city>Kragujevac</affiliation-city><affiliation-country>Serbia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14049380100</author-url><authid>14049380100</authid><authname>Vučić V.</authname><surname>Vučić</surname><given-name>Vesna</given-name><initials>V.</initials><afid>60068815</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:14031166400</author-url><authid>14031166400</authid><authname>Arsić A.</authname><surname>Arsić</surname><given-name>Aleksandra</given-name><initials>A.</initials><afid>60068815</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7101905860</author-url><authid>7101905860</authid><authname>Petrović S.</authname><surname>Petrović</surname><given-name>Snježana</given-name><initials>S.</initials><afid>60068815</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56594676300</author-url><authid>56594676300</authid><authname>Milanović S.</authname><surname>Milanović</surname><given-name>Sandra</given-name><initials>S.</initials><afid>60068809</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:34871959300</author-url><authid>34871959300</authid><authname>Gurinović M.</authname><surname>Gurinović</surname><given-name>Mirjana</given-name><initials>M.</initials><afid>60068815</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6603614993</author-url><authid>6603614993</authid><authname>Glibetić M.</authname><surname>Glibetić</surname><given-name>Maria</given-name><initials>M.</initials><afid>60068815</afid></author><authkeywords>Atherogenic index | Margarine | Monounsaturated fatty acids | Polyunsaturated fatty acids | Saturated fatty acids | Thrombogenic index | Trans fatty acids</authkeywords><intid>1785667924</intid><source-id>24039</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928248492"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928248492?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928248492&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928248492&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0308814615005671"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928248492</prism:url><dc:identifier>SCOPUS_ID:84928248492</dc:identifier><eid>2-s2.0-84928248492</eid><dc:title>Direct FTIR analysis of isolated trans fatty acids in edible oils using disposable polyethylene film</dc:title><dc:creator>Xu L.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>185</prism:volume><prism:pageRange>503-508</prism:pageRange><prism:coverDate>2015-10-15</prism:coverDate><prism:coverDisplayDate>15 October 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2015.04.021</prism:doi><pii>S0308814615005671</pii><dc:description>© 2015 Elsevier Ltd All rights reserved. A new transmission-based Fourier transform infrared (FTIR) spectroscopy method has been developed to determine trans fatty acids (TFA) content in edible oils using disposable polyethylene (PE) film as a spectral acquisition accessory. Calibration standards were devised by gravimetrically adding TFA to TFA-free oil. The response was measured at 990-945 cm&lt;sup&gt;-1&lt;/sup&gt; against the baseline. A linear relationship between the areas in the spectral regions 1670-1625 cm&lt;sup&gt;-1&lt;/sup&gt; and 990-945 cm&lt;sup&gt;-1&lt;/sup&gt; in TFA-free oil samples was established to compensate for interference due to underlying triacylglycerol absorptions in the trans measurement region (990-945 cm&lt;sup&gt;-1&lt;/sup&gt;). Subsequently, the area measured at 990-945 cm&lt;sup&gt;-1&lt;/sup&gt; was corrected for interference, using the linear equation obtained, to determine TFA content. Results indicated that the PE film-based FTIR method for analyzing TFA content in edible oils was simple and rapid, and could be used effectively as an alternative to gas chromatography and mass spectrometry methods.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112801275</affiliation-url><afid>112801275</afid><affilname>Northwest AandF University</affilname><name-variant>Northwest AandF University</name-variant><affiliation-city>Xianyang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56602025800</author-url><authid>56602025800</authid><authname>Xu L.</authname><surname>Xu</surname><given-name>Lirong</given-name><initials>L.</initials><afid>112801275</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56198171600</author-url><authid>56198171600</authid><authname>Zhu X.</authname><surname>Zhu</surname><given-name>Xufei</given-name><initials>X.</initials><afid>112801275</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55946622600</author-url><authid>55946622600</authid><authname>Chen X.</authname><surname>Chen</surname><given-name>Xiumei</given-name><initials>X.</initials><afid>112801275</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56198696100</author-url><authid>56198696100</authid><authname>Sun D.</authname><surname>Sun</surname><given-name>Daijun</given-name><initials>D.</initials><afid>112801275</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8958687800</author-url><authid>8958687800</authid><authname>Yu X.</authname><surname>Yu</surname><given-name>Xiuzhu</given-name><initials>X.</initials><afid>112801275</afid></author><authkeywords>Edible oil | FTIR | Quantitative analysis | Trans fatty acid</authkeywords><intid>1035749051</intid><source-id>24039</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927537109"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927537109?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927537109&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927537109&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0308814615004860"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927537109</prism:url><dc:identifier>SCOPUS_ID:84927537109</dc:identifier><eid>2-s2.0-84927537109</eid><dc:title>Pilot-scale subcritical solvent extraction of curcuminoids from Curcuma long L.</dc:title><dc:creator>Kwon H.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>185</prism:volume><prism:pageRange>58-64</prism:pageRange><prism:coverDate>2015-10-15</prism:coverDate><prism:coverDisplayDate>15 October 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2015.03.114</prism:doi><pii>S0308814615004860</pii><dc:description>© 2015 Elsevier Ltd. All rights reserved. Abstract Curcuminoids consisted curcumin, demethoxycurcumin and bisdemethoxycurcumin, were extracted from turmeric using subcritical solvent by varying conditions of temperature (110-150 °C), time (1-10 min), pressure (5-100 atm), solid-to-solvent ratio, and mixing ratio of solvent. Preliminary lab-scale experiments were conducted to determine the optimum extraction temperature and mixing ratio of water and ethanol for the pilot-scale extraction. The maximum yield of curcuminoids in the pilot-scale system was 13.58% (curcumin 4.94%, demethoxycurcumin 4.73%, and bisdemethoxycurcumin 3.91% in dried extracts) at 135 °C/5 min with water/ethanol mixture (50:50, v/v) as a solvent. On the other hand, the extraction yields of curcuminoids were obtained as 10.49%, 13.71% and 13.96% using the 50%, 95% and 100% ethanol, respectively, at the atmospheric condition (60 °C/120 min). Overall results showed that the subcritical solvent extraction is much faster and efficient extraction method considering extracted curcuminoids contents and has a potential to develop a commercial process for the extraction of curcuminoids.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001018</affiliation-url><afid>60001018</afid><affilname>Ewha Womans University</affilname><name-variant>Ewha Womans University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56378923900</author-url><authid>56378923900</authid><authname>Kwon H.</authname><surname>Kwon</surname><given-name>Hye Lim</given-name><initials>H.L.</initials><afid>60001018</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:15057605800</author-url><authid>15057605800</authid><authname>Chung M.</authname><surname>Chung</surname><given-name>Myong Soo</given-name><initials>M.S.</initials><afid>60001018</afid></author><authkeywords>Curcuminoids | Lab-scale system | Pilot-scale system | Subcritical solvent extraction | Turmeric</authkeywords><intid>535635025</intid><article-number>17361</article-number><source-id>24039</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927615642"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927615642?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927615642&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927615642&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0308814615002769"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927615642</prism:url><dc:identifier>SCOPUS_ID:84927615642</dc:identifier><eid>2-s2.0-84927615642</eid><dc:title>Identification and quantification of anthocyanins in fruits from Neomitranthes obscura (DC.) N. Silveira an endemic specie from Brazil by comparison of chromatographic methodologies</dc:title><dc:creator>Gouvêa A.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>185</prism:volume><prism:pageRange>277-283</prism:pageRange><prism:coverDate>2015-10-15</prism:coverDate><prism:coverDisplayDate>15 October 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2015.02.086</prism:doi><pii>S0308814615002769</pii><dc:description>© 2015 Published by Elsevier Ltd. Abstract Neomitranthes obscura (DC.) N. Silveira is a Brazilian fruit belonging to the Myrtaceae family that contains anthocyanins in the peel and was studied for the first time in this work. Delphinidin-3-O-galactoside, delphinidin-3-O-glucoside, cyanidin-3-O-galactoside, cyanidin-3-O-glucoside, cyanidin-3-O-arabinoside, petunidin-3-O-glucoside, pelargonidin-3-O-glucoside, peonidin-3-O-galactoside, peonidin-3-O-glucoside, cyanidin-3-O-xyloside were separated and identified by LC/DAD/MS and by co-elution with standards. Reliable quantification of anthocyanins in the mature fruits was performed by HPLC/DAD using weighted linear regression model from 0.05 to 50 mg of cyaniding-3-O-glucoside L&lt;sup&gt;-1&lt;/sup&gt; because it gave better fit quality than least squares linear regression. Good precision and accuracy were obtained. The total anthocyanin content of mature fruits was 263.6 ± 8.2 mg of cyanidin-3-O-glucoside equivalents 100 g&lt;sup&gt;-1&lt;/sup&gt; fresh weight, which was in the same range found in literature for anthocyanin rich fruits.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027947</affiliation-url><afid>60027947</afid><affilname>Universidade Federal Rural do Rio de Janeiro</affilname><name-variant>Universidade Federal Rural do Rio de Janeiro</name-variant><affiliation-city>Seropedica</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007249</affiliation-url><afid>60007249</afid><affilname>Universidade do Porto</affilname><name-variant>Universidade do Porto</name-variant><affiliation-city>Porto</affiliation-city><affiliation-country>Portugal</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115185978</affiliation-url><afid>115185978</afid><affilname>Laboratório de Cromatografia Líquida</affilname><name-variant>Laboratório de Cromatografia Líquida</name-variant><affiliation-city>Rio de Janeiro</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007249</affiliation-url><afid>60007249</afid><affilname>Universidade do Porto</affilname><name-variant>Universidade do Porto</name-variant><affiliation-city>Porto</affiliation-city><affiliation-country>Portugal</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:49963422600</author-url><authid>49963422600</authid><authname>Gouvêa A.</authname><surname>Gouvêa</surname><given-name>Ana Cristina M S</given-name><initials>A.C.M.S.</initials><afid>60027947</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35875954100</author-url><authid>35875954100</authid><authname>Melo A.</authname><surname>Melo</surname><given-name>Armindo</given-name><initials>A.</initials><afid>60007249</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56591899700</author-url><authid>56591899700</authid><authname>Santiago M.</authname><surname>Santiago</surname><given-name>Manuela C P A</given-name><initials>M.C.P.A.</initials><afid>115185978</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6602098499</author-url><authid>6602098499</authid><authname>Peixoto F.</authname><surname>Peixoto</surname><given-name>Fernanda M.</given-name><initials>F.M.</initials><afid>60027947</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56592155400</author-url><authid>56592155400</authid><authname>Freitas V.</authname><surname>Freitas</surname><given-name>Vitor</given-name><initials>V.</initials><afid>60007249</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8265036100</author-url><authid>8265036100</authid><authname>Godoy R.</authname><surname>Godoy</surname><given-name>Ronoel L O</given-name><initials>R.L.O.</initials><afid>115185978</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7102135210</author-url><authid>7102135210</authid><authname>Ferreira I.</authname><surname>Ferreira</surname><given-name>Isabel M P L V O</given-name><initials>I.M.P.L.V.O.</initials><afid>60007249</afid></author><authkeywords>Anthocyanins | HPLC/DAD/MS | Myrtaceae | Neomitranthes obscura</authkeywords><intid>35647038</intid><article-number>17185</article-number><source-id>24039</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84920919864"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84920919864?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84920919864&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84920919864&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84920919864</prism:url><dc:identifier>SCOPUS_ID:84920919864</dc:identifier><eid>2-s2.0-84920919864</eid><dc:title>Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer</dc:title><dc:creator>Mackey J.</dc:creator><prism:publicationName>Journal of Clinical Oncology</prism:publicationName><prism:issn>0732183X</prism:issn><prism:eIssn>15277755</prism:eIssn><prism:volume>33</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>141-148</prism:pageRange><prism:coverDate>2015-10-10</prism:coverDate><prism:coverDisplayDate>10 October 2015</prism:coverDisplayDate><prism:doi>10.1200/JCO.2014.57.1513</prism:doi><dc:description>© 2014 by American Society of Clinical Oncology. Purpose: Currently, antiangiogenic strategies in metastatic breast cancer have demonstrated modest improvements in progression-free survival (PFS) but not improved quality or duration of survival, warranting evaluation of new agents in a placebo-controlled setting. Ramucirumab is a human immunoglobulin G1 antibody that binds vascular endothelial growth factor receptor-2 and blocks ligand-stimulated activation. The ROSE/TRIO-012 trial evaluated ramucirumab with docetaxel in unresectable, locally recurrent, or metastatic breast cancer. Patients and Methods: In this double-blind, placebo-controlled, randomized, multinational phase III trial, 1,144 patients with human epidermal growth factor receptor 2 (HER2) -negative breast cancer who had not received cytotoxic chemotherapy in the advanced setting were randomly assigned at a two-to-one ratio to receive docetaxel 75 mg/m2 plus ramucirumab 10 mg/kg or docetaxel 75 mg/m2 plus placebo once every 3 weeks. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria. Patients were stratified by previous taxane therapy, visceral metastasis, hormone receptor status, and geographic region. An independent data monitoring committee oversaw the trial. The primary end point was investigator-assessed PFS. Results: Median PFS in patients treated with ramucirumab plus docetaxel was 9.5 months, compared with 8.2 months in patients who received placebo plus docetaxel (hazard ratio [HR], 0.88; P = .077). Median overall survival was 27.3 months in patients who received ramucirumab plus docetaxel, compared with 27.2 months in patients who received placebo plus docetaxel (HR, 1.01; P = .915). Toxicities seen at significantly higher rates in patients receiving ramucirumab included fatigue, hypertension, febrile neutropenia, palmar-plantar erythrodysesthesia syndrome, and stomatitis. Conclusion: Addition of ramucirumab to docetaxel in HER2-negative advanced breast cancer did not meaningfully improve important clinical outcomes.</dc:description><citedby-count>2</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030835</affiliation-url><afid>60030835</afid><affilname>University of Alberta</affilname><name-variant>University of Alberta</name-variant><affiliation-city>Edmonton</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113244981</affiliation-url><afid>113244981</afid><affilname>Translational Research in Oncology</affilname><name-variant>Translational Research in Oncology</name-variant><affiliation-city>Edmonton</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007140</affiliation-url><afid>60007140</afid><affilname>Tom Baker Cancer Centre</affilname><name-variant>Tom Baker Cancer Centre</name-variant><affiliation-city>Calgary</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028379</affiliation-url><afid>60028379</afid><affilname>British Columbia Cancer Agency</affilname><name-variant>BC Cancer Agency</name-variant><affiliation-city>Vancouver</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029150</affiliation-url><afid>60029150</afid><affilname>Sunnybrook Health Sciences Centre</affilname><name-variant>Sunnybrook Health Sciences Centre</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112659880</affiliation-url><afid>112659880</afid><affilname>Eli Lilly Canada</affilname><name-variant>Eli Lilly Canada</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001106</affiliation-url><afid>60001106</afid><affilname>Centro Oncologico de Galicia</affilname><name-variant>Centro Oncológico de Galicia</name-variant><affiliation-city>La Coruna</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027282</affiliation-url><afid>60027282</afid><affilname>Universidad Complutense de Madrid</affilname><name-variant>Universidad Complutense</name-variant><affiliation-city>Madrid</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100584874</affiliation-url><afid>100584874</afid><affilname>Ministry of Health of the Republic of Bashkortostan</affilname><name-variant>Ministry of Health of the Republic of Bashkortostan</name-variant><affiliation-city>Ufa</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112573480</affiliation-url><afid>112573480</afid><affilname>Leningrad Regional Oncology Dispensary</affilname><name-variant>Leningrad Region Tuberculosis Dispensary</name-variant><affiliation-city>Saint Petersburg (ex Leningrad)</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070959</affiliation-url><afid>60070959</afid><affilname>N.N. Petrov Research Institute of Oncology of the USSR Ministry of Health</affilname><name-variant>N.N. Petrov Res. Inst. Oncol.</name-variant><affiliation-city>Saint Petersburg (ex Leningrad)</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112632857</affiliation-url><afid>112632857</afid><affilname>City Clinical Oncology Dispensary</affilname><name-variant>City Clinical Oncology Dispensary</name-variant><affiliation-city>Saint Petersburg (ex Leningrad)</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069970</affiliation-url><afid>60069970</afid><affilname>N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences</affilname><name-variant>Russian Academy of Medical Sciences</name-variant><affiliation-city>Moscow</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113975257</affiliation-url><afid>113975257</afid><affilname>ICON Cancer Care</affilname><name-variant>ICON Cancer Care</name-variant><affiliation-city>Brisbane</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027550</affiliation-url><afid>60027550</afid><affilname>University of California, Los Angeles</affilname><name-variant>UCLA</name-variant><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114893194</affiliation-url><afid>114893194</afid><affilname>Hospital Pérola Byigton</affilname><name-variant>Hospital Pérola Byigton</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101705438</affiliation-url><afid>101705438</afid><affilname>Middle East Institute of Health</affilname><name-variant>Middle East Institute of Health</name-variant><affiliation-city>Beirut</affiliation-city><affiliation-country>Lebanon</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006316</affiliation-url><afid>60006316</afid><affilname>International Drug Development Institute, Charleroi</affilname><name-variant>Intl. Institute for Drug Development</name-variant><affiliation-city>Louvain-la-Neuve</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112429812</affiliation-url><afid>112429812</afid><affilname>ImClone Systems</affilname><name-variant>ImClone Systems LLC</name-variant><affiliation-city>Bridgewater</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><pubmed-id>25185099</pubmed-id><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">20</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56062267400</author-url><authid>56062267400</authid><authname>Mackey J.</authname><surname>Mackey</surname><given-name>John R.</given-name><initials>J.R.</initials><afid>60030835</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24464693600</author-url><authid>24464693600</authid><authname>Ramos-Vazquez M.</authname><surname>Ramos-Vazquez</surname><given-name>Manuel</given-name><initials>M.</initials><afid>60001106</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55294786600</author-url><authid>55294786600</authid><authname>Lipatov O.</authname><surname>Lipatov</surname><given-name>Oleg</given-name><initials>O.</initials><afid>100584874</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:24587733100</author-url><authid>24587733100</authid><authname>McCarthy N.</authname><surname>McCarthy</surname><given-name>Nicole</given-name><initials>N.</initials><afid>113975257</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6507150989</author-url><authid>6507150989</authid><authname>Krasnozhon D.</authname><surname>Krasnozhon</surname><given-name>Dmitriy</given-name><initials>D.</initials><afid>112573480</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:18838622600</author-url><authid>18838622600</authid><authname>Semiglazov V.</authname><surname>Semiglazov</surname><given-name>Vladimir</given-name><initials>V.</initials><afid>60070959</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6507130338</author-url><authid>6507130338</authid><authname>Manikhas A.</authname><surname>Manikhas</surname><given-name>Alexey</given-name><initials>A.</initials><afid>112632857</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7005225389</author-url><authid>7005225389</authid><authname>Gelmon K.</authname><surname>Gelmon</surname><given-name>Karen A.</given-name><initials>K.A.</initials><afid>60028379</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7004782584</author-url><authid>7004782584</authid><authname>Konecny G.</authname><surname>Konecny</surname><given-name>Gottfried E.</given-name><initials>G.E.</initials><afid>60027550</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56482758100</author-url><authid>56482758100</authid><authname>Webster M.</authname><surname>Webster</surname><given-name>Marc</given-name><initials>M.</initials><afid>60007140</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7003843785</author-url><authid>7003843785</authid><authname>Hegg R.</authname><surname>Hegg</surname><given-name>Roberto</given-name><initials>R.</initials><afid>114893194</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7402328252</author-url><authid>7402328252</authid><authname>Verma S.</authname><surname>Verma</surname><given-name>Sunil</given-name><initials>S.</initials><afid>60029150</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:7006039493</author-url><authid>7006039493</authid><authname>Gorbunova V.</authname><surname>Gorbunova</surname><given-name>Vera</given-name><initials>V.</initials><afid>60069970</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:6506009905</author-url><authid>6506009905</authid><authname>Gerges D.</authname><surname>Gerges</surname><given-name>Dany Abi</given-name><initials>D.A.</initials><afid>101705438</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:56483268300</author-url><authid>56483268300</authid><authname>Thireau F.</authname><surname>Thireau</surname><given-name>Francois</given-name><initials>F.</initials><afid>113244981</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:56482839900</author-url><authid>56482839900</authid><authname>Fung H.</authname><surname>Fung</surname><given-name>Helena</given-name><initials>H.</initials><afid>113244981</afid></author><author seq="17"><author-url>http://api.elsevier.com/content/author/author_id:7005647005</author-url><authid>7005647005</authid><authname>Simms L.</authname><surname>Simms</surname><given-name>Lorinda</given-name><initials>L.</initials><afid>112659880</afid></author><author seq="18"><author-url>http://api.elsevier.com/content/author/author_id:7004958956</author-url><authid>7004958956</authid><authname>Buyse M.</authname><surname>Buyse</surname><given-name>Marc</given-name><initials>M.</initials><afid>60006316</afid></author><author seq="19"><author-url>http://api.elsevier.com/content/author/author_id:56482723500</author-url><authid>56482723500</authid><authname>Ibrahim A.</authname><surname>Ibrahim</surname><given-name>Ayman</given-name><initials>A.</initials><afid>112429812</afid></author><author seq="20"><author-url>http://api.elsevier.com/content/author/author_id:56321728400</author-url><authid>56321728400</authid><authname>Martin M.</authname><surname>Martin</surname><given-name>Miguel</given-name><initials>M.</initials><afid>60027282</afid></author><intid>534551105</intid><source-id>29949</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84920938211"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84920938211?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84920938211&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84920938211&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84920938211</prism:url><dc:identifier>SCOPUS_ID:84920938211</dc:identifier><eid>2-s2.0-84920938211</eid><dc:title>Randomized, double-blind, placebo-controlled, multicenter phase ii study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer</dc:title><dc:creator>Edelman M.</dc:creator><prism:publicationName>Journal of Clinical Oncology</prism:publicationName><prism:issn>0732183X</prism:issn><prism:eIssn>15277755</prism:eIssn><prism:volume>33</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>189-194</prism:pageRange><prism:coverDate>2015-10-10</prism:coverDate><prism:coverDisplayDate>10 October 2015</prism:coverDisplayDate><prism:doi>10.1200/JCO.2014.55.5789</prism:doi><dc:description>© 2014 by American Society of Clinical Oncology.Copyright © 2015 American Society of Clinical Oncology. Purpose Overexpression of COX-2 correlates with advanced stage and worse outcomes in non-small-cell lung cancer (NSCLC), possibly as a result of elevated levels of COX-2-dependent prostaglandin E2 (PGE2). Exploratory analyses of studies that used COX-2 inhibitors have demonstrated potentially superior outcome in patients in whom the urinary metabolite of PGE2 (PGE-M) is suppressed. We hypothesized that patients with disease defined by PGE-M suppression would benefit from the addition of apricoxib to second-line docetaxel or pemetrexed. Patients and Methods Patients with NSCLC who had disease progression after one line of platinum-based therapy, performance status of 0 to 2, and normal organ function were potentially eligible. Only patients with a 50% decrease in urinary PGE-M after 5 days of treatment with apricoxib could enroll. Docetaxel 75 mg/m2 or pemetrexed 500 mg/m2 once every 21 days per the investigator was administered with apricoxib or placebo 400 mg once per day. The primary end point was progression-free survival (PFS). Exploratory analysis was performed regarding baseline urinary PGE-M and outcomes. Results In all, 101 patients completed screening, and 72 of the 80 who demonstrated 50% suppression were randomly assigned to apricoxib or placebo. Toxicity was similar between the arms. No improvement in PFS was seen with apricoxib versus placebo. The median PFS for the control arm was 97 days (95% CI, 52 to 193 days) versus 85 days (95% CI, 67 to 142 days) for the experimental arm (P =.91). Conclusion Apricoxib did not improve PFS, despite biomarker-driven patient selection.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014653</affiliation-url><afid>60014653</afid><affilname>University of Maryland, Baltimore</affilname><name-variant>University of Maryland</name-variant><affiliation-city>Baltimore</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023927</affiliation-url><afid>60023927</afid><affilname>Georgetown University</affilname><name-variant>Georgetown University</name-variant><affiliation-city>Washington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018691</affiliation-url><afid>60018691</afid><affilname>Rush University Medical Center</affilname><name-variant>Rush University Medical Center</name-variant><affiliation-city>Chicago</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019964</affiliation-url><afid>60019964</afid><affilname>Providence Portland Medical Center</affilname><name-variant>Providence Portland Medical Center</name-variant><affiliation-city>Portland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002058</affiliation-url><afid>60002058</afid><affilname>Ohio State University Comprehensive Cancer Center</affilname><name-variant>Ohio State University Comprehensive Cancer Center</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008130</affiliation-url><afid>60008130</afid><affilname>Massachusetts General Hospital Cancer Center</affilname><name-variant>Massachusetts Gen. Hosp. Cancer Ctr.</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006297</affiliation-url><afid>60006297</afid><affilname>University of Pennsylvania</affilname><name-variant>University of Pennsylvania</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007997</affiliation-url><afid>60007997</afid><affilname>Weill Cornell Medical College</affilname><name-variant>Cornell University Medical College</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026415</affiliation-url><afid>60026415</afid><affilname>Stony Brook University State University of New York</affilname><name-variant>State University of New York at Stony Brook</name-variant><affiliation-city>Stony Brook</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022783</affiliation-url><afid>60022783</afid><affilname>West Virginia University School of Medicine Morgantown</affilname><name-variant>West Virginia University</name-variant><affiliation-city>Morgantown</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100459431</affiliation-url><afid>100459431</afid><affilname>Mercy Neuroscience Institute</affilname><name-variant>Mercy Neuroscience Institute</name-variant><affiliation-city>Miami</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:110004066</affiliation-url><afid>110004066</afid><affilname>Tragara Pharmaceuticals</affilname><name-variant>Tragara</name-variant><affiliation-city>San Diego</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><pubmed-id>25452446</pubmed-id><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">15</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7102904195</author-url><authid>7102904195</authid><authname>Edelman M.</authname><surname>Edelman</surname><given-name>Martin J.</given-name><initials>M.J.</initials><afid>60014653</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56481024700</author-url><authid>56481024700</authid><authname>Tan M.</authname><surname>Tan</surname><given-name>Ming T.</given-name><initials>M.T.</initials><afid>60023927</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:24072857000</author-url><authid>24072857000</authid><authname>Fidler M.</authname><surname>Fidler</surname><given-name>Mary J.</given-name><initials>M.J.</initials><afid>60018691</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8934794200</author-url><authid>8934794200</authid><authname>Sanborn R.</authname><surname>Sanborn</surname><given-name>Rachel E.</given-name><initials>R.E.</initials><afid>60019964</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004708682</author-url><authid>7004708682</authid><authname>Otterson G.</authname><surname>Otterson</surname><given-name>Greg</given-name><initials>G.</initials><afid>60002058</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8696688300</author-url><authid>8696688300</authid><authname>Sequist L.</authname><surname>Sequist</surname><given-name>Lecia V.</given-name><initials>L.V.</initials><afid>60008130</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56481060000</author-url><authid>56481060000</authid><authname>Evans T.</authname><surname>Evans</surname><given-name>Tracey L.</given-name><initials>T.L.</initials><afid>60006297</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:9239782700</author-url><authid>9239782700</authid><authname>Schneider B.</authname><surname>Schneider</surname><given-name>Bryan J.</given-name><initials>B.J.</initials><afid>60007997</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6602379148</author-url><authid>6602379148</authid><authname>Keresztes R.</authname><surname>Keresztes</surname><given-name>Roger</given-name><initials>R.</initials><afid>60026415</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56480997700</author-url><authid>56480997700</authid><authname>Rogers J.</authname><surname>Rogers</surname><given-name>John S.</given-name><initials>J.S.</initials><afid>60022783</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:6507569758</author-url><authid>6507569758</authid><authname>De Mayolo J.</authname><surname>De Mayolo</surname><given-name>Jorge Antunez</given-name><initials>J.A.</initials><afid>100459431</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:36503770100</author-url><authid>36503770100</authid><authname>Feliciano J.</authname><surname>Feliciano</surname><given-name>Josephine</given-name><initials>J.</initials><afid>60014653</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:56480872400</author-url><authid>56480872400</authid><authname>Yang Y.</authname><surname>Yang</surname><given-name>Yang</given-name><initials>Y.</initials><afid>60014653</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:56481175500</author-url><authid>56481175500</authid><authname>Medeiros M.</authname><surname>Medeiros</surname><given-name>Michelle</given-name><initials>M.</initials><afid>60014653</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:6602092805</author-url><authid>6602092805</authid><authname>Zaknoen S.</authname><surname>Zaknoen</surname><given-name>Sara L.</given-name><initials>S.L.</initials><afid>110004066</afid></author><intid>1534564393</intid><source-id>29949</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84920984465"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84920984465?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84920984465&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84920984465&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84920984465</prism:url><dc:identifier>SCOPUS_ID:84920984465</dc:identifier><eid>2-s2.0-84920984465</eid><dc:title>Pre- and postdiagnosis physical activity, television viewing, and mortality among patients with colorectal cancer in the national institutes of health-AARP diet and health study</dc:title><dc:creator>Arem H.</dc:creator><prism:publicationName>Journal of Clinical Oncology</prism:publicationName><prism:issn>0732183X</prism:issn><prism:eIssn>15277755</prism:eIssn><prism:volume>33</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>180-188</prism:pageRange><prism:coverDate>2015-10-10</prism:coverDate><prism:coverDisplayDate>10 October 2015</prism:coverDisplayDate><prism:doi>10.1200/JCO.2014.58.1355</prism:doi><dc:description>Copyright © 2015 American Society of Clinical Oncology. Purpose Physical inactivity has been associated with higher mortality risk among survivors of colorectal cancer (CRC), but the independent effects of pre- versus postdiagnosis activity are unclear, and the association between watching television (TV) and mortality in survivors of CRC is previously undefined. Methods We analyzed the associations between prediagnosis (n = 3,797) and postdiagnosis (n = 1,759) leisure time physical activity (LTPA) and TV watching and overall and disease-specific mortality among patients with CRC. We used Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% CIs, adjusting for known mortality risk factors. Results Comparing survivors of CRC reporting more than 7 hours per week (h/wk) of prediagnosis LTPA with those reporting no LTPA, we found a 20% lower risk of all-cause mortality (HR, 0.80; 95% CI, 0.68 to 0.95; P for trend =.021). Postdiagnosis LTPA of &gt; 7 h/wk, compared with none, was associated with a 31% lower all-cause mortality risk (HR, 0.69; 95% CI, 0.49 to 0.98; P for trend =.006), independent of prediagnosis activity. Compared with 0 to 2 TV hours per day (h/d) before diagnosis, those reporting &gt; 5 h/d of TV before diagnosis had a 22% increased all-cause mortality risk (HR, 1.22; 95% CI, 1.06 to 1.41; P trend = .002), and more postdiagnosis TV watching was associated with a nonsignificant 25% increase in all-cause mortality risk (HR, 1.25; 95% CI, 0.93 to 1.67; P for trend = .126). Conclusion LTPA was inversely associated with all-cause mortality, whereas more TV watching was associated with increased mortality risk. For both LTPA and TV watching, postdiagnosis measures independently explained the association with mortality. Clinicians should promote both minimizing TV time and increasing physical activity for longevity among survivors of CRC, regardless of previous behaviors.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013409</affiliation-url><afid>60013409</afid><affilname>National Cancer Institute</affilname><name-variant>NIH</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015204</affiliation-url><afid>60015204</afid><affilname>AARP</affilname><name-variant>AARP Public Policy Institute</name-variant><affiliation-city>Washington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022756</affiliation-url><afid>60022756</afid><affilname>Washington University in St. Louis, School of Medicine</affilname><name-variant>Washington University, School of Medicine</name-variant><affiliation-city>St Louis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>9609 Medical Center Dr</affilname><affiliation-city>Rockville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36631451300</author-url><authid>36631451300</authid><authname>Arem H.</authname><surname>Arem</surname><given-name>Hannah</given-name><initials>H.</initials><afid>60013409</afid><afid/></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36631451300</author-url><authid>36631451300</authid><authname>Arem H.</authname><surname>Arem</surname><given-name>Hannah</given-name><initials>H.</initials><afid>60013409</afid><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56481139400</author-url><authid>56481139400</authid><authname>Pfeiffer R.</authname><surname>Pfeiffer</surname><given-name>Ruth M.</given-name><initials>R.M.</initials><afid>60013409</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006883183</author-url><authid>7006883183</authid><authname>Engels E.</authname><surname>Engels</surname><given-name>Eric A.</given-name><initials>E.A.</initials><afid>60013409</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004031584</author-url><authid>7004031584</authid><authname>Alfano C.</authname><surname>Alfano</surname><given-name>Catherine M.</given-name><initials>C.M.</initials><afid>60013409</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:26643596000</author-url><authid>26643596000</authid><authname>Hollenbeck A.</authname><surname>Hollenbeck</surname><given-name>Albert</given-name><initials>A.</initials><afid>60015204</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56480895300</author-url><authid>56480895300</authid><authname>Park Y.</authname><surname>Park</surname><given-name>Yikyung</given-name><initials>Y.</initials><afid>60022756</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7201785720</author-url><authid>7201785720</authid><authname>Matthews C.</authname><surname>Matthews</surname><given-name>Charles E.</given-name><initials>C.E.</initials><afid>60015204</afid></author><intid>2034562924</intid><source-id>29949</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928891647"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928891647?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928891647&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928891647&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0956566315300853"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928891647</prism:url><dc:identifier>SCOPUS_ID:84928891647</dc:identifier><eid>2-s2.0-84928891647</eid><dc:title>A polyaniline based ultrasensitive potentiometric immunosensor for cardiac troponin complex detection</dc:title><dc:creator>Zhang Q.</dc:creator><prism:publicationName>Biosensors and Bioelectronics</prism:publicationName><prism:issn>09565663</prism:issn><prism:eIssn>18734235</prism:eIssn><prism:volume>72</prism:volume><prism:pageRange>100-106</prism:pageRange><prism:coverDate>2015-10-05</prism:coverDate><prism:coverDisplayDate>October 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bios.2015.04.084</prism:doi><pii>S0956566315300853</pii><dc:description>© 2015 Elsevier B.V. An ultrasensitive immunosensor based on potentiometric ELISA for the detection of a cardiac biomarker, troponin I-T-C (Tn I-T-C) complex, was developed. The sensor fabrication involves typical sandwich ELISA procedures, while the final signal readout was achieved using open circuit potentiometry (OCP). Glassy carbon (GC) working electrodes were first coated with emulsion-polymerized polyaniline/dinonylnaphthalenesulfonic acid (PANI/DNNSA) and the coated surface was utilized as a transducer layer on which sandwich ELISA incubation steps were performed. An enzymatic reaction between o-phenylenediamine (OPD) and hydrogen peroxide (H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt;) was catalyzed by horseradish peroxidase (HRP) labeled on the secondary antibodies. The polymer transducer charged state was mediated through electron (e&lt;sup&gt;-&lt;/sup&gt;) and charge transfers between the transducer and charged species generated by the same enzymatic reaction. Such a change in the polymer transducer led to potential variations against an Ag/AgCl reference electrode as a function of Tn I-T-C complex concentration during incubations. The sequence of OPD and H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt; additions, electrochemical properties of the PANI/DNNSA layer and non-specific binding prevention were all crucial factors for the assay performance. Under optimized conditions, the assay has a low limit of detection (LOD) (&lt;5pg/mL or 56fM), a wide dynamic range (&gt;6 orders of magnitude), high repeatability (coefficient of variance &lt;8% for all concentrations higher than 5pg/mL) and a short detection time (&lt;10min).</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021784</affiliation-url><afid>60021784</afid><affilname>New York University</affilname><name-variant>New York University</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030623</affiliation-url><afid>60030623</afid><affilname>Rutgers, The State University of New Jersey</affilname><name-variant>Rutgers University</name-variant><affiliation-city>New Brunswick</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:22973790300</author-url><authid>22973790300</authid><authname>Zhang Q.</authname><surname>Zhang</surname><given-name>Qi</given-name><initials>Q.</initials><afid>60021784</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55821711700</author-url><authid>55821711700</authid><authname>Prabhu A.</authname><surname>Prabhu</surname><given-name>Alok</given-name><initials>A.</initials><afid>60021784</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56622895800</author-url><authid>56622895800</authid><authname>San A.</authname><surname>San</surname><given-name>Avdar</given-name><initials>A.</initials><afid>60021784</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8551174600</author-url><authid>8551174600</authid><authname>Al-Sharab J.</authname><surname>Al-Sharab</surname><given-name>Jafar F.</given-name><initials>J.F.</initials><afid>60030623</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55157862900</author-url><authid>55157862900</authid><authname>Levon K.</authname><surname>Levon</surname><given-name>Kalle</given-name><initials>K.</initials><afid>60021784</afid></author><authkeywords>ELISA | Polyaniline | Potentiometry | Troponin I-T-C | Ultrasensitive immunosensor</authkeywords><intid>1785862027</intid><source-id>15437</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929242201"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929242201?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929242201&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929242201&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0956566315300890"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929242201</prism:url><dc:identifier>SCOPUS_ID:84929242201</dc:identifier><eid>2-s2.0-84929242201</eid><dc:title>Graphene-CNT nanohybrid aptasensor for label free detection of cardiac biomarker myoglobin</dc:title><dc:creator>Kumar V.</dc:creator><prism:publicationName>Biosensors and Bioelectronics</prism:publicationName><prism:issn>09565663</prism:issn><prism:eIssn>18734235</prism:eIssn><prism:volume>72</prism:volume><prism:pageRange>56-60</prism:pageRange><prism:coverDate>2015-10-05</prism:coverDate><prism:coverDisplayDate>October 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bios.2015.04.089</prism:doi><pii>S0956566315300890</pii><dc:description>© 2015 Elsevier B.V. We report a label free electrochemical detection of cardiac bio-marker myoglobin (Mb) on aptamer functionalized rGO/CNT nanostructured electrodes by measuring its direct electron transfer (DET). Configured as a highly responsive aptasensor, the newly developed biosensing platform exhibits synergistic effect of the nano-hybrid functional construct by combining good electrical properties and the facile chemical functionality of nanohybrid for the compatible bio-interface development. The specific anti-Mb aptamer was generated by five iterative SELEX (Systematic evolution of ligands by exponential enrichment) rounds, showing high senstivity (K&lt;inf&gt;D&lt;/inf&gt; ~65pM). The aptamer functionalized rGO/CNT nanostructured electrodes demonstrated a significant increase in signal response with a detection limit of ~0.34ng/mL in the dynamic response range between 1ng/mL and 4μg/mL for Mb. The newly developed DET assay format presents a promising candidate in point-of-care diagnosis for routine screening of Mb in patient's samples.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113489629</affiliation-url><afid>113489629</afid><affilname>Institute of Nano Science and Technology</affilname><name-variant>Institute of Nano Science and Technology</name-variant><affiliation-city>Mohali</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56642193500</author-url><authid>56642193500</authid><authname>Kumar V.</authname><surname>Kumar</surname><given-name>Vinod</given-name><initials>V.</initials><afid>113489629</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55977714000</author-url><authid>55977714000</authid><authname>Shorie M.</authname><surname>Shorie</surname><given-name>Munish</given-name><initials>M.</initials><afid>113489629</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56642440900</author-url><authid>56642440900</authid><authname>Ganguli A.</authname><surname>Ganguli</surname><given-name>Ashok K.</given-name><initials>A.K.</initials><afid>113489629</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56315597300</author-url><authid>56315597300</authid><authname>Sabherwal P.</authname><surname>Sabherwal</surname><given-name>Priyanka</given-name><initials>P.</initials><afid>113489629</afid></author><authkeywords>Aptamer | Cardiac marker | Direct electron transfer | Myoglobin | RGO/CNT nanohybrid</authkeywords><intid>35922692</intid><source-id>15437</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928739950"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928739950?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928739950&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928739950&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0956566315300865"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928739950</prism:url><dc:identifier>SCOPUS_ID:84928739950</dc:identifier><eid>2-s2.0-84928739950</eid><dc:title>BODIPY-based azamacrocyclic ensemble for selective fluorescence detection and quantification of homocysteine in biological applications</dc:title><dc:creator>Li Z.</dc:creator><prism:publicationName>Biosensors and Bioelectronics</prism:publicationName><prism:issn>09565663</prism:issn><prism:eIssn>18734235</prism:eIssn><prism:volume>72</prism:volume><prism:pageRange>1-9</prism:pageRange><prism:coverDate>2015-10-05</prism:coverDate><prism:coverDisplayDate>October 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bios.2015.04.085</prism:doi><pii>S0956566315300865</pii><dc:description>© 2015 Elsevier B.V. Considering the significant role of plasma homocysteine in physiological processes, two ensembles (F&lt;inf&gt;465&lt;/inf&gt;-Cu&lt;sup&gt;2+&lt;/sup&gt; and F&lt;inf&gt;508&lt;/inf&gt;-Cu&lt;sup&gt;2+&lt;/sup&gt;) were constructed based on a BODIPY (4,4-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene) scaffold conjugated with an azamacrocyclic (1,4,7-triazacyclononane and 1,4,7,10-tetraazacyclododecane) Cu&lt;sup&gt;2+&lt;/sup&gt; complex. The results of this effort demonstrated that the F&lt;inf&gt;465&lt;/inf&gt;-Cu&lt;sup&gt;2+&lt;/sup&gt; ensemble could be employed to detect homocysteine in the presence of other biologically relevant species, including cysteine and glutathione, under physiological conditions with high selectivity and sensitivity in the turn-on fluorescence mode, while the F&lt;inf&gt;508&lt;/inf&gt;-Cu&lt;sup&gt;2+&lt;/sup&gt; ensemble showed no fluorescence responses toward biothiols. A possible mechanism for this homocysteine-specific specificity involving the formation of a homocysteine-induced six-membered ring sandwich structure was proposed and confirmed for the first time by time-dependent fluorescence spectra, ESI-MS and EPR. The detection limit of homocysteine in deproteinized human serum was calculated to be 241.4nM with a linear range of 0-90.0μM and the detection limit of F&lt;inf&gt;465&lt;/inf&gt; for Cu&lt;sup&gt;2+&lt;/sup&gt; is 74.7nM with a linear range of 0-6.0μM (F&lt;inf&gt;508&lt;/inf&gt;, 80.2nM, 0-7.0μM). We have demonstrated the application of the F&lt;inf&gt;465&lt;/inf&gt;-Cu&lt;sup&gt;2+&lt;/sup&gt; ensemble for detecting homocysteine in human serum and monitoring the activity of cystathionine β-synthase in vitro.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033100</affiliation-url><afid>60033100</afid><affilname>Nanjing University</affilname><name-variant>Nanjing University</name-variant><affiliation-city>Nanjing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56610860900</author-url><authid>56610860900</authid><authname>Li Z.</authname><surname>Li</surname><given-name>Zan</given-name><initials>Z.</initials><afid>60033100</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24466442100</author-url><authid>24466442100</authid><authname>Geng Z.</authname><surname>Geng</surname><given-name>Zhi Rong</given-name><initials>Z.R.</initials><afid>60033100</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56610906000</author-url><authid>56610906000</authid><authname>Zhang C.</authname><surname>Zhang</surname><given-name>Cui</given-name><initials>C.</initials><afid>60033100</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55836980400</author-url><authid>55836980400</authid><authname>Wang X.</authname><surname>Wang</surname><given-name>Xiao Bo</given-name><initials>X.B.</initials><afid>60033100</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7410039899</author-url><authid>7410039899</authid><authname>Wang Z.</authname><surname>Wang</surname><given-name>Zhi Lin</given-name><initials>Z.L.</initials><afid>60033100</afid></author><authkeywords>Azamacrocyclic Cu&lt;sup&gt;2+&lt;/sup&gt; ensemble | BODIPY | Cystathionine β-synthase activity | Fluorescent chemosensor | Hcy sensor | Homocysteine sensor</authkeywords><intid>535839436</intid><source-id>15437</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929454414"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929454414?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929454414&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929454414&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0956566315300944"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929454414</prism:url><dc:identifier>SCOPUS_ID:84929454414</dc:identifier><eid>2-s2.0-84929454414</eid><dc:title>Intense Raman scattering on hybrid Au/Ag nanoplatforms for the distinction of MMP-9-digested collagen type-I fiber detection</dc:title><dc:creator>Sivashanmugan K.</dc:creator><prism:publicationName>Biosensors and Bioelectronics</prism:publicationName><prism:issn>09565663</prism:issn><prism:eIssn>18734235</prism:eIssn><prism:volume>72</prism:volume><prism:pageRange>61-70</prism:pageRange><prism:coverDate>2015-10-05</prism:coverDate><prism:coverDisplayDate>October 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bios.2015.04.091</prism:doi><pii>S0956566315300944</pii><dc:description>© 2015 Elsevier B.V. Well-ordered Au-nanorod arrays were fabricated using the focused ion beam method (denoted as fibAu_NR). Au or Ag nanoclusters (NCs) of various sizes and dimensions were then deposited on the fibAu_NR arrays using electron beam deposition to improve the surface-enhanced Raman scattering (SERS) effect, which was verified using a low concentration of crystal violet (10&lt;sup&gt;-&lt;/sup&gt;&lt;sup&gt;5&lt;/sup&gt;M) as the probe molecule. An enhancement factor of 6.92×10&lt;sup&gt;8&lt;/sup&gt; was obtained for NCsfibAu_NR, which is attributed to the combination of intra-NC and NR localized surface plasmon resonance. When 4-aminobenzenethiol (4-ABT)-coated Au or Ag nanoparticles (NPs) were attached to NCsfibAu_NR, the small gaps between 4-ABT-coated NPs and intra-NCs allowed detection at the single-molecule level. Hotspots formed at the interfaces of NCs/NRs and NPs/NCs at a high density, producing a strong local electromagnetic effect. Raman spectra from as-prepared type I collagen (Col-I) and Ag-NP-coated Col-I fibers on NCsfibAu_NR were compared to determine the quantity of amino acids in their triple helix structure. Various concentrations of matrix-metalloproteinase-9-digested Col-I fibers on NCsfibAu_NR were qualitatively examined at a Raman laser wavelength of 785nm to determine the changes of amino acids in the Col-I fiber structure. The results can be used to monitor the growth of healing Col-I fibers in a micro-environment.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014982</affiliation-url><afid>60014982</afid><affilname>National Cheng Kung University</affilname><name-variant>National Cheng Kung University</name-variant><affiliation-city>Tainan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014982</affiliation-url><afid>60014982</afid><affilname>National Cheng Kung University</affilname><name-variant>National Cheng Kung University</name-variant><affiliation-city>Tainan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55876694000</author-url><authid>55876694000</authid><authname>Sivashanmugan K.</authname><surname>Sivashanmugan</surname><given-name>Kundan</given-name><initials>K.</initials><afid>60014982</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55682765100</author-url><authid>55682765100</authid><authname>Liao J.</authname><surname>Liao</surname><given-name>Jiunn Der</given-name><initials>J.D.</initials><afid>60014982</afid><afid>60014982</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55682765100</author-url><authid>55682765100</authid><authname>Liao J.</authname><surname>Liao</surname><given-name>Jiunn Der</given-name><initials>J.D.</initials><afid>60014982</afid><afid>60014982</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55948585800</author-url><authid>55948585800</authid><authname>Shao P.</authname><surname>Shao</surname><given-name>Pei Lin</given-name><initials>P.L.</initials><afid>60014982</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36936129700</author-url><authid>36936129700</authid><authname>Liu B.</authname><surname>Liu</surname><given-name>Bernard Haochih</given-name><initials>B.H.</initials><afid>60014982</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56647589400</author-url><authid>56647589400</authid><authname>Tseng T.</authname><surname>Tseng</surname><given-name>Te Yu</given-name><initials>T.Y.</initials><afid>60014982</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56647052700</author-url><authid>56647052700</authid><authname>Chang C.</authname><surname>Chang</surname><given-name>Chih Yu</given-name><initials>C.Y.</initials><afid>60014982</afid></author><authkeywords>4-aminobenzenethiol | Au nanorods | Digested type I collagen | Nanoclusters | Surface-enhanced Raman scattering</authkeywords><intid>2035958017</intid><source-id>15437</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84907775411"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84907775411?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84907775411&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84907775411&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84907775411</prism:url><dc:identifier>SCOPUS_ID:84907775411</dc:identifier><eid>2-s2.0-84907775411</eid><dc:title>Medical research: Missing patients</dc:title><dc:creator>Burchard E.</dc:creator><prism:publicationName>Nature</prism:publicationName><prism:issn>00280836</prism:issn><prism:eIssn>14764687</prism:eIssn><prism:volume>513</prism:volume><prism:issueIdentifier>7518</prism:issueIdentifier><prism:pageRange>301-302</prism:pageRange><prism:coverDate>2015-10-02</prism:coverDate><prism:coverDisplayDate>2 October 2015</prism:coverDisplayDate><prism:doi>10.1038/513301a</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023691</affiliation-url><afid>60023691</afid><affilname>University of California, San Francisco</affilname><name-variant>University of California, San Francisco</name-variant><affiliation-city>San Francisco</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><pubmed-id>25230631</pubmed-id><prism:aggregationType>Journal</prism:aggregationType><subtype>no</subtype><subtypeDescription>Note</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55663704500</author-url><authid>55663704500</authid><authname>Burchard E.</authname><surname>Burchard</surname><given-name>Esteban G.</given-name><initials>E.G.</initials><afid>60023691</afid></author><intid>532359568</intid><source-id>21206</source-id></entry></search-results>
